snehalathad
/
KonectarApp
1
0
Fork 0
Code Issues Pull Requests Packages Projects Releases Wiki Activity
KonectarApp/assets/eventsdetail.json

31762 lines
1.7 MiB
JSON
Raw Normal View History

first commit
2024-09-06 06:30:31 +00:00
{
"data": {
"eventsdetail": [
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Trastuzumab | Tucatinib | Triple Negative Breast Neoplasms",
"npi_num": "1013064823",
"hcp_pin_alias": "455769",
"session_name": "Tucatinib and trastuzumab for previously treated HER2−mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "455769",
"first_name": "Paula",
"middle_name": "Raffin",
"last_name": "Pohlmann",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232703",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232703",
"events_session": "Tucatinib and trastuzumab for previously treated HER2−mutated metastatic breast cancer (SGNTUC−019): A phase 2 basket study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Trastuzumab | Tucatinib ",
"rest_events_topic_count": 1,
"rest_events_topic": " Triple Negative Breast Neoplasms",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/455769/fromId'\u003EPohlmann, Paula Raffin\u003C/a\u003E",
"kol_full_name": "Pohlmann, Paula Raffin"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung",
"npi_num": "1669558524",
"hcp_pin_alias": "450218",
"session_name": "Innovative Therapy Options and Research to Meet Diverse Patient Needs Across NSCLC",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "450218",
"first_name": "Christopher",
"middle_name": "D",
"last_name": "Lao",
"org_name": "Michigan Medicine Melanoma Oncology Clinic - Rogel Cancer Center",
"Country": "United States",
"Region": "Michigan",
"City": "Ann Arbor",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233154",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233154",
"events_session": "Innovative Therapy Options and Research to Meet Diverse Patient Needs Across NSCLC",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/450218/fromId'\u003ELao, Christopher D\u003C/a\u003E",
"kol_full_name": "Lao, Christopher D"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Sarcoma",
"npi_num": "1174780712",
"hcp_pin_alias": "449479",
"session_name": "Can Predictive Markers Help Us Risk-Stratify Patients With Sarcoma?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "449479",
"first_name": "Christina",
"middle_name": "Vadala",
"last_name": "Angeles",
"org_name": "University of Michigan Hospital",
"Country": "United States",
"Region": "Michigan",
"City": "Ann Arbor",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232034",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232034",
"events_session": "Can Predictive Markers Help Us Risk-Stratify Patients With Sarcoma?",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Sarcoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/449479/fromId'\u003EAngeles, Christina Vadala\u003C/a\u003E",
"kol_full_name": "Angeles, Christina Vadala"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Melanoma | Nivolumab | Programmed Cell Death 1 Receptor | Clinical Trials As Topic",
"npi_num": "1235114703",
"hcp_pin_alias": "430882",
"session_name": "Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "430882",
"first_name": "Michael",
"middle_name": "Sheldon",
"last_name": "Wong",
"org_name": "UC Davis Medical Center",
"Country": "United States",
"Region": "California",
"City": "Sacramento",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232327",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232327",
"events_session": "Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Melanoma | Nivolumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Programmed Cell Death 1 Receptor | Clinical Trials As Topic",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/430882/fromId'\u003EWong, Michael Sheldon\u003C/a\u003E",
"kol_full_name": "Wong, Michael Sheldon"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Melanoma",
"npi_num": "1992842280",
"hcp_pin_alias": "424942",
"session_name": "Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424942",
"first_name": "Sapna",
"middle_name": "",
"last_name": "Patel",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233127",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233127",
"events_session": "Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pembrolizumab | Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1992842280,'424942');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPatel, Sapna",
"kol_full_name": "Patel, Sapna"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nivolumab | Immunotherapy | Relatlimab | Melanoma | Brain Neoplasms",
"npi_num": "1982729422",
"hcp_pin_alias": "424930",
"session_name": "Immunotherapy and Beyond: Advances in Systemic Therapy for Patients With Melanoma and Brain Metastases,Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424930",
"first_name": "Hussein",
"middle_name": "Abdul-Hassan",
"last_name": "Tawbi",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "366467",
"cnt_notes": "1",
"event_attendees_id": "232787",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232787",
"events_session": "Immunotherapy and Beyond: Advances in Systemic Therapy for Patients With Melanoma and Brain Metastases",
"rest_events_session_count": 1,
"rest_events_session": "Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years",
"events_topic": "Nivolumab | Immunotherapy ",
"rest_events_topic_count": 3,
"rest_events_topic": " Relatlimab | Melanoma | Brain Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1982729422,'424930');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETawbi, Hussein Abdul-Hassan",
"kol_full_name": "Tawbi, Hussein Abdul-Hassan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatectomy | Urogenital Neoplasms | Androgen Deprivation Therapy | Urinary Bladder Neoplasms | Prostatic Neoplasms | Kidney Neoplasms",
"npi_num": "1982689410",
"hcp_pin_alias": "424927",
"session_name": "Genitourinary Cancer – Kidney and Bladder: Program Commitee,Randomized PROSTATE-IQ trial to reduce ADT treatment burden for patients with biochemical recurrence after prostatectomy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424927",
"first_name": "Karen",
"middle_name": "Elizabeth",
"last_name": "Hoffman",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232676",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232676",
"events_session": "Genitourinary Cancer – Kidney and Bladder: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Randomized PROSTATE-IQ trial to reduce ADT treatment burden for patients with biochemical recurrence after prostatectomy",
"events_topic": "Prostatectomy | Urogenital Neoplasms ",
"rest_events_topic_count": 4,
"rest_events_topic": " Androgen Deprivation Therapy | Urinary Bladder Neoplasms | Prostatic Neoplasms | Kidney Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1982689410,'424927');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHoffman, Karen Elizabeth",
"kol_full_name": "Hoffman, Karen Elizabeth"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Endometrial Neoplasms | Selinexor | Tumor Suppressor Protein P53",
"npi_num": "1972769800",
"hcp_pin_alias": "424923",
"session_name": "Updates on Abstract 427956: Long-Term Follow up of Selinexor Maintenance in Patients with TP53wt Advanced or Recurrent Endometrial Cancer—A Pre-Specified Subgroup Analysis from the Phase 3 ENGOT-EN5/GOG-3055/Siendo Study,Phase 3 dose selection for selinexor in TP53wt endometrial cancer based on exposure-response analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424923",
"first_name": "Vicky",
"middle_name": "",
"last_name": "Makker",
"org_name": "Memorial Developmental Chemo Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232435",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232435",
"events_session": "Updates on Abstract 427956: Long-Term Follow up of Selinexor Maintenance in Patients with TP53wt Advanced or Recurrent Endometrial Cancer—A Pre-Specified Subgroup Analysis from the Phase 3 ENGOT-EN5/GOG-3055/Siendo Study",
"rest_events_session_count": 1,
"rest_events_session": "Phase 3 dose selection for selinexor in TP53wt endometrial cancer based on exposure-response analysis",
"events_topic": "Endometrial Neoplasms | Selinexor ",
"rest_events_topic_count": 1,
"rest_events_topic": " Tumor Suppressor Protein P53",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1972769800,'424923');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMakker, Vicky",
"kol_full_name": "Makker, Vicky"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1972527810",
"hcp_pin_alias": "424912",
"session_name": "Study of the Bria-IMT regimen and CPI vs physicians' choice in advanced metastatic breast cancer (BRIA-ABC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424912",
"first_name": "Sara",
"middle_name": "A",
"last_name": "Hurvitz",
"org_name": "Regents of The University of California",
"Country": "United States",
"Region": "California",
"City": "Santa Monica",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232715",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232715",
"events_session": "Study of the Bria-IMT regimen and CPI vs physicians' choice in advanced metastatic breast cancer (BRIA-ABC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1972527810,'424912');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHurvitz, Sara A",
"kol_full_name": "Hurvitz, Sara A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1952497075",
"hcp_pin_alias": "424898",
"session_name": "Treatment and Outcomes in Select Subpopulations With Breast Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424898",
"first_name": "Lisa",
"middle_name": "A",
"last_name": "Carey",
"org_name": "UNC Physicians Network, LLC",
"Country": "United States",
"Region": "North Carolina",
"City": "Chapel Hill",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232148",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232148",
"events_session": "Treatment and Outcomes in Select Subpopulations With Breast Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1952497075,'424898');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECarey, Lisa A",
"kol_full_name": "Carey, Lisa A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Thoracic Neoplasms | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1952331654",
"hcp_pin_alias": "424892",
"session_name": "Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other: Program Commitee,Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424892",
"first_name": "Alberto",
"middle_name": "",
"last_name": "Chiappori",
"org_name": "H. Lee Moffitt Cancer Center & Research Institute",
"Country": "United States",
"Region": "Florida",
"City": "Tampa",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232024",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232024",
"events_session": "Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers",
"events_topic": "Thoracic Neoplasms | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1952331654,'424892');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChiappori, Alberto",
"kol_full_name": "Chiappori, Alberto"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "DNA Polymerase Theta | Carboplatin | ATR Kinase Inhibitor | Recombinational DNA Repair | Ubiquitin | Solid Tumor | Olaparib | Drug Development | Tuvusertib",
"npi_num": "1942743216",
"hcp_pin_alias": "424890",
"session_name": "Developmental Therapeutcs – Molecularly Targeted Agents: Program Commitee,First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors,First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations,A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424890",
"first_name": "Timothy",
"middle_name": "A",
"last_name": "Yap",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232452",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232452",
"events_session": "Developmental Therapeutcs – Molecularly Targeted Agents: Program Commitee",
"rest_events_session_count": 8,
"rest_events_session": "First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors,First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations,A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors",
"events_topic": "DNA Polymerase Theta | Carboplatin ",
"rest_events_topic_count": 7,
"rest_events_topic": " ATR Kinase Inhibitor | Recombinational DNA Repair | Ubiquitin | Solid Tumor | Olaparib | Drug Development | Tuvusertib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1942743216,'424890');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYap, Timothy A",
"kol_full_name": "Yap, Timothy A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Enhancer Of Zeste Homolog 2 Protein | Prostatic Neoplasms | Mevrometostat | Castration",
"npi_num": "1942463450",
"hcp_pin_alias": "424888",
"session_name": "Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424888",
"first_name": "Michael",
"middle_name": "Thomas",
"last_name": "Schweizer",
"org_name": "Association of University Physicians",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232652",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232652",
"events_session": "Phase 1 trial of mevrometostat (PF-06821497)",
"rest_events_session_count": 2,
"rest_events_session": " a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC)",
"events_topic": "Enhancer Of Zeste Homolog 2 Protein | Prostatic Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Mevrometostat | Castration",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1942463450,'424888');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESchweizer, Michael Thomas",
"kol_full_name": "Schweizer, Michael Thomas"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ruxolitinib | Primary Myelofibrosis",
"npi_num": "1932583119",
"hcp_pin_alias": "424878",
"session_name": "A phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424878",
"first_name": "Lucia",
"middle_name": "",
"last_name": "Masarova",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232352",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232352",
"events_session": "A phase Ib",
"rest_events_session_count": 1,
"rest_events_session": " open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib",
"events_topic": "Ruxolitinib | Primary Myelofibrosis",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1932583119,'424878');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMasarova, Lucia",
"kol_full_name": "Masarova, Lucia"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Paclitaxel | Thymoma | Ramucirumab | Carboplatin",
"npi_num": "1932291739",
"hcp_pin_alias": "424876",
"session_name": "S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424876",
"first_name": "Anne",
"middle_name": "",
"last_name": "Tsao",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232251",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232251",
"events_session": "S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced",
"rest_events_session_count": 2,
"rest_events_session": " recurrent, or metastatic thymic carcinoma",
"events_topic": "Paclitaxel | Thymoma ",
"rest_events_topic_count": 2,
"rest_events_topic": " Ramucirumab | Carboplatin",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1932291739,'424876');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETsao, Anne",
"kol_full_name": "Tsao, Anne"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1932262458",
"hcp_pin_alias": "424874",
"session_name": "Presentation of Awards and the Fellows of the American Society of Clinical Oncology (FASCO)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424874",
"first_name": "Everett",
"middle_name": "E",
"last_name": "Vokes",
"org_name": "The University of Chicago Medical Center",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232940",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232940",
"events_session": "Presentation of Awards and the Fellows of the American Society of Clinical Oncology (FASCO)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1932262458,'424874');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVokes, Everett E",
"kol_full_name": "Vokes, Everett E"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Precision Medicine | Brain Neoplasms | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1932236395",
"hcp_pin_alias": "424873",
"session_name": "Lung Cancer – Non-Small Cell Metastatc: Program Commitee,Has the Revolution in Precision Medicine Reached Patients With Brain Metastases?,Lung Cancer—Non-Small Cell Metastatic,Navigating the Complexities of Brain Metastases Management",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424873",
"first_name": "Sarah",
"middle_name": "B",
"last_name": "Goldberg",
"org_name": "Yale University",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232056",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232056",
"events_session": "Lung Cancer – Non-Small Cell Metastatc: Program Commitee",
"rest_events_session_count": 3,
"rest_events_session": "Has the Revolution in Precision Medicine Reached Patients With Brain Metastases?,Lung Cancer—Non-Small Cell Metastatic,Navigating the Complexities of Brain Metastases Management",
"events_topic": "Precision Medicine | Brain Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Carcinoma, Non-Small-Cell Lung",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1932236395,'424873');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGoldberg, Sarah B",
"kol_full_name": "Goldberg, Sarah B"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Vepdegestrant | Triple Negative Breast Neoplasms",
"npi_num": "1932135290",
"hcp_pin_alias": "424869",
"session_name": "TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424869",
"first_name": "Melinda",
"middle_name": "L",
"last_name": "Telli",
"org_name": "Stanford Health Care",
"Country": "United States",
"Region": "California",
"City": "Stanford",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232713",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232713",
"events_session": "TACTIVE-K: Phase 1b/2 study of vepdegestrant",
"rest_events_session_count": 4,
"rest_events_session": " a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer",
"events_topic": "Vepdegestrant | Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1932135290,'424869');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETelli, Melinda L",
"kol_full_name": "Telli, Melinda L"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Translational Research, Biomedical | Social Media",
"npi_num": "1912350596",
"hcp_pin_alias": "424863",
"session_name": "How Social Media Advances Research and Promotes Professional Development",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424863",
"first_name": "Gilberto",
"middle_name": "",
"last_name": "Lopes",
"org_name": "University of Miami Leonard M. Miller School of Medicine",
"Country": "United States",
"Region": "Florida",
"City": "Miami",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232783",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232783",
"events_session": "How Social Media Advances Research and Promotes Professional Development",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Translational Research, Biomedical | Social Media",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1912350596,'424863');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELopes, Gilberto",
"kol_full_name": "Lopes, Gilberto"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Human Papillomavirus Viruses | Squamous Cell Carcinoma Of Head And Neck | Chemotherapy, Adjuvant | Circulating Tumor DNA | Pembrolizumab",
"npi_num": "1912184763",
"hcp_pin_alias": "424860",
"session_name": "A phase II trial of reirradiation combined with pembrolizumab in patients with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (HNSCC),Circulating Tumor HPV DNA and Risk-Adapted Adjuvant Therapy: Is It Ready for Prime Time?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424860",
"first_name": "Dan",
"middle_name": "Paul",
"last_name": "Zandberg",
"org_name": "University of Pittsburgh School of Medicine",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Pittsburgh",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232142",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232142",
"events_session": "A phase II trial of reirradiation combined with pembrolizumab in patients with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (HNSCC)",
"rest_events_session_count": 1,
"rest_events_session": "Circulating Tumor HPV DNA and Risk-Adapted Adjuvant Therapy: Is It Ready for Prime Time?",
"events_topic": "Human Papillomavirus Viruses | Squamous Cell Carcinoma Of Head And Neck ",
"rest_events_topic_count": 3,
"rest_events_topic": " Chemotherapy, Adjuvant | Circulating Tumor DNA | Pembrolizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1912184763,'424860');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EZandberg, Dan Paul",
"kol_full_name": "Zandberg, Dan Paul"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Interleukin-2 | Immune Checkpoint Inhibitors | Melanoma | Lymphocytes, Tumor-Infiltrating",
"npi_num": "1912053596",
"hcp_pin_alias": "424858",
"session_name": "OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424858",
"first_name": "Rodabe",
"middle_name": "",
"last_name": "Amaria",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232326",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232326",
"events_session": "OBX-115",
"rest_events_session_count": 2,
"rest_events_session": " an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma",
"events_topic": "Interleukin-2 | Immune Checkpoint Inhibitors ",
"rest_events_topic_count": 2,
"rest_events_topic": " Melanoma | Lymphocytes, Tumor-Infiltrating",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1912053596,'424858');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAmaria, Rodabe",
"kol_full_name": "Amaria, Rodabe"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Head And Neck Neoplasms",
"npi_num": "1902159148",
"hcp_pin_alias": "424849",
"session_name": "Head and Neck Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424849",
"first_name": "Renata",
"middle_name": "",
"last_name": "Ferrarotto",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232016",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232016",
"events_session": "Head and Neck Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Head And Neck Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1902159148,'424849');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFerrarotto, Renata",
"kol_full_name": "Ferrarotto, Renata"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Tebentafusp | Circulating Tumor DNA",
"npi_num": "1881696003",
"hcp_pin_alias": "424837",
"session_name": "Use of baseline and serial ctDNA dynamics to predict outcomes in patients treated with first-line tebentafusp, including those who were and were not treated beyond progression",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424837",
"first_name": "Ryan",
"middle_name": "J",
"last_name": "Sullivan",
"org_name": "Massachusetts General Physicians Organization Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232790",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232790",
"events_session": "Use of baseline and serial ctDNA dynamics to predict outcomes in patients treated with first-line tebentafusp",
"rest_events_session_count": 1,
"rest_events_session": " including those who were and were not treated beyond progression",
"events_topic": "Tebentafusp | Circulating Tumor DNA",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1881696003,'424837');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESullivan, Ryan J",
"kol_full_name": "Sullivan, Ryan J"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Trastuzumab | Therapeutics | Triple Negative Breast Neoplasms | Neratinib | Neoplasms | Drug Development",
"npi_num": "1871822288",
"hcp_pin_alias": "424833",
"session_name": "Developmental Therapeutcs – Molecularly Targeted Agents: Program Commitee,Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial,Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424833",
"first_name": "Komal",
"middle_name": "",
"last_name": "Jhaveri",
"org_name": "Memorial Solid Tumor Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232065",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232065",
"events_session": "Developmental Therapeutcs – Molecularly Targeted Agents: Program Commitee",
"rest_events_session_count": 3,
"rest_events_session": "Efficacy and genomic analysis of HER2-mutant, metastatic triple-negative breast cancer treated with neratinib alone or in combination with trastuzumab in the phase 2 SUMMIT basket trial,Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology",
"events_topic": "Trastuzumab | Therapeutics ",
"rest_events_topic_count": 4,
"rest_events_topic": " Triple Negative Breast Neoplasms | Neratinib | Neoplasms | Drug Development",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1871822288,'424833');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJhaveri, Komal",
"kol_full_name": "Jhaveri, Komal"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Melanoma, Cutaneous Malignant | Carcinoma, Non-Small-Cell Lung | Pembrolizumab | Brentuximab Vedotin",
"npi_num": "1871756163",
"hcp_pin_alias": "424830",
"session_name": "Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with previously treated metastatic non-small cell lung cancer (NSCLC) or cutaneous melanoma (SGN35-033): Overall survival",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424830",
"first_name": "Yousef",
"middle_name": "",
"last_name": "Zakharia",
"org_name": "State University of Iowa",
"Country": "United States",
"Region": "Iowa",
"City": "Iowa City",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233014",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233014",
"events_session": "Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with previously treated metastatic non-small cell lung cancer (NSCLC) or cutaneous melanoma (SGN35-033): Overall survival",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Melanoma, Cutaneous Malignant | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 2,
"rest_events_topic": " Pembrolizumab | Brentuximab Vedotin",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1871756163,'424830');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EZakharia, Yousef",
"kol_full_name": "Zakharia, Yousef"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Dabrafenib | Proto-Oncogene Proteins B-raf | Trametinib",
"npi_num": "1871744490",
"hcp_pin_alias": "424829",
"session_name": "Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424829",
"first_name": "April",
"middle_name": "K.S.",
"last_name": "Salama",
"org_name": "Private Diagnostic Clinic, PLLC",
"Country": "United States",
"Region": "North Carolina",
"City": "Chapel Hill",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232960",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232960",
"events_session": "Dabrafenib and trametinib in patients with tumors with BRAF V600E/k mutations: Updated results from NCI-MATCH arm H",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Dabrafenib | Proto-Oncogene Proteins B-raf ",
"rest_events_topic_count": 1,
"rest_events_topic": " Trametinib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1871744490,'424829');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESalama, April K.S.",
"kol_full_name": "Salama, April K.S."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1861420291",
"hcp_pin_alias": "424805",
"session_name": "Breast Cancer—Metastatic",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424805",
"first_name": "Antonio",
"middle_name": "",
"last_name": "Wolff",
"org_name": "Johns Hopkins University",
"Country": "United States",
"Region": "Maryland",
"City": "Columbia",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232720",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232720",
"events_session": "Breast Cancer—Metastatic",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1861420291,'424805');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWolff, Antonio",
"kol_full_name": "Wolff, Antonio"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy | Pembrolizumab | Human Papillomavirus 16 | Head And Neck Neoplasms",
"npi_num": "1851567879",
"hcp_pin_alias": "424802",
"session_name": "HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424802",
"first_name": "Alan",
"middle_name": "Loh",
"last_name": "Ho",
"org_name": "Memorial Solid Tumor Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232100",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232100",
"events_session": "HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunotherapy | Pembrolizumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Human Papillomavirus 16 | Head And Neck Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1851567879,'424802');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHo, Alan Loh",
"kol_full_name": "Ho, Alan Loh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Atezolizumab | Carcinoma, Hepatocellular | Immunotherapy | Bevacizumab",
"npi_num": "1851485056",
"hcp_pin_alias": "424799",
"session_name": "An open-label, multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424799",
"first_name": "Kevin",
"middle_name": "B.",
"last_name": "Kim",
"org_name": "",
"Country": "United States",
"Region": "California",
"City": "San Francisco",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232855",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232855",
"events_session": "An open-label",
"rest_events_session_count": 1,
"rest_events_session": " multicenter study investigating RP2 oncolytic immunotherapy in combination with second-line systemic atezolizumab combined with bevacizumab in patients with locally advanced unresectable or metastatic hepatocellular carcinoma",
"events_topic": "Atezolizumab | Carcinoma, Hepatocellular ",
"rest_events_topic_count": 2,
"rest_events_topic": " Immunotherapy | Bevacizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1851485056,'424799');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKim, Kevin B.",
"kol_full_name": "Kim, Kevin B."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms",
"npi_num": "1831393883",
"hcp_pin_alias": "424780",
"session_name": "Novel Therapies in Metastatic Colorectal Cancer: Where Is the Field Heading?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424780",
"first_name": "Dustin",
"middle_name": "A",
"last_name": "Deming",
"org_name": "University of Wisconsin Medical Foundation Inc",
"Country": "United States",
"Region": "Wisconsin",
"City": "Windsor",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232747",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232747",
"events_session": "Novel Therapies in Metastatic Colorectal Cancer: Where Is the Field Heading?",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colorectal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1831393883,'424780');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDeming, Dustin A",
"kol_full_name": "Deming, Dustin A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Myelodysplastic Syndromes | Hematologic Neoplasms | Leukemia",
"npi_num": "1831391200",
"hcp_pin_alias": "424778",
"session_name": "Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424778",
"first_name": "Jessica",
"middle_name": "Kaplan",
"last_name": "Altman",
"org_name": "Northwestern Medical Faculty Foundation",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232449",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232449",
"events_session": "Hematologic Malignancies—Leukemia",
"rest_events_session_count": 2,
"rest_events_session": " Myelodysplastic Syndromes, and Allotransplant",
"events_topic": "Myelodysplastic Syndromes | Hematologic Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Leukemia",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1831391200,'424778');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAltman, Jessica Kaplan",
"kol_full_name": "Altman, Jessica Kaplan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Interleukin-2 | Immune Checkpoint Inhibitors | Melanoma | Nivolumab | Ipilimumab | Immunotherapy",
"npi_num": "1811934755",
"hcp_pin_alias": "424764",
"session_name": "A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) as a predictor of ICI immunotherapeutic benefits,High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424764",
"first_name": "Ahmad",
"middle_name": "",
"last_name": "Tarhini",
"org_name": "H. Lee Moffitt Cancer Center & Research Institute",
"Country": "United States",
"Region": "Florida",
"City": "Tampa",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232793",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232793",
"events_session": "A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) as a predictor of ICI immunotherapeutic benefits",
"rest_events_session_count": 1,
"rest_events_session": "High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition",
"events_topic": "Interleukin-2 | Immune Checkpoint Inhibitors ",
"rest_events_topic_count": 4,
"rest_events_topic": " Melanoma | Nivolumab | Ipilimumab | Immunotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1811934755,'424764');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETarhini, Ahmad",
"kol_full_name": "Tarhini, Ahmad"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms",
"npi_num": "1801829114",
"hcp_pin_alias": "424750",
"session_name": "Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424750",
"first_name": "Denise",
"middle_name": "A",
"last_name": "Yardley",
"org_name": "Tennessee Oncology",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233131",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233131",
"events_session": "Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1801829114,'424750');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYardley, Denise A",
"kol_full_name": "Yardley, Denise A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Admin. & Management | Neoplasms",
"npi_num": "1801068366",
"hcp_pin_alias": "424746",
"session_name": "Pediatric Oncology: Program Commitee,Pediatric Oncology",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424746",
"first_name": "Damon",
"middle_name": "R",
"last_name": "Reed",
"org_name": "H. Lee Moffitt Cancer Center & Research Institute",
"Country": "United States",
"Region": "Florida",
"City": "Tampa",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231994",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231994",
"events_session": "Pediatric Oncology: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Pediatric Oncology",
"events_topic": "Admin. & Management | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1801068366,'424746');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EReed, Damon R",
"kol_full_name": "Reed, Damon R"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Multiple Myeloma | Iberdomide | Elranatamab",
"npi_num": "1790950863",
"hcp_pin_alias": "424742",
"session_name": "MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424742",
"first_name": "Alexander",
"middle_name": "M",
"last_name": "Lesokhin",
"org_name": "Memorial Developmental Chemo Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232367",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232367",
"events_session": "MagnetisMM-30: A phase 1b",
"rest_events_session_count": 1,
"rest_events_session": " open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM)",
"events_topic": "Multiple Myeloma | Iberdomide ",
"rest_events_topic_count": 1,
"rest_events_topic": " Elranatamab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790950863,'424742');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELesokhin, Alexander M",
"kol_full_name": "Lesokhin, Alexander M"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Stereotaxic Techniques | Glioblastoma",
"npi_num": "1790869691",
"hcp_pin_alias": "424737",
"session_name": "Longitudinal stereotactic injections of oncolytic immunoactivating rQNestin345v2 (CAN-3110) with concomitant biopsies for “-omic” analyses in recurrent glioblastoma (GBM)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424737",
"first_name": "David",
"middle_name": "Allen",
"last_name": "Reardon",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233085",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233085",
"events_session": "Longitudinal stereotactic injections of oncolytic immunoactivating rQNestin345v2 (CAN-3110) with concomitant biopsies for “-omic” analyses in recurrent glioblastoma (GBM)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Stereotaxic Techniques | Glioblastoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790869691,'424737');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EReardon, David Allen",
"kol_full_name": "Reardon, David Allen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Anthracyclines | Triple Negative Breast Neoplasms",
"npi_num": "1790727709",
"hcp_pin_alias": "424730",
"session_name": "Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424730",
"first_name": "Joyce",
"middle_name": "Ann",
"last_name": "O'shaughnessy",
"org_name": "Texas Oncology PA",
"Country": "United States",
"Region": "Texas",
"City": "Rowlett",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233130",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233130",
"events_session": "Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Chemotherapy | Anthracyclines ",
"rest_events_topic_count": 1,
"rest_events_topic": " Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790727709,'424730');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EO'shaughnessy, Joyce Ann",
"kol_full_name": "O'shaughnessy, Joyce Ann"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Frailty | Neoplasms",
"npi_num": "1770665580",
"hcp_pin_alias": "424716",
"session_name": "Association of frailty assessed by a ten-item frailty index (FI-CGA-10) with health-related quality of life in older adults with cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424716",
"first_name": "Hyman",
"middle_name": "B",
"last_name": "Muss",
"org_name": "UNC Physicians Network, LLC",
"Country": "United States",
"Region": "North Carolina",
"City": "Chapel Hill",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232393",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232393",
"events_session": "Association of frailty assessed by a ten-item frailty index (FI-CGA-10) with health-related quality of life in older adults with cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Frailty | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1770665580,'424716');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMuss, Hyman B",
"kol_full_name": "Muss, Hyman B"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Recurrence | Blood-Brain Barrier | Vaccines | Triple Negative Breast Neoplasms | Pembrolizumab | Nivolumab | Randomized Controlled Trials As Topic | Capecitabine | Ultrasonography | Temozolomide | Trastuzumab | Radiosurgery | Glioblastoma | Bevacizumab | Liquid Biopsy | Tucatinib",
"npi_num": "1760623557",
"hcp_pin_alias": "424711",
"session_name": "A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE),A prospective, multicenter trial of low-intensity focused ultrasound (LIFU) for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE),A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR),A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL),Phase 2 trial of pembrolizumab plus SurVaxM for patients with glioblastoma at first recurrence (RESURGe)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424711",
"first_name": "Manmeet",
"middle_name": "Singh",
"last_name": "Ahluwalia",
"org_name": "Cleveland Clinic Foundation",
"Country": "United States",
"Region": "Ohio",
"City": "Cleveland",
"num_sess": "5",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232519",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232519",
"events_session": "A multicenter",
"rest_events_session_count": 10,
"rest_events_session": " randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE),A prospective, multicenter trial of low-intensity focused ultrasound (LIFU) for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE),A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR),A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL),Phase 2 trial of pembrolizumab plus SurVaxM for patients with glioblastoma at first recurrence (RESURGe)",
"events_topic": "Recurrence | Blood-Brain Barrier ",
"rest_events_topic_count": 14,
"rest_events_topic": " Vaccines | Triple Negative Breast Neoplasms | Pembrolizumab | Nivolumab | Randomized Controlled Trials As Topic | Capecitabine | Ultrasonography | Temozolomide | Trastuzumab | Radiosurgery | Glioblastoma | Bevacizumab | Liquid Biopsy | Tucatinib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1760623557,'424711');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAhluwalia, Manmeet Singh",
"kol_full_name": "Ahluwalia, Manmeet Singh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Human Papillomavirus 16",
"npi_num": "1760436927",
"hcp_pin_alias": "424708",
"session_name": "Taking Our Best Shot: Targeting HPV-16",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424708",
"first_name": "Maura",
"middle_name": "L",
"last_name": "Gillison",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232101",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232101",
"events_session": "Taking Our Best Shot: Targeting HPV-16",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Human Papillomavirus 16",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1760436927,'424708');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGillison, Maura L",
"kol_full_name": "Gillison, Maura L"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Selpercatinib | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1750593844",
"hcp_pin_alias": "424703",
"session_name": "LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET+) NSCLC",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424703",
"first_name": "Jonathan",
"middle_name": "Wade",
"last_name": "Goldman",
"org_name": "Regents of The University of California",
"Country": "United States",
"Region": "California",
"City": "Los Angeles",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232252",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232252",
"events_session": "LIBRETTO-432: A phase 3 study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive (RET+) NSCLC",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Selpercatinib | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1750593844,'424703');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGoldman, Jonathan Wade",
"kol_full_name": "Goldman, Jonathan Wade"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Germinoma | Chemotherapy",
"npi_num": "1750552055",
"hcp_pin_alias": "424701",
"session_name": "Real-world evidence of overall survival (OS) and treatment patterns of patients (pts) with testicular germ cell tumors (GCT) receiving palliative chemotherapy in the United States",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424701",
"first_name": "Darren",
"middle_name": "Richard",
"last_name": "Feldman",
"org_name": "Memorial Solid Tumor Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232647",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232647",
"events_session": "Real-world evidence of overall survival (OS) and treatment patterns of patients (pts) with testicular germ cell tumors (GCT) receiving palliative chemotherapy in the United States",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Germinoma | Chemotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1750552055,'424701');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFeldman, Darren Richard",
"kol_full_name": "Feldman, Darren Richard"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Bromodomain Containing Proteins | Myeloproliferative Neoplasms",
"npi_num": "1750517959",
"hcp_pin_alias": "424700",
"session_name": "Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424700",
"first_name": "Justin",
"middle_name": "M.",
"last_name": "Watts",
"org_name": "University of Miami Leonard M. Miller School of Medicine",
"Country": "United States",
"Region": "Florida",
"City": "Miami",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232350",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232350",
"events_session": "Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Bromodomain Containing Proteins | Myeloproliferative Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1750517959,'424700');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWatts, Justin M.",
"kol_full_name": "Watts, Justin M."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Proto-Oncogene Proteins C-bcl-2 | Lymphoma, Large B-Cell, Diffuse",
"npi_num": "1740262484",
"hcp_pin_alias": "424685",
"session_name": "Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424685",
"first_name": "Jeremy",
"middle_name": "Slade",
"last_name": "Abramson",
"org_name": "Massachusetts General Physicians Organization Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232500",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232500",
"events_session": "Randomized phase II/III study of R-CHOP +/- venetoclax in previously untreated MYC/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Proto-Oncogene Proteins C-bcl-2 | Lymphoma, Large B-Cell, Diffuse",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1740262484,'424685');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAbramson, Jeremy Slade",
"kol_full_name": "Abramson, Jeremy Slade"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Enzalutamide | Mifepristone | Breast Neoplasms",
"npi_num": "1730285990",
"hcp_pin_alias": "424680",
"session_name": "TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424680",
"first_name": "Tiffany",
"middle_name": "A",
"last_name": "Traina",
"org_name": "Memorial Solid Tumor Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232716",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232716",
"events_session": "TBCRC 058: A randomized phase II study of enzalutamide",
"rest_events_session_count": 2,
"rest_events_session": " enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769)",
"events_topic": "Enzalutamide | Mifepristone ",
"rest_events_topic_count": 1,
"rest_events_topic": " Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1730285990,'424680');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETraina, Tiffany A",
"kol_full_name": "Traina, Tiffany A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatectomy | Radiotherapy | Enzalutamide",
"npi_num": "1720140270",
"hcp_pin_alias": "424670",
"session_name": "Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424670",
"first_name": "Edwin",
"middle_name": "",
"last_name": "Posadas",
"org_name": "Cedars-Sinai Medical Center",
"Country": "United States",
"Region": "California",
"City": "West Hollywood",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232664",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232664",
"events_session": "Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatectomy | Radiotherapy ",
"rest_events_topic_count": 1,
"rest_events_topic": " Enzalutamide",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1720140270,'424670');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPosadas, Edwin",
"kol_full_name": "Posadas, Edwin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Small Cell Lung Carcinoma | Brain Neoplasms | Immunotherapy",
"npi_num": "1710327721",
"hcp_pin_alias": "424658",
"session_name": "Developmental Therapeutcs – Immunotherapy: Program Commitee,Pushing the Envelope in Non–Small Cell Lung Cancer Brain Metastases",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424658",
"first_name": "Jarushka",
"middle_name": "",
"last_name": "Naidoo",
"org_name": "Johns Hopkins University",
"Country": "United States",
"Region": "Maryland",
"City": "Baltimore",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232460",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232460",
"events_session": "Developmental Therapeutcs – Immunotherapy: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Pushing the Envelope in Non–Small Cell Lung Cancer Brain Metastases",
"events_topic": "Small Cell Lung Carcinoma | Brain Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Immunotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1710327721,'424658');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENaidoo, Jarushka",
"kol_full_name": "Naidoo, Jarushka"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Thyroid Neoplasms | Larotrectinib",
"npi_num": "1710071204",
"hcp_pin_alias": "424653",
"session_name": "Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424653",
"first_name": "Maria",
"middle_name": "E.",
"last_name": "Cabanillas",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232569",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232569",
"events_session": "Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Thyroid Neoplasms | Larotrectinib",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1710071204,'424653');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECabanillas, Maria E.",
"kol_full_name": "Cabanillas, Maria E."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Non-Muscle Invasive Bladder Neoplasms | Erdafitinib | Pembrolizumab",
"npi_num": "1700979275",
"hcp_pin_alias": "424649",
"session_name": "FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs pembrolizumab (pembro)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424649",
"first_name": "Arlene",
"middle_name": "O.",
"last_name": "Siefker-Radtke",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232597",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232597",
"events_session": "FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC)",
"rest_events_session_count": 1,
"rest_events_session": " and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs pembrolizumab (pembro)",
"events_topic": "Non-Muscle Invasive Bladder Neoplasms | Erdafitinib ",
"rest_events_topic_count": 1,
"rest_events_topic": " Pembrolizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700979275,'424649');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESiefker-Radtke, Arlene O.",
"kol_full_name": "Siefker-Radtke, Arlene O."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Emavusertib | Leukemia, Myeloid, Acute",
"npi_num": "1700854718",
"hcp_pin_alias": "424645",
"session_name": "Preliminary safety, efficacy and molecular characterization of emavusertib (CA-4948) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation (FLT3m)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424645",
"first_name": "Eric",
"middle_name": "P.",
"last_name": "Winer",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232339",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232339",
"events_session": "Preliminary safety",
"rest_events_session_count": 1,
"rest_events_session": " efficacy and molecular characterization of emavusertib (CA-4948) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation (FLT3m)",
"events_topic": "Emavusertib | Leukemia, Myeloid, Acute",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700854718,'424645');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWiner, Eric P.",
"kol_full_name": "Winer, Eric P."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Myelodysplastic Syndromes | Hematologic Neoplasms | Hematopoietic Stem Cell Transplantation | Leukemia, Myeloid, Acute | Palliative Care",
"npi_num": "1699901199",
"hcp_pin_alias": "424638",
"session_name": "Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy,Randomized trial of a multimodal intervention to enhance sexual function and quality of life (QOL) in hematopoietic stem cell transplant (HSCT) survivors,Understanding the Evidence: Can Palliative Care and Hematologic Malignancies Coexist?,Integrating Palliative Care and Hematologic Malignancies: Bridging the Gap for Our Patients",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424638",
"first_name": "Areej",
"middle_name": "R",
"last_name": "El-Jawahri",
"org_name": "Massachusetts General Physicians Organization Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "4",
"opt_in_out_status": "0",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231999",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231999",
"events_session": "Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy",
"rest_events_session_count": 3,
"rest_events_session": "Randomized trial of a multimodal intervention to enhance sexual function and quality of life (QOL) in hematopoietic stem cell transplant (HSCT) survivors,Understanding the Evidence: Can Palliative Care and Hematologic Malignancies Coexist?,Integrating Palliative Care and Hematologic Malignancies: Bridging the Gap for Our Patients",
"events_topic": "Myelodysplastic Syndromes | Hematologic Neoplasms ",
"rest_events_topic_count": 3,
"rest_events_topic": " Hematopoietic Stem Cell Transplantation | Leukemia, Myeloid, Acute | Palliative Care",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1699901199,'424638');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEl-Jawahri, Areej R",
"kol_full_name": "El-Jawahri, Areej R"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab | Gastrointestinal Neoplasms",
"npi_num": "1699706812",
"hcp_pin_alias": "424631",
"session_name": "Efficacy, safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a phase Ib dose expansion in resistant NSCLC, melanoma, and GI malignancy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424631",
"first_name": "Adil",
"middle_name": "",
"last_name": "Daud",
"org_name": "UCSF Medical Center",
"Country": "United States",
"Region": "California",
"City": "San Francisco",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232999",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232999",
"events_session": "Efficacy",
"rest_events_session_count": 6,
"rest_events_session": " safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a phase Ib dose expansion in resistant NSCLC, melanoma, and GI malignancy",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Gastrointestinal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1699706812,'424631');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDaud, Adil",
"kol_full_name": "Daud, Adil"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1689879967",
"hcp_pin_alias": "424628",
"session_name": "Presenter Share: Balancing Leadership Responsibilities and Personal Academic Goals",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424628",
"first_name": "Pavani",
"middle_name": "",
"last_name": "Chalasani",
"org_name": "Banner - University Medical Center Phoenix",
"Country": "United States",
"Region": "Arizona",
"City": "Tucson",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233101",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233101",
"events_session": "Presenter Share: Balancing Leadership Responsibilities and Personal Academic Goals",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1689879967,'424628');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChalasani, Pavani",
"kol_full_name": "Chalasani, Pavani"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Early Detection Of Cancer",
"npi_num": "1669487179",
"hcp_pin_alias": "424604",
"session_name": "Pioneering a Paradigm Shift in Cancer Screening: The Era of Multi-Cancer Early Detection Testing",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424604",
"first_name": "Tomasz",
"middle_name": "M.",
"last_name": "Beer",
"org_name": "Oregon Health & Science University",
"Country": "United States",
"Region": "Oregon",
"City": "Portland",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233158",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233158",
"events_session": "Pioneering a Paradigm Shift in Cancer Screening: The Era of Multi-Cancer Early Detection Testing",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Early Detection Of Cancer",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1669487179,'424604');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBeer, Tomasz M.",
"kol_full_name": "Beer, Tomasz M."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Giredestrant | Triple Negative Breast Neoplasms | Abemaciclib | Cyclin-Dependent Kinase 4 | Anti-Mullerian Hormone | Fulvestrant | Endocrine Therapy | Premenopause | Breast Neoplasms | Chemotherapy, Adjuvant",
"npi_num": "1669430310",
"hcp_pin_alias": "424601",
"session_name": "Breast Cancer – Local/Regional/Adjuvant: Program Commitee,Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial,pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2– locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET),Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424601",
"first_name": "Kevin",
"middle_name": "M",
"last_name": "Kalinsky",
"org_name": "Trustees of Columbia University in the City of New York",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232147",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232147",
"events_session": "Breast Cancer – Local/Regional/Adjuvant: Program Commitee",
"rest_events_session_count": 9,
"rest_events_session": "Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial,pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2– locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET),Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER)",
"events_topic": "Giredestrant | Triple Negative Breast Neoplasms ",
"rest_events_topic_count": 8,
"rest_events_topic": " Abemaciclib | Cyclin-Dependent Kinase 4 | Anti-Mullerian Hormone | Fulvestrant | Endocrine Therapy | Premenopause | Breast Neoplasms | Chemotherapy, Adjuvant",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1669430310,'424601');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKalinsky, Kevin M",
"kol_full_name": "Kalinsky, Kevin M"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunoconjugates | Breast Neoplasms",
"npi_num": "1669425286",
"hcp_pin_alias": "424600",
"session_name": "SV-BR-1-GM after progression on ADC in patients with metastatic breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424600",
"first_name": "Chaitali",
"middle_name": "",
"last_name": "Nangia",
"org_name": "John Lee MD and Leonard Sender MD Inc",
"Country": "United States",
"Region": "California",
"City": "Costa Mesa",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232697",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232697",
"events_session": "SV-BR-1-GM after progression on ADC in patients with metastatic breast cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunoconjugates | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1669425286,'424600');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENangia, Chaitali",
"kol_full_name": "Nangia, Chaitali"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Delivery Of Health Care | Admin. & Management | Neoplasms",
"npi_num": "1669422143",
"hcp_pin_alias": "424598",
"session_name": "Care Delivery/Models of Care: Program Commitee,Care Delivery/Models of Care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424598",
"first_name": "Ray",
"middle_name": "",
"last_name": "Page",
"org_name": "Oncology-Hematology Consultants Pa",
"Country": "United States",
"Region": "Texas",
"City": "Weatherford",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232018",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232018",
"events_session": "Care Delivery/Models of Care: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Care Delivery/Models of Care",
"events_topic": "Delivery Of Health Care | Admin. & Management ",
"rest_events_topic_count": 1,
"rest_events_topic": " Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1669422143,'424598');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPage, Ray",
"kol_full_name": "Page, Ray"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Non-Muscle Invasive Bladder Neoplasms | Castration | Proteolysis Targeting Chimera | Prostatic Neoplasms | Enfortumab Vedotin | Receptors, Androgen",
"npi_num": "1659387306",
"hcp_pin_alias": "424591",
"session_name": "Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer,ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424591",
"first_name": "Daniel",
"middle_name": "Peter",
"last_name": "Petrylak",
"org_name": "Yale University",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232283",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232283",
"events_session": "Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer",
"rest_events_session_count": 3,
"rest_events_session": "ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study",
"events_topic": "Non-Muscle Invasive Bladder Neoplasms | Castration ",
"rest_events_topic_count": 4,
"rest_events_topic": " Proteolysis Targeting Chimera | Prostatic Neoplasms | Enfortumab Vedotin | Receptors, Androgen",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1659387306,'424591');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPetrylak, Daniel Peter",
"kol_full_name": "Petrylak, Daniel Peter"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nervous System Diseases | Intracranial Pressure",
"npi_num": "1649410036",
"hcp_pin_alias": "424587",
"session_name": "Novel non-invasive method for measuring intracranial pressure for drug delivery and other neurologic disorders",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424587",
"first_name": "Priya",
"middle_name": "Uday",
"last_name": "Kumthekar",
"org_name": "Northwestern Medical Faculty Foundation",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233068",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233068",
"events_session": "Novel non-invasive method for measuring intracranial pressure for drug delivery and other neurologic disorders",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Nervous System Diseases | Intracranial Pressure",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1649410036,'424587');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKumthekar, Priya Uday",
"kol_full_name": "Kumthekar, Priya Uday"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Delivery Of Health Care | Clinical Trials As Topic | Admin. & Management",
"npi_num": "1649359530",
"hcp_pin_alias": "424586",
"session_name": "Care Delivery/Models of Care: Program Commitee,Risk prediction model for acute care use among patients with advanced cancer on clinical trials",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424586",
"first_name": "Dawn",
"middle_name": "Lauryn",
"last_name": "Hershman",
"org_name": "Trustees of Columbia University in the City of New York",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232401",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232401",
"events_session": "Care Delivery/Models of Care: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Risk prediction model for acute care use among patients with advanced cancer on clinical trials",
"events_topic": "Neoplasms | Delivery Of Health Care ",
"rest_events_topic_count": 2,
"rest_events_topic": " Clinical Trials As Topic | Admin. & Management",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1649359530,'424586');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHershman, Dawn Lauryn",
"kol_full_name": "Hershman, Dawn Lauryn"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ramucirumab | Carcinoma, Non-Small-Cell Lung | Pembrolizumab | Immunotherapy",
"npi_num": "1649290248",
"hcp_pin_alias": "424583",
"session_name": "SWOG S2302, PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424583",
"first_name": "Karen",
"middle_name": "Lynn",
"last_name": "Reckamp",
"org_name": "City of Hope Medical Foundation",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232196",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232196",
"events_session": "SWOG S2302",
"rest_events_session_count": 1,
"rest_events_session": " PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (PR) versus standard of care (SOC) for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer",
"events_topic": "Ramucirumab | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 2,
"rest_events_topic": " Pembrolizumab | Immunotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1649290248,'424583');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EReckamp, Karen Lynn",
"kol_full_name": "Reckamp, Karen Lynn"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Letrozole | Endometrial Neoplasms | Abemaciclib | Circulating Tumor DNA",
"npi_num": "1649218942",
"hcp_pin_alias": "424580",
"session_name": "Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424580",
"first_name": "Panagiotis",
"middle_name": "",
"last_name": "Konstantinopoulos",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232434",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232434",
"events_session": "Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Letrozole | Endometrial Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Abemaciclib | Circulating Tumor DNA",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1649218942,'424580');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKonstantinopoulos, Panagiotis",
"kol_full_name": "Konstantinopoulos, Panagiotis"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Interleukin-3 Receptor Alpha Subunit | Hematologic Neoplasms",
"npi_num": "1639226517",
"hcp_pin_alias": "424575",
"session_name": "An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics of VIP943 monotherapy in patients with advanced CD123+ hematologic malignancies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424575",
"first_name": "Stephen",
"middle_name": "Anthony",
"last_name": "Strickland",
"org_name": "Vanderbilt University Medical Center",
"Country": "United States",
"Region": "Tennessee",
"City": "Franklin",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232975",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232975",
"events_session": "An open-label",
"rest_events_session_count": 5,
"rest_events_session": " multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics of VIP943 monotherapy in patients with advanced CD123+ hematologic malignancies",
"events_topic": "Interleukin-3 Receptor Alpha Subunit | Hematologic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1639226517,'424575');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EStrickland, Stephen Anthony",
"kol_full_name": "Strickland, Stephen Anthony"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "DNA Damage | Sacituzumab Govitecan | Immunoconjugates | Biomarkers | Triple Negative Breast Neoplasms | Receptor, Epidermal Growth Factor",
"npi_num": "1639210107",
"hcp_pin_alias": "424573",
"session_name": "An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC),Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424573",
"first_name": "Aditya",
"middle_name": "",
"last_name": "Bardia",
"org_name": "Massachusetts General Physicians Organization Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232693",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232693",
"events_session": "An open-label",
"rest_events_session_count": 5,
"rest_events_session": " multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC),Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study",
"events_topic": "DNA Damage | Sacituzumab Govitecan ",
"rest_events_topic_count": 4,
"rest_events_topic": " Immunoconjugates | Biomarkers | Triple Negative Breast Neoplasms | Receptor, Epidermal Growth Factor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1639210107,'424573');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBardia, Aditya",
"kol_full_name": "Bardia, Aditya"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Central Nervous System Neoplasms",
"npi_num": "1629137161",
"hcp_pin_alias": "424566",
"session_name": "Central Nervous System Tumors: Program Commitee,Central Nervous System Tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424566",
"first_name": "Steven",
"middle_name": "",
"last_name": "Chmura",
"org_name": "University Of Chicago Medical Center",
"Country": "United States",
"Region": "Illinois",
"City": "Orland Park",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232014",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232014",
"events_session": "Central Nervous System Tumors: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Central Nervous System Tumors",
"events_topic": "Central Nervous System Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1629137161,'424566');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChmura, Steven",
"kol_full_name": "Chmura, Steven"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Paraproteinemias | Hematologic Neoplasms",
"npi_num": "1609918556",
"hcp_pin_alias": "424554",
"session_name": "Hematologic Malignancies—Plasma Cell Dyscrasia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424554",
"first_name": "Michaela",
"middle_name": "",
"last_name": "Liedtke",
"org_name": "Stanford Health Care",
"Country": "United States",
"Region": "California",
"City": "Stanford",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231967",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231967",
"events_session": "Hematologic Malignancies—Plasma Cell Dyscrasia",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Paraproteinemias | Hematologic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1609918556,'424554');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELiedtke, Michaela",
"kol_full_name": "Liedtke, Michaela"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy, Adoptive | Lymphoma, Large B-Cell, Diffuse",
"npi_num": "1609085356",
"hcp_pin_alias": "424552",
"session_name": "Phase 2 open label, multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424552",
"first_name": "Armin",
"middle_name": "",
"last_name": "Ghobadi",
"org_name": "Washington University",
"Country": "United States",
"Region": "Missouri",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232385",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232385",
"events_session": "Phase 2 open label",
"rest_events_session_count": 3,
"rest_events_session": " multicenter study evaluating CRG-022, a CD22-directed autologous CAR T-cell therapy, in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after CD19-directed CAR T-cell therapy",
"events_topic": "Immunotherapy, Adoptive | Lymphoma, Large B-Cell, Diffuse",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1609085356,'424552');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGhobadi, Armin",
"kol_full_name": "Ghobadi, Armin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Immunotherapy",
"npi_num": "1609039148",
"hcp_pin_alias": "424549",
"session_name": "Timing of immunotherapy in stage IV non-small cell lung cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424549",
"first_name": "Takefumi",
"middle_name": "",
"last_name": "Komiya",
"org_name": "Parkview Health System Inc",
"Country": "United States",
"Region": "Indiana",
"City": "Fort Wayne",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232163",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232163",
"events_session": "Timing of immunotherapy in stage IV non-small cell lung cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Immunotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1609039148,'424549');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKomiya, Takefumi",
"kol_full_name": "Komiya, Takefumi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Palbociclib | Triple Negative Breast Neoplasms",
"npi_num": "1598965972",
"hcp_pin_alias": "424546",
"session_name": "Impact of prior anticancer treatments on palbociclib (PAL) clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) in real-world settings",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424546",
"first_name": "Gabrielle",
"middle_name": "B",
"last_name": "Rocque",
"org_name": "University Of Alabama Health Services Foundation, Pc",
"Country": "United States",
"Region": "Alabama",
"City": "Birmingham",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232685",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232685",
"events_session": "Impact of prior anticancer treatments on palbociclib (PAL) clinical outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) in real-world settings",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Palbociclib | Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1598965972,'424546');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERocque, Gabrielle B",
"kol_full_name": "Rocque, Gabrielle B"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1598851198",
"hcp_pin_alias": "424542",
"session_name": "Pathological complete response to predict long term outcomes in the I-SPY2 TRIAL",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424542",
"first_name": "Douglas",
"middle_name": "",
"last_name": "Yee",
"org_name": "Fairview Health Services",
"Country": "United States",
"Region": "Minnesota",
"City": "Minneapolis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232632",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232632",
"events_session": "Pathological complete response to predict long term outcomes in the I-SPY2 TRIAL",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1598851198,'424542');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYee, Douglas",
"kol_full_name": "Yee, Douglas"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Larotrectinib | Repotrectinib | Lung Neoplasms",
"npi_num": "1578876876",
"hcp_pin_alias": "424523",
"session_name": "Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer,Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424523",
"first_name": "Alexander Edward",
"middle_name": "Dela Cruz",
"last_name": "Drilon",
"org_name": "Memorial Solid Tumor Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232160",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232160",
"events_session": "Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer",
"rest_events_session_count": 2,
"rest_events_session": "Repotrectinib in tyrosine kinase inhibitor (TKI)-naïve patients (pts) with advanced ROS1 fusion-positive (ROS1+) NSCLC in the phase 1/2 TRIDENT-1 trial: Clinical update, treatment beyond progression and subsequent therapies",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Larotrectinib ",
"rest_events_topic_count": 2,
"rest_events_topic": " Repotrectinib | Lung Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1578876876,'424523');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDrilon, Alexander Edward Dela Cruz",
"kol_full_name": "Drilon, Alexander Edward Dela Cruz"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Small Cell Lung Carcinoma | Alisertib | Ifinatamab Deruxtecan",
"npi_num": "1578770871",
"hcp_pin_alias": "424521",
"session_name": "Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study,IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424521",
"first_name": "Taofeek",
"middle_name": "Kunkle",
"last_name": "Owonikoko",
"org_name": "The Emory Clinic, Inc",
"Country": "United States",
"Region": "Georgia",
"City": "Atlanta",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232256",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232256",
"events_session": "Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study",
"rest_events_session_count": 3,
"rest_events_session": "IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC)",
"events_topic": "Small Cell Lung Carcinoma | Alisertib ",
"rest_events_topic_count": 1,
"rest_events_topic": " Ifinatamab Deruxtecan",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1578770871,'424521');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EOwonikoko, Taofeek Kunkle",
"kol_full_name": "Owonikoko, Taofeek Kunkle"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Squamous Cell | Enfortumab Vedotin | Penile Neoplasms",
"npi_num": "1568553311",
"hcp_pin_alias": "424510",
"session_name": "A phase II trial of enfortumab vedotin for locally advanced and metastatic squamous cell carcinoma of the penis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424510",
"first_name": "Lance",
"middle_name": "C.",
"last_name": "Pagliaro",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232666",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232666",
"events_session": "A phase II trial of enfortumab vedotin for locally advanced and metastatic squamous cell carcinoma of the penis",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Squamous Cell | Enfortumab Vedotin ",
"rest_events_topic_count": 1,
"rest_events_topic": " Penile Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1568553311,'424510');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPagliaro, Lance C.",
"kol_full_name": "Pagliaro, Lance C."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy | Adrenal Insufficiency | Breast Neoplasms",
"npi_num": "1568524015",
"hcp_pin_alias": "424505",
"session_name": "Breast Cancer – Metastatc:: Program Commitee,Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424505",
"first_name": "Rita",
"middle_name": "",
"last_name": "Nanda",
"org_name": "The University of Chicago Medical Center",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232630",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232630",
"events_session": "Breast Cancer – Metastatc:: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial",
"events_topic": "Immunotherapy | Adrenal Insufficiency ",
"rest_events_topic_count": 1,
"rest_events_topic": " Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1568524015,'424505');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENanda, Rita",
"kol_full_name": "Nanda, Rita"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Induction Chemotherapy | Oropharyngeal Neoplasms | Human Papillomavirus Viruses | Hypoxia",
"npi_num": "1568406445",
"hcp_pin_alias": "424500",
"session_name": "Induction chemotherapy effects on very advanced (T3/T4) human papillomavirus-related oropharyngeal cancer for participation in hypoxia-directed major de-escalation (30 Gy) definitive treatment trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424500",
"first_name": "Eric",
"middle_name": "J",
"last_name": "Sherman",
"org_name": "Memorial Solid Tumor Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232563",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232563",
"events_session": "Induction chemotherapy effects on very advanced (T3/T4) human papillomavirus-related oropharyngeal cancer for participation in hypoxia-directed major de-escalation (30 Gy) definitive treatment trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Induction Chemotherapy | Oropharyngeal Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Human Papillomavirus Viruses | Hypoxia",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1568406445,'424500');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESherman, Eric J",
"kol_full_name": "Sherman, Eric J"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Radiotherapy | Brain Neoplasms",
"npi_num": "1558323519",
"hcp_pin_alias": "424492",
"session_name": "Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases,Radiation Therapy Should Be the Default Standard of Care Option for Patients With Brain Metastases",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424492",
"first_name": "Minesh",
"middle_name": "P",
"last_name": "Mehta",
"org_name": "Baptist Health Medical Group Oncology LLC",
"Country": "United States",
"Region": "Florida",
"City": "South Miami",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232287",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232287",
"events_session": "Results from METIS (EF-25)",
"rest_events_session_count": 3,
"rest_events_session": " an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases,Radiation Therapy Should Be the Default Standard of Care Option for Patients With Brain Metastases",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Radiotherapy ",
"rest_events_topic_count": 1,
"rest_events_topic": " Brain Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1558323519,'424492');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMehta, Minesh P",
"kol_full_name": "Mehta, Minesh P"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "SDHA Protein, Human | Neoplasms",
"npi_num": "1548278005",
"hcp_pin_alias": "424487",
"session_name": "Novel models for the functional characterization of SDHA germline variants to predict cancer risk",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424487",
"first_name": "Michael",
"middle_name": "Charles",
"last_name": "Heinrich",
"org_name": "Oregon Health & Science University",
"Country": "United States",
"Region": "Oregon",
"City": "Portland",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232906",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232906",
"events_session": "Novel models for the functional characterization of SDHA germline variants to predict cancer risk",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "SDHA Protein, Human | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1548278005,'424487');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHeinrich, Michael Charles",
"kol_full_name": "Heinrich, Michael Charles"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptors, CCR8 | KRASG12D Inhibitor MRTX1133 | Solid Tumor",
"npi_num": "1538162029",
"hcp_pin_alias": "424479",
"session_name": "Preliminary results of a phase 1, first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors,A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation,An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424479",
"first_name": "Amita",
"middle_name": "",
"last_name": "Patnaik",
"org_name": "South Texas Oncology And Hematology PLLC",
"Country": "United States",
"Region": "Texas",
"City": "San Antonio",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232972",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232972",
"events_session": "Preliminary results of a phase 1",
"rest_events_session_count": 10,
"rest_events_session": " first-in-human, dose escalation study of the anti-CCR8 cytolytic antibody, CHS-114 (formerly SRF114) in patients with advanced solid tumors,A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation,An open-label phase 1 study to investigate SGNCEACAM5C/SAR445953 in adults with advanced solid tumors (SGNCEA5C-001)",
"events_topic": "Receptors, CCR8 | KRASG12D Inhibitor MRTX1133 ",
"rest_events_topic_count": 1,
"rest_events_topic": " Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1538162029,'424479');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPatnaik, Amita",
"kol_full_name": "Patnaik, Amita"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Skin Neoplasms | Melanoma",
"npi_num": "1528042819",
"hcp_pin_alias": "424465",
"session_name": "Melanoma/Skin Cancers: Program Commitee,Melanoma/Skin Cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424465",
"first_name": "Harriet",
"middle_name": "Margot",
"last_name": "Kluger",
"org_name": "Yale University",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232008",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232008",
"events_session": "Melanoma/Skin Cancers: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Melanoma/Skin Cancers",
"events_topic": "Skin Neoplasms | Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1528042819,'424465');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKluger, Harriet Margot",
"kol_full_name": "Kluger, Harriet Margot"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1518948082",
"hcp_pin_alias": "424457",
"session_name": "Care Delivery/Models of Care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424457",
"first_name": "Kathryn",
"middle_name": "Jean",
"last_name": "Ruddy",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231962",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231962",
"events_session": "Care Delivery/Models of Care",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1518948082,'424457');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERuddy, Kathryn Jean",
"kol_full_name": "Ruddy, Kathryn Jean"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms | Palbociclib | Aromatase Inhibitors",
"npi_num": "1518939537",
"hcp_pin_alias": "424456",
"session_name": "Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: A SEER-Medicare analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424456",
"first_name": "Adam",
"middle_name": "M",
"last_name": "Brufsky",
"org_name": "University of Pittsburgh School of Medicine",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Pittsburgh",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232705",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232705",
"events_session": "Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo",
"rest_events_session_count": 1,
"rest_events_session": " HR+/HER2− metastatic breast cancer: A SEER-Medicare analysis",
"events_topic": "Triple Negative Breast Neoplasms | Palbociclib ",
"rest_events_topic_count": 1,
"rest_events_topic": " Aromatase Inhibitors",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1518939537,'424456');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBrufsky, Adam M",
"kol_full_name": "Brufsky, Adam M"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Diffuse Large B-Cell Lymphoma | Lymphoma, Non-Hodgkin | Rituximab | Lenalidomide | Epcoritamab | Lymphoma, Follicular",
"npi_num": "1508922907",
"hcp_pin_alias": "424447",
"session_name": "Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL‑2 arms 6 and 7,Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424447",
"first_name": "Joshua",
"middle_name": "",
"last_name": "Brody",
"org_name": "Icahn School of Medicine at Mount Sinai",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232374",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232374",
"events_session": "Epcoritamab with rituximab + lenalidomide (R2) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL‑2 arms 6 and 7",
"rest_events_session_count": 1,
"rest_events_session": "Subcutaneous epcoritamab + GemOx in patients with relapsed or refractory DLBCL: Updated results from EPCORE NHL-2",
"events_topic": "Diffuse Large B-Cell Lymphoma | Lymphoma, Non-Hodgkin ",
"rest_events_topic_count": 4,
"rest_events_topic": " Rituximab | Lenalidomide | Epcoritamab | Lymphoma, Follicular",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1508922907,'424447');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBrody, Joshua",
"kol_full_name": "Brody, Joshua"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms | Ado-Trastuzumab Emtansine | Chemotherapy, Adjuvant",
"npi_num": "1508908328",
"hcp_pin_alias": "424445",
"session_name": "Safety run-in phase of the multi-epitope HER2 peptide vaccine in combination with trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424445",
"first_name": "Saranya",
"middle_name": "",
"last_name": "Chumsri",
"org_name": "Mayo Clinic - Florida",
"Country": "United States",
"Region": "Florida",
"City": "Jacksonville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232624",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232624",
"events_session": "Safety run-in phase of the multi-epitope HER2 peptide vaccine in combination with trastuzumab emtansine in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms | Ado-Trastuzumab Emtansine ",
"rest_events_topic_count": 1,
"rest_events_topic": " Chemotherapy, Adjuvant",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1508908328,'424445');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChumsri, Saranya",
"kol_full_name": "Chumsri, Saranya"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Abemaciclib | Neurofibromatosis 2 | Cyclin-Dependent Kinases | Meningioma",
"npi_num": "1508906355",
"hcp_pin_alias": "424444",
"session_name": "Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424444",
"first_name": "Priscilla",
"middle_name": "Kaliopi",
"last_name": "Brastianos",
"org_name": "Massachusetts General Physicians Organization Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232455",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232455",
"events_session": "Alliance A071401: Phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Abemaciclib | Neurofibromatosis 2 ",
"rest_events_topic_count": 2,
"rest_events_topic": " Cyclin-Dependent Kinases | Meningioma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1508906355,'424444');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBrastianos, Priscilla Kaliopi",
"kol_full_name": "Brastianos, Priscilla Kaliopi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Skin Neoplasms | Molecular Targeted Therapy | Melanoma",
"npi_num": "1487853594",
"hcp_pin_alias": "424428",
"session_name": "Melanoma/Skin Cancers: Program Commitee,First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment,Role of Other Novel Targeted Therapies,Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424428",
"first_name": "Michael",
"middle_name": "",
"last_name": "Postow",
"org_name": "Memorial Solid Tumor Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232057",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232057",
"events_session": "Melanoma/Skin Cancers: Program Commitee",
"rest_events_session_count": 3,
"rest_events_session": "First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment,Role of Other Novel Targeted Therapies,Breaking the Mold: Trailblazing Melanoma Therapy Beyond Checkpoint Through Innovative Approaches",
"events_topic": "Skin Neoplasms | Molecular Targeted Therapy ",
"rest_events_topic_count": 1,
"rest_events_topic": " Melanoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1487853594,'424428');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPostow, Michael",
"kol_full_name": "Postow, Michael"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ramucirumab | Paclitaxel | Gastroesophageal Junction Adenocarcinoma",
"npi_num": "1477846715",
"hcp_pin_alias": "424416",
"session_name": "A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with Caprin-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424416",
"first_name": "Ronan",
"middle_name": "J",
"last_name": "Kelly",
"org_name": "",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232849",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232849",
"events_session": "A randomized",
"rest_events_session_count": 3,
"rest_events_session": " multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with Caprin-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma",
"events_topic": "Ramucirumab | Paclitaxel ",
"rest_events_topic_count": 1,
"rest_events_topic": " Gastroesophageal Junction Adenocarcinoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1477846715,'424416');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKelly, Ronan J",
"kol_full_name": "Kelly, Ronan J"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Chemotherapy",
"npi_num": "1477744316",
"hcp_pin_alias": "424415",
"session_name": "Real-world treatment patterns and outcomes in US patients (pts) with advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy (PBC) and anti–PD-(L)1 treatment",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424415",
"first_name": "Vamsidhar",
"middle_name": "",
"last_name": "Velcheti",
"org_name": "New York University",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232183",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232183",
"events_session": "Real-world treatment patterns and outcomes in US patients (pts) with advanced non-small cell lung cancer (NSCLC) after platinum-based chemotherapy (PBC) and anti–PD-(L)1 treatment",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Chemotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1477744316,'424415');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVelcheti, Vamsidhar",
"kol_full_name": "Velcheti, Vamsidhar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ciltacabtagene Autoleucel | Multiple Myeloma",
"npi_num": "1477606309",
"hcp_pin_alias": "424409",
"session_name": "Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424409",
"first_name": "Luciano",
"middle_name": "J",
"last_name": "Costa",
"org_name": "University Of Alabama Health Services Foundation, Pc",
"Country": "United States",
"Region": "Alabama",
"City": "Birmingham",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232135",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232135",
"events_session": "Ciltacabtagene autoleucel vs standard of care in patients with functional high-risk multiple myeloma: CARTITUDE-4 subgroup analysis",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Ciltacabtagene Autoleucel | Multiple Myeloma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1477606309,'424409');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECosta, Luciano J",
"kol_full_name": "Costa, Luciano J"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung",
"npi_num": "1467733113",
"hcp_pin_alias": "424403",
"session_name": "Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other: Program Commitee,Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424403",
"first_name": "Patrick",
"middle_name": "",
"last_name": "Forde",
"org_name": "Johns Hopkins University",
"Country": "United States",
"Region": "Maryland",
"City": "Columbia",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232119",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232119",
"events_session": "Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other",
"events_topic": "Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1467733113,'424403');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EForde, Patrick",
"kol_full_name": "Forde, Patrick"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sarcomatoid Mesothelioma | Immunotherapy",
"npi_num": "1437278959",
"hcp_pin_alias": "424367",
"session_name": "Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424367",
"first_name": "Aaron",
"middle_name": "S",
"last_name": "Mansfield",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232255",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232255",
"events_session": "Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Sarcomatoid Mesothelioma | Immunotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1437278959,'424367');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMansfield, Aaron S",
"kol_full_name": "Mansfield, Aaron S"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms | Sacituzumab Govitecan | Trilaciclib",
"npi_num": "1437268174",
"hcp_pin_alias": "424366",
"session_name": "Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424366",
"first_name": "Lasika",
"middle_name": "Chandradatta",
"last_name": "Seneviratne",
"org_name": "Los Angeles Hematology-Oncology",
"Country": "United States",
"Region": "California",
"City": "Los Angeles",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232698",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232698",
"events_session": "Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Triple Negative Breast Neoplasms | Sacituzumab Govitecan ",
"rest_events_topic_count": 1,
"rest_events_topic": " Trilaciclib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1437268174,'424366');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESeneviratne, Lasika Chandradatta",
"kol_full_name": "Seneviratne, Lasika Chandradatta"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms",
"npi_num": "1437241510",
"hcp_pin_alias": "424362",
"session_name": "Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424362",
"first_name": "Lajos",
"middle_name": "",
"last_name": "Pusztai",
"org_name": "Yale University",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232150",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232150",
"events_session": "Development and validation of RSClin N+ tool for hormone receptor-positive (HR+)",
"rest_events_session_count": 2,
"rest_events_session": " HER2-negative (HER2-), node-positive breast cancer",
"events_topic": "Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1437241510,'424362');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPusztai, Lajos",
"kol_full_name": "Pusztai, Lajos"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy, Adjuvant | Breast Neoplasms",
"npi_num": "1437187929",
"hcp_pin_alias": "424359",
"session_name": "Breast Cancer – Metastatc:: Program Commitee,Tailoring Treatment to Risk: Adjuvant Therapy for Breast Cancer,Systemic Therapy in Breast Cancer: Current State of the Art and Future Horizons",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424359",
"first_name": "William",
"middle_name": "",
"last_name": "Gradishar",
"org_name": "Northwestern Medical Faculty Foundation",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232021",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232021",
"events_session": "Breast Cancer – Metastatc:: Program Commitee",
"rest_events_session_count": 2,
"rest_events_session": "Tailoring Treatment to Risk: Adjuvant Therapy for Breast Cancer,Systemic Therapy in Breast Cancer: Current State of the Art and Future Horizons",
"events_topic": "Chemotherapy, Adjuvant | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1437187929,'424359');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGradishar, William",
"kol_full_name": "Gradishar, William"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Durvalumab | Small Cell Lung Carcinoma",
"npi_num": "1427074210",
"hcp_pin_alias": "424348",
"session_name": "ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424348",
"first_name": "David",
"middle_name": "R",
"last_name": "Spigel",
"org_name": "Tennessee Oncology",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232516",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232516",
"events_session": "ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Durvalumab | Small Cell Lung Carcinoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1427074210,'424348');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESpigel, David R",
"kol_full_name": "Spigel, David R"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Admin. & Management | Neoplasms",
"npi_num": "1417948316",
"hcp_pin_alias": "424345",
"session_name": "Melina Marmarelis: Program Commitee,Discussion of LBA4",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424345",
"first_name": "Lecia",
"middle_name": "V",
"last_name": "Sequist",
"org_name": "Newton Wellesley Medical Group Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Newton",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232515",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232515",
"events_session": "Melina Marmarelis: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Discussion of LBA4",
"events_topic": "Admin. & Management | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1417948316,'424345');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESequist, Lecia V",
"kol_full_name": "Sequist, Lecia V"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Zongertinib | Carcinoma, Non-Small-Cell Lung | Triple Negative Breast Neoplasms | Durvalumab",
"npi_num": "1417056565",
"hcp_pin_alias": "424335",
"session_name": "Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data,Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424335",
"first_name": "John",
"middle_name": "V.",
"last_name": "Heymach",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232493",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232493",
"events_session": "Phase Ia/Ib trial of zongertinib (BI 1810631)",
"rest_events_session_count": 4,
"rest_events_session": " a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data,Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN",
"events_topic": "Zongertinib | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 2,
"rest_events_topic": " Triple Negative Breast Neoplasms | Durvalumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1417056565,'424335');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHeymach, John V.",
"kol_full_name": "Heymach, John V."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms | Prostate-Specific Antigen | Castration",
"npi_num": "1417011529",
"hcp_pin_alias": "424333",
"session_name": "Association between prostate-specific antigen (PSA) level \u003C02 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424333",
"first_name": "Alicia",
"middle_name": "Katherine",
"last_name": "Morgans",
"org_name": "Northwestern Medical Faculty Foundation",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232643",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232643",
"events_session": "Association between prostate-specific antigen (PSA) level \u003C02 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms | Prostate-Specific Antigen ",
"rest_events_topic_count": 1,
"rest_events_topic": " Castration",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1417011529,'424333');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMorgans, Alicia Katherine",
"kol_full_name": "Morgans, Alicia Katherine"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pelabresib | Ruxolitinib | Janus Kinase Inhibitors | Primary Myelofibrosis",
"npi_num": "1407019722",
"hcp_pin_alias": "424326",
"session_name": "Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424326",
"first_name": "Raajit",
"middle_name": "",
"last_name": "Rampal",
"org_name": "Memorial Hematology Lymphoma Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233106",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233106",
"events_session": "Updated safety and efficacy data from the phase 3 MANIFEST-2 study of pelabresib in combination with ruxolitinib for JAK inhibitor treatment-naïve patients with myelofibrosis",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pelabresib | Ruxolitinib ",
"rest_events_topic_count": 2,
"rest_events_topic": " Janus Kinase Inhibitors | Primary Myelofibrosis",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1407019722,'424326');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERampal, Raajit",
"kol_full_name": "Rampal, Raajit"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Myelodysplastic Syndromes | Hematologic Neoplasms | Leukemia | Head And Neck Neoplasms",
"npi_num": "1386625598",
"hcp_pin_alias": "424311",
"session_name": "Head and Neck Cancer: Program Commitee,Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424311",
"first_name": "Eunice",
"middle_name": "",
"last_name": "Wang",
"org_name": "Roswell Park Cancer Institute",
"Country": "United States",
"Region": "New York",
"City": "Buffalo",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232086",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232086",
"events_session": "Head and Neck Cancer: Program Commitee",
"rest_events_session_count": 3,
"rest_events_session": "Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant",
"events_topic": "Myelodysplastic Syndromes | Hematologic Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Leukemia | Head And Neck Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1386625598,'424311');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWang, Eunice",
"kol_full_name": "Wang, Eunice"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chordoma | Nirogacestat | Cetuximab | Fibromatosis, Aggressive",
"npi_num": "1376758821",
"hcp_pin_alias": "424306",
"session_name": "Nirogacestat for Desmoid Tumors,Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424306",
"first_name": "Mrinal",
"middle_name": "M",
"last_name": "Gounder",
"org_name": "Memorial Solid Tumor Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232903",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232903",
"events_session": "Nirogacestat for Desmoid Tumors",
"rest_events_session_count": 1,
"rest_events_session": "Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma",
"events_topic": "Chordoma | Nirogacestat ",
"rest_events_topic_count": 2,
"rest_events_topic": " Cetuximab | Fibromatosis, Aggressive",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1376758821,'424306');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGounder, Mrinal M",
"kol_full_name": "Gounder, Mrinal M"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nivolumab | Ipilimumab | Carcinoma, Renal Cell | Ovarian Neoplasms",
"npi_num": "1376573394",
"hcp_pin_alias": "424299",
"session_name": "Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424299",
"first_name": "Don",
"middle_name": "S",
"last_name": "Dizon",
"org_name": "Rhode Island Hospital",
"Country": "United States",
"Region": "Rhode Island",
"City": "Providence",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232732",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232732",
"events_session": "Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Nivolumab | Ipilimumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Carcinoma, Renal Cell | Ovarian Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1376573394,'424299');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDizon, Don S",
"kol_full_name": "Dizon, Don S"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pharmacokinetic | Beta Catenin | Transcription Factors | Solid Tumor",
"npi_num": "1376546861",
"hcp_pin_alias": "424296",
"session_name": "A first-in-human, phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors,Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424296",
"first_name": "Kyriakos",
"middle_name": "Peter",
"last_name": "Papadopoulos",
"org_name": "South Texas Oncology And Hematology PLLC",
"Country": "United States",
"Region": "Texas",
"City": "San Antonio",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232961",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232961",
"events_session": "A first-in-human",
"rest_events_session_count": 7,
"rest_events_session": " phase 1/2 trial of FOG-001, a β-catenin:TCF antagonist, in patients with locally advanced or metastatic solid tumors,Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data",
"events_topic": "Pharmacokinetic | Beta Catenin ",
"rest_events_topic_count": 2,
"rest_events_topic": " Transcription Factors | Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1376546861,'424296');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPapadopoulos, Kyriakos Peter",
"kol_full_name": "Papadopoulos, Kyriakos Peter"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Trastuzumab Imbotolimod | Immunoconjugates | Triple Negative Breast Neoplasms",
"npi_num": "1356361554",
"hcp_pin_alias": "424283",
"session_name": "Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424283",
"first_name": "Mark",
"middle_name": "Daniel",
"last_name": "Pegram",
"org_name": "Stanford Health Care",
"Country": "United States",
"Region": "California",
"City": "Stanford",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232708",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232708",
"events_session": "Phase 2 study of novel HER2-targeting",
"rest_events_session_count": 1,
"rest_events_session": " TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd)",
"events_topic": "Trastuzumab Imbotolimod | Immunoconjugates ",
"rest_events_topic_count": 1,
"rest_events_topic": " Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356361554,'424283');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPegram, Mark Daniel",
"kol_full_name": "Pegram, Mark Daniel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Antigens, CD19 | Leukemia, Lymphocytic, Chronic, B-Cell",
"npi_num": "1346484821",
"hcp_pin_alias": "424281",
"session_name": "Interim results from the ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424281",
"first_name": "Krish",
"middle_name": "",
"last_name": "Patel",
"org_name": "Swedish Medical Center",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232369",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232369",
"events_session": "Interim results from the ELiPSE-1 study: A phase 1",
"rest_events_session_count": 2,
"rest_events_session": " multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies",
"events_topic": "Antigens, CD19 | Leukemia, Lymphocytic, Chronic, B-Cell",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1346484821,'424281');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPatel, Krish",
"kol_full_name": "Patel, Krish"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Carcinoma, Non-Small-Cell Lung | Datopotamab Deruxtecan | Chemotherapy",
"npi_num": "1346276326",
"hcp_pin_alias": "424277",
"session_name": "Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424277",
"first_name": "Benjamin",
"middle_name": "P",
"last_name": "Levy",
"org_name": "Johns Hopkins University",
"Country": "United States",
"Region": "District of Columbia",
"City": "Washington",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232180",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232180",
"events_session": "Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pembrolizumab | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 2,
"rest_events_topic": " Datopotamab Deruxtecan | Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1346276326,'424277');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELevy, Benjamin P",
"kol_full_name": "Levy, Benjamin P"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunoconjugates | Breast Neoplasms",
"npi_num": "1346211141",
"hcp_pin_alias": "424272",
"session_name": "The Ongoing Antibody–Drug Conjugates Revolution in Breast Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424272",
"first_name": "Shanu",
"middle_name": "",
"last_name": "Modi",
"org_name": "Memorial Solid Tumor Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232776",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232776",
"events_session": "The Ongoing Antibody–Drug Conjugates Revolution in Breast Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunoconjugates | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1346211141,'424272');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EModi, Shanu",
"kol_full_name": "Modi, Shanu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Telisotuzumab Vedotin | Radiotherapy | ErbB Receptors | Carcinoma, Non-Small-Cell Lung | Brain Neoplasms",
"npi_num": "1336239912",
"hcp_pin_alias": "424266",
"session_name": "Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial,Systemic Therapy Is a Reasonable Alternative to Radiation Therapy in Patients with Brain Metastases",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424266",
"first_name": "David",
"middle_name": "",
"last_name": "Camidge",
"org_name": "University Physicians Inc",
"Country": "United States",
"Region": "Colorado",
"City": "Aurora",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232288",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232288",
"events_session": "Telisotuzumab vedotin monotherapy in patients with previously treated c-Met–overexpressing non-squamous EGFR wildtype advanced NSCLC: Primary analysis of the LUMINOSITY trial",
"rest_events_session_count": 1,
"rest_events_session": "Systemic Therapy Is a Reasonable Alternative to Radiation Therapy in Patients with Brain Metastases",
"events_topic": "Telisotuzumab Vedotin | Radiotherapy ",
"rest_events_topic_count": 3,
"rest_events_topic": " ErbB Receptors | Carcinoma, Non-Small-Cell Lung | Brain Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1336239912,'424266');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECamidge, David",
"kol_full_name": "Camidge, David"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Thyroid Neoplasms | TRK Inhibitors | Larotrectinib | Randomized Controlled Trials As Topic",
"npi_num": "1316975451",
"hcp_pin_alias": "424253",
"session_name": "Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study,Comparative patient-reported tolerability (PRT): A multiplicity-controlled analysis of LIBRETTO-531, a randomized controlled trial (RCT) in medullary thyroid cancer (MTC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424253",
"first_name": "Marcia",
"middle_name": "S",
"last_name": "Brose",
"org_name": "University of Pennsylvania Health System",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Berwyn",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232409",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232409",
"events_session": "Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study",
"rest_events_session_count": 2,
"rest_events_session": "Comparative patient-reported tolerability (PRT): A multiplicity-controlled analysis of LIBRETTO-531, a randomized controlled trial (RCT) in medullary thyroid cancer (MTC)",
"events_topic": "Neoplasms | Thyroid Neoplasms ",
"rest_events_topic_count": 3,
"rest_events_topic": " TRK Inhibitors | Larotrectinib | Randomized Controlled Trials As Topic",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1316975451,'424253');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBrose, Marcia S",
"kol_full_name": "Brose, Marcia S"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Radiotherapy | Brain Neoplasms",
"npi_num": "1316906498",
"hcp_pin_alias": "424249",
"session_name": "Choosing Between Options for Patients With Brain Metastases: What Outcomes Matter Most?,Brain Metastases Management: Weighing the Options—Radiation Versus Systemic Therapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424249",
"first_name": "Nancy",
"middle_name": "Uan-Tsin",
"last_name": "Lin",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Milford",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231989",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231989",
"events_session": "Choosing Between Options for Patients With Brain Metastases: What Outcomes Matter Most?",
"rest_events_session_count": 1,
"rest_events_session": "Brain Metastases Management: Weighing the Options—Radiation Versus Systemic Therapy",
"events_topic": "Radiotherapy | Brain Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1316906498,'424249');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELin, Nancy Uan-Tsin",
"kol_full_name": "Lin, Nancy Uan-Tsin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Solid Tumor | Biomarkers",
"npi_num": "1306878228",
"hcp_pin_alias": "424240",
"session_name": "MyTACTIC: Activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424240",
"first_name": "Lee",
"middle_name": "S",
"last_name": "Schwartzberg",
"org_name": "West Clinic PC",
"Country": "United States",
"Region": "Tennessee",
"City": "Brighton",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232956",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232956",
"events_session": "MyTACTIC: Activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Solid Tumor | Biomarkers",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1306878228,'424240');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESchwartzberg, Lee S",
"kol_full_name": "Schwartzberg, Lee S"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Inavolisib | Fulvestrant | Palbociclib | Ribociclib | Breast Neoplasms | Triple Negative Breast Neoplasms",
"npi_num": "1306041975",
"hcp_pin_alias": "424230",
"session_name": "First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses,INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC),BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424230",
"first_name": "Dejan",
"middle_name": "",
"last_name": "Juric",
"org_name": "Massachusetts General Physicians Organization Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232686",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232686",
"events_session": "First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated",
"rest_events_session_count": 12,
"rest_events_session": " hormone receptor-positive, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses,INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC),BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC)",
"events_topic": "Inavolisib | Fulvestrant ",
"rest_events_topic_count": 4,
"rest_events_topic": " Palbociclib | Ribociclib | Breast Neoplasms | Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1306041975,'424230');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJuric, Dejan",
"kol_full_name": "Juric, Dejan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Melanoma, Cutaneous Malignant | Fecal Microbiota Transplantation | Lenvatinib | Pembrolizumab",
"npi_num": "1295965523",
"hcp_pin_alias": "424227",
"session_name": "Randomized phase II trial of pembrolizumab/lenvatinib (P+L) +/- responder fecal microbiota transplant (R-FMT) in PD-1 relapsed/refractory (R/R) cutaneous melanoma (MEL)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424227",
"first_name": "Diwakar",
"middle_name": "",
"last_name": "Davar",
"org_name": "University of Pittsburgh School of Medicine",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Pittsburgh",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232804",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232804",
"events_session": "Randomized phase II trial of pembrolizumab/lenvatinib (P+L) +/- responder fecal microbiota transplant (R-FMT) in PD-1 relapsed/refractory (R/R) cutaneous melanoma (MEL)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Melanoma, Cutaneous Malignant | Fecal Microbiota Transplantation ",
"rest_events_topic_count": 2,
"rest_events_topic": " Lenvatinib | Pembrolizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1295965523,'424227');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDavar, Diwakar",
"kol_full_name": "Davar, Diwakar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Odronextamab | Lymphoma, Follicular",
"npi_num": "1295735058",
"hcp_pin_alias": "424223",
"session_name": "Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424223",
"first_name": "Ruemu",
"middle_name": "E",
"last_name": "Birhiray",
"org_name": "American Oncology Partners PA",
"Country": "United States",
"Region": "Indiana",
"City": "Noblesville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232390",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232390",
"events_session": "Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Odronextamab | Lymphoma, Follicular",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1295735058,'424223');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBirhiray, Ruemu E",
"kol_full_name": "Birhiray, Ruemu E"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1285690156",
"hcp_pin_alias": "424216",
"session_name": "Oncologist Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424216",
"first_name": "Anne",
"middle_name": "Hudson",
"last_name": "Blaes",
"org_name": "Fairview Health Services",
"Country": "United States",
"Region": "Minnesota",
"City": "Minneapolis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233096",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233096",
"events_session": "Oncologist Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1285690156,'424216');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBlaes, Anne Hudson",
"kol_full_name": "Blaes, Anne Hudson"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy",
"npi_num": "1275635971",
"hcp_pin_alias": "424207",
"session_name": "Developmental Therapeutcs – Immunotherapy: Program Commitee,Developmental Therapeutics—Immunotherapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424207",
"first_name": "Hatem",
"middle_name": "",
"last_name": "Soliman",
"org_name": "H. Lee Moffitt Cancer Center & Research Institute",
"Country": "United States",
"Region": "Florida",
"City": "Tampa",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232037",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232037",
"events_session": "Developmental Therapeutcs – Immunotherapy: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Developmental Therapeutics—Immunotherapy",
"events_topic": "Immunotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1275635971,'424207');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESoliman, Hatem",
"kol_full_name": "Soliman, Hatem"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Melanoma",
"npi_num": "1265696348",
"hcp_pin_alias": "424197",
"session_name": "Everything and the Kitchen Sink: First-Line Therapy for Advanced Melanoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424197",
"first_name": "Sunandana",
"middle_name": "",
"last_name": "Chandra",
"org_name": "Northwestern Medical Faculty Foundation",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233125",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233125",
"events_session": "Everything and the Kitchen Sink: First-Line Therapy for Advanced Melanoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1265696348,'424197');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChandra, Sunandana",
"kol_full_name": "Chandra, Sunandana"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy | Melanoma | Central Nervous System Neoplasms",
"npi_num": "1255429486",
"hcp_pin_alias": "424187",
"session_name": "Incidence and risk factors for central nervous system (CNS) metastasis (met) in patients (pts) with stage III melanoma treated with adjuvant (ADJ) anti-PD1 immunotherapy (IMT)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424187",
"first_name": "Michael",
"middle_name": "A.",
"last_name": "Davies",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232797",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232797",
"events_session": "Incidence and risk factors for central nervous system (CNS) metastasis (met) in patients (pts) with stage III melanoma treated with adjuvant (ADJ) anti-PD1 immunotherapy (IMT)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunotherapy | Melanoma ",
"rest_events_topic_count": 1,
"rest_events_topic": " Central Nervous System Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1255429486,'424187');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDavies, Michael A.",
"kol_full_name": "Davies, Michael A."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lasofoxifene | Triple Negative Breast Neoplasms",
"npi_num": "1255310611",
"hcp_pin_alias": "424182",
"session_name": "Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424182",
"first_name": "Matthew",
"middle_name": "P",
"last_name": "Goetz",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232711",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232711",
"events_session": "Open-label",
"rest_events_session_count": 5,
"rest_events_session": " randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation",
"events_topic": "Lasofoxifene | Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1255310611,'424182');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGoetz, Matthew P",
"kol_full_name": "Goetz, Matthew P"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Programmed Cell Death 1 Receptor | Neoplasms",
"npi_num": "1245277698",
"hcp_pin_alias": "424175",
"session_name": "Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424175",
"first_name": "Minal",
"middle_name": "Atul",
"last_name": "Barve",
"org_name": "Texas Oncology PA",
"Country": "United States",
"Region": "Texas",
"City": "Plano",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232994",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232994",
"events_session": "Phase 1 study of CTX-471",
"rest_events_session_count": 2,
"rest_events_session": " a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies",
"events_topic": "Programmed Cell Death 1 Receptor | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1245277698,'424175');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBarve, Minal Atul",
"kol_full_name": "Barve, Minal Atul"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms | Castration",
"npi_num": "1245258045",
"hcp_pin_alias": "424173",
"session_name": "Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424173",
"first_name": "Scott",
"middle_name": "",
"last_name": "Tagawa",
"org_name": "Weill Medical College of Cornell",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232656",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232656",
"events_session": "Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms | Castration",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1245258045,'424173');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETagawa, Scott",
"kol_full_name": "Tagawa, Scott"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Brigimadlin | Glioblastoma | Radiotherapy | Brain Diseases",
"npi_num": "1225018419",
"hcp_pin_alias": "424152",
"session_name": "A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424152",
"first_name": "Jann",
"middle_name": "N",
"last_name": "Sarkaria",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Wisconsin",
"City": "La Crosse",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232522",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232522",
"events_session": "A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized",
"rest_events_session_count": 2,
"rest_events_session": " open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM)",
"events_topic": "Brigimadlin | Glioblastoma ",
"rest_events_topic_count": 2,
"rest_events_topic": " Radiotherapy | Brain Diseases",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1225018419,'424152');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESarkaria, Jann N",
"kol_full_name": "Sarkaria, Jann N"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "B-Cell Maturation Antigen | Multiple Myeloma | Admin. & Management",
"npi_num": "1215948690",
"hcp_pin_alias": "424147",
"session_name": "Amandeep Godara – Track Leader: Program Commitee,Moving BCMA-Directed Therapies to Earlier Use in Multiple Myeloma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424147",
"first_name": "Amrita",
"middle_name": "",
"last_name": "Krishnan",
"org_name": "City of Hope Medical Foundation",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232136",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232136",
"events_session": "Amandeep Godara – Track Leader: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Moving BCMA-Directed Therapies to Earlier Use in Multiple Myeloma",
"events_topic": "B-Cell Maturation Antigen | Multiple Myeloma ",
"rest_events_topic_count": 1,
"rest_events_topic": " Admin. & Management",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1215948690,'424147');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKrishnan, Amrita",
"kol_full_name": "Krishnan, Amrita"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Reproductive Health Services | Neoplasms",
"npi_num": "1194833020",
"hcp_pin_alias": "424135",
"session_name": "Ethical Considerations for Oncologists Practicing in States That Limit Reproductive Care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424135",
"first_name": "Abby",
"middle_name": "R",
"last_name": "Rosenberg",
"org_name": "The Association Of Chrmc And University Physicians",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232483",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232483",
"events_session": "Ethical Considerations for Oncologists Practicing in States That Limit Reproductive Care",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Reproductive Health Services | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1194833020,'424135');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERosenberg, Abby R",
"kol_full_name": "Rosenberg, Abby R"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Radiosurgery | Radiotherapy | Azeliragon | Brain Neoplasms",
"npi_num": "1184990871",
"hcp_pin_alias": "424129",
"session_name": "A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424129",
"first_name": "Rupesh",
"middle_name": "Rajesh",
"last_name": "Kotecha",
"org_name": "Baptist Health Medical Group Oncology LLC",
"Country": "United States",
"Region": "Florida",
"City": "Miami",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233083",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233083",
"events_session": "A phase I/II study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metastases (ADORATION)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Radiosurgery | Radiotherapy ",
"rest_events_topic_count": 2,
"rest_events_topic": " Azeliragon | Brain Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1184990871,'424129');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKotecha, Rupesh Rajesh",
"kol_full_name": "Kotecha, Rupesh Rajesh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Tarlatamab | Neuroendocrine Prostate Cancer",
"npi_num": "1174794309",
"hcp_pin_alias": "424122",
"session_name": "Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424122",
"first_name": "Rahul",
"middle_name": "",
"last_name": "Aggarwal",
"org_name": "UCSF Medical Center",
"Country": "United States",
"Region": "California",
"City": "San Francisco",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232284",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232284",
"events_session": "Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Tarlatamab | Neuroendocrine Prostate Cancer",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1174794309,'424122');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAggarwal, Rahul",
"kol_full_name": "Aggarwal, Rahul"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Avelumab | Axitinib | Sunitinib | Carcinoma, Renal Cell",
"npi_num": "1164493961",
"hcp_pin_alias": "424112",
"session_name": "Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424112",
"first_name": "Robert",
"middle_name": "J",
"last_name": "Motzer",
"org_name": "Memorial Solid Tumor Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232471",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232471",
"events_session": "Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Avelumab | Axitinib ",
"rest_events_topic_count": 2,
"rest_events_topic": " Sunitinib | Carcinoma, Renal Cell",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1164493961,'424112');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMotzer, Robert J",
"kol_full_name": "Motzer, Robert J"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Human Papillomavirus 16 | Squamous Cell Carcinoma Of Head And Neck",
"npi_num": "1164440616",
"hcp_pin_alias": "424108",
"session_name": "A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424108",
"first_name": "Douglas",
"middle_name": "R",
"last_name": "Adkins",
"org_name": "Washington University",
"Country": "United States",
"Region": "Missouri",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232099",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232099",
"events_session": "A phase 1 dose-escalation and expansion study of CUE-101",
"rest_events_session_count": 2,
"rest_events_session": " given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC)",
"events_topic": "Pembrolizumab | Human Papillomavirus 16 ",
"rest_events_topic_count": 1,
"rest_events_topic": " Squamous Cell Carcinoma Of Head And Neck",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1164440616,'424108');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAdkins, Douglas R",
"kol_full_name": "Adkins, Douglas R"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Primary Myelofibrosis | Thrombocytopenia | Pacritinib | Anemia",
"npi_num": "1154449114",
"hcp_pin_alias": "424103",
"session_name": "Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424103",
"first_name": "Prithviraj",
"middle_name": "",
"last_name": "Bose",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232351",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232351",
"events_session": "Efficacy of pacritinib in patients with myelofibrosis who have both thrombocytopenia and anemia",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Primary Myelofibrosis | Thrombocytopenia ",
"rest_events_topic_count": 2,
"rest_events_topic": " Pacritinib | Anemia",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1154449114,'424103');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBose, Prithviraj",
"kol_full_name": "Bose, Prithviraj"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy | Lung Neoplasms | Brain Neoplasms",
"npi_num": "1154434645",
"hcp_pin_alias": "424102",
"session_name": "Immunotherapy outcomes and profile in lung cancer brain metastases",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424102",
"first_name": "John",
"middle_name": "L.",
"last_name": "Villano",
"org_name": "Kentucky Medical Services Foundation",
"Country": "United States",
"Region": "Kentucky",
"City": "Lexington",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232187",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232187",
"events_session": "Immunotherapy outcomes and profile in lung cancer brain metastases",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunotherapy | Lung Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Brain Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1154434645,'424102');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVillano, John L.",
"kol_full_name": "Villano, John L."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Drug Shortages | Patient Care | Neoplasms",
"npi_num": "1144300146",
"hcp_pin_alias": "424088",
"session_name": "Making a Global Impact: ASCO Strategy,The Impact of Quality Programs on Patient Care Around the World,Solving Decades of Drug Shortages in Oncology: What, Who, and When?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424088",
"first_name": "Julie",
"middle_name": "R",
"last_name": "Gralow",
"org_name": "Association of University Physicians",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232003",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232003",
"events_session": "Making a Global Impact: ASCO Strategy",
"rest_events_session_count": 4,
"rest_events_session": "The Impact of Quality Programs on Patient Care Around the World,Solving Decades of Drug Shortages in Oncology: What, Who, and When?",
"events_topic": "Drug Shortages | Patient Care ",
"rest_events_topic_count": 1,
"rest_events_topic": " Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1144300146,'424088');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGralow, Julie R",
"kol_full_name": "Gralow, Julie R"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ductal Carcinoma In Situ | Radiotherapy | Mastectomy, Segmental",
"npi_num": "1144205519",
"hcp_pin_alias": "424083",
"session_name": "Identification of patients with DCIS with low-risk clinicopathology who benefit from radiation therapy with and without endocrine therapy after breast-conserving surgery assessed with the 7-gene biosignature",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424083",
"first_name": "Pat",
"middle_name": "W",
"last_name": "Whitworth",
"org_name": "Advanced Diagnostic Imaging PC",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232617",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232617",
"events_session": "Identification of patients with DCIS with low-risk clinicopathology who benefit from radiation therapy with and without endocrine therapy after breast-conserving surgery assessed with the 7-gene biosignature",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Ductal Carcinoma In Situ | Radiotherapy ",
"rest_events_topic_count": 1,
"rest_events_topic": " Mastectomy, Segmental",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1144205519,'424083');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWhitworth, Pat W",
"kol_full_name": "Whitworth, Pat W"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1134381692",
"hcp_pin_alias": "424081",
"session_name": "Breast Cancer—Local/Regional/Adjuvant",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424081",
"first_name": "Cesar",
"middle_name": "Augusto",
"last_name": "Santa-Maria",
"org_name": "Johns Hopkins University",
"Country": "United States",
"Region": "District of Columbia",
"City": "Washington",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231979",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231979",
"events_session": "Breast Cancer—Local/Regional/Adjuvant",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1134381692,'424081');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESanta-Maria, Cesar Augusto",
"kol_full_name": "Santa-Maria, Cesar Augusto"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Teclistamab | Antibodies, Bispecific | Multiple Myeloma",
"npi_num": "1134103476",
"hcp_pin_alias": "424072",
"session_name": "OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424072",
"first_name": "Robert",
"middle_name": "Melvin",
"last_name": "Rifkin",
"org_name": "Yampa Valley Medical Center",
"Country": "United States",
"Region": "Colorado",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232358",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232358",
"events_session": "OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec)",
"rest_events_session_count": 2,
"rest_events_session": " a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM)",
"events_topic": "Teclistamab | Antibodies, Bispecific ",
"rest_events_topic_count": 1,
"rest_events_topic": " Multiple Myeloma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1134103476,'424072');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERifkin, Robert Melvin",
"kol_full_name": "Rifkin, Robert Melvin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Castration | Prednisone | Apalutamide | Prostatic Neoplasms | Abiraterone Acetate",
"npi_num": "1124101381",
"hcp_pin_alias": "424066",
"session_name": "Overall survival from PANTHER: A multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424066",
"first_name": "Daniel",
"middle_name": "",
"last_name": "George",
"org_name": "Private Diagnostic Clinic, PLLC",
"Country": "United States",
"Region": "North Carolina",
"City": "Durham",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232655",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232655",
"events_session": "Overall survival from PANTHER: A multicenter trial of apalutamide",
"rest_events_session_count": 1,
"rest_events_session": " abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC)",
"events_topic": "Castration | Prednisone ",
"rest_events_topic_count": 3,
"rest_events_topic": " Apalutamide | Prostatic Neoplasms | Abiraterone Acetate",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1124101381,'424066');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGeorge, Daniel",
"kol_full_name": "George, Daniel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy, Adoptive | Multiple Myeloma | Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma | Antibodies, Bispecific | Drug-Related Side Effects And Adverse Reactions",
"npi_num": "1124030028",
"hcp_pin_alias": "424064",
"session_name": "Durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects,PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease,Improving Access to Bispecific Antibodies in the Community: Challenges and Opportunities,Optimizing Bispecific Therapy Use in Lymphoma and Multiple Myeloma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424064",
"first_name": "Lihua",
"middle_name": "Elizabeth",
"last_name": "Budde",
"org_name": "City of Hope Medical Foundation",
"Country": "United States",
"Region": "California",
"City": "South Pasadena",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231971",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231971",
"events_session": "Durable complete response and overall survival in patients with heavily pretreated",
"rest_events_session_count": 5,
"rest_events_session": " poor-prognosis non-Hodgkin lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects,PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease,Improving Access to Bispecific Antibodies in the Community: Challenges and Opportunities,Optimizing Bispecific Therapy Use in Lymphoma and Multiple Myeloma",
"events_topic": "Immunotherapy, Adoptive | Multiple Myeloma ",
"rest_events_topic_count": 5,
"rest_events_topic": " Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell | Lymphoma | Antibodies, Bispecific | Drug-Related Side Effects And Adverse Reactions",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1124030028,'424064');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBudde, Lihua Elizabeth",
"kol_full_name": "Budde, Lihua Elizabeth"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Durvalumab | Carcinoma, Non-Small-Cell Lung | Oleclumab | Immune Checkpoint Inhibitors | Valacyclovir",
"npi_num": "1114181740",
"hcp_pin_alias": "424059",
"session_name": "Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC),Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with an inadequate response to ICI",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424059",
"first_name": "Charu",
"middle_name": "",
"last_name": "Aggarwal",
"org_name": "University of Pennsylvania Health System",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232185",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232185",
"events_session": "Updated results from COAST",
"rest_events_session_count": 2,
"rest_events_session": " a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC),Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with an inadequate response to ICI",
"events_topic": "Durvalumab | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 3,
"rest_events_topic": " Oleclumab | Immune Checkpoint Inhibitors | Valacyclovir",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1114181740,'424059');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAggarwal, Charu",
"kol_full_name": "Aggarwal, Charu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Isocitrate Dehydrogenase | Glioma",
"npi_num": "1114030707",
"hcp_pin_alias": "424056",
"session_name": "Targeting Isocitrate Dehydrogenase in Diffuse Gliomas,State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424056",
"first_name": "Ingo",
"middle_name": "K.",
"last_name": "Mellinghoff",
"org_name": "Memorial Neurology Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232002",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232002",
"events_session": "Targeting Isocitrate Dehydrogenase in Diffuse Gliomas",
"rest_events_session_count": 1,
"rest_events_session": "State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond",
"events_topic": "Isocitrate Dehydrogenase | Glioma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1114030707,'424056');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMellinghoff, Ingo K.",
"kol_full_name": "Mellinghoff, Ingo K."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Biomarkers | Gastrointestinal Neoplasms",
"npi_num": "1104837590",
"hcp_pin_alias": "424053",
"session_name": "Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424053",
"first_name": "Aung",
"middle_name": "",
"last_name": "Naing",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232997",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232997",
"events_session": "Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pembrolizumab | Biomarkers ",
"rest_events_topic_count": 1,
"rest_events_topic": " Gastrointestinal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1104837590,'424053');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENaing, Aung",
"kol_full_name": "Naing, Aung"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nivolumab | Cabozantinib | Carcinoma, Renal Cell | Immunotherapy | Admin. & Management",
"npi_num": "1083858443",
"hcp_pin_alias": "424039",
"session_name": "Andrea Troxel: Program Commitee,Phase 2 trial for sequential treatment of high dose cabozantinib (CABO) or CABO plus nivolumab (NIVO) on/after progression on CABO monotherapy in advanced renal cell carcinoma (RCC): Seq-Cabo,Developmental Therapeutics—Immunotherapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424039",
"first_name": "Tian",
"middle_name": "",
"last_name": "Zhang",
"org_name": "Private Diagnostic Clinic, PLLC",
"Country": "United States",
"Region": "North Carolina",
"City": "Chapel Hill",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231997",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231997",
"events_session": "Andrea Troxel: Program Commitee",
"rest_events_session_count": 2,
"rest_events_session": "Phase 2 trial for sequential treatment of high dose cabozantinib (CABO) or CABO plus nivolumab (NIVO) on/after progression on CABO monotherapy in advanced renal cell carcinoma (RCC): Seq-Cabo,Developmental Therapeutics—Immunotherapy",
"events_topic": "Nivolumab | Cabozantinib ",
"rest_events_topic_count": 3,
"rest_events_topic": " Carcinoma, Renal Cell | Immunotherapy | Admin. & Management",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1083858443,'424039');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EZhang, Tian",
"kol_full_name": "Zhang, Tian"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Sacituzumab Govitecan | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1083649792",
"hcp_pin_alias": "424030",
"session_name": "Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424030",
"first_name": "Jyoti",
"middle_name": "",
"last_name": "Patel",
"org_name": "Northwestern Medical Faculty Foundation",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232174",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232174",
"events_session": "Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pembrolizumab | Sacituzumab Govitecan ",
"rest_events_topic_count": 1,
"rest_events_topic": " Carcinoma, Non-Small-Cell Lung",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1083649792,'424030');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPatel, Jyoti",
"kol_full_name": "Patel, Jyoti"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms | Tumor Microenvironment",
"npi_num": "1073664660",
"hcp_pin_alias": "424026",
"session_name": "Comparison of tumor immune microenvironments (TIMEs) between primary and metastatic sites (Mets) in triple-negative breast cancer (TNBC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424026",
"first_name": "Yuan",
"middle_name": "",
"last_name": "Yuan",
"org_name": "City of Hope Medical Foundation",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232700",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232700",
"events_session": "Comparison of tumor immune microenvironments (TIMEs) between primary and metastatic sites (Mets) in triple-negative breast cancer (TNBC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Triple Negative Breast Neoplasms | Tumor Microenvironment",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1073664660,'424026');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYuan, Yuan",
"kol_full_name": "Yuan, Yuan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Small Cell Lung Carcinoma",
"npi_num": "1073619490",
"hcp_pin_alias": "424025",
"session_name": "Small Cell Lung Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424025",
"first_name": "Anne",
"middle_name": "C",
"last_name": "Chiang",
"org_name": "Yale University",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232785",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232785",
"events_session": "Small Cell Lung Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Small Cell Lung Carcinoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1073619490,'424025');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChiang, Anne C",
"kol_full_name": "Chiang, Anne C"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Myeloid Malignancy | Tumor Suppressor Protein P53",
"npi_num": "1063733343",
"hcp_pin_alias": "424015",
"session_name": "Updates on Novel Therapy for Treatment of TP53-Mutated Myeloid Malignancies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424015",
"first_name": "David",
"middle_name": "A",
"last_name": "Sallman",
"org_name": "H. Lee Moffitt Cancer Center & Research Institute",
"Country": "United States",
"Region": "Florida",
"City": "Tampa",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232536",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232536",
"events_session": "Updates on Novel Therapy for Treatment of TP53-Mutated Myeloid Malignancies",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Myeloid Malignancy | Tumor Suppressor Protein P53",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1063733343,'424015');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESallman, David A",
"kol_full_name": "Sallman, David A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Renal Cell | Nivolumab",
"npi_num": "1063686418",
"hcp_pin_alias": "424012",
"session_name": "Health-related quality of life (HRQoL) with nivolumab (NIVO) subcutaneous (SC) or intravenous (IV) in patients (pts) with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior therapy in the phase 3 CheckMate 67T trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424012",
"first_name": "Saby",
"middle_name": "",
"last_name": "George",
"org_name": "Roswell Park Cancer Institute",
"Country": "United States",
"Region": "New York",
"City": "Buffalo",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232584",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232584",
"events_session": "Health-related quality of life (HRQoL) with nivolumab (NIVO) subcutaneous (SC) or intravenous (IV) in patients (pts) with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior therapy in the phase 3 CheckMate 67T trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Renal Cell | Nivolumab",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1063686418,'424012');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGeorge, Saby",
"kol_full_name": "George, Saby"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Palliative Care | Lung Neoplasms",
"npi_num": "1063496479",
"hcp_pin_alias": "424006",
"session_name": "Multi-site randomized trial of stepped palliative care (PC) for patients with advanced lung cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424006",
"first_name": "Jennifer",
"middle_name": "S",
"last_name": "Temel",
"org_name": "The General Hospital Corporation",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232735",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232735",
"events_session": "Multi-site randomized trial of stepped palliative care (PC) for patients with advanced lung cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Palliative Care | Lung Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1063496479,'424006');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETemel, Jennifer S",
"kol_full_name": "Temel, Jennifer S"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "LILRB2 Protein, Human | Solid Tumor | Neoplasms",
"npi_num": "1053554717",
"hcp_pin_alias": "424002",
"session_name": "Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation,Cost trends in standard-of-care cancer treatments, 2017-2021",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "424002",
"first_name": "Judy",
"middle_name": "S",
"last_name": "Wang",
"org_name": "Florida Cancer Specialists And Research Institute, LLC",
"Country": "United States",
"Region": "Florida",
"City": "Sarasota",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232400",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232400",
"events_session": "Phase 1/2 study of NGM707",
"rest_events_session_count": 4,
"rest_events_session": " an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation,Cost trends in standard-of-care cancer treatments, 2017-2021",
"events_topic": "LILRB2 Protein, Human | Solid Tumor ",
"rest_events_topic_count": 1,
"rest_events_topic": " Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1053554717,'424002');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWang, Judy S",
"kol_full_name": "Wang, Judy S"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "ErbB Receptors | Glioblastoma",
"npi_num": "1053393496",
"hcp_pin_alias": "423999",
"session_name": "Phase 1 study of BDTX-1535, an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "423999",
"first_name": "Patrick",
"middle_name": "Yung",
"last_name": "Wen",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233074",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233074",
"events_session": "Phase 1 study of BDTX-1535",
"rest_events_session_count": 2,
"rest_events_session": " an oral 4th generation covalent EGFR inhibitor, in patients with recurrent glioblastoma: Preliminary dose escalation results",
"events_topic": "ErbB Receptors | Glioblastoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1053393496,'423999');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWen, Patrick Yung",
"kol_full_name": "Wen, Patrick Yung"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Melanoma",
"npi_num": "1053354936",
"hcp_pin_alias": "423997",
"session_name": "Therapies for Resectable Melanoma: Now, Later, or Not at All?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "423997",
"first_name": "Paul",
"middle_name": "B",
"last_name": "Chapman",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233123",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233123",
"events_session": "Therapies for Resectable Melanoma: Now",
"rest_events_session_count": 2,
"rest_events_session": " Later, or Not at All?",
"events_topic": "Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1053354936,'423997');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChapman, Paul B",
"kol_full_name": "Chapman, Paul B"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Interleukin-6 | Pembrolizumab | Placebos | Nivolumab | Ipilimumab | Immunotherapy, Adoptive | Tocilizumab | Melanoma",
"npi_num": "1053348706",
"hcp_pin_alias": "423996",
"session_name": "To Each Their Own: Individualized Antigen Therapy in Melanoma,INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma,Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma,Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "423996",
"first_name": "Jeffrey",
"middle_name": "",
"last_name": "Weber",
"org_name": "New York University",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232325",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232325",
"events_session": "To Each Their Own: Individualized Antigen Therapy in Melanoma",
"rest_events_session_count": 3,
"rest_events_session": "INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma,Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma,Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial",
"events_topic": "Interleukin-6 | Pembrolizumab ",
"rest_events_topic_count": 6,
"rest_events_topic": " Placebos | Nivolumab | Ipilimumab | Immunotherapy, Adoptive | Tocilizumab | Melanoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1053348706,'423996');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWeber, Jeffrey",
"kol_full_name": "Weber, Jeffrey"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Castration | Antineoplastic Agents, Hormonal | Pembrolizumab | Prostatic Neoplasms | Olaparib | Biomarkers | Receptors, Androgen",
"npi_num": "1043390016",
"hcp_pin_alias": "423994",
"session_name": "CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy: Phase 3 MK-5684-003 trial,A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer,Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "423994",
"first_name": "Evan",
"middle_name": "Ya-Wen",
"last_name": "Yu",
"org_name": "Seattle Cancer Care Alliance",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232653",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232653",
"events_session": "CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy: Phase 3 MK-5684-003 trial",
"rest_events_session_count": 4,
"rest_events_session": "A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer,Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC)",
"events_topic": "Chemotherapy | Castration ",
"rest_events_topic_count": 6,
"rest_events_topic": " Antineoplastic Agents, Hormonal | Pembrolizumab | Prostatic Neoplasms | Olaparib | Biomarkers | Receptors, Androgen",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1043390016,'423994');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYu, Evan Ya-Wen",
"kol_full_name": "Yu, Evan Ya-Wen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genomics | Neoplasms",
"npi_num": "1023034261",
"hcp_pin_alias": "423975",
"session_name": "In-Person Workshop: Genomics 101 for Oncologists",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "423975",
"first_name": "Ramaswamy",
"middle_name": "",
"last_name": "Govindan",
"org_name": "Washington University",
"Country": "United States",
"Region": "Missouri",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232095",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232095",
"events_session": "In-Person Workshop: Genomics 101 for Oncologists",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Genomics | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1023034261,'423975');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGovindan, Ramaswamy",
"kol_full_name": "Govindan, Ramaswamy"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sacituzumab Govitecan | Glioblastoma",
"npi_num": "1013905512",
"hcp_pin_alias": "423968",
"session_name": "A phase II, multicenter, prospective study of sacituzumab govitecan in recurrent glioblastoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "423968",
"first_name": "William",
"middle_name": "Kevin",
"last_name": "Kelly",
"org_name": "Jefferson University Physicians",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233084",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233084",
"events_session": "A phase II",
"rest_events_session_count": 2,
"rest_events_session": " multicenter, prospective study of sacituzumab govitecan in recurrent glioblastoma",
"events_topic": "Sacituzumab Govitecan | Glioblastoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1013905512,'423968');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKelly, William Kevin",
"kol_full_name": "Kelly, William Kevin"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Tebentafusp | Uveal Melanoma",
"npi_num": "1962402321",
"hcp_pin_alias": "413216",
"session_name": "Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "413216",
"first_name": "Alexandra",
"middle_name": "",
"last_name": "Ikeguchi",
"org_name": "Oklahoma University Medical Center",
"Country": "United States",
"Region": "Oklahoma",
"City": "Oklahoma City",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232789",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232789",
"events_session": "Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Tebentafusp | Uveal Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/413216/fromId'\u003EIkeguchi, Alexandra\u003C/a\u003E",
"kol_full_name": "Ikeguchi, Alexandra"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Multiple Myeloma",
"npi_num": "1912235946",
"hcp_pin_alias": "413149",
"session_name": "Addressing Unmet Needs in Multiple Myeloma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "413149",
"first_name": "Sham",
"middle_name": "",
"last_name": "Mailankody",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232139",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232139",
"events_session": "Addressing Unmet Needs in Multiple Myeloma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Multiple Myeloma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/413149/fromId'\u003EMailankody, Sham\u003C/a\u003E",
"kol_full_name": "Mailankody, Sham"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Delivery Of Health Care | Healthcare Disparities | Admin. & Management | Clinical Trials As Topic",
"npi_num": "1154564961",
"hcp_pin_alias": "403597",
"session_name": "Care Delivery/Models of Care: Program Commitee,Bridging Health Disparity Gaps in Clinical Trials and Routine Care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "403597",
"first_name": "Samilia",
"middle_name": "",
"last_name": "Obeng-Gyasi",
"org_name": "Ohio State University Wexner Medical Center",
"Country": "United States",
"Region": "Ohio",
"City": "Columbus",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232106",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232106",
"events_session": "Care Delivery/Models of Care: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Bridging Health Disparity Gaps in Clinical Trials and Routine Care",
"events_topic": "Delivery Of Health Care | Healthcare Disparities ",
"rest_events_topic_count": 2,
"rest_events_topic": " Admin. & Management | Clinical Trials As Topic",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/403597/fromId'\u003EObeng-Gyasi, Samilia\u003C/a\u003E",
"kol_full_name": "Obeng-Gyasi, Samilia"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Melanoma | Immunotherapy, Adoptive",
"npi_num": "1114989761",
"hcp_pin_alias": "390438",
"session_name": "T Cell Therapy, A New Treatment Pathway for Advanced Melanoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "390438",
"first_name": "Brian",
"middle_name": "R",
"last_name": "Gastman",
"org_name": "Cleveland Clinic - Main Campus",
"Country": "United States",
"Region": "Ohio",
"City": "Cleveland",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233159",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233159",
"events_session": "T Cell Therapy",
"rest_events_session_count": 1,
"rest_events_session": " A New Treatment Pathway for Advanced Melanoma",
"events_topic": "Melanoma | Immunotherapy, Adoptive",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/390438/fromId'\u003EGastman, Brian R\u003C/a\u003E",
"kol_full_name": "Gastman, Brian R"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Central Nervous System Neoplasms",
"npi_num": "1396954269",
"hcp_pin_alias": "376249",
"session_name": "Central Nervous System Tumors: Program Commitee,Central Nervous System Tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "376249",
"first_name": "Rimas",
"middle_name": "Vincas",
"last_name": "Lukas",
"org_name": "Northwestern Medical Faculty Foundation",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232036",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232036",
"events_session": "Central Nervous System Tumors: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Central Nervous System Tumors",
"events_topic": "Central Nervous System Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/376249/fromId'\u003ELukas, Rimas Vincas\u003C/a\u003E",
"kol_full_name": "Lukas, Rimas Vincas"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Oropharyngeal Neoplasms | Human Papillomavirus Viruses",
"npi_num": "1952714636",
"hcp_pin_alias": "368843",
"session_name": "Making the Cut: Decision Support Tools in Surgically Treated HPV+ Oropharyngeal Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "368843",
"first_name": "Aditya",
"middle_name": "",
"last_name": "Juloori",
"org_name": "University Of Chicago Medical Center",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231978",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231978",
"events_session": "Making the Cut: Decision Support Tools in Surgically Treated HPV+ Oropharyngeal Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Oropharyngeal Neoplasms | Human Papillomavirus Viruses",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1952714636,'368843');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJuloori, Aditya",
"kol_full_name": "Juloori, Aditya"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Risk Reduction Behavior",
"npi_num": "1669482659",
"hcp_pin_alias": "368393",
"session_name": "Prevention, Risk Reduction, and Hereditary Cancer: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "368393",
"first_name": "Heather",
"middle_name": "Lynn",
"last_name": "Hampel",
"org_name": "",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233248",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233248",
"events_session": "Prevention",
"rest_events_session_count": 2,
"rest_events_session": " Risk Reduction, and Hereditary Cancer: Program Commitee",
"events_topic": "Neoplasms | Risk Reduction Behavior",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1669482659,'368393');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHampel, Heather Lynn",
"kol_full_name": "Hampel, Heather Lynn"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Mastectomy, Segmental | Triple Negative Breast Neoplasms",
"npi_num": "1356392385",
"hcp_pin_alias": "367933",
"session_name": "NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "367933",
"first_name": "Julia",
"middle_name": "R.",
"last_name": "White",
"org_name": "Osu Radiation Oncology Llc",
"Country": "United States",
"Region": "Ohio",
"City": "Columbus",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232640",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232640",
"events_session": "NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1",
"rest_events_session_count": 3,
"rest_events_session": " HR+, HER2-, RS ≤18 breast cancer",
"events_topic": "Mastectomy, Segmental | Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356392385,'367933');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWhite, Julia R.",
"kol_full_name": "White, Julia R."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoadjuvant Therapy | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1205168887",
"hcp_pin_alias": "367712",
"session_name": "NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "367712",
"first_name": "Puneeth",
"middle_name": "",
"last_name": "Iyengar",
"org_name": "",
"Country": "United States",
"Region": "Texas",
"City": "Dallas",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233139",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233139",
"events_session": "NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoadjuvant Therapy | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1205168887,'367712');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EIyengar, Puneeth",
"kol_full_name": "Iyengar, Puneeth"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemoradiotherapy | Hysterectomy | Uterine Cervical Neoplasms | Genital Neoplasms, Female | Chemotherapy, Adjuvant",
"npi_num": "1437244522",
"hcp_pin_alias": "367129",
"session_name": "Gynecologic Cancer: Program Commitee,Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724,Gynecologic Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "367129",
"first_name": "Anuja",
"middle_name": "",
"last_name": "Jhingran",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232081",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232081",
"events_session": "Gynecologic Cancer: Program Commitee",
"rest_events_session_count": 2,
"rest_events_session": "Adjuvant chemotherapy following concurrent chemoradiation (CRT) in patients with high-risk early-stage cervical carcinoma following radical hysterectomy: Results of NRG oncology/RTOG 0724/GOG-0724,Gynecologic Cancer",
"events_topic": "Chemoradiotherapy | Hysterectomy ",
"rest_events_topic_count": 3,
"rest_events_topic": " Uterine Cervical Neoplasms | Genital Neoplasms, Female | Chemotherapy, Adjuvant",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1437244522,'367129');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJhingran, Anuja",
"kol_full_name": "Jhingran, Anuja"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Epcoritamab | Lymphoma, Follicular",
"npi_num": "1598717845",
"hcp_pin_alias": "366162",
"session_name": "EPCORE NHL‑1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "366162",
"first_name": "Julie",
"middle_name": "Marie",
"last_name": "Vose",
"org_name": "",
"Country": "United States",
"Region": "Nebraska",
"City": "Omaha",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232503",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232503",
"events_session": "EPCORE NHL‑1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R/R) FL",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Epcoritamab | Lymphoma, Follicular",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1598717845,'366162');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVose, Julie Marie",
"kol_full_name": "Vose, Julie Marie"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Rituximab | Lenalidomide | Lymphoma, Non-Hodgkin | Immunotherapy",
"npi_num": "1114155603",
"hcp_pin_alias": "366160",
"session_name": "Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "366160",
"first_name": "Jose",
"middle_name": "Caetano",
"last_name": "Villasboas Bisneto",
"org_name": "Mayo Clinic - Rochester",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232382",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232382",
"events_session": "Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL (EONHL1-20/SIDNEY)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Rituximab | Lenalidomide ",
"rest_events_topic_count": 2,
"rest_events_topic": " Lymphoma, Non-Hodgkin | Immunotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1114155603,'366160');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVillasboas Bisneto, Jose Caetano",
"kol_full_name": "Villasboas Bisneto, Jose Caetano"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy, Adoptive | Lymphoma",
"npi_num": "1578580460",
"hcp_pin_alias": "366133",
"session_name": "Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "366133",
"first_name": "Jakub",
"middle_name": "",
"last_name": "Svoboda",
"org_name": "University of Pennsylvania Health System",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232778",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232778",
"events_session": "Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunotherapy, Adoptive | Lymphoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1578580460,'366133');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESvoboda, Jakub",
"kol_full_name": "Svoboda, Jakub"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptor-CD3 Complex, Antigen, T-Cell",
"npi_num": "1154737765",
"hcp_pin_alias": "366128",
"session_name": "New Agents on the Horizon: Targets Other Than CD3/CD20, New Constructs and Trispecifics",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "366128",
"first_name": "Paolo",
"middle_name": "",
"last_name": "Strati",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232127",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232127",
"events_session": "New Agents on the Horizon: Targets Other Than CD3/CD20",
"rest_events_session_count": 1,
"rest_events_session": " New Constructs and Trispecifics",
"events_topic": "Receptor-CD3 Complex, Antigen, T-Cell",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1154737765,'366128');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EStrati, Paolo",
"kol_full_name": "Strati, Paolo"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptors, Chimeric Antigen | Thyroid Neoplasms",
"npi_num": "1598900698",
"hcp_pin_alias": "366119",
"session_name": "Safety and efficacy of AIC100 chimeric antigen receptor (CAR) T-cell therapy in patients with advanced thyroid cancers: Results from the phase 1 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "366119",
"first_name": "Samer",
"middle_name": "",
"last_name": "Srour",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232572",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232572",
"events_session": "Safety and efficacy of AIC100 chimeric antigen receptor (CAR) T-cell therapy in patients with advanced thyroid cancers: Results from the phase 1 study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Receptors, Chimeric Antigen | Thyroid Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1598900698,'366119');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESrour, Samer",
"kol_full_name": "Srour, Samer"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "PARP1 Protein, Human | Solid Tumor",
"npi_num": "1083655716",
"hcp_pin_alias": "366114",
"session_name": "A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "366114",
"first_name": "Guru",
"middle_name": "P",
"last_name": "Sonpavde",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232989",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232989",
"events_session": "A first-in-human (FIH)",
"rest_events_session_count": 4,
"rest_events_session": " phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor IMP1734 in participants with advanced solid tumors",
"events_topic": "PARP1 Protein, Human | Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1083655716,'366114');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESonpavde, Guru P",
"kol_full_name": "Sonpavde, Guru P"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Leukemia, Lymphocytic, Chronic, B-Cell | Zanzalintinib | Venetoclax | Obinutuzumab | Bruton's Tyrosine Kinase | Sonrotoclax",
"npi_num": "1750554077",
"hcp_pin_alias": "366098",
"session_name": "CELESTIAL-TNCLL: An ongoing, open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL,Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "366098",
"first_name": "Mazyar",
"middle_name": "",
"last_name": "Shadman",
"org_name": "Fred Hutchinson Cancer Research Center",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232378",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232378",
"events_session": "CELESTIAL-TNCLL: An ongoing",
"rest_events_session_count": 4,
"rest_events_session": " open-label, multiregional, phase 3 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-naïve (TN) CLL,Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA)",
"events_topic": "Leukemia, Lymphocytic, Chronic, B-Cell | Zanzalintinib ",
"rest_events_topic_count": 4,
"rest_events_topic": " Venetoclax | Obinutuzumab | Bruton's Tyrosine Kinase | Sonrotoclax",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1750554077,'366098');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShadman, Mazyar",
"kol_full_name": "Shadman, Mazyar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lymphoma, Mantle-Cell | Glofitamab | Lisocabtagene Maraleucel",
"npi_num": "1568607653",
"hcp_pin_alias": "366032",
"session_name": "Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study,Estimating the health care costs associated with receipt of lisocabtagene maraleucel: Insights from adults with mantle cell lymphoma (TRANSCEND NHL 001)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "366032",
"first_name": "Tycel",
"middle_name": "Jovelle",
"last_name": "Phillips",
"org_name": "University of Michigan Health System",
"Country": "United States",
"Region": "Michigan",
"City": "Ann Arbor",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232371",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232371",
"events_session": "Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study",
"rest_events_session_count": 1,
"rest_events_session": "Estimating the health care costs associated with receipt of lisocabtagene maraleucel: Insights from adults with mantle cell lymphoma (TRANSCEND NHL 001)",
"events_topic": "Lymphoma, Mantle-Cell | Glofitamab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Lisocabtagene Maraleucel",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1568607653,'366032');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPhillips, Tycel Jovelle",
"kol_full_name": "Phillips, Tycel Jovelle"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "CD70 Protein, Human | Nivolumab | Zanzalintinib | Solid Tumor | Carcinoma, Renal Cell | Biomarkers | Clustered Regularly Interspaced Short Palindromic Repeats",
"npi_num": "1700938180",
"hcp_pin_alias": "366020",
"session_name": "Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma,A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors,Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study,Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001,What Is Variant Histology Renal Cell Cancer and What Are the Available Treatment Options?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "366020",
"first_name": "Sumanta",
"middle_name": "K.",
"last_name": "Pal",
"org_name": "City of Hope Medical Foundation",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "5",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232157",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232157",
"events_session": "Preliminary safety",
"rest_events_session_count": 10,
"rest_events_session": " pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma,A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors,Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study,Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001,What Is Variant Histology Renal Cell Cancer and What Are the Available Treatment Options?",
"events_topic": "CD70 Protein, Human | Nivolumab ",
"rest_events_topic_count": 5,
"rest_events_topic": " Zanzalintinib | Solid Tumor | Carcinoma, Renal Cell | Biomarkers | Clustered Regularly Interspaced Short Palindromic Repeats",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700938180,'366020');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPal, Sumanta K.",
"kol_full_name": "Pal, Sumanta K."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lymphoma, Follicular",
"npi_num": "1407048630",
"hcp_pin_alias": "365997",
"session_name": "Follicular Lymphoma: A Case-Based Exploration of Treatment Choices and Management",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365997",
"first_name": "Loretta",
"middle_name": "J",
"last_name": "Nastoupil",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232078",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232078",
"events_session": "Follicular Lymphoma: A Case-Based Exploration of Treatment Choices and Management",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Lymphoma, Follicular",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1407048630,'365997');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENastoupil, Loretta J",
"kol_full_name": "Nastoupil, Loretta J"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Leukemia | Head And Neck Neoplasms | Immune System",
"npi_num": "1427256254",
"hcp_pin_alias": "365988",
"session_name": "Head and Neck Cancer: Program Commitee,Harnessing the Power of the Immune System for Acute Leukemias",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365988",
"first_name": "Lori",
"middle_name": "S",
"last_name": "Muffly",
"org_name": "Stanford Health Care",
"Country": "United States",
"Region": "California",
"City": "Stanford",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233111",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233111",
"events_session": "Head and Neck Cancer: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Harnessing the Power of the Immune System for Acute Leukemias",
"events_topic": "Leukemia | Head And Neck Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Immune System",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1427256254,'365988');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMuffly, Lori S",
"kol_full_name": "Muffly, Lori S"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Primary Myelofibrosis | Danazol",
"npi_num": "1962480475",
"hcp_pin_alias": "365979",
"session_name": "Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365979",
"first_name": "Ruben",
"middle_name": "Anthony",
"last_name": "Mesa",
"org_name": "University of Texas Health Science Center at San Antonio",
"Country": "United States",
"Region": "Texas",
"City": "San Antonio",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232346",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232346",
"events_session": "Long-term survival adjusted for treatment crossover in patients (pts) with myelofibrosis (MF) treated with momelotinib (MMB) vs danazol (DAN) in the MOMENTUM trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Primary Myelofibrosis | Danazol",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1962480475,'365979');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMesa, Ruben Anthony",
"kol_full_name": "Mesa, Ruben Anthony"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Rituximab | Odronextamab | Lymphoma, Large B-Cell, Diffuse",
"npi_num": "1629237987",
"hcp_pin_alias": "365965",
"session_name": "Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365965",
"first_name": "Matthew",
"middle_name": "J",
"last_name": "Matasar",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "Commack",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232386",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232386",
"events_session": "Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Rituximab | Odronextamab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Lymphoma, Large B-Cell, Diffuse",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1629237987,'365965');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMatasar, Matthew J",
"kol_full_name": "Matasar, Matthew J"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lymphoma, Mantle-Cell | Bruton's Tyrosine Kinase",
"npi_num": "1689698284",
"hcp_pin_alias": "365952",
"session_name": "Beyond BTK Inhibitors in Mantle Cell Lymphoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365952",
"first_name": "Kami",
"middle_name": "J.",
"last_name": "Maddocks",
"org_name": "Ohio State University Wexner Medical Center",
"Country": "United States",
"Region": "Ohio",
"City": "Columbus",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232781",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232781",
"events_session": "Beyond BTK Inhibitors in Mantle Cell Lymphoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Lymphoma, Mantle-Cell | Bruton's Tyrosine Kinase",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1689698284,'365952');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMaddocks, Kami J.",
"kol_full_name": "Maddocks, Kami J."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pharmaceutical Preparations",
"npi_num": "1487762118",
"hcp_pin_alias": "365941",
"session_name": "Antibody, Linker, Drug: Teasing Apart What Matters",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365941",
"first_name": "Sagar",
"middle_name": "",
"last_name": "Lonial",
"org_name": "Emory University Hospital",
"Country": "United States",
"Region": "Georgia",
"City": "Atlanta",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232543",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232543",
"events_session": "Antibody",
"rest_events_session_count": 2,
"rest_events_session": " Linker, Drug: Teasing Apart What Matters",
"events_topic": "Pharmaceutical Preparations",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1487762118,'365941');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELonial, Sagar",
"kol_full_name": "Lonial, Sagar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Paraproteinemias | Hematologic Neoplasms | Admin. & Management",
"npi_num": "1104853324",
"hcp_pin_alias": "365925",
"session_name": "Amandeep Godara – Track Leader: Program Commitee,Hematologic Malignancies—Plasma Cell Dyscrasia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365925",
"first_name": "Suzanne",
"middle_name": "",
"last_name": "Lentzsch",
"org_name": "Trustees of Columbia University in the City of New York",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231977",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231977",
"events_session": "Amandeep Godara – Track Leader: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Hematologic Malignancies—Plasma Cell Dyscrasia",
"events_topic": "Paraproteinemias | Hematologic Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Admin. & Management",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1104853324,'365925');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELentzsch, Suzanne",
"kol_full_name": "Lentzsch, Suzanne"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hematologic Neoplasms | Chronic Lymphocytic Leukemia | Lymphoma",
"npi_num": "1336156983",
"hcp_pin_alias": "365908",
"session_name": "Hematologic Malignancies – Lymphoma and CLL: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365908",
"first_name": "Ann",
"middle_name": "S",
"last_name": "Lacasce",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Milford",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233222",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233222",
"events_session": "Hematologic Malignancies – Lymphoma and CLL: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Hematologic Neoplasms | Chronic Lymphocytic Leukemia ",
"rest_events_topic_count": 1,
"rest_events_topic": " Lymphoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1336156983,'365908');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELacasce, Ann S",
"kol_full_name": "Lacasce, Ann S"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Linvoseltamab | Multiple Myeloma",
"npi_num": "1568434090",
"hcp_pin_alias": "365902",
"session_name": "How Do We Define High-Risk and Ultra-High-Risk Multiple Myeloma?,Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365902",
"first_name": "Shaji",
"middle_name": "Kunnathu",
"last_name": "Kumar",
"org_name": "Mayo Clinic - Rochester",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232363",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232363",
"events_session": "How Do We Define High-Risk and Ultra-High-Risk Multiple Myeloma?",
"rest_events_session_count": 1,
"rest_events_session": "Comparative effectiveness of linvoseltamab versus standard-of-care (SOC) treatment (tx) in real-world patients (pts) in the United States (US) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)",
"events_topic": "Linvoseltamab | Multiple Myeloma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1568434090,'365902');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKumar, Shaji Kunnathu",
"kol_full_name": "Kumar, Shaji Kunnathu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Leukemia, Lymphocytic, Chronic, B-Cell | Hematologic Neoplasms",
"npi_num": "1831313691",
"hcp_pin_alias": "365893",
"session_name": "Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365893",
"first_name": "Justin",
"middle_name": "Paul",
"last_name": "Kline",
"org_name": "University Of Chicago Medical Center",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232068",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232068",
"events_session": "Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Leukemia, Lymphocytic, Chronic, B-Cell | Hematologic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1831313691,'365893');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKline, Justin Paul",
"kol_full_name": "Kline, Justin Paul"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Stem Cell Transplantation | Chemotherapy | Lisocabtagene Maraleucel | Lymphoma, Large B-Cell, Diffuse",
"npi_num": "1184817959",
"hcp_pin_alias": "365875",
"session_name": "Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365875",
"first_name": "Manali",
"middle_name": "K",
"last_name": "Kamdar",
"org_name": "University of Colorado Health Science Center",
"Country": "United States",
"Region": "Colorado",
"City": "Aurora",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232501",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232501",
"events_session": "Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized",
"rest_events_session_count": 1,
"rest_events_session": " phase 3 TRANSFORM study",
"events_topic": "Stem Cell Transplantation | Chemotherapy ",
"rest_events_topic_count": 2,
"rest_events_topic": " Lisocabtagene Maraleucel | Lymphoma, Large B-Cell, Diffuse",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1184817959,'365875');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKamdar, Manali K",
"kol_full_name": "Kamdar, Manali K"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Admin. & Management",
"npi_num": "1134205081",
"hcp_pin_alias": "365860",
"session_name": "Amandeep Godara – Track Leader: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365860",
"first_name": "Andrzej",
"middle_name": "J",
"last_name": "Jakubowiak",
"org_name": "University Of Chicago Medical Center",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233224",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233224",
"events_session": "Amandeep Godara – Track Leader: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Admin. & Management",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1134205081,'365860');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJakubowiak, Andrzej J",
"kol_full_name": "Jakubowiak, Andrzej J"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genetics | Risk Reduction Behavior",
"npi_num": "1164414751",
"hcp_pin_alias": "365851",
"session_name": "Prevention, Risk Reduction, and Genetics",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365851",
"first_name": "Claudine",
"middle_name": "Janet Diana",
"last_name": "Isaacs",
"org_name": "",
"Country": "United States",
"Region": "District of Columbia",
"City": "Washington",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232084",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232084",
"events_session": "Prevention",
"rest_events_session_count": 2,
"rest_events_session": " Risk Reduction, and Genetics",
"events_topic": "Genetics | Risk Reduction Behavior",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1164414751,'365851');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EIsaacs, Claudine Janet Diana",
"kol_full_name": "Isaacs, Claudine Janet Diana"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Carcinoma, Transitional Cell | Tazemetostat",
"npi_num": "1245316199",
"hcp_pin_alias": "365848",
"session_name": "A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365848",
"first_name": "Maha",
"middle_name": "H. A.",
"last_name": "Hussain",
"org_name": "Northwestern Memorial Hospital",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232594",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232594",
"events_session": "A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pembrolizumab | Carcinoma, Transitional Cell ",
"rest_events_topic_count": 1,
"rest_events_topic": " Tazemetostat",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1245316199,'365848');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHussain, Maha H. A.",
"kol_full_name": "Hussain, Maha H. A."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Central Nervous System Neoplasms | Glioma",
"npi_num": "1386709046",
"hcp_pin_alias": "365842",
"session_name": "Nontargeted and Targeted Approaches to Glioma and Central Nervous System Lymphoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365842",
"first_name": "Matthias",
"middle_name": "",
"last_name": "Holdhoff",
"org_name": "The Johns Hopkins Hospital",
"Country": "United States",
"Region": "District of Columbia",
"City": "Washington",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232458",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232458",
"events_session": "Nontargeted and Targeted Approaches to Glioma and Central Nervous System Lymphoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Central Nervous System Neoplasms | Glioma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1386709046,'365842');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHoldhoff, Matthias",
"kol_full_name": "Holdhoff, Matthias"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hodgkin Disease",
"npi_num": "1275761553",
"hcp_pin_alias": "365838",
"session_name": "Paradigm Changes for Newly Diagnosed Hodgkin Lymphoma: Discussion of Recent Trial Results,Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365838",
"first_name": "Alex",
"middle_name": "",
"last_name": "Herrera",
"org_name": "City of Hope Medical Foundation",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231984",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231984",
"events_session": "Paradigm Changes for Newly Diagnosed Hodgkin Lymphoma: Discussion of Recent Trial Results",
"rest_events_session_count": 1,
"rest_events_session": "Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease",
"events_topic": "Hodgkin Disease",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1275761553,'365838');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHerrera, Alex",
"kol_full_name": "Herrera, Alex"
},
{
"proj_kol_id": 2,
"eid": "23416",
"event_topics": "Myelodysplastic Syndromes | Azacitidine | Interleukin-1 Receptor-Associated Kinases",
"npi_num": "1013078294",
"hcp_pin_alias": "365808",
"session_name": "Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial,Phase 1b trial of IRAK 1/4 inhibition for low-risk myelodysplastic syndrome refractory/resistant to prior therapies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365808",
"first_name": "Guillermo",
"middle_name": "",
"last_name": "Garcia-Manero",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "0",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232356",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232356",
"events_session": "Preliminary safety and efficacy of oral azacitidine (Oral-AZA) in patients (pts) with low-/Intermediate (Int)-risk myelodysplastic syndromes (MDS): Phase 2 results from the ASTREON trial",
"rest_events_session_count": 1,
"rest_events_session": "Phase 1b trial of IRAK 1/4 inhibition for low-risk myelodysplastic syndrome refractory/resistant to prior therapies",
"events_topic": "Myelodysplastic Syndromes | Azacitidine ",
"rest_events_topic_count": 1,
"rest_events_topic": " Interleukin-1 Receptor-Associated Kinases",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/365808'\u003EGarcia-Manero, Guillermo\u003C/a\u003E",
"kol_full_name": "Garcia-Manero, Guillermo"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hematologic Neoplasms",
"npi_num": "1316000771",
"hcp_pin_alias": "365760",
"session_name": "Testing for Hereditary Hematologic Malignancies and Recommended Surveillance in Patients and Family Members",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365760",
"first_name": "Courtney",
"middle_name": "Denton",
"last_name": "Dinardo",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233143",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233143",
"events_session": "Testing for Hereditary Hematologic Malignancies and Recommended Surveillance in Patients and Family Members",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Hematologic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1316000771,'365760');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDinardo, Courtney Denton",
"kol_full_name": "Dinardo, Courtney Denton"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Entrectinib | Neuroblastoma | Neoplasms | Central Nervous System Neoplasms | Combined Modality Therapy",
"npi_num": "1790967164",
"hcp_pin_alias": "365755",
"session_name": "A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group,Efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring NTRK or ROS1 fusions,Pediatric Oncologist Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365755",
"first_name": "Ami",
"middle_name": "Vijay",
"last_name": "Desai",
"org_name": "University Of Chicago Medical Center",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232154",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232154",
"events_session": "A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group",
"rest_events_session_count": 2,
"rest_events_session": "Efficacy and safety of entrectinib in children with extracranial solid or primary central nervous system (CNS) tumors harboring NTRK or ROS1 fusions,Pediatric Oncologist Perspective",
"events_topic": "Entrectinib | Neuroblastoma ",
"rest_events_topic_count": 3,
"rest_events_topic": " Neoplasms | Central Nervous System Neoplasms | Combined Modality Therapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790967164,'365755');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDesai, Ami Vijay",
"kol_full_name": "Desai, Ami Vijay"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Multiple Myeloma | Neoplasm, Residual",
"npi_num": "1730526310",
"hcp_pin_alias": "365754",
"session_name": "Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365754",
"first_name": "Benjamin",
"middle_name": "A",
"last_name": "Derman",
"org_name": "University Of Chicago Medical Center",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232312",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232312",
"events_session": "Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Multiple Myeloma | Neoplasm, Residual",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1730526310,'365754');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDerman, Benjamin A",
"kol_full_name": "Derman, Benjamin A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ponatinib | Leukemia, Myeloid, Chronic-Phase",
"npi_num": "1932115524",
"hcp_pin_alias": "365752",
"session_name": "Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365752",
"first_name": "Michael",
"middle_name": "Werner Nikolaus",
"last_name": "Deininger",
"org_name": "University of Utah Hospitals and Clinics",
"Country": "United States",
"Region": "Utah",
"City": "Salt Lake City",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233105",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233105",
"events_session": "Ponatinib (PON) in patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) and the T315I mutation (mut): 4-year results from OPTIC",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Ponatinib | Leukemia, Myeloid, Chronic-Phase",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1932115524,'365752');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDeininger, Michael Werner Nikolaus",
"kol_full_name": "Deininger, Michael Werner Nikolaus"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia | Hematologic Neoplasms | Lymphoma",
"npi_num": "1487769733",
"hcp_pin_alias": "365746",
"session_name": "Hematologic Malignancies – Lymphoma and CLL: Program Commitee,Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365746",
"first_name": "Alexey",
"middle_name": "",
"last_name": "Danilov",
"org_name": "City Of Hope Comprehensive Cancer Center - Duarte",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232028",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232028",
"events_session": "Hematologic Malignancies – Lymphoma and CLL: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia",
"events_topic": "Leukemia, Lymphocytic, Chronic, B-Cell | Chronic Lymphocytic Leukemia ",
"rest_events_topic_count": 2,
"rest_events_topic": " Hematologic Neoplasms | Lymphoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1487769733,'365746');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDanilov, Alexey",
"kol_full_name": "Danilov, Alexey"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Paraproteinemias | Hematologic Neoplasms | Admin. & Management",
"npi_num": "1194722462",
"hcp_pin_alias": "365711",
"session_name": "Amandeep Godara – Track Leader: Program Commitee,Hematologic Malignancies—Plasma Cell Dyscrasia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365711",
"first_name": "Asher",
"middle_name": "A.",
"last_name": "Chanan-Khan",
"org_name": "Mayo Clinic Jacksonville",
"Country": "United States",
"Region": "Florida",
"City": "Jacksonville",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231966",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231966",
"events_session": "Amandeep Godara – Track Leader: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Hematologic Malignancies—Plasma Cell Dyscrasia",
"events_topic": "Paraproteinemias | Hematologic Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Admin. & Management",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1194722462,'365711');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChanan-Khan, Asher A.",
"kol_full_name": "Chanan-Khan, Asher A."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Non-Muscle Invasive Bladder Neoplasms | Avelumab | Immune Checkpoint Inhibitors | Carcinoma, Transitional Cell",
"npi_num": "1124462726",
"hcp_pin_alias": "365674",
"session_name": "Combined high-resolution H3K27ac epigenomic and single-cell transcriptional profiling as a signature predictive of response to neoadjuvant immune checkpoint inhibitors (ICI) in urothelial cancer (UC),Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365674",
"first_name": "Joaquin",
"middle_name": "",
"last_name": "Bellmunt Molins",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232590",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232590",
"events_session": "Combined high-resolution H3K27ac epigenomic and single-cell transcriptional profiling as a signature predictive of response to neoadjuvant immune checkpoint inhibitors (ICI) in urothelial cancer (UC)",
"rest_events_session_count": 1,
"rest_events_session": "Avelumab first-line maintenance (1LM) for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in patients (pts) with low tumor burden",
"events_topic": "Non-Muscle Invasive Bladder Neoplasms | Avelumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Immune Checkpoint Inhibitors | Carcinoma, Transitional Cell",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1124462726,'365674');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBellmunt Molins, Joaquin",
"kol_full_name": "Bellmunt Molins, Joaquin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lymphoma, Non-Hodgkin | Glofitamab",
"npi_num": "1316965759",
"hcp_pin_alias": "365668",
"session_name": "Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365668",
"first_name": "Nancy",
"middle_name": "Lee",
"last_name": "Bartlett",
"org_name": "Washington University School Of Medicine",
"Country": "United States",
"Region": "Missouri",
"City": "St. Louis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232368",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232368",
"events_session": "Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): Results from a phase I/II study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Lymphoma, Non-Hodgkin | Glofitamab",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1316965759,'365668');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBartlett, Nancy Lee",
"kol_full_name": "Bartlett, Nancy Lee"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Belzutifan | Clear-cell Metastatic Renal Cell Carcinoma",
"npi_num": "1306874201",
"hcp_pin_alias": "365660",
"session_name": "Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365660",
"first_name": "Michael",
"middle_name": "B.",
"last_name": "Atkins",
"org_name": "",
"Country": "United States",
"Region": "District of Columbia",
"City": "Washington",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232583",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232583",
"events_session": "Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Belzutifan | Clear-cell Metastatic Renal Cell Carcinoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1306874201,'365660');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAtkins, Michael B.",
"kol_full_name": "Atkins, Michael B."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "ABVD Chemotherapy | Hodgkin Disease",
"npi_num": "1558335935",
"hcp_pin_alias": "365655",
"session_name": "Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365655",
"first_name": "Stephen",
"middle_name": "Maxted",
"last_name": "Ansell",
"org_name": "Mayo Clinic - Rochester",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232379",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232379",
"events_session": "Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "ABVD Chemotherapy | Hodgkin Disease",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1558335935,'365655');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAnsell, Stephen Maxted",
"kol_full_name": "Ansell, Stephen Maxted"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Epcoritamab | Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse",
"npi_num": "1609061837",
"hcp_pin_alias": "365650",
"session_name": "Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365650",
"first_name": "David",
"middle_name": "Jacob",
"last_name": "Andorsky",
"org_name": "Rocky Mountain Cancer Centers LLP",
"Country": "United States",
"Region": "Colorado",
"City": "Boulder",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232372",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232372",
"events_session": "Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Epcoritamab | Lymphoma, Follicular ",
"rest_events_topic_count": 1,
"rest_events_topic": " Lymphoma, Large B-Cell, Diffuse",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1609061837,'365650');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAndorsky, David Jacob",
"kol_full_name": "Andorsky, David Jacob"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms | Castration",
"npi_num": "1255302055",
"hcp_pin_alias": "365603",
"session_name": "A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365603",
"first_name": "Michael",
"middle_name": "",
"last_name": "Morris",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232282",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232282",
"events_session": "A phase 1 study of JNJ-69086420 (JNJ-6420)",
"rest_events_session_count": 2,
"rest_events_session": " an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC)",
"events_topic": "Prostatic Neoplasms | Castration",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1255302055,'365603');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMorris, Michael",
"kol_full_name": "Morris, Michael"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell",
"npi_num": "1770599664",
"hcp_pin_alias": "365577",
"session_name": "A phase I, first-in-human study of ONO-7018 in patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365577",
"first_name": "John",
"middle_name": "C.",
"last_name": "Byrd",
"org_name": "Ohio State University Wexner Medical Center",
"Country": "United States",
"Region": "Ohio",
"City": "Dublin",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232384",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232384",
"events_session": "A phase I",
"rest_events_session_count": 1,
"rest_events_session": " first-in-human study of ONO-7018 in patients with relapsed/refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia",
"events_topic": "Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1770599664,'365577');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EByrd, John C.",
"kol_full_name": "Byrd, John C."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Melanoma | Fluorodeoxyglucose F18 | Positron-Emission Tomography | Immunotherapy",
"npi_num": "1942247978",
"hcp_pin_alias": "365243",
"session_name": "FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "365243",
"first_name": "Li",
"middle_name": "",
"last_name": "Zhou",
"org_name": "Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232786",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232786",
"events_session": "FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Melanoma | Fluorodeoxyglucose F18 ",
"rest_events_topic_count": 2,
"rest_events_topic": " Positron-Emission Tomography | Immunotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1942247978,'365243');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EZhou, Li",
"kol_full_name": "Zhou, Li"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Fertility",
"npi_num": "1942241641",
"hcp_pin_alias": "364379",
"session_name": "Critical Concepts in Oncofertility for Clinicians and Primary Care Providers,Rethinking Oncofertility: Empowering Education and Advocacy in Cancer Care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "364379",
"first_name": "Alison",
"middle_name": "Wakoff",
"last_name": "Loren",
"org_name": "University of Pennsylvania Health System",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232020",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232020",
"events_session": "Critical Concepts in Oncofertility for Clinicians and Primary Care Providers",
"rest_events_session_count": 1,
"rest_events_session": "Rethinking Oncofertility: Empowering Education and Advocacy in Cancer Care",
"events_topic": "Neoplasms | Fertility",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1942241641,'364379');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELoren, Alison Wakoff",
"kol_full_name": "Loren, Alison Wakoff"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Renal Cell | Urogenital Neoplasms | Urinary Bladder Neoplasms | Immunotherapy | Kidney Neoplasms",
"npi_num": "1477991933",
"hcp_pin_alias": "364325",
"session_name": "Genitourinary Cancer – Kidney and Bladder: Program Commitee,Harnessing the Immune System in Renal Cell Carcinoma: Current and Novel Immunotherapy Approaches",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "364325",
"first_name": "David",
"middle_name": "Alexander",
"last_name": "Braun",
"org_name": "Brigham and Womens Hospital",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232929",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232929",
"events_session": "Genitourinary Cancer – Kidney and Bladder: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Harnessing the Immune System in Renal Cell Carcinoma: Current and Novel Immunotherapy Approaches",
"events_topic": "Carcinoma, Renal Cell | Urogenital Neoplasms ",
"rest_events_topic_count": 3,
"rest_events_topic": " Urinary Bladder Neoplasms | Immunotherapy | Kidney Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1477991933,'364325');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBraun, David Alexander",
"kol_full_name": "Braun, David Alexander"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Leukemia, Lymphocytic, Chronic, B-Cell | Hematologic Neoplasms",
"npi_num": "1457319717",
"hcp_pin_alias": "364321",
"session_name": "Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "364321",
"first_name": "Hetty",
"middle_name": "",
"last_name": "Carraway",
"org_name": "Cleveland Clinic - Main Campus",
"Country": "United States",
"Region": "Ohio",
"City": "Cleveland",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232067",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232067",
"events_session": "Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Leukemia, Lymphocytic, Chronic, B-Cell | Hematologic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/364321/fromId'\u003ECarraway, Hetty\u003C/a\u003E",
"kol_full_name": "Carraway, Hetty"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Platelet Transfusion | Erythropoiesis | Erythrocytes | Imetelstat | Myelodysplastic Syndromes",
"npi_num": "1083819528",
"hcp_pin_alias": "364278",
"session_name": "Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge,Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "364278",
"first_name": "Amer",
"middle_name": "",
"last_name": "Zeidan",
"org_name": "",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232343",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232343",
"events_session": "Efficacy of imetelstat on red blood cell (RBC)-transfusion independence (TI) in the absence of platelet transfusions or myeloid growth factors in IMerge",
"rest_events_session_count": 3,
"rest_events_session": "Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial",
"events_topic": "Platelet Transfusion | Erythropoiesis ",
"rest_events_topic_count": 3,
"rest_events_topic": " Erythrocytes | Imetelstat | Myelodysplastic Syndromes",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1083819528,'364278');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EZeidan, Amer",
"kol_full_name": "Zeidan, Amer"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Azacitidine | Immunotherapy, Adoptive | Venetoclax | Clustered Regularly Interspaced Short Palindromic Repeats | Leukemia, Myeloid, Acute",
"npi_num": "1740422823",
"hcp_pin_alias": "364264",
"session_name": "A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify),A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "364264",
"first_name": "Naval",
"middle_name": "Gustad",
"last_name": "Daver",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232354",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232354",
"events_session": "A first-in-human phase 1",
"rest_events_session_count": 5,
"rest_events_session": " multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify),A phase 1b/2 study of pivekimab sunirine (PVEK, IMGN632) in combination with venetoclax/azacitidine for patients with newly diagnosed CD123-positive acute myeloid leukemia",
"events_topic": "Azacitidine | Immunotherapy, Adoptive ",
"rest_events_topic_count": 3,
"rest_events_topic": " Venetoclax | Clustered Regularly Interspaced Short Palindromic Repeats | Leukemia, Myeloid, Acute",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1740422823,'364264');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDaver, Naval Gustad",
"kol_full_name": "Daver, Naval Gustad"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nivolumab | Solid Tumor | Ipilimumab",
"npi_num": "1962596551",
"hcp_pin_alias": "309201",
"session_name": "Nivolumab plus ipilimumab (N+I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "309201",
"first_name": "John",
"middle_name": "K",
"last_name": "Chan",
"org_name": "Sutter Bay Medical Foundation",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232965",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232965",
"events_session": "Nivolumab plus ipilimumab (N+I) in patients (pts) with solid tumors with high tumor mutational burden (HTMB): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Nivolumab | Solid Tumor ",
"rest_events_topic_count": 1,
"rest_events_topic": " Ipilimumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1962596551,'309201');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChan, John K",
"kol_full_name": "Chan, John K"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Endometrial Neoplasms | Breast Neoplasms",
"npi_num": "1871818534",
"hcp_pin_alias": "302267",
"session_name": "Borrowing From Breast Cancer: Endocrine Combinations in Endometrial Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "302267",
"first_name": "Lauren",
"middle_name": "Patterson",
"last_name": "Cobb",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232919",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232919",
"events_session": "Borrowing From Breast Cancer: Endocrine Combinations in Endometrial Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Endometrial Neoplasms | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1871818534,'302267');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECobb, Lauren Patterson",
"kol_full_name": "Cobb, Lauren Patterson"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pancreatic Neoplasms | Ovarian Neoplasms | Killer Cells, Natural | Adenocarcinoma",
"npi_num": "1871099465",
"hcp_pin_alias": "301679",
"session_name": "Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "301679",
"first_name": "Anne",
"middle_name": "",
"last_name": "Knisely",
"org_name": "Trustees of Columbia University in the City of New York",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232440",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232440",
"events_session": "Phase I/II study of TROP2 CAR engineered IL15-transduced cord blood-derived NK cells delivered intraperitoneally for the management of platinum resistant ovarian cancer",
"rest_events_session_count": 2,
"rest_events_session": " mesonephric-like adenocarcinoma, and pancreatic cancer",
"events_topic": "Pancreatic Neoplasms | Ovarian Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Killer Cells, Natural | Adenocarcinoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1871099465,'301679');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKnisely, Anne",
"kol_full_name": "Knisely, Anne"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Advance Care Planning",
"npi_num": "1851788285",
"hcp_pin_alias": "300779",
"session_name": "Trends in the providers’ uptake of advance care planning from 2016 to 2021",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "300779",
"first_name": "Nan",
"middle_name": "",
"last_name": "Wang",
"org_name": "Nash OB-GYN Associates, PA",
"Country": "United States",
"Region": "North Carolina",
"City": "Rocky Mount",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233046",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233046",
"events_session": "Trends in the providers’ uptake of advance care planning from 2016 to 2021",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Advance Care Planning",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1851788285,'300779');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWang, Nan",
"kol_full_name": "Wang, Nan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1801949540",
"hcp_pin_alias": "296829",
"session_name": "Discussion on Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "296829",
"first_name": "Shitanshu",
"middle_name": "",
"last_name": "Uppal",
"org_name": "Midmichigan Medical Center-Midland",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232734",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232734",
"events_session": "Discussion on Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1801949540,'296829');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EUppal, Shitanshu",
"kol_full_name": "Uppal, Shitanshu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sudocetaxel Zendusortide | Immunoconjugates | Solid Tumor",
"npi_num": "1790982031",
"hcp_pin_alias": "296108",
"session_name": "Long-term efficacy, safety and PK data of TH1902 (sudocetaxel zendusortide) in solid tumors: A novel SORT1-targeting peptide-drug-conjugate (PDC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "296108",
"first_name": "Ira",
"middle_name": "Seth",
"last_name": "Winer",
"org_name": "University of Michigan Health System",
"Country": "United States",
"Region": "Michigan",
"City": "Detroit",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232954",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232954",
"events_session": "Long-term efficacy",
"rest_events_session_count": 1,
"rest_events_session": " safety and PK data of TH1902 (sudocetaxel zendusortide) in solid tumors: A novel SORT1-targeting peptide-drug-conjugate (PDC)",
"events_topic": "Sudocetaxel Zendusortide | Immunoconjugates ",
"rest_events_topic_count": 1,
"rest_events_topic": " Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790982031,'296108');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWiner, Ira Seth",
"kol_full_name": "Winer, Ira Seth"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genital Neoplasms, Female | Neuroendocrine Tumors",
"npi_num": "1770750598",
"hcp_pin_alias": "294256",
"session_name": "Neuroendocrine Gynecologic Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "294256",
"first_name": "Amanda",
"middle_name": "",
"last_name": "Nickles Fader",
"org_name": "Johns Hopkins University",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232507",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232507",
"events_session": "Neuroendocrine Gynecologic Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Genital Neoplasms, Female | Neuroendocrine Tumors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1770750598,'294256');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENickles Fader, Amanda",
"kol_full_name": "Nickles Fader, Amanda"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genital Neoplasms, Female",
"npi_num": "1770598278",
"hcp_pin_alias": "294011",
"session_name": "Gynecologic Cancer: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "294011",
"first_name": "Tanja",
"middle_name": "Branko",
"last_name": "Pejovic",
"org_name": "Oregon Health & Science University",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233215",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233215",
"events_session": "Gynecologic Cancer: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Genital Neoplasms, Female",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1770598278,'294011');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPejovic, Tanja Branko",
"kol_full_name": "Pejovic, Tanja Branko"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Microsatellite Instability | DNA Mismatch Repair | Endometrial Neoplasms",
"npi_num": "1659300556",
"hcp_pin_alias": "284255",
"session_name": "Real-world treatment patterns and outcomes by mismatch repair/microsatellite instability (MMR/MSI) status in patients (pts) with advanced endometrial cancer (aEC), 2018-2023",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "284255",
"first_name": "Bhavana",
"middle_name": "",
"last_name": "Pothuri",
"org_name": "New York University",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232437",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232437",
"events_session": "Real-world treatment patterns and outcomes by mismatch repair/microsatellite instability (MMR/MSI) status in patients (pts) with advanced endometrial cancer (aEC)",
"rest_events_session_count": 1,
"rest_events_session": " 2018-2023",
"events_topic": "Microsatellite Instability | DNA Mismatch Repair ",
"rest_events_topic_count": 1,
"rest_events_topic": " Endometrial Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1659300556,'284255');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPothuri, Bhavana",
"kol_full_name": "Pothuri, Bhavana"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Randomized Controlled Trials As Topic | Endometrial Neoplasms | Ovarian Neoplasms | Genes, ErbB-2",
"npi_num": "1619909850",
"hcp_pin_alias": "281688",
"session_name": "Relationship of cancer stem cell functional assay and objective response rate of patients with recurrent platinum-resistant ovarian cancer in a randomized trial,Endometrial cancer (EC) by ERBB2 amplification (ERBB2amp) status: Differences in molecular subtypes, ancestry, and real-world outcomes",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "281688",
"first_name": "Thomas",
"middle_name": "",
"last_name": "Herzog",
"org_name": "University of Cincinnati Medical Center",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232438",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232438",
"events_session": "Relationship of cancer stem cell functional assay and objective response rate of patients with recurrent platinum-resistant ovarian cancer in a randomized trial",
"rest_events_session_count": 3,
"rest_events_session": "Endometrial cancer (EC) by ERBB2 amplification (ERBB2amp) status: Differences in molecular subtypes, ancestry, and real-world outcomes",
"events_topic": "Randomized Controlled Trials As Topic | Endometrial Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Ovarian Neoplasms | Genes, ErbB-2",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1619909850,'281688');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHerzog, Thomas",
"kol_full_name": "Herzog, Thomas"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ovarian Neoplasms | Folate Receptor 1 | Mirvetuximab Soravtansine | Rucaparib | Clinical Trials As Topic",
"npi_num": "1609819424",
"hcp_pin_alias": "280773",
"session_name": "Characterization of long-term survivors from four clinical trials examining patients with folate receptor alpha–positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine,Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "280773",
"first_name": "David",
"middle_name": "M",
"last_name": "O'Malley",
"org_name": "The James Gynecologic Oncology Mill Run",
"Country": "United States",
"Region": "Ohio",
"City": "Hilliard",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232427",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232427",
"events_session": "Characterization of long-term survivors from four clinical trials examining patients with folate receptor alpha–positive recurrent ovarian cancer treated with single-agent mirvetuximab soravtansine",
"rest_events_session_count": 5,
"rest_events_session": "Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer",
"events_topic": "Ovarian Neoplasms | Folate Receptor 1 ",
"rest_events_topic_count": 3,
"rest_events_topic": " Mirvetuximab Soravtansine | Rucaparib | Clinical Trials As Topic",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1609819424,'280773');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EO'Malley, David M",
"kol_full_name": "O'Malley, David M"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genital Neoplasms, Female",
"npi_num": "1598772550",
"hcp_pin_alias": "279956",
"session_name": "Gynecologic Cancer: Program Commitee,Gynecologic Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "279956",
"first_name": "Carolyn",
"middle_name": "Y",
"last_name": "Muller",
"org_name": "University Of New Mexico School Of Medicine",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232052",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232052",
"events_session": "Gynecologic Cancer: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Gynecologic Cancer",
"events_topic": "Genital Neoplasms, Female",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1598772550,'279956');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMuller, Carolyn Y",
"kol_full_name": "Muller, Carolyn Y"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy | Uterine Cervical Neoplasms",
"npi_num": "1548827496",
"hcp_pin_alias": "276270",
"session_name": "Triage of advanced cervical cancer through immunotherapy induction (TRACTION)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "276270",
"first_name": "Jeffrey",
"middle_name": "Andrew",
"last_name": "How",
"org_name": "Jeffrey Andrew How Private Practice",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232439",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232439",
"events_session": "Triage of advanced cervical cancer through immunotherapy induction (TRACTION)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunotherapy | Uterine Cervical Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1548827496,'276270');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHow, Jeffrey Andrew",
"kol_full_name": "How, Jeffrey Andrew"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genital Neoplasms, Female",
"npi_num": "1518930601",
"hcp_pin_alias": "273664",
"session_name": "Gynecologic Cancer: Program Commitee,Gynecologic Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "273664",
"first_name": "John",
"middle_name": "W.",
"last_name": "Moroney",
"org_name": "Northwest Community Health Services Inc",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232448",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232448",
"events_session": "Gynecologic Cancer: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Gynecologic Cancer",
"events_topic": "Genital Neoplasms, Female",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1518930601,'273664');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMoroney, John W.",
"kol_full_name": "Moroney, John W."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy | Endometrial Neoplasms",
"npi_num": "1336464734",
"hcp_pin_alias": "259451",
"session_name": "AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "259451",
"first_name": "Evelyn",
"middle_name": "",
"last_name": "Cantillo",
"org_name": "University of Vermont Medical Center Inc",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232445",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232445",
"events_session": "AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunotherapy | Endometrial Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1336464734,'259451');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECantillo, Evelyn",
"kol_full_name": "Cantillo, Evelyn"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ovarian Neoplasms",
"npi_num": "1326606070",
"hcp_pin_alias": "258822",
"session_name": "Molecular and immune characterization of squamous cell ovarian cancers for identification of therapeutic targets",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "258822",
"first_name": "Jessie",
"middle_name": "",
"last_name": "Hollingsworth",
"org_name": "Rutgers Robert Wood Johnson Medical School",
"Country": "United States",
"Region": "New Jersey",
"City": "New Brunswick",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232433",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232433",
"events_session": "Molecular and immune characterization of squamous cell ovarian cancers for identification of therapeutic targets",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Ovarian Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1326606070,'258822');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHollingsworth, Jessie",
"kol_full_name": "Hollingsworth, Jessie"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Ovarian Neoplasms | Chemotherapy",
"npi_num": "1255571568",
"hcp_pin_alias": "252983",
"session_name": "Association of physical activity with self-reported quality of life after primary chemotherapy for ovarian cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "252983",
"first_name": "Larissa",
"middle_name": "A",
"last_name": "Meyer",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232430",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232430",
"events_session": "Association of physical activity with self-reported quality of life after primary chemotherapy for ovarian cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Ovarian Neoplasms | Chemotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/252983/fromId'\u003EMeyer, Larissa A\u003C/a\u003E",
"kol_full_name": "Meyer, Larissa A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Letrozole | Leiomyosarcoma",
"npi_num": "1255566964",
"hcp_pin_alias": "252975",
"session_name": "GOG 3088: A randomized phase II study of letrozole versus observation in patients with newly diagnosed uterine leiomyosarcoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "252975",
"first_name": "Bradley",
"middle_name": "Robert",
"last_name": "Corr",
"org_name": "University Physicians Inc",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232446",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232446",
"events_session": "GOG 3088: A randomized phase II study of letrozole versus observation in patients with newly diagnosed uterine leiomyosarcoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Letrozole | Leiomyosarcoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1255566964,'252975');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECorr, Bradley Robert",
"kol_full_name": "Corr, Bradley Robert"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Clinical Trials As Topic",
"npi_num": "1144486929",
"hcp_pin_alias": "244267",
"session_name": "Clinical Trialist Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "244267",
"first_name": "Ramez",
"middle_name": "Nassef",
"last_name": "Eskander",
"org_name": "Regents Of The Univesity Of California - Ucsd Medical Group",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232528",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232528",
"events_session": "Clinical Trialist Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Clinical Trials As Topic",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1144486929,'244267');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEskander, Ramez Nassef",
"kol_full_name": "Eskander, Ramez Nassef"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Biomarkers | Nivolumab | Melanoma",
"npi_num": "1124352315",
"hcp_pin_alias": "242814",
"session_name": "Biomarker analysis and updated clinical outcomes: Neoadjuvant systemic treatment (NST) with nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "242814",
"first_name": "Elizabeth",
"middle_name": "",
"last_name": "Burton",
"org_name": "Jefferson Abington Hospital",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232798",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232798",
"events_session": "Biomarker analysis and updated clinical outcomes: Neoadjuvant systemic treatment (NST) with nivolumab (nivo) and relatlimab (rela) in surgically resectable melanoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Biomarkers | Nivolumab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Melanoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1124352315,'242814');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBurton, Elizabeth",
"kol_full_name": "Burton, Elizabeth"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Minority Health | Neoplasms | Reproductive Health",
"npi_num": "1124149281",
"hcp_pin_alias": "242571",
"session_name": "If you build it, they will come: Success of the EROS (Engendering Reproductive Health Within Oncologic Survivorship)—ECOG-ACRIN E1Q11 in recruitment of minority patients,EROS: Engendering reproductive health within oncologic survivorship—ECOG-ACRIN E1Q11 paradoxical provision of reproductive health",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "242571",
"first_name": "Ashlesha",
"middle_name": "",
"last_name": "Patel",
"org_name": "Northwestern University Feinberg School of Medicine",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232412",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232412",
"events_session": "If you build it",
"rest_events_session_count": 2,
"rest_events_session": " they will come: Success of the EROS (Engendering Reproductive Health Within Oncologic Survivorship)—ECOG-ACRIN E1Q11 in recruitment of minority patients,EROS: Engendering reproductive health within oncologic survivorship—ECOG-ACRIN E1Q11 paradoxical provision of reproductive health",
"events_topic": "Minority Health | Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Reproductive Health",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1124149281,'242571');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPatel, Ashlesha",
"kol_full_name": "Patel, Ashlesha"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Patient Care",
"npi_num": "1073531083",
"hcp_pin_alias": "238500",
"session_name": "Perspective on Patient Guidance",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "238500",
"first_name": "Angeles",
"middle_name": "Alvarez",
"last_name": "Secord",
"org_name": "Duke University School of Medicine",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232529",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232529",
"events_session": "Perspective on Patient Guidance",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Patient Care",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1073531083,'238500');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESecord, Angeles Alvarez",
"kol_full_name": "Secord, Angeles Alvarez"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Pancreatic Ductal | Neoadjuvant Therapy",
"npi_num": "1811303001",
"hcp_pin_alias": "232780",
"session_name": "Extracellular (EC) Mucin5AC (MUC5AC) detection after neoadjuvant therapy (NAT) and the risk of recurrence in resected pancreatic ductal adenocarcinoma (R-PDA)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "232780",
"first_name": "Ashish",
"middle_name": "",
"last_name": "Manne",
"org_name": "Ohio State Martha Morehouse Outpatient Care",
"Country": "United States",
"Region": "Ohio",
"City": "Columbus",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232843",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232843",
"events_session": "Extracellular (EC) Mucin5AC (MUC5AC) detection after neoadjuvant therapy (NAT) and the risk of recurrence in resected pancreatic ductal adenocarcinoma (R-PDA)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Pancreatic Ductal | Neoadjuvant Therapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1811303001,'232780');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EManne, Ashish",
"kol_full_name": "Manne, Ashish"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genetic Testing | Breast Neoplasms",
"npi_num": "1396851663",
"hcp_pin_alias": "232528",
"session_name": "PARPi eligibility amongst women with newly diagnosed invasive breast cancer enrolled in the GREAT universal genetic testing study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "232528",
"first_name": "Stephanie",
"middle_name": "",
"last_name": "Wong",
"org_name": "Sutter Health",
"Country": "United States",
"Region": "California",
"City": "Mountain View",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232618",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232618",
"events_session": "PARPi eligibility amongst women with newly diagnosed invasive breast cancer enrolled in the GREAT universal genetic testing study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Genetic Testing | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1396851663,'232528');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWong, Stephanie",
"kol_full_name": "Wong, Stephanie"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Solid Tumor | Cemiplimab",
"npi_num": "1225201304",
"hcp_pin_alias": "232430",
"session_name": "A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "232430",
"first_name": "Neil",
"middle_name": "Howard",
"last_name": "Segal",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232301",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232301",
"events_session": "A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Solid Tumor | Cemiplimab",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1225201304,'232430');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESegal, Neil Howard",
"kol_full_name": "Segal, Neil Howard"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Rectal Neoplasms | Randomized Controlled Trials As Topic | Laparoscopy",
"npi_num": "1962761320",
"hcp_pin_alias": "232240",
"session_name": "Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): Primary outcome of a multicenter randomized controlled trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "232240",
"first_name": "Jianmin",
"middle_name": "",
"last_name": "Xu",
"org_name": "Diagnostic Pathology Medical Group Inc",
"Country": "United States",
"Region": "California",
"City": "Vallejo",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232891",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232891",
"events_session": "Robotic versus laparoscopic surgery for middle and low rectal cancer (REAL): Primary outcome of a multicenter randomized controlled trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Rectal Neoplasms | Randomized Controlled Trials As Topic ",
"rest_events_topic_count": 1,
"rest_events_topic": " Laparoscopy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1962761320,'232240');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EXu, Jianmin",
"kol_full_name": "Xu, Jianmin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Radiotherapy | Neoplasms",
"npi_num": "1962493874",
"hcp_pin_alias": "232231",
"session_name": "Radiation Oncologist Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "232231",
"first_name": "Lisa",
"middle_name": "Ann",
"last_name": "Kachnic",
"org_name": "Columbia University Irving Medical Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232158",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232158",
"events_session": "Radiation Oncologist Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Radiotherapy | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1962493874,'232231');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKachnic, Lisa Ann",
"kol_full_name": "Kachnic, Lisa Ann"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms | Prostatectomy | Positron-Emission Tomography",
"npi_num": "1881991495",
"hcp_pin_alias": "232086",
"session_name": "CLARIFY: Positron emission tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy (a phase 3 diagnostic study)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "232086",
"first_name": "Michael",
"middle_name": "A.",
"last_name": "Gorin",
"org_name": "Johns Hopkins University",
"Country": "United States",
"Region": "Maryland",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232675",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232675",
"events_session": "CLARIFY: Positron emission tomography using 64Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy (a phase 3 diagnostic study)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms | Prostatectomy ",
"rest_events_topic_count": 1,
"rest_events_topic": " Positron-Emission Tomography",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1881991495,'232086');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGorin, Michael A.",
"kol_full_name": "Gorin, Michael A."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pheochromocytoma | Axitinib | Paraganglioma",
"npi_num": "1821212473",
"hcp_pin_alias": "231949",
"session_name": "Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "231949",
"first_name": "Antonio",
"middle_name": "Tito",
"last_name": "Fojo",
"org_name": "Trustees of Columbia University in the City of New York",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232605",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232605",
"events_session": "Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pheochromocytoma | Axitinib ",
"rest_events_topic_count": 1,
"rest_events_topic": " Paraganglioma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1821212473,'231949');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFojo, Antonio Tito",
"kol_full_name": "Fojo, Antonio Tito"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms | Clinical Studies As Topic | Immune Checkpoint Inhibitors",
"npi_num": "1801154711",
"hcp_pin_alias": "231888",
"session_name": "A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC),Association of higher baseline stress and pain with clinical outcomes: Secondary analysis from Alliance A011502",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "231888",
"first_name": "Shipra",
"middle_name": "",
"last_name": "Gandhi",
"org_name": "Roswell Park Cancer Institute",
"Country": "United States",
"Region": "New York",
"City": "Buffalo",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232281",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232281",
"events_session": "A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC)",
"rest_events_session_count": 1,
"rest_events_session": "Association of higher baseline stress and pain with clinical outcomes: Secondary analysis from Alliance A011502",
"events_topic": "Triple Negative Breast Neoplasms | Clinical Studies As Topic ",
"rest_events_topic_count": 1,
"rest_events_topic": " Immune Checkpoint Inhibitors",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1801154711,'231888');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGandhi, Shipra",
"kol_full_name": "Gandhi, Shipra"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Appendix | Biomarkers | Colorectal Neoplasms | Adenocarcinoma, Mucinous",
"npi_num": "1750546735",
"hcp_pin_alias": "231789",
"session_name": "Allele-specific KRAS mutations as prognostic biomarkers in mucinous adenocarcinoma of the appendix and colorectal cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "231789",
"first_name": "Moh'D",
"middle_name": "M.",
"last_name": "Khushman",
"org_name": "Monroe County Health Care Authority",
"Country": "United States",
"Region": "Alabama",
"City": "Monroeville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232893",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232893",
"events_session": "Allele-specific KRAS mutations as prognostic biomarkers in mucinous adenocarcinoma of the appendix and colorectal cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Appendix | Biomarkers ",
"rest_events_topic_count": 2,
"rest_events_topic": " Colorectal Neoplasms | Adenocarcinoma, Mucinous",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1750546735,'231789');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKhushman, Moh'D M.",
"kol_full_name": "Khushman, Moh'D M."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Anus Neoplasms | Gastrointestinal Neoplasms",
"npi_num": "1720106693",
"hcp_pin_alias": "231720",
"session_name": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "231720",
"first_name": "Mary",
"middle_name": "Uan-Sian",
"last_name": "Feng",
"org_name": "UCSF Health",
"Country": "United States",
"Region": "California",
"City": "San Francisco",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233200",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233200",
"events_session": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colorectal Neoplasms | Anus Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Gastrointestinal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1720106693,'231720');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFeng, Mary Uan-Sian",
"kol_full_name": "Feng, Mary Uan-Sian"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms | Radiosurgery | Sacituzumab Govitecan | Zimberelimab | Brain Neoplasms",
"npi_num": "1659633915",
"hcp_pin_alias": "231575",
"session_name": "Phase I/II study of stereotactic radiation and sacituzumab govitecan with zimberelimab in the management of metastatic triple negative breast cancer with brain metastases",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "231575",
"first_name": "Kamran",
"middle_name": "Ali",
"last_name": "Ahmed",
"org_name": "H. Lee Moffitt Cancer Center & Research Institute",
"Country": "United States",
"Region": "Florida",
"City": "Tampa",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232717",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232717",
"events_session": "Phase I/II study of stereotactic radiation and sacituzumab govitecan with zimberelimab in the management of metastatic triple negative breast cancer with brain metastases",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Triple Negative Breast Neoplasms | Radiosurgery ",
"rest_events_topic_count": 3,
"rest_events_topic": " Sacituzumab Govitecan | Zimberelimab | Brain Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1659633915,'231575');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAhmed, Kamran Ali",
"kol_full_name": "Ahmed, Kamran Ali"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoadjuvant Therapy | Chemotherapy | Cisplatin | Carcinoma, Transitional Cell | Pembrolizumab | Gemcitabine | Non-Muscle Invasive Bladder Neoplasms | Disitamab Vedotin | Nivolumab",
"npi_num": "1639140668",
"hcp_pin_alias": "231524",
"session_name": "Using Molecular Testing to Guide Perioperative Systemic Therapy for Urothelial Cancer,Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001),Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "231524",
"first_name": "Matthew",
"middle_name": "D",
"last_name": "Galsky",
"org_name": "Icahn School of Medicine at Mount Sinai",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232472",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232472",
"events_session": "Using Molecular Testing to Guide Perioperative Systemic Therapy for Urothelial Cancer",
"rest_events_session_count": 2,
"rest_events_session": "Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001),Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial",
"events_topic": "Neoadjuvant Therapy | Chemotherapy ",
"rest_events_topic_count": 7,
"rest_events_topic": " Cisplatin | Carcinoma, Transitional Cell | Pembrolizumab | Gemcitabine | Non-Muscle Invasive Bladder Neoplasms | Disitamab Vedotin | Nivolumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1639140668,'231524');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGalsky, Matthew D",
"kol_full_name": "Galsky, Matthew D"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Fruquintinib | Colorectal Neoplasms",
"npi_num": "1558469767",
"hcp_pin_alias": "231363",
"session_name": "Fruquintinib in Refractory Metastatic Colorectal Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "231363",
"first_name": "Cathy",
"middle_name": "",
"last_name": "Eng",
"org_name": "Vanderbilt University Medical Center",
"Country": "United States",
"Region": "Tennessee",
"City": "Franklin",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233151",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233151",
"events_session": "Fruquintinib in Refractory Metastatic Colorectal Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Fruquintinib | Colorectal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1558469767,'231363');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEng, Cathy",
"kol_full_name": "Eng, Cathy"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Pharmaceutical Preparations | Genital Neoplasms, Female | Immunotherapy",
"npi_num": "1306885512",
"hcp_pin_alias": "230864",
"session_name": "Novel Immunotherapy Combinations in Gynecologic Cancer and When to Use Them,State of the Art in Gynecologic Cancer: New Drugs and Companion Diagnostics",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "230864",
"first_name": "Brian",
"middle_name": "M",
"last_name": "Slomovitz",
"org_name": "University of Miami Leonard M. Miller School of Medicine",
"Country": "United States",
"Region": "Florida",
"City": "Miami",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231991",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231991",
"events_session": "Novel Immunotherapy Combinations in Gynecologic Cancer and When to Use Them",
"rest_events_session_count": 1,
"rest_events_session": "State of the Art in Gynecologic Cancer: New Drugs and Companion Diagnostics",
"events_topic": "Pharmaceutical Preparations | Genital Neoplasms, Female ",
"rest_events_topic_count": 1,
"rest_events_topic": " Immunotherapy",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/230864/fromId'\u003ESlomovitz, Brian M\u003C/a\u003E",
"kol_full_name": "Slomovitz, Brian M"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunoconjugates | Biomarkers",
"npi_num": "1245239367",
"hcp_pin_alias": "230723",
"session_name": "Evaluation of a predictive biomarker for antibody drug conjugates (ADCs)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "230723",
"first_name": "Sachdev",
"middle_name": "P",
"last_name": "Thomas",
"org_name": "Vallejo Medical Center",
"Country": "United States",
"Region": "California",
"City": "Vallejo",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232967",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232967",
"events_session": "Evaluation of a predictive biomarker for antibody drug conjugates (ADCs)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunoconjugates | Biomarkers",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1245239367,'230723');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EThomas, Sachdev P",
"kol_full_name": "Thomas, Sachdev P"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Anus Neoplasms | Gastrointestinal Neoplasms",
"npi_num": "1184999336",
"hcp_pin_alias": "230596",
"session_name": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee,Gastrointestinal Cancer—Colorectal and Anal",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "230596",
"first_name": "Michael",
"middle_name": "",
"last_name": "Cecchini",
"org_name": "Yale University",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231985",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231985",
"events_session": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Gastrointestinal Cancer—Colorectal and Anal",
"events_topic": "Colorectal Neoplasms | Anus Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Gastrointestinal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1184999336,'230596');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECecchini, Michael",
"kol_full_name": "Cecchini, Michael"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Radiotherapy | Ablation Techniques | Colorectal Neoplasms",
"npi_num": "1023375128",
"hcp_pin_alias": "230244",
"session_name": "Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "230244",
"first_name": "Eric",
"middle_name": "David",
"last_name": "Miller",
"org_name": "Osu Radiation Oncology Llc",
"Country": "United States",
"Region": "Ohio",
"City": "Columbus",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232895",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232895",
"events_session": "Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation",
"rest_events_session_count": 2,
"rest_events_session": " ablation, and surgery (ERASur)",
"events_topic": "Radiotherapy | Ablation Techniques ",
"rest_events_topic_count": 1,
"rest_events_topic": " Colorectal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1023375128,'230244');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMiller, Eric David",
"kol_full_name": "Miller, Eric David"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Urogenital Neoplasms | Urinary Bladder Neoplasms | Kidney Neoplasms",
"npi_num": "1508029703",
"hcp_pin_alias": "230150",
"session_name": "Genitourinary Cancer – Kidney and Bladder: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "230150",
"first_name": "Russell",
"middle_name": "Zelig",
"last_name": "Szmulewitz",
"org_name": "The University of Chicago Medical Center",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233210",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233210",
"events_session": "Genitourinary Cancer – Kidney and Bladder: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Urogenital Neoplasms | Urinary Bladder Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Kidney Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1508029703,'230150');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESzmulewitz, Russell Zelig",
"kol_full_name": "Szmulewitz, Russell Zelig"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Therapeutics | Neoplasms",
"npi_num": "1356487763",
"hcp_pin_alias": "230124",
"session_name": "Living Your Best Life on Treatment",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "230124",
"first_name": "Channing",
"middle_name": "",
"last_name": "Paller",
"org_name": "Sibley Memorial Hospital",
"Country": "United States",
"Region": "District of Columbia",
"City": "Washington",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232764",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232764",
"events_session": "Living Your Best Life on Treatment",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Therapeutics | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356487763,'230124');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPaller, Channing",
"kol_full_name": "Paller, Channing"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Amivantamab | Carcinoma, Non-Small-Cell Lung | Lazertinib | Osimertinib | Chemotherapy | Biomarkers",
"npi_num": "1821511098",
"hcp_pin_alias": "228916",
"session_name": "Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study,Association of RNA-sequencing signatures with clinical outcomes of pembrolizumab + chemotherapy in patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) enrolled in the phase 2 KEYNOTE-782 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "228916",
"first_name": "Enriqueta",
"middle_name": "",
"last_name": "Steele",
"org_name": "LAC + USC Medical Center",
"Country": "United States",
"Region": "California",
"City": "Los Angeles",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232172",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232172",
"events_session": "Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study",
"rest_events_session_count": 1,
"rest_events_session": "Association of RNA-sequencing signatures with clinical outcomes of pembrolizumab + chemotherapy in patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) enrolled in the phase 2 KEYNOTE-782 trial",
"events_topic": "Pembrolizumab | Amivantamab ",
"rest_events_topic_count": 5,
"rest_events_topic": " Carcinoma, Non-Small-Cell Lung | Lazertinib | Osimertinib | Chemotherapy | Biomarkers",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1821511098,'228916');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESteele, Enriqueta",
"kol_full_name": "Steele, Enriqueta"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Encorafenib | Irinotecan | Stomach Neoplasms | Cetuximab",
"npi_num": "1710252861",
"hcp_pin_alias": "228225",
"session_name": "Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study,GEMINI-Gastric: A phase 2 study of novel treatment combinations in patients with locally advanced unresectable or metastatic gastric cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "228225",
"first_name": "Lin",
"middle_name": "",
"last_name": "Shen",
"org_name": "Brigham and Womens Hospital",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232850",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232850",
"events_session": "Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study",
"rest_events_session_count": 1,
"rest_events_session": "GEMINI-Gastric: A phase 2 study of novel treatment combinations in patients with locally advanced unresectable or metastatic gastric cancers",
"events_topic": "Colorectal Neoplasms | Encorafenib ",
"rest_events_topic_count": 3,
"rest_events_topic": " Irinotecan | Stomach Neoplasms | Cetuximab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1710252861,'228225');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShen, Lin",
"kol_full_name": "Shen, Lin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Trastuzumab Deruxtecan | Triple Negative Breast Neoplasms | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1992712178",
"hcp_pin_alias": "223760",
"session_name": "Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "223760",
"first_name": "Pasi Antero",
"middle_name": "",
"last_name": "Janne",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232162",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232162",
"events_session": "Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Trastuzumab Deruxtecan | Triple Negative Breast Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Carcinoma, Non-Small-Cell Lung",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1992712178,'223760');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJanne, Pasi Antero",
"kol_full_name": "Janne, Pasi Antero"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms",
"npi_num": "1982680583",
"hcp_pin_alias": "223669",
"session_name": "IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "223669",
"first_name": "Alex",
"middle_name": "A",
"last_name": "Adjei",
"org_name": "Mayo Clinic - Rochester",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232985",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232985",
"events_session": "IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1982680583,'223669');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAdjei, Alex A",
"kol_full_name": "Adjei, Alex A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Gastrointestinal Neoplasms",
"npi_num": "1942425350",
"hcp_pin_alias": "223303",
"session_name": "Evaluating speaker gender in scientific sessions at ASCO and ASCO GI (2019-2023)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "223303",
"first_name": "Rachna",
"middle_name": "",
"last_name": "Shroff",
"org_name": "Banner - University Medical Center Phoenix",
"Country": "United States",
"Region": "Arizona",
"City": "Tucson",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232320",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232320",
"events_session": "Evaluating speaker gender in scientific sessions at ASCO and ASCO GI (2019-2023)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Gastrointestinal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1942425350,'223303');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShroff, Rachna",
"kol_full_name": "Shroff, Rachna"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunoconjugates | Triple Negative Breast Neoplasms",
"npi_num": "1932146420",
"hcp_pin_alias": "223157",
"session_name": "Role of Payload and Antibody in Predicting Resistance to Antibody-Drug Conjugates,A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "223157",
"first_name": "Patricia",
"middle_name": "Mucci",
"last_name": "Lorusso",
"org_name": "",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232769",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232769",
"events_session": "Role of Payload and Antibody in Predicting Resistance to Antibody-Drug Conjugates",
"rest_events_session_count": 1,
"rest_events_session": "A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer",
"events_topic": "Immunoconjugates | Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1932146420,'223157');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELorusso, Patricia Mucci",
"kol_full_name": "Lorusso, Patricia Mucci"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Thyroid Neoplasms",
"npi_num": "1922260504",
"hcp_pin_alias": "223106",
"session_name": "Clinical and genomic characterization of sporadic medullary thyroid carcinoma in Chinese patients",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "223106",
"first_name": "Yang",
"middle_name": "",
"last_name": "Liu",
"org_name": "Andrews And Patel Associates, PC",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Camp Hill",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232568",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232568",
"events_session": "Clinical and genomic characterization of sporadic medullary thyroid carcinoma in Chinese patients",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Thyroid Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1922260504,'223106');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELiu, Yang",
"kol_full_name": "Liu, Yang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptors, Interleukin-2 | PRMT5 Protein, Human | ErbB Receptors | Naporafenib | Amivantamab | Immunoconjugates | Furmonertinib | Trametinib | Capmatinib | Solid Tumor | Chemotherapy | Neoplasms | Carcinoma, Non-Small-Cell Lung | Ovarian Neoplasms",
"npi_num": "1902874514",
"hcp_pin_alias": "222950",
"session_name": "Safety and activity of Diakine DK210 (EGFR), a next generation tumor-targeted IL2 x IL10 dual immunocytokine, in patients with advanced cancer: Initial results of the phase 1 first-in-human trial,PRIMROSE: A modular phase 1/2a study of AZD3470, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP deficient advanced solid tumors,An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations (SEACRAFT-1),A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors,FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004),Amivantamab plus capmatinib in advanced non-small cell lung cancer (NSCLC) harboring MET alterations: Recommended phase 2 combination dose and preliminary dose-escalation results from the phase 1/2 METalmark study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "222950",
"first_name": "Alexander",
"middle_name": "I",
"last_name": "Spira",
"org_name": "Virginia Cancer Specialists",
"Country": "United States",
"Region": "Virginia",
"City": "Fairfax",
"num_sess": "6",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232181",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232181",
"events_session": "Safety and activity of Diakine DK210 (EGFR)",
"rest_events_session_count": 12,
"rest_events_session": " a next generation tumor-targeted IL2 x IL10 dual immunocytokine, in patients with advanced cancer: Initial results of the phase 1 first-in-human trial,PRIMROSE: A modular phase 1/2a study of AZD3470, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP deficient advanced solid tumors,An open-label study to assess the safety and efficacy of naporafenib (ERAS-254) administered with trametinib in previously treated patients with locally advanced unresectable or metastatic solid tumor malignancies with RAS Q61X mutations (SEACRAFT-1),A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors,FURVENT: Phase 3 trial of furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004),Amivantamab plus capmatinib in advanced non-small cell lung cancer (NSCLC) harboring MET alterations: Recommended phase 2 combination dose and preliminary dose-escalation results from the phase 1/2 METalmark study",
"events_topic": "Receptors, Interleukin-2 | PRMT5 Protein, Human ",
"rest_events_topic_count": 12,
"rest_events_topic": " ErbB Receptors | Naporafenib | Amivantamab | Immunoconjugates | Furmonertinib | Trametinib | Capmatinib | Solid Tumor | Chemotherapy | Neoplasms | Carcinoma, Non-Small-Cell Lung | Ovarian Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1902874514,'222950');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESpira, Alexander I",
"kol_full_name": "Spira, Alexander I"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Hepatocellular | Regorafenib | Immune Checkpoint Inhibitors | Pembrolizumab | Solid Tumor",
"npi_num": "1891730412",
"hcp_pin_alias": "222834",
"session_name": "A phase I monotherapy dose escalation study of HFB301001, a novel next generation OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors,International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "222834",
"first_name": "Anthony",
"middle_name": "B.",
"last_name": "El-Khoueiry",
"org_name": "USC Norris Comprehensive Cancer Center",
"Country": "United States",
"Region": "California",
"City": "Los Angeles",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232110",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232110",
"events_session": "A phase I monotherapy dose escalation study of HFB301001",
"rest_events_session_count": 4,
"rest_events_session": " a novel next generation OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors,International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI)",
"events_topic": "Carcinoma, Hepatocellular | Regorafenib ",
"rest_events_topic_count": 3,
"rest_events_topic": " Immune Checkpoint Inhibitors | Pembrolizumab | Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1891730412,'222834');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEl-Khoueiry, Anthony B.",
"kol_full_name": "El-Khoueiry, Anthony B."
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Melanoma",
"npi_num": "1881913259",
"hcp_pin_alias": "222790",
"session_name": "Persistent poverty impacts survival and National Comprehensive Cancer Network guideline-concordant care for patients with melanoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "222790",
"first_name": "Joal",
"middle_name": "David",
"last_name": "Beane",
"org_name": "The Ohio State University Wexner Medical Center",
"Country": "United States",
"Region": "Ohio",
"City": "Columbus",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233056",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233056",
"events_session": "Persistent poverty impacts survival and National Comprehensive Cancer Network guideline-concordant care for patients with melanoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/222790/fromId'\u003EBeane, Joal David\u003C/a\u003E",
"kol_full_name": "Beane, Joal David"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy, Adjuvant | Neoplasms",
"npi_num": "1861422966",
"hcp_pin_alias": "222546",
"session_name": "What New Therapies for “Undruggable Targets” Are on the Horizon?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "222546",
"first_name": "Keith",
"middle_name": "",
"last_name": "Flaherty",
"org_name": "The General Hospital Corporation",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232540",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232540",
"events_session": "What New Therapies for “Undruggable Targets” Are on the Horizon?",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Chemotherapy, Adjuvant | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1861422966,'222546');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFlaherty, Keith",
"kol_full_name": "Flaherty, Keith"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Pemetrexed | Carboplatin",
"npi_num": "1831507367",
"hcp_pin_alias": "222325",
"session_name": "Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "222325",
"first_name": "Bob",
"middle_name": "T.",
"last_name": "Li",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232926",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232926",
"events_session": "Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Pemetrexed ",
"rest_events_topic_count": 1,
"rest_events_topic": " Carboplatin",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1831507367,'222325');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELi, Bob T.",
"kol_full_name": "Li, Bob T."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Zongertinib | Tomography, X-Ray Computed | Protein-Tyrosine Kinases | Carcinoma, Non-Small-Cell Lung | Chemotherapy | Triple Negative Breast Neoplasms",
"npi_num": "1821269465",
"hcp_pin_alias": "222211",
"session_name": "Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations,eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression \u003C50%,MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "222211",
"first_name": "Melissa",
"middle_name": "Lynne",
"last_name": "Johnson",
"org_name": "Tennessee Oncology",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232166",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232166",
"events_session": "Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations",
"rest_events_session_count": 2,
"rest_events_session": "eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression \u003C50%,MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study",
"events_topic": "Pembrolizumab | Zongertinib ",
"rest_events_topic_count": 5,
"rest_events_topic": " Tomography, X-Ray Computed | Protein-Tyrosine Kinases | Carcinoma, Non-Small-Cell Lung | Chemotherapy | Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1821269465,'222211');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJohnson, Melissa Lynne",
"kol_full_name": "Johnson, Melissa Lynne"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Panitumumab | Solid Tumor | Sotorasib | Carcinoma, Non-Small-Cell Lung | Pembrolizumab",
"npi_num": "1811918501",
"hcp_pin_alias": "222143",
"session_name": "A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors,Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRAS G12C mutation: A phase 1b study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "222143",
"first_name": "Corey",
"middle_name": "J",
"last_name": "Langer",
"org_name": "Penn Medicine Rena Rowan Breast Center",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232167",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232167",
"events_session": "A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors",
"rest_events_session_count": 1,
"rest_events_session": "Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRAS G12C mutation: A phase 1b study",
"events_topic": "Panitumumab | Solid Tumor ",
"rest_events_topic_count": 3,
"rest_events_topic": " Sotorasib | Carcinoma, Non-Small-Cell Lung | Pembrolizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1811918501,'222143');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELanger, Corey J",
"kol_full_name": "Langer, Corey J"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cisplatin | Carcinoma, Hepatocellular | Pembrolizumab | Gemcitabine | Biliary Tract Neoplasms | Sorafenib",
"npi_num": "1811912074",
"hcp_pin_alias": "222141",
"session_name": "Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study,Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "222141",
"first_name": "Richard",
"middle_name": "Samuel",
"last_name": "Finn",
"org_name": "UCLA Santa Monica Medical Center",
"Country": "United States",
"Region": "California",
"City": "Santa Monica",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232825",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232825",
"events_session": "Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study",
"rest_events_session_count": 1,
"rest_events_session": "Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC)",
"events_topic": "Cisplatin | Carcinoma, Hepatocellular ",
"rest_events_topic_count": 4,
"rest_events_topic": " Pembrolizumab | Gemcitabine | Biliary Tract Neoplasms | Sorafenib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1811912074,'222141');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFinn, Richard Samuel",
"kol_full_name": "Finn, Richard Samuel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Squamous Cell Lung Cancer | Paclitaxel | Conflict, Psychological | Carboplatin",
"npi_num": "1790199719",
"hcp_pin_alias": "221907",
"session_name": "A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC),Conflicts (of Interest) and Conundrums: Perspectives From the Global Oncology Community",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "221907",
"first_name": "Bruna",
"middle_name": "",
"last_name": "Pellini Ferreira",
"org_name": "H Lee Moffitt Cancer Center And Research Institute",
"Country": "United States",
"Region": "Florida",
"City": "Tampa",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232074",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232074",
"events_session": "A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC)",
"rest_events_session_count": 1,
"rest_events_session": "Conflicts (of Interest) and Conundrums: Perspectives From the Global Oncology Community",
"events_topic": "Neoplasms | Squamous Cell Lung Cancer ",
"rest_events_topic_count": 3,
"rest_events_topic": " Paclitaxel | Conflict, Psychological | Carboplatin",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790199719,'221907');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPellini Ferreira, Bruna",
"kol_full_name": "Pellini Ferreira, Bruna"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms",
"npi_num": "1780905901",
"hcp_pin_alias": "221865",
"session_name": "Prospective iterative data visualization (DV) study to enhance health literacy in prostate cancer (PC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "221865",
"first_name": "Daniel",
"middle_name": "E",
"last_name": "Spratt",
"org_name": "University of Michigan Health System",
"Country": "United States",
"Region": "Michigan",
"City": "Ann Arbor",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232397",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232397",
"events_session": "Prospective iterative data visualization (DV) study to enhance health literacy in prostate cancer (PC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1780905901,'221865');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESpratt, Daniel E",
"kol_full_name": "Spratt, Daniel E"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Patient Reported Outcome Measures | Telemedicine",
"npi_num": "1780900167",
"hcp_pin_alias": "221863",
"session_name": "A Pro's Take on Patient-Reported Outcomes and Virtual Care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "221863",
"first_name": "Ryan",
"middle_name": "David",
"last_name": "Nipp",
"org_name": "Massachusetts General Physicians Organization Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232104",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232104",
"events_session": "A Pro's Take on Patient-Reported Outcomes and Virtual Care",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Patient Reported Outcome Measures | Telemedicine",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1780900167,'221863');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENipp, Ryan David",
"kol_full_name": "Nipp, Ryan David"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nivolumab | Radiotherapy | Gastroesophageal Junction Adenocarcinoma",
"npi_num": "1750473922",
"hcp_pin_alias": "221553",
"session_name": "Multicenter randomized phase II study of short course FOLFOX + nivolumab (Nivo) followed by maintenance Nivo +/- radiation (RT) in the first line treatment of metastatic or unresectable gastroesophageal adenocarcinoma (mGEA)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "221553",
"first_name": "Manish",
"middle_name": "A",
"last_name": "Shah",
"org_name": "Weill Medical College of Cornell",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232819",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232819",
"events_session": "Multicenter randomized phase II study of short course FOLFOX + nivolumab (Nivo) followed by maintenance Nivo +/- radiation (RT) in the first line treatment of metastatic or unresectable gastroesophageal adenocarcinoma (mGEA)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Nivolumab | Radiotherapy ",
"rest_events_topic_count": 1,
"rest_events_topic": " Gastroesophageal Junction Adenocarcinoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1750473922,'221553');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShah, Manish A",
"kol_full_name": "Shah, Manish A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Bizaxofusp | Glioblastoma",
"npi_num": "1720158553",
"hcp_pin_alias": "221311",
"session_name": "Phase 2 study of bizaxofusp, an IL-4R targeted toxin payload, in nonresectable recurrent GBM: Comparison of overall survival with contemporaneous eligibility-matched and propensity score balanced external control arm",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "221311",
"first_name": "John",
"middle_name": "",
"last_name": "Sampson",
"org_name": "Private Diagnostic Clinic, PLLC",
"Country": "United States",
"Region": "North Carolina",
"City": "Durham",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233077",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233077",
"events_session": "Phase 2 study of bizaxofusp",
"rest_events_session_count": 2,
"rest_events_session": " an IL-4R targeted toxin payload, in nonresectable recurrent GBM: Comparison of overall survival with contemporaneous eligibility-matched and propensity score balanced external control arm",
"events_topic": "Bizaxofusp | Glioblastoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1720158553,'221311');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESampson, John",
"kol_full_name": "Sampson, John"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Hepatocellular | Cholangiocarcinoma | Durvalumab | Nivolumab | Tremelimumab | IDH1 Gene | Bevacizumab | Ivosidenib",
"npi_num": "1700805223",
"hcp_pin_alias": "221140",
"session_name": "A phase 1/2, safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma,T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "221140",
"first_name": "Robin",
"middle_name": "Kate",
"last_name": "Kelley",
"org_name": "UCSF Health",
"Country": "United States",
"Region": "California",
"City": "San Francisco",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232811",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232811",
"events_session": "A phase 1/2",
"rest_events_session_count": 6,
"rest_events_session": " safety lead-in and dose expansion, open-label, multicenter trial investigating the safety, tolerability, and preliminary activity of ivosidenib in combination with nivolumab and ipilimumab in previously treated subjects with IDH1-mutated nonresectable or metastatic cholangiocarcinoma,T cell receptor and immune gene expression pharmacodynamics for durvalumab monotherapy and in combination with tremelimumab or bevacizumab in unresectable hepatocellular carcinoma (uHCC)",
"events_topic": "Carcinoma, Hepatocellular | Cholangiocarcinoma ",
"rest_events_topic_count": 6,
"rest_events_topic": " Durvalumab | Nivolumab | Tremelimumab | IDH1 Gene | Bevacizumab | Ivosidenib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700805223,'221140');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKelley, Robin Kate",
"kol_full_name": "Kelley, Robin Kate"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Azeliragon | Pancreatic Neoplasms",
"npi_num": "1649473414",
"hcp_pin_alias": "220594",
"session_name": "A phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "220594",
"first_name": "Andrew",
"middle_name": "Eugene",
"last_name": "Hendifar",
"org_name": "Cedars-Sinai Medical Center",
"Country": "United States",
"Region": "California",
"City": "Santa Monica",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232865",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232865",
"events_session": "A phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to first-line treatment of metastatic pancreatic cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Azeliragon | Pancreatic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1649473414,'220594');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHendifar, Andrew Eugene",
"kol_full_name": "Hendifar, Andrew Eugene"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Melphalan | Uveal Melanoma",
"npi_num": "1629080304",
"hcp_pin_alias": "220350",
"session_name": "Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "220350",
"first_name": "Jonathan",
"middle_name": "",
"last_name": "Zager",
"org_name": "H. Lee Moffitt Cancer Center & Research Institute",
"Country": "United States",
"Region": "Florida",
"City": "Tampa",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232794",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232794",
"events_session": "Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Melphalan | Uveal Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/220350/fromId'\u003EZager, Jonathan\u003C/a\u003E",
"kol_full_name": "Zager, Jonathan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | HLA-A*02:01 Antigen | Anus Neoplasms | Esophageal Neoplasms | Gastrointestinal Neoplasms | Neoplasms",
"npi_num": "1619146347",
"hcp_pin_alias": "220262",
"session_name": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee,A phase 1, open-label, dose escalation, and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers,Is Timing Everything in Gastroesophageal Cancers?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "220262",
"first_name": "Nataliya",
"middle_name": "V",
"last_name": "Uboha",
"org_name": "Medical College of Wisconsin",
"Country": "United States",
"Region": "Wisconsin",
"City": "Richland Center",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232108",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232108",
"events_session": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"rest_events_session_count": 7,
"rest_events_session": "A phase 1, open-label, dose escalation, and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in patients with HLA-A*0201-positive disease and WT1-positive recurrent/metastatic cancers,Is Timing Everything in Gastroesophageal Cancers?",
"events_topic": "Colorectal Neoplasms | HLA-A*02:01 Antigen ",
"rest_events_topic_count": 4,
"rest_events_topic": " Anus Neoplasms | Esophageal Neoplasms | Gastrointestinal Neoplasms | Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1619146347,'220262');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EUboha, Nataliya V",
"kol_full_name": "Uboha, Nataliya V"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hematologic Neoplasms | Palliative Care",
"npi_num": "1619139235",
"hcp_pin_alias": "220258",
"session_name": "A longitudinal, palliative care educational pilot in hematology-oncology fellowship training",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "220258",
"first_name": "Jessica",
"middle_name": "R",
"last_name": "Bauman",
"org_name": "Fox Chase Cancer Center",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232318",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232318",
"events_session": "A longitudinal",
"rest_events_session_count": 1,
"rest_events_session": " palliative care educational pilot in hematology-oncology fellowship training",
"events_topic": "Hematologic Neoplasms | Palliative Care",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1619139235,'220258');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBauman, Jessica R",
"kol_full_name": "Bauman, Jessica R"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Liver Neoplasms | Colorectal Neoplasms | Hepatic Arterial Infusion",
"npi_num": "1609938778",
"hcp_pin_alias": "220222",
"session_name": "Do Hepatic Artery Infusion Pumps Still Live?,Thinking Outside the Box: Management of Limited Metastatic Colorectal Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "220222",
"first_name": "Flavio",
"middle_name": "G",
"last_name": "Rocha",
"org_name": "Virginia Mason Medical Center",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231972",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231972",
"events_session": "Do Hepatic Artery Infusion Pumps Still Live?",
"rest_events_session_count": 1,
"rest_events_session": "Thinking Outside the Box: Management of Limited Metastatic Colorectal Cancer",
"events_topic": "Liver Neoplasms | Colorectal Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Hepatic Arterial Infusion",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/220222/fromId'\u003ERocha, Flavio G\u003C/a\u003E",
"kol_full_name": "Rocha, Flavio G"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Fruquintinib | Colorectal Neoplasms",
"npi_num": "1598770331",
"hcp_pin_alias": "220095",
"session_name": "Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "220095",
"first_name": "Tanios",
"middle_name": "S.",
"last_name": "Bekaii-Saab",
"org_name": "Mayo Clinic - Rochester",
"Country": "United States",
"Region": "Arizona",
"City": "Scottsdale",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232879",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232879",
"events_session": "Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Fruquintinib | Colorectal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1598770331,'220095');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBekaii-Saab, Tanios S.",
"kol_full_name": "Bekaii-Saab, Tanios S."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Leiomyosarcoma",
"npi_num": "1568608669",
"hcp_pin_alias": "219820",
"session_name": "Leiomyosarcoma: A Patient-Centered Approach to a Complex Journey",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "219820",
"first_name": "Jiping",
"middle_name": "",
"last_name": "Wang",
"org_name": "Brigham and Womens Hospital",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231992",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231992",
"events_session": "Leiomyosarcoma: A Patient-Centered Approach to a Complex Journey",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Leiomyosarcoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1568608669,'219820');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWang, Jiping",
"kol_full_name": "Wang, Jiping"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Zanzalintinib | Squamous Cell Carcinoma Of Head And Neck",
"npi_num": "1558479188",
"hcp_pin_alias": "219696",
"session_name": "STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "219696",
"first_name": "Nabil",
"middle_name": "F",
"last_name": "Saba",
"org_name": "Emory University Hospital Midtown",
"Country": "United States",
"Region": "Georgia",
"City": "Atlanta",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232574",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232574",
"events_session": "STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pembrolizumab | Zanzalintinib ",
"rest_events_topic_count": 1,
"rest_events_topic": " Squamous Cell Carcinoma Of Head And Neck",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1558479188,'219696');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESaba, Nabil F",
"kol_full_name": "Saba, Nabil F"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1528024270",
"hcp_pin_alias": "219416",
"session_name": "Discussion on Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "219416",
"first_name": "Monica",
"middle_name": "Marie",
"last_name": "Bertagnolli",
"org_name": "Brigham and Womens Hospital",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232917",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232917",
"events_session": "Discussion on Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1528024270,'219416');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBertagnolli, Monica Marie",
"kol_full_name": "Bertagnolli, Monica Marie"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Artificial Intelligence | Precision Medicine",
"npi_num": "1518029065",
"hcp_pin_alias": "219322",
"session_name": "Transforming Precision Medicine: AI and Molecular Insights Intersect Across the Cancer Care Continuum",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "219322",
"first_name": "Ezra",
"middle_name": "E",
"last_name": "Cohen",
"org_name": "UC San Diego Health",
"Country": "United States",
"Region": "California",
"City": "San Diego",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233156",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233156",
"events_session": "Transforming Precision Medicine: AI and Molecular Insights Intersect Across the Cancer Care Continuum",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms | Artificial Intelligence ",
"rest_events_topic_count": 1,
"rest_events_topic": " Precision Medicine",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1518029065,'219322');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECohen, Ezra E",
"kol_full_name": "Cohen, Ezra E"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptor, Epidermal Growth Factor | Carcinoma, Non-Small-Cell Lung | Radiotherapy | Chemoradiotherapy",
"npi_num": "1457326936",
"hcp_pin_alias": "218771",
"session_name": "Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "218771",
"first_name": "Suresh",
"middle_name": "Sakkarai",
"last_name": "Ramalingam",
"org_name": "Emory University Hospital",
"Country": "United States",
"Region": "Georgia",
"City": "Atlanta",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232514",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232514",
"events_session": "Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Receptor, Epidermal Growth Factor | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 2,
"rest_events_topic": " Radiotherapy | Chemoradiotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1457326936,'218771');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERamalingam, Suresh Sakkarai",
"kol_full_name": "Ramalingam, Suresh Sakkarai"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Social Determinants Of Health | Breast Neoplasms",
"npi_num": "1417202623",
"hcp_pin_alias": "218438",
"session_name": "Associations of social determinants of health with avoidance of information, treatment receipt, and physician mistrust for women with breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "218438",
"first_name": "Olga",
"middle_name": "",
"last_name": "Kantor",
"org_name": "Brigham and Womens Hospital",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232105",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232105",
"events_session": "Associations of social determinants of health with avoidance of information",
"rest_events_session_count": 2,
"rest_events_session": " treatment receipt, and physician mistrust for women with breast cancer",
"events_topic": "Social Determinants Of Health | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1417202623,'218438');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKantor, Olga",
"kol_full_name": "Kantor, Olga"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Datopotamab Deruxtecan | Valemetostat Tosilate | Immunoconjugates | Solid Tumor | Lung Diseases, Interstitial | Trastuzumab Deruxtecan",
"npi_num": "1356491237",
"hcp_pin_alias": "217897",
"session_name": "A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors,Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "217897",
"first_name": "Jacob",
"middle_name": "Magee",
"last_name": "Sands",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232182",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232182",
"events_session": "A phase 1b",
"rest_events_session_count": 5,
"rest_events_session": " multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors,Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd)",
"events_topic": "Datopotamab Deruxtecan | Valemetostat Tosilate ",
"rest_events_topic_count": 4,
"rest_events_topic": " Immunoconjugates | Solid Tumor | Lung Diseases, Interstitial | Trastuzumab Deruxtecan",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356491237,'217897');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESands, Jacob Magee",
"kol_full_name": "Sands, Jacob Magee"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Electronic Health Records | Lung Neoplasms",
"npi_num": "1306817333",
"hcp_pin_alias": "217437",
"session_name": "Feasibility and utilization of electronic patient-reported outcome measures for lung cancer in routine clinical care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "217437",
"first_name": "Ethan",
"middle_name": "M",
"last_name": "Basch",
"org_name": "",
"Country": "United States",
"Region": "North Carolina",
"City": "Chapel Hill",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232408",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232408",
"events_session": "Feasibility and utilization of electronic patient-reported outcome measures for lung cancer in routine clinical care",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Electronic Health Records | Lung Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/217437/fromId'\u003EBasch, Ethan M\u003C/a\u003E",
"kol_full_name": "Basch, Ethan M"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Circulating Tumor DNA | Lung Neoplasms",
"npi_num": "1285996082",
"hcp_pin_alias": "217308",
"session_name": "Sparking the Conversation: Integrating ctDNA and Quality of Life in Adjuvant Lung Cancer Care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "217308",
"first_name": "Julia",
"middle_name": "K",
"last_name": "Rotow",
"org_name": "Regents of The University of California",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232476",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232476",
"events_session": "Sparking the Conversation: Integrating ctDNA and Quality of Life in Adjuvant Lung Cancer Care",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Circulating Tumor DNA | Lung Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1285996082,'217308');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERotow, Julia K",
"kol_full_name": "Rotow, Julia K"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Esophageal Squamous Cell Carcinoma | Tislelizumab",
"npi_num": "1255408258",
"hcp_pin_alias": "216994",
"session_name": "Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "216994",
"first_name": "Harry",
"middle_name": "",
"last_name": "Yoon",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232813",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232813",
"events_session": "Global",
"rest_events_session_count": 2,
"rest_events_session": " randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up",
"events_topic": "Chemotherapy | Esophageal Squamous Cell Carcinoma ",
"rest_events_topic_count": 1,
"rest_events_topic": " Tislelizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1255408258,'216994');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYoon, Harry",
"kol_full_name": "Yoon, Harry"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Solid Tumor | CDK9 Protein, Human",
"npi_num": "1235227794",
"hcp_pin_alias": "216811",
"session_name": "Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "216811",
"first_name": "Brian",
"middle_name": "Andrew",
"last_name": "Van Tine",
"org_name": "Washington University School of Medicine in St. Louis",
"Country": "United States",
"Region": "Missouri",
"City": "St. Louis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232957",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232957",
"events_session": "Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Solid Tumor | CDK9 Protein, Human",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1235227794,'216811');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVan Tine, Brian Andrew",
"kol_full_name": "Van Tine, Brian Andrew"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Gastroenteropancreatic Neuroendocrine Tumors",
"npi_num": "1225121932",
"hcp_pin_alias": "216714",
"session_name": "Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "216714",
"first_name": "Pamela",
"middle_name": "Lyn",
"last_name": "Kunz",
"org_name": "Stanford Health Care",
"Country": "United States",
"Region": "California",
"City": "Stanford",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232834",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232834",
"events_session": "Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3",
"rest_events_session_count": 1,
"rest_events_session": " well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study",
"events_topic": "Gastroenteropancreatic Neuroendocrine Tumors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1225121932,'216714');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKunz, Pamela Lyn",
"kol_full_name": "Kunz, Pamela Lyn"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cancer Survivors",
"npi_num": "1215463823",
"hcp_pin_alias": "216649",
"session_name": "Age-normed patient-reported outcome measures among cancer survivors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "216649",
"first_name": "Samantha",
"middle_name": "",
"last_name": "Tam",
"org_name": "Henry Ford Medical Group",
"Country": "United States",
"Region": "Michigan",
"City": "Clinton Township",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232411",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232411",
"events_session": "Age-normed patient-reported outcome measures among cancer survivors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Cancer Survivors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1215463823,'216649');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETam, Samantha",
"kol_full_name": "Tam, Samantha"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasm, Residual",
"npi_num": "1215167648",
"hcp_pin_alias": "216609",
"session_name": "Use of MRD-Guided Strategies to Optimize Therapeutic Interventions",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "216609",
"first_name": "Pashtoon",
"middle_name": "M",
"last_name": "Kasi",
"org_name": "University Of Iowa Hospital & Clinics",
"Country": "United States",
"Region": "Iowa",
"City": "Iowa City",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232004",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232004",
"events_session": "Use of MRD-Guided Strategies to Optimize Therapeutic Interventions",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasm, Residual",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1215167648,'216609');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKasi, Pashtoon M",
"kol_full_name": "Kasi, Pashtoon M"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Anaplastic Lymphoma Kinase | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1215129085",
"hcp_pin_alias": "216605",
"session_name": "Lung Cancer – Non-Small Cell Metastatc: Program Commitee,ALK testing patterns in early-stage non-small cell lung cancer: A real-world evidence study,Lung Cancer—Non-Small Cell Metastatic",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "216605",
"first_name": "Ticiana",
"middle_name": "B",
"last_name": "Leal",
"org_name": "Medical College of Wisconsin",
"Country": "United States",
"Region": "Wisconsin",
"City": "Portage",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232091",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232091",
"events_session": "Lung Cancer – Non-Small Cell Metastatc: Program Commitee",
"rest_events_session_count": 2,
"rest_events_session": "ALK testing patterns in early-stage non-small cell lung cancer: A real-world evidence study,Lung Cancer—Non-Small Cell Metastatic",
"events_topic": "Anaplastic Lymphoma Kinase | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1215129085,'216605');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELeal, Ticiana B",
"kol_full_name": "Leal, Ticiana B"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunoconjugates | Colorectal Neoplasms",
"npi_num": "1205920048",
"hcp_pin_alias": "216566",
"session_name": "First-in-human trial of M9140, an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "216566",
"first_name": "Edmund",
"middle_name": "S.",
"last_name": "Kopetz",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232766",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232766",
"events_session": "First-in-human trial of M9140",
"rest_events_session_count": 2,
"rest_events_session": " an anti-CEACAM5 antibody drug conjugate (ADC) with exatecan payload, in patients (pts) with metastatic colorectal cancer (mCRC)",
"events_topic": "Immunoconjugates | Colorectal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1205920048,'216566');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKopetz, Edmund S.",
"kol_full_name": "Kopetz, Edmund S."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Paraproteinemias | Hematologic Neoplasms",
"npi_num": "1144470758",
"hcp_pin_alias": "215907",
"session_name": "Hematologic Malignancies—Plasma Cell Dyscrasia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "215907",
"first_name": "Hans",
"middle_name": "",
"last_name": "Lee",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231976",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231976",
"events_session": "Hematologic Malignancies—Plasma Cell Dyscrasia",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Paraproteinemias | Hematologic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1144470758,'215907');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELee, Hans",
"kol_full_name": "Lee, Hans"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunohistochemistry | Colorectal Neoplasms | Immune Checkpoint Inhibitors | Anus Neoplasms | Stomach Neoplasms | Gastrointestinal Neoplasms",
"npi_num": "1134329378",
"hcp_pin_alias": "215802",
"session_name": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee,PD-L1 immunohistochemistry in gastric cancer: Comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "215802",
"first_name": "Samuel",
"middle_name": "Jacob",
"last_name": "Klempner",
"org_name": "Samuel Klempner Private Practice",
"Country": "United States",
"Region": "California",
"City": "Los Angeles",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233019",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233019",
"events_session": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"rest_events_session_count": 3,
"rest_events_session": "PD-L1 immunohistochemistry in gastric cancer: Comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays",
"events_topic": "Immunohistochemistry | Colorectal Neoplasms ",
"rest_events_topic_count": 4,
"rest_events_topic": " Immune Checkpoint Inhibitors | Anus Neoplasms | Stomach Neoplasms | Gastrointestinal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1134329378,'215802');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKlempner, Samuel Jacob",
"kol_full_name": "Klempner, Samuel Jacob"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Hepatocellular | Budigalimab | Livmoniplimab",
"npi_num": "1134190168",
"hcp_pin_alias": "215771",
"session_name": "Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma,Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "215771",
"first_name": "Ghassan",
"middle_name": "K",
"last_name": "Abou-Alfa",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232853",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232853",
"events_session": "Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma",
"rest_events_session_count": 1,
"rest_events_session": "Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma",
"events_topic": "Carcinoma, Hepatocellular | Budigalimab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Livmoniplimab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1134190168,'215771');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAbou-Alfa, Ghassan K",
"kol_full_name": "Abou-Alfa, Ghassan K"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Datopotamab Deruxtecan",
"npi_num": "1043509797",
"hcp_pin_alias": "214970",
"session_name": "Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "214970",
"first_name": "Aaron",
"middle_name": "",
"last_name": "Lisberg",
"org_name": "UCLA Health",
"Country": "United States",
"Region": "California",
"City": "Santa Monica",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232175",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232175",
"events_session": "Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Datopotamab Deruxtecan",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1043509797,'214970');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELisberg, Aaron",
"kol_full_name": "Lisberg, Aaron"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1033535000",
"hcp_pin_alias": "214897",
"session_name": "Breast Cancer – Local/Regional/Adjuvant: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "214897",
"first_name": "Alastair",
"middle_name": "Mark",
"last_name": "Thompson",
"org_name": "Baylor College of Medicine",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233174",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233174",
"events_session": "Breast Cancer – Local/Regional/Adjuvant: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1033535000,'214897');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EThompson, Alastair Mark",
"kol_full_name": "Thompson, Alastair Mark"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sacituzumab Govitecan | Elacestrant | Solid Tumor | Triple Negative Breast Neoplasms",
"npi_num": "1033176581",
"hcp_pin_alias": "214827",
"session_name": "Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types,Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "214827",
"first_name": "Hope",
"middle_name": "S.",
"last_name": "Rugo",
"org_name": "UCSF Health",
"Country": "United States",
"Region": "California",
"City": "San Francisco",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232691",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232691",
"events_session": "Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types",
"rest_events_session_count": 5,
"rest_events_session": "Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study",
"events_topic": "Sacituzumab Govitecan | Elacestrant ",
"rest_events_topic_count": 2,
"rest_events_topic": " Solid Tumor | Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1033176581,'214827');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERugo, Hope S.",
"kol_full_name": "Rugo, Hope S."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptors, Somatostatin | Neuroendocrine Tumors",
"npi_num": "1013960988",
"hcp_pin_alias": "214710",
"session_name": "Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "214710",
"first_name": "Jonathan",
"middle_name": "",
"last_name": "Strosberg",
"org_name": "H. Lee Moffitt Cancer Center & Research Institute",
"Country": "United States",
"Region": "Florida",
"City": "Tampa",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232324",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232324",
"events_session": "Safety",
"rest_events_session_count": 1,
"rest_events_session": " tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study",
"events_topic": "Receptors, Somatostatin | Neuroendocrine Tumors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1013960988,'214710');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EStrosberg, Jonathan",
"kol_full_name": "Strosberg, Jonathan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Squamous Cell Carcinoma Of Head And Neck | Head And Neck Neoplasms | Chemoradiotherapy",
"npi_num": "1942259098",
"hcp_pin_alias": "213084",
"session_name": "eVOLVE-HNSCC: A global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT),Head and Neck Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "213084",
"first_name": "Robert",
"middle_name": "I",
"last_name": "Haddad",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231961",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231961",
"events_session": "eVOLVE-HNSCC: A global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT)",
"rest_events_session_count": 1,
"rest_events_session": "Head and Neck Cancer",
"events_topic": "Squamous Cell Carcinoma Of Head And Neck | Head And Neck Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Chemoradiotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1942259098,'213084');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHaddad, Robert I",
"kol_full_name": "Haddad, Robert I"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Head And Neck Neoplasms",
"npi_num": "1841208378",
"hcp_pin_alias": "210522",
"session_name": "Otolaryngologist Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "210522",
"first_name": "Neil",
"middle_name": "Dwayne",
"last_name": "Gross",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232332",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232332",
"events_session": "Otolaryngologist Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Head And Neck Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1841208378,'210522');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGross, Neil Dwayne",
"kol_full_name": "Gross, Neil Dwayne"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Infliximab | Immune Checkpoint Inhibitors | Vedolizumab | Colitis | Gastrointestinal Neoplasms | Clinical Trials As Topic | Fecal Microbiota Transplantation",
"npi_num": "1164699047",
"hcp_pin_alias": "193299",
"session_name": "Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis,The impact of proton-pump inhibitor use on the incidence and severity of gastrointestinal toxicity to checkpoint inhibition,Effect of fecal transplantation on patient reported outcomes after immune checkpoint inhibitor colitis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "193299",
"first_name": "Yinghong",
"middle_name": "",
"last_name": "Wang",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232524",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232524",
"events_session": "Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis",
"rest_events_session_count": 2,
"rest_events_session": "The impact of proton-pump inhibitor use on the incidence and severity of gastrointestinal toxicity to checkpoint inhibition,Effect of fecal transplantation on patient reported outcomes after immune checkpoint inhibitor colitis",
"events_topic": "Infliximab | Immune Checkpoint Inhibitors ",
"rest_events_topic_count": 5,
"rest_events_topic": " Vedolizumab | Colitis | Gastrointestinal Neoplasms | Clinical Trials As Topic | Fecal Microbiota Transplantation",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1164699047,'193299');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWang, Yinghong",
"kol_full_name": "Wang, Yinghong"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Anus Neoplasms | Gastrointestinal Neoplasms",
"npi_num": "1144381617",
"hcp_pin_alias": "192703",
"session_name": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "192703",
"first_name": "Yi-Qian",
"middle_name": "",
"last_name": "You",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233198",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233198",
"events_session": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colorectal Neoplasms | Anus Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Gastrointestinal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1144381617,'192703');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYou, Yi-Qian",
"kol_full_name": "You, Yi-Qian"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Atezolizumab | Colorectal Neoplasms | Neoplasms | Microsatellite Repeats",
"npi_num": "1952351009",
"hcp_pin_alias": "151774",
"session_name": "A phase II, multicenter, open-label study of polyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301),Communicating With Patients Through the Portal—A Busy Oncologist's Perspective,When Bad News Comes Through the Portal: Strengthening Trust and Guiding Patients When They Receive Bad Results Before Their Clinicians Do",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "151774",
"first_name": "Joleen",
"middle_name": "M",
"last_name": "Hubbard",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232041",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232041",
"events_session": "A phase II",
"rest_events_session_count": 4,
"rest_events_session": " multicenter, open-label study of polyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer (Oberto-301),Communicating With Patients Through the Portal—A Busy Oncologist's Perspective,When Bad News Comes Through the Portal: Strengthening Trust and Guiding Patients When They Receive Bad Results Before Their Clinicians Do",
"events_topic": "Atezolizumab | Colorectal Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Neoplasms | Microsatellite Repeats",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1952351009,'151774');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHubbard, Joleen M",
"kol_full_name": "Hubbard, Joleen M"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Circulating Tumor DNA | Fluorouracil | Leucovorin | Bevacizumab | Colorectal Neoplasms",
"npi_num": "1871708198",
"hcp_pin_alias": "151594",
"session_name": "Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer,A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA (ctDNA): TACT-D",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "151594",
"first_name": "Kanwal",
"middle_name": "Pratap Singh",
"last_name": "Raghav",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232876",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232876",
"events_session": "Phase 2 randomized study evaluating safety",
"rest_events_session_count": 5,
"rest_events_session": " efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer,A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA (ctDNA): TACT-D",
"events_topic": "Circulating Tumor DNA | Fluorouracil ",
"rest_events_topic_count": 3,
"rest_events_topic": " Leucovorin | Bevacizumab | Colorectal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1871708198,'151594');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERaghav, Kanwal Pratap Singh",
"kol_full_name": "Raghav, Kanwal Pratap Singh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Rectal Neoplasms | Programmed Cell Death 1 Receptor | DNA Mismatch Repair",
"npi_num": "1710201280",
"hcp_pin_alias": "151231",
"session_name": "Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "151231",
"first_name": "Andrea",
"middle_name": "",
"last_name": "Cercek",
"org_name": "Memorial Solid Tumor Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232273",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232273",
"events_session": "Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Rectal Neoplasms | Programmed Cell Death 1 Receptor ",
"rest_events_topic_count": 1,
"rest_events_topic": " DNA Mismatch Repair",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1710201280,'151231');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECercek, Andrea",
"kol_full_name": "Cercek, Andrea"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Neuroendocrine | Atezolizumab | Etoposide",
"npi_num": "1568758431",
"hcp_pin_alias": "150900",
"session_name": "SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "150900",
"first_name": "David",
"middle_name": "B",
"last_name": "Zhen",
"org_name": "Association of University Physicians",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232859",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232859",
"events_session": "SWOG S2012: Randomized phase II/III trial of first line platinum (P)/etoposide (E) with or without atezolizumab (NSC #783608) in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas (NEC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Neuroendocrine | Atezolizumab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Etoposide",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1568758431,'150900');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EZhen, David B",
"kol_full_name": "Zhen, David B"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms",
"npi_num": "1487670147",
"hcp_pin_alias": "150701",
"session_name": "Quality of Life Considerations in the Curative Colorectal Cancer Population",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "150701",
"first_name": "Smitha",
"middle_name": "S",
"last_name": "Krishnamurthi",
"org_name": "Cleveland Clinic Foundation",
"Country": "United States",
"Region": "Ohio",
"City": "Cleveland",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232539",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232539",
"events_session": "Quality of Life Considerations in the Curative Colorectal Cancer Population",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colorectal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1487670147,'150701');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKrishnamurthi, Smitha S",
"kol_full_name": "Krishnamurthi, Smitha S"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "DNA Mismatch Repair | Anus Neoplasms | Colorectal Neoplasms | Gastrointestinal Neoplasms",
"npi_num": "1356542369",
"hcp_pin_alias": "150392",
"session_name": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee,Harmonizing Therapies for Mismatch Repair-Deficient Colorectal Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "150392",
"first_name": "Kristen",
"middle_name": "Keon",
"last_name": "Ciombor",
"org_name": "Vanderbilt University Medical Center",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232729",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232729",
"events_session": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Harmonizing Therapies for Mismatch Repair-Deficient Colorectal Cancer",
"events_topic": "DNA Mismatch Repair | Anus Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Colorectal Neoplasms | Gastrointestinal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356542369,'150392');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECiombor, Kristen Keon",
"kol_full_name": "Ciombor, Kristen Keon"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Oncolytic Viruses | Carcinoma, Hepatocellular | Blinatumomab | Solid Tumor | Biliary Tract Neoplasms | Combined Modality Therapy | Beta Catenin",
"npi_num": "1285877209",
"hcp_pin_alias": "150214",
"session_name": "Combination therapy with the oncolytic virus CF33-CD19 and blinatumomab for the treatment of advanced solid tumors,A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations,Safety of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in patients (pts) with biliary tract cancer with peritoneal metastases",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "150214",
"first_name": "Daneng",
"middle_name": "",
"last_name": "Li",
"org_name": "City of Hope Medical Foundation",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232851",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232851",
"events_session": "Combination therapy with the oncolytic virus CF33-CD19 and blinatumomab for the treatment of advanced solid tumors",
"rest_events_session_count": 4,
"rest_events_session": "A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations,Safety of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in patients (pts) with biliary tract cancer with peritoneal metastases",
"events_topic": "Chemotherapy | Oncolytic Viruses ",
"rest_events_topic_count": 6,
"rest_events_topic": " Carcinoma, Hepatocellular | Blinatumomab | Solid Tumor | Biliary Tract Neoplasms | Combined Modality Therapy | Beta Catenin",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1285877209,'150214');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELi, Daneng",
"kol_full_name": "Li, Daneng"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sarcoma",
"npi_num": "1134409923",
"hcp_pin_alias": "149886",
"session_name": "Sarcoma: Program Commitee,Sarcoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "149886",
"first_name": "Abhijeet",
"middle_name": "",
"last_name": "Kumar",
"org_name": "Banner - University Medical Center Phoenix",
"Country": "United States",
"Region": "Arizona",
"City": "Tucson",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232093",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232093",
"events_session": "Sarcoma: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Sarcoma",
"events_topic": "Sarcoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1134409923,'149886');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKumar, Abhijeet",
"kol_full_name": "Kumar, Abhijeet"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immune Checkpoint Inhibitors | Chemoradiotherapy | Stomach Neoplasms",
"npi_num": "1104027549",
"hcp_pin_alias": "149793",
"session_name": "Neoadjuvant dual checkpoint inhibition followed by immune-chemoradiation in patients with resectable gastric adenocarcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "149793",
"first_name": "Mariela",
"middle_name": "Anabel",
"last_name": "Blum Murphy",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232820",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232820",
"events_session": "Neoadjuvant dual checkpoint inhibition followed by immune-chemoradiation in patients with resectable gastric adenocarcinoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immune Checkpoint Inhibitors | Chemoradiotherapy ",
"rest_events_topic_count": 1,
"rest_events_topic": " Stomach Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1104027549,'149793');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBlum Murphy, Mariela Anabel",
"kol_full_name": "Blum Murphy, Mariela Anabel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cisplatin | Gemcitabine | Biliary Tract Neoplasms",
"npi_num": "1992904023",
"hcp_pin_alias": "149564",
"session_name": "Phase 1b/2 results of a multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "149564",
"first_name": "Vaibhav",
"middle_name": "",
"last_name": "Sahai",
"org_name": "University of Michigan Health System",
"Country": "United States",
"Region": "Michigan",
"City": "Ann Arbor",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232830",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232830",
"events_session": "Phase 1b/2 results of a multicenter",
"rest_events_session_count": 1,
"rest_events_session": " randomized phase 1b/2 study of gemcitabine and cisplatin +/- devimistat as first-line therapy for patients with advanced biliary tract cancer (BilT-04)",
"events_topic": "Cisplatin | Gemcitabine ",
"rest_events_topic_count": 1,
"rest_events_topic": " Biliary Tract Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1992904023,'149564');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESahai, Vaibhav",
"kol_full_name": "Sahai, Vaibhav"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genital Neoplasms, Female",
"npi_num": "1992870638",
"hcp_pin_alias": "148988",
"session_name": "Stronger Together: Novel Combinations Across the Gynecologic Cancer Spectrum",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "148988",
"first_name": "Ursula",
"middle_name": "Anne",
"last_name": "Matulonis",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232918",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232918",
"events_session": "Stronger Together: Novel Combinations Across the Gynecologic Cancer Spectrum",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Genital Neoplasms, Female",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1992870638,'148988');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMatulonis, Ursula Anne",
"kol_full_name": "Matulonis, Ursula Anne"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Trastuzumab Deruxtecan | Ado-Trastuzumab Emtansine | Admin. & Management | Immunoconjugates | Triple Negative Breast Neoplasms",
"npi_num": "1902007107",
"hcp_pin_alias": "146975",
"session_name": "Scientific Program Committee,Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03,The ABCs of ADCs: What Does the Future Hold?,H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC),Next-Generation Antibody–Drug Conjugates: The Revolution Continues",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "146975",
"first_name": "Erika",
"middle_name": "P",
"last_name": "Hamilton",
"org_name": "Tennessee Oncology",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "5",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232046",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232046",
"events_session": "Scientific Program Committee",
"rest_events_session_count": 5,
"rest_events_session": "Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03,The ABCs of ADCs: What Does the Future Hold?,H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC),Next-Generation Antibody–Drug Conjugates: The Revolution Continues",
"events_topic": "Trastuzumab Deruxtecan | Ado-Trastuzumab Emtansine ",
"rest_events_topic_count": 3,
"rest_events_topic": " Admin. & Management | Immunoconjugates | Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1902007107,'146975');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHamilton, Erika P",
"kol_full_name": "Hamilton, Erika P"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunoconjugates | Human Papillomavirus Viruses | Neuroendocrine Tumors | Drug Development | Biomarkers",
"npi_num": "1902062433",
"hcp_pin_alias": "146686",
"session_name": "Developmental Therapeutcs – Molecularly Targeted Agents: Program Commitee,Dynamic Evaluation of Biomarkers in Patients Treated With Antibody-Drug Conjugates,Differences in genomic and transcriptomic landscapes of human papillomavirus (HPV)–positive neuroendocrine neoplasms and HPV-positive carcinoma,Circulating Biomarkers: Who, What, Where, When, and Why?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "146686",
"first_name": "Emil",
"middle_name": "",
"last_name": "Lou",
"org_name": "University of Minnesota Medical School",
"Country": "United States",
"Region": "Minnesota",
"City": "Minneapolis",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231975",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231975",
"events_session": "Developmental Therapeutcs – Molecularly Targeted Agents: Program Commitee",
"rest_events_session_count": 7,
"rest_events_session": "Dynamic Evaluation of Biomarkers in Patients Treated With Antibody-Drug Conjugates,Differences in genomic and transcriptomic landscapes of human papillomavirus (HPV)–positive neuroendocrine neoplasms and HPV-positive carcinoma,Circulating Biomarkers: Who, What, Where, When, and Why?",
"events_topic": "Immunoconjugates | Human Papillomavirus Viruses ",
"rest_events_topic_count": 3,
"rest_events_topic": " Neuroendocrine Tumors | Drug Development | Biomarkers",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1902062433,'146686');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELou, Emil",
"kol_full_name": "Lou, Emil"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Teclistamab | Multiple Myeloma",
"npi_num": "1902064629",
"hcp_pin_alias": "146682",
"session_name": "Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "146682",
"first_name": "Alfred",
"middle_name": "L",
"last_name": "Garfall",
"org_name": "University of Pennsylvania Health System",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232359",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232359",
"events_session": "Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Teclistamab | Multiple Myeloma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1902064629,'146682');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGarfall, Alfred L",
"kol_full_name": "Garfall, Alfred L"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Endometrial Neoplasms | Ovarian Neoplasms | Hormone Replacement Therapy",
"npi_num": "1902876386",
"hcp_pin_alias": "146669",
"session_name": "Menopausal hormone therapy and ovarian and endometrial cancers: Long-term follow-up of the Women’s Health Initiative randomized trials",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "146669",
"first_name": "Rowan",
"middle_name": "",
"last_name": "Chlebowski",
"org_name": "City of Hope National Medical Center",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232761",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232761",
"events_session": "Menopausal hormone therapy and ovarian and endometrial cancers: Long-term follow-up of the Women’s Health Initiative randomized trials",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Endometrial Neoplasms | Ovarian Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Hormone Replacement Therapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1902876386,'146669');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChlebowski, Rowan",
"kol_full_name": "Chlebowski, Rowan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Panitumumab | Microsatellite Repeats | Sotorasib | Liver Neoplasms | KRASG12D Inhibitor MRTX1133 | Botensilimab Plus Balstilimab | Colorectal Neoplasms",
"npi_num": "1861498271",
"hcp_pin_alias": "146186",
"session_name": "Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites,Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "146186",
"first_name": "Marwan",
"middle_name": "G",
"last_name": "Fakih",
"org_name": "City of Hope Medical Foundation",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232271",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232271",
"events_session": "Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites",
"rest_events_session_count": 1,
"rest_events_session": "Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC)",
"events_topic": "Panitumumab | Microsatellite Repeats ",
"rest_events_topic_count": 5,
"rest_events_topic": " Sotorasib | Liver Neoplasms | KRASG12D Inhibitor MRTX1133 | Botensilimab Plus Balstilimab | Colorectal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1861498271,'146186');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFakih, Marwan G",
"kol_full_name": "Fakih, Marwan G"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Paclitaxel | Defactinib | Carcinoma, Pancreatic Ductal | Avutometinib",
"npi_num": "1851597108",
"hcp_pin_alias": "146019",
"session_name": "Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "146019",
"first_name": "Kian Huat",
"middle_name": "",
"last_name": "Lim",
"org_name": "Washington University School of Medicine in St. Louis",
"Country": "United States",
"Region": "Missouri",
"City": "St. Louis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232839",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232839",
"events_session": "Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Paclitaxel | Defactinib ",
"rest_events_topic_count": 2,
"rest_events_topic": " Carcinoma, Pancreatic Ductal | Avutometinib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1851597108,'146019');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELim, Kian Huat",
"kol_full_name": "Lim, Kian Huat"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Peritoneal Cancer | Circulating Tumor DNA | Cytoreduction Surgical Procedures | Hyperthermic Intraperitoneal Chemotherapy | Colorectal Neoplasms",
"npi_num": "1841429750",
"hcp_pin_alias": "145789",
"session_name": "Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosis: Insights from a phase II randomized trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "145789",
"first_name": "Anup Kumar",
"middle_name": "",
"last_name": "Kasi Loknath Kumar",
"org_name": "The University of Kansas Health System",
"Country": "United States",
"Region": "Kansas",
"City": "Kansas City",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232887",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232887",
"events_session": "Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosis: Insights from a phase II randomized trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Peritoneal Cancer | Circulating Tumor DNA ",
"rest_events_topic_count": 3,
"rest_events_topic": " Cytoreduction Surgical Procedures | Hyperthermic Intraperitoneal Chemotherapy | Colorectal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1841429750,'145789');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKasi Loknath Kumar, Anup Kumar",
"kol_full_name": "Kasi Loknath Kumar, Anup Kumar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "DNA Damage",
"npi_num": "1821196759",
"hcp_pin_alias": "145210",
"session_name": "Combining DNA Damaging Response Inhibitors With DNA-Damaging Agents",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "145210",
"first_name": "Jennifer",
"middle_name": "K.",
"last_name": "Litton",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232116",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232116",
"events_session": "Combining DNA Damaging Response Inhibitors With DNA-Damaging Agents",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "DNA Damage",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1821196759,'145210');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELitton, Jennifer K.",
"kol_full_name": "Litton, Jennifer K."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Antibody Therapy | Anus Neoplasms | Gastrointestinal Neoplasms",
"npi_num": "1871741025",
"hcp_pin_alias": "145200",
"session_name": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee,Building Novel Antibody-Based Approaches in Gastrointestinal Cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "145200",
"first_name": "Namrata",
"middle_name": "",
"last_name": "Vijayvergia",
"org_name": "Fox Chase Cancer Center",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232029",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232029",
"events_session": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Building Novel Antibody-Based Approaches in Gastrointestinal Cancers",
"events_topic": "Colorectal Neoplasms | Antibody Therapy ",
"rest_events_topic_count": 2,
"rest_events_topic": " Anus Neoplasms | Gastrointestinal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1871741025,'145200');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVijayvergia, Namrata",
"kol_full_name": "Vijayvergia, Namrata"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genetics | Risk Reduction Behavior",
"npi_num": "1811953433",
"hcp_pin_alias": "145094",
"session_name": "Prevention, Risk Reduction, and Genetics",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "145094",
"first_name": "Bryan",
"middle_name": "P",
"last_name": "Schneider",
"org_name": "University Medical Diagnostic Associates Inc",
"Country": "United States",
"Region": "Indiana",
"City": "Indianapolis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232063",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232063",
"events_session": "Prevention",
"rest_events_session_count": 2,
"rest_events_session": " Risk Reduction, and Genetics",
"events_topic": "Genetics | Risk Reduction Behavior",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1811953433,'145094');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESchneider, Bryan P",
"kol_full_name": "Schneider, Bryan P"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pancreatic Neoplasms | Folfirinox",
"npi_num": "1811102205",
"hcp_pin_alias": "144981",
"session_name": "A phase I/II open-label clinical trial of CPI-613 in combination with modified FOLFIRINOX in patients with locally advanced (LAPC) or borderline resectable pancreatic cancer (BRPC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "144981",
"first_name": "David",
"middle_name": "L",
"last_name": "Bajor",
"org_name": "UH Cleveland Medical Center",
"Country": "United States",
"Region": "Ohio",
"City": "Beachwood",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232844",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232844",
"events_session": "A phase I/II open-label clinical trial of CPI-613 in combination with modified FOLFIRINOX in patients with locally advanced (LAPC) or borderline resectable pancreatic cancer (BRPC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pancreatic Neoplasms | Folfirinox",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1811102205,'144981');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBajor, David L",
"kol_full_name": "Bajor, David L"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Small Cell Lung Carcinoma | Neuroendocrine Tumors",
"npi_num": "1801950704",
"hcp_pin_alias": "144924",
"session_name": "Updated results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "144924",
"first_name": "Himisha",
"middle_name": "",
"last_name": "Beltran",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232246",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232246",
"events_session": "Updated results from a phase 1/2 study of HPN328",
"rest_events_session_count": 2,
"rest_events_session": " a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine cancers (NEC)",
"events_topic": "Small Cell Lung Carcinoma | Neuroendocrine Tumors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1801950704,'144924');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBeltran, Himisha",
"kol_full_name": "Beltran, Himisha"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptors, Albumin | Solid Tumor",
"npi_num": "1790955623",
"hcp_pin_alias": "144744",
"session_name": "Phase 1 study (NCT04931823) of CPO100 (albumin bound docetaxel) in patients with advanced solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "144744",
"first_name": "Dale",
"middle_name": "Randall",
"last_name": "Shepard",
"org_name": "Cleveland Clinic Foundation",
"Country": "United States",
"Region": "Ohio",
"City": "Cleveland",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232941",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232941",
"events_session": "Phase 1 study (NCT04931823) of CPO100 (albumin bound docetaxel) in patients with advanced solid tumors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Receptors, Albumin | Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790955623,'144744');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShepard, Dale Randall",
"kol_full_name": "Shepard, Dale Randall"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1801971635",
"hcp_pin_alias": "143761",
"session_name": "Drugging the “Undruggable” Target: Successes, Challenges, and the Road Ahead",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "143761",
"first_name": "Philip",
"middle_name": "D",
"last_name": "Greenberg",
"org_name": "Seattle Cancer Care Alliance At South Lake Union",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232045",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232045",
"events_session": "Drugging the “Undruggable” Target: Successes",
"rest_events_session_count": 2,
"rest_events_session": " Challenges, and the Road Ahead",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1801971635,'143761');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGreenberg, Philip D",
"kol_full_name": "Greenberg, Philip D"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy, Adjuvant | Pancreatic Neoplasms",
"npi_num": "1801030226",
"hcp_pin_alias": "143755",
"session_name": "Sequential neoadjuvant chemotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "143755",
"first_name": "Ravikumar",
"middle_name": "",
"last_name": "Paluri",
"org_name": "University Of Alabama Health Services Foundation, Pc",
"Country": "United States",
"Region": "Alabama",
"City": "Birmingham",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232864",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232864",
"events_session": "Sequential neoadjuvant chemotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Chemotherapy, Adjuvant | Pancreatic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1801030226,'143755');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPaluri, Ravikumar",
"kol_full_name": "Paluri, Ravikumar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lymphoma, Non-Hodgkin | Solid Tumor | CD24 Antigen",
"npi_num": "1770682338",
"hcp_pin_alias": "143722",
"session_name": "A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "143722",
"first_name": "Siqing",
"middle_name": "",
"last_name": "Fu",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233039",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233039",
"events_session": "A first-in-human phase I study of ATG-031",
"rest_events_session_count": 2,
"rest_events_session": " anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM)",
"events_topic": "Lymphoma, Non-Hodgkin | Solid Tumor ",
"rest_events_topic_count": 1,
"rest_events_topic": " CD24 Antigen",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1770682338,'143722');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFu, Siqing",
"kol_full_name": "Fu, Siqing"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "DNA Repair",
"npi_num": "1770554511",
"hcp_pin_alias": "143714",
"session_name": "Targeting Predominant DNA Repair Pathways,The State of DNA Repair Targeting: Current Advances and Future Prospects",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "143714",
"first_name": "Mark",
"middle_name": "E",
"last_name": "Robson",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231968",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231968",
"events_session": "Targeting Predominant DNA Repair Pathways",
"rest_events_session_count": 1,
"rest_events_session": "The State of DNA Repair Targeting: Current Advances and Future Prospects",
"events_topic": "DNA Repair",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1770554511,'143714');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERobson, Mark E",
"kol_full_name": "Robson, Mark E"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Anus Neoplasms | Gastrointestinal Neoplasms",
"npi_num": "1760431472",
"hcp_pin_alias": "143711",
"session_name": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "143711",
"first_name": "Wells",
"middle_name": "",
"last_name": "Messersmith",
"org_name": "University of Colorado Health Science Center",
"Country": "United States",
"Region": "Colorado",
"City": "Aurora",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233196",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233196",
"events_session": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colorectal Neoplasms | Anus Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Gastrointestinal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1760431472,'143711');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMessersmith, Wells",
"kol_full_name": "Messersmith, Wells"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Admin. & Management",
"npi_num": "1740263045",
"hcp_pin_alias": "142222",
"session_name": "Scientific Program Committee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "142222",
"first_name": "Kimmie",
"middle_name": "",
"last_name": "Ng",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233162",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233162",
"events_session": "Scientific Program Committee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Admin. & Management",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1740263045,'142222');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENg, Kimmie",
"kol_full_name": "Ng, Kimmie"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Leucovorin | Paclitaxel | Pancreatic Neoplasms | Gemcitabine | Fluorouracil",
"npi_num": "1740312990",
"hcp_pin_alias": "142218",
"session_name": "A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "142218",
"first_name": "Efrat",
"middle_name": "",
"last_name": "Dotan",
"org_name": "Fox Chase Cancer Center",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232109",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232109",
"events_session": "A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil",
"rest_events_session_count": 2,
"rest_events_session": " leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186",
"events_topic": "Leucovorin | Paclitaxel ",
"rest_events_topic_count": 3,
"rest_events_topic": " Pancreatic Neoplasms | Gemcitabine | Fluorouracil",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1740312990,'142218');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDotan, Efrat",
"kol_full_name": "Dotan, Efrat"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Atezolizumab | Carcinoma, Non-Small-Cell Lung | Disease-Free Survival",
"npi_num": "1720137094",
"hcp_pin_alias": "142216",
"session_name": "IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "142216",
"first_name": "Heather",
"middle_name": "Ann",
"last_name": "Wakelee",
"org_name": "Stanford Health Care",
"Country": "United States",
"Region": "California",
"City": "Stanford",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232237",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232237",
"events_session": "IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Atezolizumab | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 1,
"rest_events_topic": " Disease-Free Survival",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1720137094,'142216');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWakelee, Heather Ann",
"kol_full_name": "Wakelee, Heather Ann"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Microsatellite Instability | DNA Mismatch Repair | Nivolumab | Ipilimumab | Chemotherapy",
"npi_num": "1700814209",
"hcp_pin_alias": "142214",
"session_name": "Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "142214",
"first_name": "Heinz-Josef",
"middle_name": "",
"last_name": "Lenz",
"org_name": "Keck School of Medicine of USC",
"Country": "United States",
"Region": "California",
"City": "Los Angeles",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232728",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232728",
"events_session": "Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colorectal Neoplasms | Microsatellite Instability ",
"rest_events_topic_count": 4,
"rest_events_topic": " DNA Mismatch Repair | Nivolumab | Ipilimumab | Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700814209,'142214');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELenz, Heinz-Josef",
"kol_full_name": "Lenz, Heinz-Josef"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Randomized Controlled Trials As Topic | Neoplasms",
"npi_num": "1730374661",
"hcp_pin_alias": "142212",
"session_name": "Results of IMPACT 2, a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "142212",
"first_name": "Apostolia",
"middle_name": "Maria",
"last_name": "Tsimberidou",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232970",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232970",
"events_session": "Results of IMPACT 2",
"rest_events_session_count": 1,
"rest_events_session": " a randomized study evaluating molecular profiling and targeted agents in metastatic cancer at MD Anderson Cancer Center",
"events_topic": "Randomized Controlled Trials As Topic | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1730374661,'142212');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETsimberidou, Apostolia Maria",
"kol_full_name": "Tsimberidou, Apostolia Maria"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1700971421",
"hcp_pin_alias": "142211",
"session_name": "Moderate Penetrance Cancer Susceptibility Genes for Breast Cancer Risk: Managing the Gray Areas",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "142211",
"first_name": "Banu",
"middle_name": "K.",
"last_name": "Arun",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232547",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232547",
"events_session": "Moderate Penetrance Cancer Susceptibility Genes for Breast Cancer Risk: Managing the Gray Areas",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700971421,'142211');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EArun, Banu K.",
"kol_full_name": "Arun, Banu K."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Circulating Tumor DNA | Breast Neoplasms",
"npi_num": "1639111065",
"hcp_pin_alias": "140781",
"session_name": "Breast Cancer – Metastatc:: Program Commitee,The Dr Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: Emerging Role of ctDNA in Breast Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "140781",
"first_name": "Maryam",
"middle_name": "Beheshti",
"last_name": "Lustberg",
"org_name": "The Ohio State University James Cancer Hospital",
"Country": "United States",
"Region": "Ohio",
"City": "Columbus",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232023",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232023",
"events_session": "Breast Cancer – Metastatc:: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "The Dr Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: Emerging Role of ctDNA in Breast Cancer",
"events_topic": "Circulating Tumor DNA | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1639111065,'140781');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELustberg, Maryam Beheshti",
"kol_full_name": "Lustberg, Maryam Beheshti"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Radiotherapy | Peposertib | Pancreatic Neoplasms",
"npi_num": "1659576163",
"hcp_pin_alias": "140772",
"session_name": "ETCTN 10366: A phase 1 study of DNA-PK inhibitor peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "140772",
"first_name": "Sarah",
"middle_name": "Lindsey",
"last_name": "Davis",
"org_name": "University of Colorado Health Science Center",
"Country": "United States",
"Region": "Colorado",
"City": "Aurora",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232842",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232842",
"events_session": "ETCTN 10366: A phase 1 study of DNA-PK inhibitor peposertib in combination with hypofractionated radiotherapy for the treatment of locally advanced pancreatic adenocarcinoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Radiotherapy | Peposertib ",
"rest_events_topic_count": 1,
"rest_events_topic": " Pancreatic Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1659576163,'140772');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDavis, Sarah Lindsey",
"kol_full_name": "Davis, Sarah Lindsey"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Granulocyte-Macrophage Colony-Stimulating Factor | Neoplasm, Residual | Triple Negative Breast Neoplasms",
"npi_num": "1629038393",
"hcp_pin_alias": "140587",
"session_name": "Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in patients with breast cancer with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "140587",
"first_name": "Snehal",
"middle_name": "",
"last_name": "Patel",
"org_name": "Partners In Family Health, PC",
"Country": "United States",
"Region": "Pennsylvania",
"City": "York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232639",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232639",
"events_session": "Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in patients with breast cancer with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Granulocyte-Macrophage Colony-Stimulating Factor | Neoplasm, Residual ",
"rest_events_topic_count": 1,
"rest_events_topic": " Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1629038393,'140587');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPatel, Snehal",
"kol_full_name": "Patel, Snehal"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "MEK/RAF Kinase Inhibitor | Glucocorticoid-Induced TNFR-Related Protein | Cemiplimab | Solid Tumor",
"npi_num": "1598986986",
"hcp_pin_alias": "140072",
"session_name": "A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results,A first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "140072",
"first_name": "Nehal",
"middle_name": "Jagdish",
"last_name": "Lakhani",
"org_name": "Cancer and Hematology Centers of Western Michigan PC",
"Country": "United States",
"Region": "Michigan",
"City": "Grand Rapids",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232984",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232984",
"events_session": "A phase 1 study of REGN6569",
"rest_events_session_count": 5,
"rest_events_session": " a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results,A first-in-human study of IK-595, an oral MEK/RAF molecular glue, in patients with RAS- or RAF-altered advanced solid tumors",
"events_topic": "MEK/RAF Kinase Inhibitor | Glucocorticoid-Induced TNFR-Related Protein ",
"rest_events_topic_count": 2,
"rest_events_topic": " Cemiplimab | Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1598986986,'140072');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELakhani, Nehal Jagdish",
"kol_full_name": "Lakhani, Nehal Jagdish"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Carcinoma, Pancreatic Ductal | Rectal Neoplasms | Colorectal Neoplasms",
"npi_num": "1598064941",
"hcp_pin_alias": "139860",
"session_name": "Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings,Mining the Data in Early-Stage Rectal Cancer: Is There a Best Approach?,Evolving Standards of Care in the Management of Localized Colorectal Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "139860",
"first_name": "Benjamin",
"middle_name": "Adam",
"last_name": "Weinberg",
"org_name": "Medical Group in Washington District of Columbia",
"Country": "United States",
"Region": "District of Columbia",
"City": "Washington",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232043",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232043",
"events_session": "Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings",
"rest_events_session_count": 2,
"rest_events_session": "Mining the Data in Early-Stage Rectal Cancer: Is There a Best Approach?,Evolving Standards of Care in the Management of Localized Colorectal Cancer",
"events_topic": "Pembrolizumab | Carcinoma, Pancreatic Ductal ",
"rest_events_topic_count": 2,
"rest_events_topic": " Rectal Neoplasms | Colorectal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1598064941,'139860');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWeinberg, Benjamin Adam",
"kol_full_name": "Weinberg, Benjamin Adam"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Myeloproliferative Disorders",
"npi_num": "1588613376",
"hcp_pin_alias": "139695",
"session_name": "Predictors of symptom scores in myeloproliferative neoplasms: A real-world retrospective cohort study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "139695",
"first_name": "Muhammad",
"middle_name": "Amir",
"last_name": "Khan",
"org_name": "Cano Health, Llc",
"Country": "United States",
"Region": "Florida",
"City": "Kissimmee",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232353",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232353",
"events_session": "Predictors of symptom scores in myeloproliferative neoplasms: A real-world retrospective cohort study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Myeloproliferative Disorders",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/139695/fromId'\u003EKhan, Muhammad Amir\u003C/a\u003E",
"kol_full_name": "Khan, Muhammad Amir"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hematopoietic Progenitor Kinase 1 | Pembrolizumab",
"npi_num": "1568634814",
"hcp_pin_alias": "139409",
"session_name": "Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "139409",
"first_name": "Marcus",
"middle_name": "S",
"last_name": "Noel",
"org_name": "University of Rochester",
"Country": "United States",
"Region": "New York",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232955",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232955",
"events_session": "Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Hematopoietic Progenitor Kinase 1 | Pembrolizumab",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1568634814,'139409');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENoel, Marcus S",
"kol_full_name": "Noel, Marcus S"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Capecitabine | Carcinoma, Pancreatic Ductal | Ivaltinostat",
"npi_num": "1558672105",
"hcp_pin_alias": "139185",
"session_name": "A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "139185",
"first_name": "Christos",
"middle_name": "",
"last_name": "Fountzilas",
"org_name": "Roswell Park Cancer Institute",
"Country": "United States",
"Region": "New York",
"City": "Buffalo",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232862",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232862",
"events_session": "A randomized",
"rest_events_session_count": 2,
"rest_events_session": " multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC)",
"events_topic": "Capecitabine | Carcinoma, Pancreatic Ductal ",
"rest_events_topic_count": 1,
"rest_events_topic": " Ivaltinostat",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1558672105,'139185');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFountzilas, Christos",
"kol_full_name": "Fountzilas, Christos"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Interleukin-2 Receptor Alpha Subunit | Solid Tumor | Neuroendocrine Tumors",
"npi_num": "1558311225",
"hcp_pin_alias": "138970",
"session_name": "Updated results of a phase 1/2 study of AU-007, a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors,Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "138970",
"first_name": "Drew",
"middle_name": "W",
"last_name": "Rasco",
"org_name": "South Texas Oncology And Hematology PLLC",
"Country": "United States",
"Region": "Texas",
"City": "San Antonio",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232833",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232833",
"events_session": "Updated results of a phase 1/2 study of AU-007",
"rest_events_session_count": 7,
"rest_events_session": " a monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, in patients with advanced solid tumors,Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced neuroendocrine cancers: Results from a multi-center multi-country phase 1/2a expansion cohort",
"events_topic": "Interleukin-2 Receptor Alpha Subunit | Solid Tumor ",
"rest_events_topic_count": 1,
"rest_events_topic": " Neuroendocrine Tumors",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1558311225,'138970');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERasco, Drew W",
"kol_full_name": "Rasco, Drew W"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Squamous Cell | Race Factors",
"npi_num": "1538172143",
"hcp_pin_alias": "138651",
"session_name": "Racial/ethnic differences in incidence of squamous cell carcinoma in California",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "138651",
"first_name": "Deepti",
"middle_name": "",
"last_name": "Behl",
"org_name": "Sutter Roseville Medical Center",
"Country": "United States",
"Region": "California",
"City": "Sacramento",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232417",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232417",
"events_session": "Racial/ethnic differences in incidence of squamous cell carcinoma in California",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Squamous Cell | Race Factors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1538172143,'138651');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBehl, Deepti",
"kol_full_name": "Behl, Deepti"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Atezolizumab | Ovarian Neoplasms",
"npi_num": "1508868837",
"hcp_pin_alias": "136862",
"session_name": "SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-FHAB) and atezolizumab in patients with platinum-resistant ovarian cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "136862",
"first_name": "Sant",
"middle_name": "P",
"last_name": "Chawla",
"org_name": "Sant P. Chawla M.D. Inc.",
"Country": "United States",
"Region": "California",
"City": "Santa Monica",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232441",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232441",
"events_session": "SB221: A proof-of-concept study to assess the combination of SON-1010 (IL12-FHAB) and atezolizumab in patients with platinum-resistant ovarian cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Atezolizumab | Ovarian Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1508868837,'136862');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChawla, Sant P",
"kol_full_name": "Chawla, Sant P"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Enfortumab Vedotin | Non-Muscle Invasive Bladder Neoplasms | Pembrolizumab | Chemotherapy | Carcinoma, Transitional Cell",
"npi_num": "1548455355",
"hcp_pin_alias": "136788",
"session_name": "Age and other criteria influencing nontreatment of patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a physician survey in five European countries (Eu5),Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "136788",
"first_name": "Shilpa",
"middle_name": "",
"last_name": "Gupta",
"org_name": "Cleveland Clinic Foundation",
"Country": "United States",
"Region": "Ohio",
"City": "Cleveland",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232464",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232464",
"events_session": "Age and other criteria influencing nontreatment of patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Results of a physician survey in five European countries (Eu5)",
"rest_events_session_count": 2,
"rest_events_session": "Patient-reported outcomes (PROs) from a randomized, phase 3 trial of enfortumab vedotin plus pembrolizumab (EV+P) versus platinum-based chemotherapy (PBC) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)",
"events_topic": "Enfortumab Vedotin | Non-Muscle Invasive Bladder Neoplasms ",
"rest_events_topic_count": 3,
"rest_events_topic": " Pembrolizumab | Chemotherapy | Carcinoma, Transitional Cell",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1548455355,'136788');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGupta, Shilpa",
"kol_full_name": "Gupta, Shilpa"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Biomarkers",
"npi_num": "1508993957",
"hcp_pin_alias": "136782",
"session_name": "Circulating Biomarkers: Waiting for a MIRACLE",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "136782",
"first_name": "Ryan",
"middle_name": "Bruce",
"last_name": "Corcoran",
"org_name": "Massachusetts General Physicians Organization Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232131",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232131",
"events_session": "Circulating Biomarkers: Waiting for a MIRACLE",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Biomarkers",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1508993957,'136782');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECorcoran, Ryan Bruce",
"kol_full_name": "Corcoran, Ryan Bruce"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Sunvozertinib | ErbB Receptors",
"npi_num": "1558699710",
"hcp_pin_alias": "136778",
"session_name": "A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "136778",
"first_name": "James",
"middle_name": "Chung-Yin",
"last_name": "Yang",
"org_name": "NATIONAL CANCER INSTITUTE",
"Country": "United States",
"Region": "Maryland",
"City": "Bethesda",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232751",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232751",
"events_session": "A multinational pivotal study of sunvozertinib in platinum pretreated non-small cell lung cancer with EGFR exon 20 insertion mutations: Primary analysis of WU-KONG1 study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Sunvozertinib ",
"rest_events_topic_count": 1,
"rest_events_topic": " ErbB Receptors",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1558699710,'136778');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYang, James Chung-Yin",
"kol_full_name": "Yang, James Chung-Yin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Melanoma",
"npi_num": "1568433290",
"hcp_pin_alias": "136768",
"session_name": "Implementing the Future Where There Is Cure for All,Daring to Cure: Advances in Melanoma at Every Stage",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "136768",
"first_name": "Jedd",
"middle_name": "D",
"last_name": "Wolchok",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232033",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232033",
"events_session": "Implementing the Future Where There Is Cure for All",
"rest_events_session_count": 1,
"rest_events_session": "Daring to Cure: Advances in Melanoma at Every Stage",
"events_topic": "Neoplasms | Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1568433290,'136768');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWolchok, Jedd D",
"kol_full_name": "Wolchok, Jedd D"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Atezolizumab | Receptors, Estrogen | Solid Tumor | Breast Neoplasms",
"npi_num": "1457408254",
"hcp_pin_alias": "136246",
"session_name": "Safety and preliminary efficacy of EIK1001 in combination with atezolizumab in participants with advanced solid tumors,Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "136246",
"first_name": "Manish",
"middle_name": "R.",
"last_name": "Patel",
"org_name": "Florida Cancer Specialists And Research Institute, LLC",
"Country": "United States",
"Region": "Florida",
"City": "Sarasota",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232949",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232949",
"events_session": "Safety and preliminary efficacy of EIK1001 in combination with atezolizumab in participants with advanced solid tumors",
"rest_events_session_count": 3,
"rest_events_session": "Preliminary results from a phase 1 study of AC699, an orally bioavailable chimeric estrogen receptor degrader, in patients with advanced or metastatic breast cancer",
"events_topic": "Atezolizumab | Receptors, Estrogen ",
"rest_events_topic_count": 2,
"rest_events_topic": " Solid Tumor | Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1457408254,'136246');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPatel, Manish R.",
"kol_full_name": "Patel, Manish R."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lynch Syndrome | Therapeutics | Colorectal Neoplasms, Hereditary Nonpolyposis | Neoplasms",
"npi_num": "1447584131",
"hcp_pin_alias": "136181",
"session_name": "Prevention Strategies for Patients With Lynch Syndrome,Exploring Novel Therapeutic Approaches to Cancer Prevention: Vaccines and Beyond",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "136181",
"first_name": "Eduardo",
"middle_name": "",
"last_name": "Vilar Sanchez",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232072",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232072",
"events_session": "Prevention Strategies for Patients With Lynch Syndrome",
"rest_events_session_count": 1,
"rest_events_session": "Exploring Novel Therapeutic Approaches to Cancer Prevention: Vaccines and Beyond",
"events_topic": "Lynch Syndrome | Therapeutics ",
"rest_events_topic_count": 2,
"rest_events_topic": " Colorectal Neoplasms, Hereditary Nonpolyposis | Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1447584131,'136181');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVilar Sanchez, Eduardo",
"kol_full_name": "Vilar Sanchez, Eduardo"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Gastroesophageal Junction Adenocarcinoma | Ipilimumab | Colorectal Neoplasms | Nivolumab",
"npi_num": "1487842100",
"hcp_pin_alias": "136013",
"session_name": "Classical and New Age Therapies for Colorectal Cancer,A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "136013",
"first_name": "Jennifer",
"middle_name": "",
"last_name": "Eads",
"org_name": "University of Pennsylvania Health System",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232107",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232107",
"events_session": "Classical and New Age Therapies for Colorectal Cancer",
"rest_events_session_count": 1,
"rest_events_session": "A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174)",
"events_topic": "Gastroesophageal Junction Adenocarcinoma | Ipilimumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Colorectal Neoplasms | Nivolumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1487842100,'136013');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEads, Jennifer",
"kol_full_name": "Eads, Jennifer"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Palliative Care | Neoplasms | Randomized Controlled Trials As Topic",
"npi_num": "1467760371",
"hcp_pin_alias": "136005",
"session_name": "Technology-enhanced palliative care for patients with advanced cancer undergoing phase I therapies: A pilot randomized clinical trial (RCT)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "136005",
"first_name": "David",
"middle_name": "",
"last_name": "Hui",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232329",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232329",
"events_session": "Technology-enhanced palliative care for patients with advanced cancer undergoing phase I therapies: A pilot randomized clinical trial (RCT)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Palliative Care | Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Randomized Controlled Trials As Topic",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/136005/fromId'\u003EHui, David\u003C/a\u003E",
"kol_full_name": "Hui, David"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ibrutinib | Venetoclax | Leukemia, Lymphocytic, Chronic, B-Cell",
"npi_num": "1497848279",
"hcp_pin_alias": "136004",
"session_name": "Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 55 years of follow-up in the phase 2 CAPTIVATE study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "136004",
"first_name": "William",
"middle_name": "G.",
"last_name": "Wierda",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232499",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232499",
"events_session": "Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 55 years of follow-up in the phase 2 CAPTIVATE study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Ibrutinib | Venetoclax ",
"rest_events_topic_count": 1,
"rest_events_topic": " Leukemia, Lymphocytic, Chronic, B-Cell",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1497848279,'136004');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWierda, William G.",
"kol_full_name": "Wierda, William G."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1497882369",
"hcp_pin_alias": "135997",
"session_name": "ASCO Plenary Series: Rapid Abstract Updates",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "135997",
"first_name": "Mohamed",
"middle_name": "",
"last_name": "Salem",
"org_name": "Levine Cancer Institute",
"Country": "United States",
"Region": "North Carolina",
"City": "Charlotte",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232079",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232079",
"events_session": "ASCO Plenary Series: Rapid Abstract Updates",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1497882369,'135997');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESalem, Mohamed",
"kol_full_name": "Salem, Mohamed"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunoconjugates | Solid Tumor",
"npi_num": "1386790517",
"hcp_pin_alias": "135438",
"session_name": "Study of ELU001, a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "135438",
"first_name": "Wen Wee",
"middle_name": "",
"last_name": "Ma",
"org_name": "Mayo Clinic - Rochester",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232977",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232977",
"events_session": "Study of ELU001",
"rest_events_session_count": 1,
"rest_events_session": " a C’Dot drug conjugate (CDC) targeting folate receptor α (FRα) overexpressing solid tumors",
"events_topic": "Immunoconjugates | Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1386790517,'135438');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMa, Wen Wee",
"kol_full_name": "Ma, Wen Wee"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1417992397",
"hcp_pin_alias": "135264",
"session_name": "Presentation and Recognition of Conquer Cancer Top Donors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "135264",
"first_name": "Howard",
"middle_name": "A",
"last_name": "Burris",
"org_name": "Tennessee Oncology",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232939",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232939",
"events_session": "Presentation and Recognition of Conquer Cancer Top Donors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1417992397,'135264');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBurris, Howard A",
"kol_full_name": "Burris, Howard A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1386619500",
"hcp_pin_alias": "135261",
"session_name": "Care Delivery/Models of Care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "135261",
"first_name": "Veena",
"middle_name": "",
"last_name": "Shankaran",
"org_name": "Washington University School Of Medicine",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231963",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231963",
"events_session": "Care Delivery/Models of Care",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1386619500,'135261');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShankaran, Veena",
"kol_full_name": "Shankaran, Veena"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Paclitaxel | Carcinoma, Pancreatic Ductal | Gemcitabine",
"npi_num": "1356332506",
"hcp_pin_alias": "134981",
"session_name": "NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "134981",
"first_name": "Maen",
"middle_name": "A",
"last_name": "Hussein",
"org_name": "Florida Cancer Specialists P L",
"Country": "United States",
"Region": "Florida",
"City": "Tavares",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232836",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232836",
"events_session": "NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Paclitaxel | Carcinoma, Pancreatic Ductal ",
"rest_events_topic_count": 1,
"rest_events_topic": " Gemcitabine",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356332506,'134981');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHussein, Maen A",
"kol_full_name": "Hussein, Maen A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Glioma | Dendritic Cell Vaccine | Glioblastoma",
"npi_num": "1356307821",
"hcp_pin_alias": "134962",
"session_name": "Phase IIb randomized, blinded, controlled trial evaluating neoadjuvant PD-1 blockade combined with A2B5+ glioma stem-like cell lysate-loaded DC vaccine in recurrent glioblastoma (IDH1/2 -)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "134962",
"first_name": "Yu",
"middle_name": "",
"last_name": "Yao",
"org_name": "Yu Yao Private Practice",
"Country": "United States",
"Region": "California",
"City": "San Gabriel",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233072",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233072",
"events_session": "Phase IIb randomized",
"rest_events_session_count": 2,
"rest_events_session": " blinded, controlled trial evaluating neoadjuvant PD-1 blockade combined with A2B5+ glioma stem-like cell lysate-loaded DC vaccine in recurrent glioblastoma (IDH1/2 -)",
"events_topic": "Glioma | Dendritic Cell Vaccine ",
"rest_events_topic_count": 1,
"rest_events_topic": " Glioblastoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356307821,'134962');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYao, Yu",
"kol_full_name": "Yao, Yu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Gemcitabine | Sirolimus | Chemotherapy, Combination | Pexidartinib | Paclitaxel | Pancreatic Neoplasms | Nerve Sheath Neoplasms",
"npi_num": "1346484680",
"hcp_pin_alias": "134947",
"session_name": "A phase II study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable malignant peripheral nerve sheath tumors,CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "134947",
"first_name": "Gulam",
"middle_name": "Abbas",
"last_name": "Manji",
"org_name": "Trustees of Columbia University in the City of New York",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232863",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232863",
"events_session": "A phase II study of the combination of pexidartinib and sirolimus to target tumor-associated macrophages in unresectable malignant peripheral nerve sheath tumors",
"rest_events_session_count": 3,
"rest_events_session": "CheMo4METPANC: A randomized phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) compared to chemotherapy alone in metastatic treatment-naïve pancreatic adenocarcinoma",
"events_topic": "Gemcitabine | Sirolimus ",
"rest_events_topic_count": 5,
"rest_events_topic": " Chemotherapy, Combination | Pexidartinib | Paclitaxel | Pancreatic Neoplasms | Nerve Sheath Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1346484680,'134947');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EManji, Gulam Abbas",
"kol_full_name": "Manji, Gulam Abbas"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pancreatic Neoplasms | Gastrointestinal Neoplasms",
"npi_num": "1346417268",
"hcp_pin_alias": "134936",
"session_name": "Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "134936",
"first_name": "Kim",
"middle_name": "Anna",
"last_name": "Reiss Binder",
"org_name": "University of Pennsylvania Health System",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231964",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231964",
"events_session": "Gastrointestinal Cancer—Gastroesophageal",
"rest_events_session_count": 2,
"rest_events_session": " Pancreatic, and Hepatobiliary",
"events_topic": "Pancreatic Neoplasms | Gastrointestinal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1346417268,'134936');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EReiss Binder, Kim Anna",
"kol_full_name": "Reiss Binder, Kim Anna"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Clinical Trials As Topic | Minority Health | Pancreatic Neoplasms",
"npi_num": "1326148446",
"hcp_pin_alias": "134689",
"session_name": "Geographic distribution and accessibility of clinic trials for advanced-stage pancreatic cancer in the United States: A focus on rural and minority health disparities",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "134689",
"first_name": "Wade",
"middle_name": "T",
"last_name": "Swenson",
"org_name": "Tri-County Hospital Inc.",
"Country": "United States",
"Region": "Minnesota",
"City": "Fergus Falls",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232394",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232394",
"events_session": "Geographic distribution and accessibility of clinic trials for advanced-stage pancreatic cancer in the United States: A focus on rural and minority health disparities",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Clinical Trials As Topic | Minority Health ",
"rest_events_topic_count": 1,
"rest_events_topic": " Pancreatic Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1326148446,'134689');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESwenson, Wade T",
"kol_full_name": "Swenson, Wade T"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Programmed Cell Death 1 Receptor | Antibodies, Bispecific | Neoplasms",
"npi_num": "1366541294",
"hcp_pin_alias": "134490",
"session_name": "Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "134490",
"first_name": "Gerald",
"middle_name": "Steven",
"last_name": "Falchook",
"org_name": "Presbyterian St. Luke's Medical Center",
"Country": "United States",
"Region": "Colorado",
"City": "Denver",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232992",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232992",
"events_session": "Phase 1 trial safety and efficacy of ragistomig",
"rest_events_session_count": 2,
"rest_events_session": " a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors",
"events_topic": "Programmed Cell Death 1 Receptor | Antibodies, Bispecific ",
"rest_events_topic_count": 1,
"rest_events_topic": " Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1366541294,'134490');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFalchook, Gerald Steven",
"kol_full_name": "Falchook, Gerald Steven"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Genetic Testing | Neoplasms",
"npi_num": "1275793044",
"hcp_pin_alias": "134082",
"session_name": "Attitudes and engagement about cascade genetic testing in a population-based cohort of women diagnosed with cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "134082",
"first_name": "Steven",
"middle_name": "C",
"last_name": "Katz",
"org_name": "Prospect Chartercare Rwmc, LLC",
"Country": "United States",
"Region": "Rhode Island",
"City": "Providence",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232231",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232231",
"events_session": "Attitudes and engagement about cascade genetic testing in a population-based cohort of women diagnosed with cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Genetic Testing | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/134082/fromId'\u003EKatz, Steven C\u003C/a\u003E",
"kol_full_name": "Katz, Steven C"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Clinical Trials As Topic | Pancreatic Neoplasms",
"npi_num": "1275759318",
"hcp_pin_alias": "134076",
"session_name": "Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "134076",
"first_name": "Deirdre",
"middle_name": "Jill",
"last_name": "Cohen",
"org_name": "New York University",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232846",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232846",
"events_session": "Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: An AGICC clinical trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Clinical Trials As Topic | Pancreatic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1275759318,'134076');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECohen, Deirdre Jill",
"kol_full_name": "Cohen, Deirdre Jill"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Urogenital Neoplasms | Urinary Bladder Neoplasms | Kidney Neoplasms",
"npi_num": "1265675433",
"hcp_pin_alias": "133946",
"session_name": "Genitourinary Cancer – Kidney and Bladder: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "133946",
"first_name": "Manojkumar",
"middle_name": "",
"last_name": "Bupathi",
"org_name": "Rocky Mountain Cancer Centers LLP",
"Country": "United States",
"Region": "Colorado",
"City": "Denver",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233207",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233207",
"events_session": "Genitourinary Cancer – Kidney and Bladder: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Urogenital Neoplasms | Urinary Bladder Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Kidney Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1265675433,'133946');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBupathi, Manojkumar",
"kol_full_name": "Bupathi, Manojkumar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Glioma | Chromosomes, Human, Pair 1",
"npi_num": "1275575714",
"hcp_pin_alias": "133745",
"session_name": "Therapeutic insights for the aggressive subset of high-grade gliomas (HGG) driven by chromosome 1q32 MDM4-containing amplicon and unmethylated MGMT",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "133745",
"first_name": "Wafik",
"middle_name": "",
"last_name": "El Deiry",
"org_name": "Rhode Island Hospital",
"Country": "United States",
"Region": "Rhode Island",
"City": "Providence",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233078",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233078",
"events_session": "Therapeutic insights for the aggressive subset of high-grade gliomas (HGG) driven by chromosome 1q32 MDM4-containing amplicon and unmethylated MGMT",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Glioma | Chromosomes, Human, Pair 1",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1275575714,'133745');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEl Deiry, Wafik",
"kol_full_name": "El Deiry, Wafik"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Central Nervous System Neoplasms",
"npi_num": "1295979524",
"hcp_pin_alias": "133743",
"session_name": "Central Nervous System Tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "133743",
"first_name": "Jian",
"middle_name": "Li",
"last_name": "Campian",
"org_name": "Washington University School of Medicine in St. Louis",
"Country": "United States",
"Region": "Missouri",
"City": "St. Louis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232015",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232015",
"events_session": "Central Nervous System Tumors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Central Nervous System Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1295979524,'133743');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECampian, Jian Li",
"kol_full_name": "Campian, Jian Li"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Trastuzumab Deruxtecan | Immunoconjugates | Pertuzumab | Head And Neck Neoplasms | Trastuzumab | Genes, ErbB-2 | Triple Negative Breast Neoplasms | Solid Tumor",
"npi_num": "1306932074",
"hcp_pin_alias": "133736",
"session_name": "Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2 or ERBB3 amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study,Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02),The ABCs of Antibody–Drug Conjugates in HER2+ Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "133736",
"first_name": "Funda",
"middle_name": "",
"last_name": "Meric-Bernstam",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232506",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232506",
"events_session": "Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2 or ERBB3 amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study",
"rest_events_session_count": 2,
"rest_events_session": "Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02),The ABCs of Antibody–Drug Conjugates in HER2+ Cancer",
"events_topic": "Trastuzumab Deruxtecan | Immunoconjugates ",
"rest_events_topic_count": 6,
"rest_events_topic": " Pertuzumab | Head And Neck Neoplasms | Trastuzumab | Genes, ErbB-2 | Triple Negative Breast Neoplasms | Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1306932074,'133736');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMeric-Bernstam, Funda",
"kol_full_name": "Meric-Bernstam, Funda"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Clinical Trials As Topic",
"npi_num": "1235361353",
"hcp_pin_alias": "133543",
"session_name": "Biologically Driven Trial Design",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "133543",
"first_name": "Mustafa",
"middle_name": "",
"last_name": "Khasraw",
"org_name": "Duke University Cancer Center",
"Country": "United States",
"Region": "North Carolina",
"City": "Durham",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232758",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232758",
"events_session": "Biologically Driven Trial Design",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Clinical Trials As Topic",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1235361353,'133543');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKhasraw, Mustafa",
"kol_full_name": "Khasraw, Mustafa"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Relatlimab | Nivolumab | Fianlimab | Uveal Melanoma | Melanoma",
"npi_num": "1194758805",
"hcp_pin_alias": "133009",
"session_name": "First-in-human study of 225actinium mti-201 (225Ac-MTI-201) in metastatic uveal melanoma (UM),A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "133009",
"first_name": "Nikhil",
"middle_name": "Ishwar",
"last_name": "Khushalani",
"org_name": "H. Lee Moffitt Cancer Center & Research Institute",
"Country": "United States",
"Region": "Florida",
"City": "Tampa",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232807",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232807",
"events_session": "First-in-human study of 225actinium mti-201 (225Ac-MTI-201) in metastatic uveal melanoma (UM)",
"rest_events_session_count": 1,
"rest_events_session": "A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma",
"events_topic": "Relatlimab | Nivolumab ",
"rest_events_topic_count": 3,
"rest_events_topic": " Fianlimab | Uveal Melanoma | Melanoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1194758805,'133009');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKhushalani, Nikhil Ishwar",
"kol_full_name": "Khushalani, Nikhil Ishwar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nucleic Acid Denaturation",
"npi_num": "1255309316",
"hcp_pin_alias": "132964",
"session_name": "Novel Weapons of DNA Disruption",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "132964",
"first_name": "Geoffrey",
"middle_name": "Ira",
"last_name": "Shapiro",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232770",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232770",
"events_session": "Novel Weapons of DNA Disruption",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Nucleic Acid Denaturation",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1255309316,'132964');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShapiro, Geoffrey Ira",
"kol_full_name": "Shapiro, Geoffrey Ira"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cachexia | Palliative Care | Rectal Neoplasms | Neoplasms",
"npi_num": "1194909630",
"hcp_pin_alias": "132958",
"session_name": "Symptom Science and Palliatve Care: Program Commitee,Estimating adult cancer cachexia prevalence and impact on survival in the US: Real-world data analysis,Multidisciplinary Approach to Navigating Early-Stage Rectal Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "132958",
"first_name": "Eric",
"middle_name": "",
"last_name": "Roeland",
"org_name": "Newton Wellesley Medical Group Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Newton",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231982",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231982",
"events_session": "Symptom Science and Palliatve Care: Program Commitee",
"rest_events_session_count": 2,
"rest_events_session": "Estimating adult cancer cachexia prevalence and impact on survival in the US: Real-world data analysis,Multidisciplinary Approach to Navigating Early-Stage Rectal Cancer",
"events_topic": "Cachexia | Palliative Care ",
"rest_events_topic_count": 2,
"rest_events_topic": " Rectal Neoplasms | Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1194909630,'132958');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERoeland, Eric",
"kol_full_name": "Roeland, Eric"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Education, Medical | Conflict, Psychological",
"npi_num": "1235227844",
"hcp_pin_alias": "132957",
"session_name": "Medical Educaton and Professional Development: Program Commitee,Conflicts (of Interest) and Conundrums: Perspectives From the Global Oncology Community",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "132957",
"first_name": "Richard",
"middle_name": "Francis",
"last_name": "Riedel",
"org_name": "Duke University Hospital",
"Country": "United States",
"Region": "North Carolina",
"City": "Durham",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232075",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232075",
"events_session": "Medical Educaton and Professional Development: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Conflicts (of Interest) and Conundrums: Perspectives From the Global Oncology Community",
"events_topic": "Neoplasms | Education, Medical ",
"rest_events_topic_count": 1,
"rest_events_topic": " Conflict, Psychological",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1235227844,'132957');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERiedel, Richard Francis",
"kol_full_name": "Riedel, Richard Francis"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Blood-Brain Barrier | Nemvaleukin Alfa | Solid Tumor",
"npi_num": "1235381179",
"hcp_pin_alias": "132955",
"session_name": "Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3),Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "132955",
"first_name": "Sarina",
"middle_name": "Anne",
"last_name": "Piha-Paul",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232959",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232959",
"events_session": "Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3)",
"rest_events_session_count": 3,
"rest_events_session": "Interim analysis of ABM-1310, a blood-brain barrier-penetrant BRAF inhibitor, in patients with BRAF V600-mutated solid tumors",
"events_topic": "Blood-Brain Barrier | Nemvaleukin Alfa ",
"rest_events_topic_count": 1,
"rest_events_topic": " Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1235381179,'132955');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPiha-Paul, Sarina Anne",
"kol_full_name": "Piha-Paul, Sarina Anne"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Melanoma, Cutaneous Malignant",
"npi_num": "1215966775",
"hcp_pin_alias": "132953",
"session_name": "Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "132953",
"first_name": "Omid",
"middle_name": "",
"last_name": "Hamid",
"org_name": "Cedars-Sinai Medical Center",
"Country": "United States",
"Region": "California",
"City": "Los Angeles",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233126",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233126",
"events_session": "Phase 1 safety and efficacy of IMC-F106C",
"rest_events_session_count": 2,
"rest_events_session": " a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)",
"events_topic": "Melanoma, Cutaneous Malignant",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1215966775,'132953');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHamid, Omid",
"kol_full_name": "Hamid, Omid"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Therapeutics | Neoplasms | Drug Development",
"npi_num": "1154649440",
"hcp_pin_alias": "132598",
"session_name": "Developmental Therapeutcs – Molecularly Targeted Agents: Program Commitee,Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "132598",
"first_name": "Christos",
"middle_name": "",
"last_name": "Vaklavas",
"org_name": "University of Utah Health Huntsman Cancer Institute",
"Country": "United States",
"Region": "Utah",
"City": "Salt Lake City",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232721",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232721",
"events_session": "Developmental Therapeutcs – Molecularly Targeted Agents: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology",
"events_topic": "Therapeutics | Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Drug Development",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1154649440,'132598');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVaklavas, Christos",
"kol_full_name": "Vaklavas, Christos"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Immune Checkpoint Inhibitors | Oncolytic Viruses",
"npi_num": "1184745739",
"hcp_pin_alias": "132217",
"session_name": "Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "132217",
"first_name": "Anthony",
"middle_name": "Paul",
"last_name": "Conley",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232302",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232302",
"events_session": "Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus",
"rest_events_session_count": 2,
"rest_events_session": " AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers",
"events_topic": "Neoplasms | Immune Checkpoint Inhibitors ",
"rest_events_topic_count": 1,
"rest_events_topic": " Oncolytic Viruses",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1184745739,'132217');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EConley, Anthony Paul",
"kol_full_name": "Conley, Anthony Paul"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Breast Neoplasms | Genetic Testing | Early Detection Of Cancer",
"npi_num": "1144385758",
"hcp_pin_alias": "132205",
"session_name": "Real-world cancer care utilization among patients with breast cancer with germline variants of uncertain significance,Genetics of Cancer Detection in 2024: How and Why,Timing of genetic testing referral and genetic testing results in patients with multiple primary cancers,Uptake of risk-reduction, surveillance, and therapeutic interventions among patients with breast cancer with pathogenic germline variants",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "132205",
"first_name": "Allison",
"middle_name": "Walsh",
"last_name": "Kurian",
"org_name": "Stanford Health Care",
"Country": "United States",
"Region": "California",
"City": "Stanford",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232229",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232229",
"events_session": "Real-world cancer care utilization among patients with breast cancer with germline variants of uncertain significance",
"rest_events_session_count": 5,
"rest_events_session": "Genetics of Cancer Detection in 2024: How and Why,Timing of genetic testing referral and genetic testing results in patients with multiple primary cancers,Uptake of risk-reduction, surveillance, and therapeutic interventions among patients with breast cancer with pathogenic germline variants",
"events_topic": "Neoplasms | Breast Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Genetic Testing | Early Detection Of Cancer",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1144385758,'132205');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKurian, Allison Walsh",
"kol_full_name": "Kurian, Allison Walsh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Solid Tumor | Oncolytic Viruses | ATR Kinase Inhibitor | Avelumab | Pembrolizumab | Tuvusertib",
"npi_num": "1184627663",
"hcp_pin_alias": "132202",
"session_name": "Phase I, open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors,Pharmacokinetic (PK) and pharmacodynamic (PD) findings from a phase 1b study of ATR inhibitor tuvusertib + anti-PD-L1 avelumab in patients with advanced unresectable solid tumors,Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "132202",
"first_name": "Anthony",
"middle_name": "W.",
"last_name": "Tolcher",
"org_name": "Texas Oncology, San Antonio Babcock",
"Country": "United States",
"Region": "Texas",
"City": "San Antonio",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232526",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232526",
"events_session": "Phase I",
"rest_events_session_count": 4,
"rest_events_session": " open-label, dose-escalation trial investigating the safety and efficacy of oncolytic virus BI 1821736 in patients with advanced solid tumors,Pharmacokinetic (PK) and pharmacodynamic (PD) findings from a phase 1b study of ATR inhibitor tuvusertib + anti-PD-L1 avelumab in patients with advanced unresectable solid tumors,Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors",
"events_topic": "Solid Tumor | Oncolytic Viruses ",
"rest_events_topic_count": 4,
"rest_events_topic": " ATR Kinase Inhibitor | Avelumab | Pembrolizumab | Tuvusertib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1184627663,'132202');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETolcher, Anthony W.",
"kol_full_name": "Tolcher, Anthony W."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genetic Testing | Carcinoma, Non-Small-Cell Lung | Clinical Research",
"npi_num": "1174726384",
"hcp_pin_alias": "132200",
"session_name": "Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline-recommended biomarker selection in non-small cell lung cancer (NSCLC),Clinical Research Investigator Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "132200",
"first_name": "Vivek",
"middle_name": "",
"last_name": "Subbiah",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232155",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232155",
"events_session": "Performance of comprehensive genomic profiling (CGP) versus single gene testing (SGT) in guideline-recommended biomarker selection in non-small cell lung cancer (NSCLC)",
"rest_events_session_count": 1,
"rest_events_session": "Clinical Research Investigator Perspective",
"events_topic": "Genetic Testing | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 1,
"rest_events_topic": " Clinical Research",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1174726384,'132200');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESubbiah, Vivek",
"kol_full_name": "Subbiah, Vivek"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Biomarkers | Colorectal Neoplasms | Circulating Tumor DNA | Microsatellite Repeats | Human Papillomavirus Viruses | Nivolumab | Anus Neoplasms | Cetuximab",
"npi_num": "1134396534",
"hcp_pin_alias": "132199",
"session_name": "SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer,Time dependency for HPV ctDNA detection as a prognostic biomarker for anal cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "132199",
"first_name": "Van",
"middle_name": "Karlyle",
"last_name": "Morris",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232274",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232274",
"events_session": "SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated",
"rest_events_session_count": 3,
"rest_events_session": " microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer,Time dependency for HPV ctDNA detection as a prognostic biomarker for anal cancer",
"events_topic": "Biomarkers | Colorectal Neoplasms ",
"rest_events_topic_count": 6,
"rest_events_topic": " Circulating Tumor DNA | Microsatellite Repeats | Human Papillomavirus Viruses | Nivolumab | Anus Neoplasms | Cetuximab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1134396534,'132199');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMorris, Van Karlyle",
"kol_full_name": "Morris, Van Karlyle"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Solid Tumor | Pembrolizumab | Chemotherapy",
"npi_num": "1124087135",
"hcp_pin_alias": "132165",
"session_name": "TransCon IL-2 β/γ alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "132165",
"first_name": "Alexander",
"middle_name": "N",
"last_name": "Starodub",
"org_name": "Peninsula Cancer Institute, LLC",
"Country": "United States",
"Region": "Virginia",
"City": "Newport News",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233009",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233009",
"events_session": "TransCon IL-2 β/γ alone or in combination with pembrolizumab",
"rest_events_session_count": 1,
"rest_events_session": " standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study",
"events_topic": "Solid Tumor | Pembrolizumab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1124087135,'132165');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EStarodub, Alexander N",
"kol_full_name": "Starodub, Alexander N"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Artificial Intelligence | Precision Medicine",
"npi_num": "1093992497",
"hcp_pin_alias": "131861",
"session_name": "Transforming Precision Medicine: AI and Molecular Insights Intersect Across the Cancer Care Continuum",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "131861",
"first_name": "Halla",
"middle_name": "",
"last_name": "Nimeiri",
"org_name": "Northwestern Medical Faculty Foundation",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233157",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233157",
"events_session": "Transforming Precision Medicine: AI and Molecular Insights Intersect Across the Cancer Care Continuum",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms | Artificial Intelligence ",
"rest_events_topic_count": 1,
"rest_events_topic": " Precision Medicine",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1093992497,'131861');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENimeiri, Halla",
"kol_full_name": "Nimeiri, Halla"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Vusolimogene Oderparepvec | Solid Tumor | Nivolumab | Interleukin-12 | Melanoma | Pembrolizumab",
"npi_num": "1093989196",
"hcp_pin_alias": "131441",
"session_name": "A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors,A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "131441",
"first_name": "Jason",
"middle_name": "",
"last_name": "Luke",
"org_name": "University of Pittsburgh School of Medicine",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Pittsburgh",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232802",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232802",
"events_session": "A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors",
"rest_events_session_count": 4,
"rest_events_session": "A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3)",
"events_topic": "Vusolimogene Oderparepvec | Solid Tumor ",
"rest_events_topic_count": 4,
"rest_events_topic": " Nivolumab | Interleukin-12 | Melanoma | Pembrolizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1093989196,'131441');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELuke, Jason",
"kol_full_name": "Luke, Jason"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Fianlimab | Cemiplimab | Chemotherapy",
"npi_num": "1104854751",
"hcp_pin_alias": "131440",
"session_name": "A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%,A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "131440",
"first_name": "Nashat",
"middle_name": "",
"last_name": "Gabrail",
"org_name": "Gabrail Cancer Center",
"Country": "United States",
"Region": "Ohio",
"City": "Canton",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232197",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232197",
"events_session": "A phase 2/3 study of fianlimab plus cemiplimab versus cemiplimab in patients with advanced non-small cell lung cancer with tumors expressing PD-L1 ≥50%",
"rest_events_session_count": 3,
"rest_events_session": "A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Fianlimab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Cemiplimab | Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1104854751,'131440');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGabrail, Nashat",
"kol_full_name": "Gabrail, Nashat"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cetuximab | Colorectal Neoplasms | Squamous Cell Carcinoma Of Head And Neck | HLA-G Antigens",
"npi_num": "1033369988",
"hcp_pin_alias": "131116",
"session_name": "Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "131116",
"first_name": "Susanna",
"middle_name": "V.",
"last_name": "Ulahannan",
"org_name": "University of Oklahoma Health Sciences Center",
"Country": "United States",
"Region": "Oklahoma",
"City": "Oklahoma City",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232990",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232990",
"events_session": "Results from phase 1a/1b analyses of TTX-080",
"rest_events_session_count": 2,
"rest_events_session": " a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma",
"events_topic": "Cetuximab | Colorectal Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Squamous Cell Carcinoma Of Head And Neck | HLA-G Antigens",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1033369988,'131116');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EUlahannan, Susanna V.",
"kol_full_name": "Ulahannan, Susanna V."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Anus Neoplasms | Gastrointestinal Neoplasms",
"npi_num": "1033349337",
"hcp_pin_alias": "131112",
"session_name": "Gastrointestinal Cancer—Colorectal and Anal",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "131112",
"first_name": "Katrina",
"middle_name": "S",
"last_name": "Pedersen",
"org_name": "Washington University",
"Country": "United States",
"Region": "Missouri",
"City": "St. Louis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232447",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232447",
"events_session": "Gastrointestinal Cancer—Colorectal and Anal",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colorectal Neoplasms | Anus Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Gastrointestinal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1033349337,'131112');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPedersen, Katrina S",
"kol_full_name": "Pedersen, Katrina S"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | DNA Mismatch Repair | Microsatellite Instability | Atezolizumab | Bevacizumab",
"npi_num": "1023040094",
"hcp_pin_alias": "130907",
"session_name": "NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130907",
"first_name": "Caio Max",
"middle_name": "S",
"last_name": "Rocha Lima",
"org_name": "Wake Forest University Health Sciences",
"Country": "United States",
"Region": "North Carolina",
"City": "Winston Salem",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232894",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232894",
"events_session": "NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colorectal Neoplasms | DNA Mismatch Repair ",
"rest_events_topic_count": 3,
"rest_events_topic": " Microsatellite Instability | Atezolizumab | Bevacizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1023040094,'130907');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERocha Lima, Caio Max S",
"kol_full_name": "Rocha Lima, Caio Max S"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms | Cholangiocarcinoma | Zanidatamab | Receptors, Fibroblast Growth Factor | Biliary Tract Neoplasms | Erdafitinib",
"npi_num": "1831300318",
"hcp_pin_alias": "130593",
"session_name": "Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies,Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130593",
"first_name": "Shubham",
"middle_name": "",
"last_name": "Pant",
"org_name": "University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232824",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232824",
"events_session": "Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies",
"rest_events_session_count": 1,
"rest_events_session": "Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study",
"events_topic": "Triple Negative Breast Neoplasms | Cholangiocarcinoma ",
"rest_events_topic_count": 4,
"rest_events_topic": " Zanidatamab | Receptors, Fibroblast Growth Factor | Biliary Tract Neoplasms | Erdafitinib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1831300318,'130593');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPant, Shubham",
"kol_full_name": "Pant, Shubham"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunoconjugates | Therapeutics | Liver Neoplasms | Pembrolizumab | Colorectal Neoplasms | Neoplasms | Drug Development",
"npi_num": "1013110030",
"hcp_pin_alias": "130564",
"session_name": "Developmental Therapeutcs – Molecularly Targeted Agents: Program Commitee,Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases,First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer,Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130564",
"first_name": "Manish",
"middle_name": "",
"last_name": "Sharma",
"org_name": "Jefferson University Physicians",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232064",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232064",
"events_session": "Developmental Therapeutcs – Molecularly Targeted Agents: Program Commitee",
"rest_events_session_count": 5,
"rest_events_session": "Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases,First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer,Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology",
"events_topic": "Immunoconjugates | Therapeutics ",
"rest_events_topic_count": 5,
"rest_events_topic": " Liver Neoplasms | Pembrolizumab | Colorectal Neoplasms | Neoplasms | Drug Development",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1013110030,'130564');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESharma, Manish",
"kol_full_name": "Sharma, Manish"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy",
"npi_num": "1487700688",
"hcp_pin_alias": "130556",
"session_name": "Developmental Therapeutcs – Immunotherapy: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130556",
"first_name": "Dung",
"middle_name": "Thi",
"last_name": "Le",
"org_name": "Johns Hopkins University",
"Country": "United States",
"Region": "Maryland",
"City": "Baltimore",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233184",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233184",
"events_session": "Developmental Therapeutcs – Immunotherapy: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1487700688,'130556');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELe, Dung Thi",
"kol_full_name": "Le, Dung Thi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Trastuzumab | Tucatinib | Triple Negative Breast Neoplasms | Colorectal Neoplasms",
"npi_num": "1265523377",
"hcp_pin_alias": "130529",
"session_name": "Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130529",
"first_name": "John",
"middle_name": "H",
"last_name": "Strickler",
"org_name": "Duke University Hospital",
"Country": "United States",
"Region": "North Carolina",
"City": "Durham",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232270",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232270",
"events_session": "Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Trastuzumab | Tucatinib ",
"rest_events_topic_count": 2,
"rest_events_topic": " Triple Negative Breast Neoplasms | Colorectal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1265523377,'130529');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EStrickler, John H",
"kol_full_name": "Strickler, John H"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colonic Neoplasms | Gastrointestinal Neoplasms | Neoadjuvant Therapy | Pembrolizumab",
"npi_num": "1609810779",
"hcp_pin_alias": "130516",
"session_name": "A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors,Neoadjuvant Approach to Localized Colon Cancer: Ready for Prime Time?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130516",
"first_name": "Richard",
"middle_name": "D",
"last_name": "Kim",
"org_name": "H. Lee Moffitt Cancer Center & Research Institute",
"Country": "United States",
"Region": "Florida",
"City": "Tampa",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232538",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232538",
"events_session": "A phase 2a study of NT-I7 (efineptakin alfa)",
"rest_events_session_count": 5,
"rest_events_session": " a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors,Neoadjuvant Approach to Localized Colon Cancer: Ready for Prime Time?",
"events_topic": "Colonic Neoplasms | Gastrointestinal Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Neoadjuvant Therapy | Pembrolizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1609810779,'130516');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKim, Richard D",
"kol_full_name": "Kim, Richard D"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Domvanalimab | Zimberelimab | Esophageal Neoplasms",
"npi_num": "1831330034",
"hcp_pin_alias": "130513",
"session_name": "Updates on Abstract 433248: EDGE-Gastric Arm A1: Phase 2 Study of Domvanalimab, Zimberelimab, and FOLFOX in First-Line (1L) Advanced Gastroesophageal Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130513",
"first_name": "Yelena",
"middle_name": "Y",
"last_name": "Janjigian",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232935",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232935",
"events_session": "Updates on Abstract 433248: EDGE-Gastric Arm A1: Phase 2 Study of Domvanalimab",
"rest_events_session_count": 2,
"rest_events_session": " Zimberelimab, and FOLFOX in First-Line (1L) Advanced Gastroesophageal Cancer",
"events_topic": "Domvanalimab | Zimberelimab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Esophageal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1831330034,'130513');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJanjigian, Yelena Y",
"kol_full_name": "Janjigian, Yelena Y"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Bezuclastinib | Giant Cell Tumor Of Tendon Sheath | Sunitinib | Gastrointestinal Stromal Tumors | Vimseltinib",
"npi_num": "1538193446",
"hcp_pin_alias": "130510",
"session_name": "Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST),Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130510",
"first_name": "William",
"middle_name": "D",
"last_name": "Tap",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232151",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232151",
"events_session": "Peak study: A phase 3",
"rest_events_session_count": 5,
"rest_events_session": " randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST),Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial",
"events_topic": "Bezuclastinib | Giant Cell Tumor Of Tendon Sheath ",
"rest_events_topic_count": 3,
"rest_events_topic": " Sunitinib | Gastrointestinal Stromal Tumors | Vimseltinib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1538193446,'130510');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETap, William D",
"kol_full_name": "Tap, William D"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms",
"npi_num": "1104850932",
"hcp_pin_alias": "130508",
"session_name": "ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130508",
"first_name": "Zev",
"middle_name": "Aryeh",
"last_name": "Wainberg",
"org_name": "UCLA Health",
"Country": "United States",
"Region": "California",
"City": "Los Angeles",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232730",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232730",
"events_session": "ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colorectal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1104850932,'130508');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWainberg, Zev Aryeh",
"kol_full_name": "Wainberg, Zev Aryeh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1275670671",
"hcp_pin_alias": "130507",
"session_name": "Discussion on Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130507",
"first_name": "Karyn",
"middle_name": "A",
"last_name": "Goodman",
"org_name": "Icahn School of Medicine at Mount Sinai",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232513",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232513",
"events_session": "Discussion on Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1275670671,'130507');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGoodman, Karyn A",
"kol_full_name": "Goodman, Karyn A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Stereotactic Ablative Radiotherapy | Carcinoma, Renal Cell | Immunotherapy",
"npi_num": "1104069251",
"hcp_pin_alias": "130126",
"session_name": "NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130126",
"first_name": "William",
"middle_name": "Adrian",
"last_name": "Hall",
"org_name": "Medical College of Wisconsin",
"Country": "United States",
"Region": "Wisconsin",
"City": "West Bend",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232610",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232610",
"events_session": "NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Stereotactic Ablative Radiotherapy | Carcinoma, Renal Cell ",
"rest_events_topic_count": 1,
"rest_events_topic": " Immunotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1104069251,'130126');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHall, William Adrian",
"kol_full_name": "Hall, William Adrian"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Drug Development | Pancreatic Neoplasms",
"npi_num": "1609071208",
"hcp_pin_alias": "130123",
"session_name": "Advances in Systemic Therapy for Advanced Pancreas Cancer With a Focus on Novel Agents and Drug Development",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130123",
"first_name": "Andrew",
"middle_name": "J",
"last_name": "Aguirre",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233099",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233099",
"events_session": "Advances in Systemic Therapy for Advanced Pancreas Cancer With a Focus on Novel Agents and Drug Development",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Drug Development | Pancreatic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/130123/fromId'\u003EAguirre, Andrew J\u003C/a\u003E",
"kol_full_name": "Aguirre, Andrew J"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nivolumab | Chemotherapy | Chloroquine | Hydroxychloroquine | Ipilimumab | Pancreatic Neoplasms",
"npi_num": "1477644896",
"hcp_pin_alias": "130120",
"session_name": "Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130120",
"first_name": "Eileen",
"middle_name": "M.",
"last_name": "O'Reilly",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232837",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232837",
"events_session": "Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Nivolumab | Chemotherapy ",
"rest_events_topic_count": 4,
"rest_events_topic": " Chloroquine | Hydroxychloroquine | Ipilimumab | Pancreatic Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1477644896,'130120');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EO'Reilly, Eileen M.",
"kol_full_name": "O'Reilly, Eileen M."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms | Androgen Deprivation Therapy | Hormone Replacement Therapy",
"npi_num": "1942403837",
"hcp_pin_alias": "130051",
"session_name": "ADT Sparing Approaches in the Metastatic Hormone-Sensitive and Castrate-Resistant Space,Balancing Hormone Therapy: Minimizing Effects of Androgen Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130051",
"first_name": "Karen",
"middle_name": "Anne",
"last_name": "Autio",
"org_name": "Memorial Solid Tumor Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232032",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232032",
"events_session": "ADT Sparing Approaches in the Metastatic Hormone-Sensitive and Castrate-Resistant Space",
"rest_events_session_count": 1,
"rest_events_session": "Balancing Hormone Therapy: Minimizing Effects of Androgen Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management",
"events_topic": "Prostatic Neoplasms | Androgen Deprivation Therapy ",
"rest_events_topic_count": 1,
"rest_events_topic": " Hormone Replacement Therapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1942403837,'130051');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAutio, Karen Anne",
"kol_full_name": "Autio, Karen Anne"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Zipalertinib | ErbB Receptors | Amivantamab | Chemotherapy | Receptor, Epidermal Growth Factor | Central Nervous System Diseases",
"npi_num": "1871791665",
"hcp_pin_alias": "130000",
"session_name": "A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease,REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations,REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "130000",
"first_name": "Helena",
"middle_name": "",
"last_name": "Yu",
"org_name": "Memorial Solid Tumor Group",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232202",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232202",
"events_session": "A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease",
"rest_events_session_count": 3,
"rest_events_session": "REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations,REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Lung Neoplasms ",
"rest_events_topic_count": 6,
"rest_events_topic": " Zipalertinib | ErbB Receptors | Amivantamab | Chemotherapy | Receptor, Epidermal Growth Factor | Central Nervous System Diseases",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1871791665,'130000');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYu, Helena",
"kol_full_name": "Yu, Helena"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab",
"npi_num": "1316172299",
"hcp_pin_alias": "129607",
"session_name": "A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "129607",
"first_name": "Gregory",
"middle_name": "Andrew",
"last_name": "Durm",
"org_name": "Indiana University Health",
"Country": "United States",
"Region": "Indiana",
"City": "Indianapolis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232254",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232254",
"events_session": "A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1316172299,'129607');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDurm, Gregory Andrew",
"kol_full_name": "Durm, Gregory Andrew"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Olomorasib | Pancreatic Neoplasms",
"npi_num": "1184697278",
"hcp_pin_alias": "129527",
"session_name": "Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "129527",
"first_name": "Rebecca",
"middle_name": "Suk",
"last_name": "Heist",
"org_name": "Massachusetts General Physicians Organization Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232771",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232771",
"events_session": "Pan-tumor activity of olomorasib (LY3537982)",
"rest_events_session_count": 2,
"rest_events_session": " a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors",
"events_topic": "Olomorasib | Pancreatic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1184697278,'129527');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHeist, Rebecca Suk",
"kol_full_name": "Heist, Rebecca Suk"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Drug Development | Encorafenib | Proto-Oncogene Proteins B-raf | Cetuximab | Tumor Microenvironment",
"npi_num": "1154557650",
"hcp_pin_alias": "129510",
"session_name": "Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study,Beyond Tumor Types: Advancing Tumor-Agnostic Drug Development and the Role of the Tumor Microenvironment",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "129510",
"first_name": "Aparna",
"middle_name": "Raj",
"last_name": "Parikh",
"org_name": "Massachusetts General Physicians Organization Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231981",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231981",
"events_session": "Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study",
"rest_events_session_count": 1,
"rest_events_session": "Beyond Tumor Types: Advancing Tumor-Agnostic Drug Development and the Role of the Tumor Microenvironment",
"events_topic": "Colorectal Neoplasms | Drug Development ",
"rest_events_topic_count": 4,
"rest_events_topic": " Encorafenib | Proto-Oncogene Proteins B-raf | Cetuximab | Tumor Microenvironment",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1154557650,'129510');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EParikh, Aparna Raj",
"kol_full_name": "Parikh, Aparna Raj"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung",
"npi_num": "1144515024",
"hcp_pin_alias": "129501",
"session_name": "Lung Cancer—Non–Small Cell Metastatic",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "129501",
"first_name": "Ibiayi",
"middle_name": "",
"last_name": "Dagogo-Jack",
"org_name": "Massachusetts General Physicians Organization Inc",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232722",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232722",
"events_session": "Lung Cancer—Non–Small Cell Metastatic",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1144515024,'129501');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDagogo-Jack, Ibiayi",
"kol_full_name": "Dagogo-Jack, Ibiayi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung",
"npi_num": "1093154353",
"hcp_pin_alias": "129468",
"session_name": "Lung Cancer – Non-Small Cell Metastatc: Program Commitee,Lung Cancer—Non-Small Cell Metastatic",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "129468",
"first_name": "Natalie",
"middle_name": "",
"last_name": "Vokes",
"org_name": "Natalie Vokes Private Practice",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232058",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232058",
"events_session": "Lung Cancer – Non-Small Cell Metastatc: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Lung Cancer—Non-Small Cell Metastatic",
"events_topic": "Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1093154353,'129468');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVokes, Natalie",
"kol_full_name": "Vokes, Natalie"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "NUT Carcinoma",
"npi_num": "1093133811",
"hcp_pin_alias": "129467",
"session_name": "Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "129467",
"first_name": "Jia",
"middle_name": "",
"last_name": "Luo",
"org_name": "Jia Luo Private Practice",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232165",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232165",
"events_session": "Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "NUT Carcinoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1093133811,'129467');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELuo, Jia",
"kol_full_name": "Luo, Jia"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Leukocytes | Carcinoma, Renal Cell | Pimivalimab | Immunoglobulins",
"npi_num": "1972585743",
"hcp_pin_alias": "96202",
"session_name": "Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti-PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl)­ pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "96202",
"first_name": "Primo",
"middle_name": "Nery",
"last_name": "Lara",
"org_name": "Primo Nery Lara Private Practice",
"Country": "United States",
"Region": "California",
"City": "Sacramento",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232581",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232581",
"events_session": "Leukocyte immunoglobulin-like receptor (LILRB2)-targeted JTX-8064 plus the anti-PD1 inhibitor JTX-4014 (pimivalimab) in immune-checkpoint inhibitor (ICl)­ pretreated patients (pts) with advanced or metastatic renal cell cancer (mRCC): Results from the multi-stage phase 1-2 INNATE trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Leukocytes | Carcinoma, Renal Cell ",
"rest_events_topic_count": 2,
"rest_events_topic": " Pimivalimab | Immunoglobulins",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1972585743,'96202');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELara, Primo Nery",
"kol_full_name": "Lara, Primo Nery"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Mental Health | Prostatic Neoplasms",
"npi_num": "1891082772",
"hcp_pin_alias": "94883",
"session_name": "Impact of mental health illness (MHI) prior to prostate cancer (PC) diagnosis (Dx) on treatment (Tx) received and PC outcomes",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "94883",
"first_name": "Zachary",
"middle_name": "William Abraham",
"last_name": "Klaassen",
"org_name": "AU Medical Associates Inc",
"Country": "United States",
"Region": "Georgia",
"City": "Washington",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232644",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232644",
"events_session": "Impact of mental health illness (MHI) prior to prostate cancer (PC) diagnosis (Dx) on treatment (Tx) received and PC outcomes",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Mental Health | Prostatic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1891082772,'94883');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKlaassen, Zachary William Abraham",
"kol_full_name": "Klaassen, Zachary William Abraham"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "SRK-181 | Transforming Growth Factor Beta1 | Programmed Cell Death 1 Receptor | Solid Tumor | Pembrolizumab",
"npi_num": "1659318640",
"hcp_pin_alias": "91120",
"session_name": "Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "91120",
"first_name": "Ulka",
"middle_name": "Nitin",
"last_name": "Vaishampayan",
"org_name": "Michigan Medicine",
"Country": "United States",
"Region": "Michigan",
"City": "Ann Arbor",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232303",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232303",
"events_session": "Phase 1 study (DRAGON) of SRK-181 (linavonkibart)",
"rest_events_session_count": 2,
"rest_events_session": " a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part",
"events_topic": "SRK-181 | Transforming Growth Factor Beta1 ",
"rest_events_topic_count": 3,
"rest_events_topic": " Programmed Cell Death 1 Receptor | Solid Tumor | Pembrolizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1659318640,'91120');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVaishampayan, Ulka Nitin",
"kol_full_name": "Vaishampayan, Ulka Nitin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hemangioblastoma | Girentuximab | Belzutifan | Von Hippel-Lindau Disease | Cabozantinib | Carcinoma, Renal Cell | Central Nervous System Neoplasms | Nivolumab",
"npi_num": "1558457028",
"hcp_pin_alias": "89611",
"session_name": "Belzutifan for Advanced Renal Cell Carcinoma,Real-world monitoring and treatment patterns in von Hippel-Lindau (VHL) disease-associated central nervous system hemangioblastomas (CNS-Hb),Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "89611",
"first_name": "Eric",
"middle_name": "",
"last_name": "Jonasch",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232608",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232608",
"events_session": "Belzutifan for Advanced Renal Cell Carcinoma",
"rest_events_session_count": 2,
"rest_events_session": "Real-world monitoring and treatment patterns in von Hippel-Lindau (VHL) disease-associated central nervous system hemangioblastomas (CNS-Hb),Phase 1b/2 study of combination 177Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC",
"events_topic": "Hemangioblastoma | Girentuximab ",
"rest_events_topic_count": 6,
"rest_events_topic": " Belzutifan | Von Hippel-Lindau Disease | Cabozantinib | Carcinoma, Renal Cell | Central Nervous System Neoplasms | Nivolumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1558457028,'89611');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJonasch, Eric",
"kol_full_name": "Jonasch, Eric"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Gastroesophageal Junction Adenocarcinoma | Nivolumab",
"npi_num": "1548356306",
"hcp_pin_alias": "89447",
"session_name": "Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "89447",
"first_name": "Daniel",
"middle_name": "Wei",
"last_name": "Lin",
"org_name": "University of Washington Medical Centre",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232817",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232817",
"events_session": "Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer",
"rest_events_session_count": 2,
"rest_events_session": " gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649)",
"events_topic": "Chemotherapy | Gastroesophageal Junction Adenocarcinoma ",
"rest_events_topic_count": 1,
"rest_events_topic": " Nivolumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1548356306,'89447');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELin, Daniel Wei",
"kol_full_name": "Lin, Daniel Wei"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Skin Neoplasms | Melanoma",
"npi_num": "1154597458",
"hcp_pin_alias": "83364",
"session_name": "Melanoma/Skin Cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "83364",
"first_name": "Douglas",
"middle_name": "Buckner",
"last_name": "Johnson",
"org_name": "Vanderbilt University Medical Center",
"Country": "United States",
"Region": "Tennessee",
"City": "Franklin",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232089",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232089",
"events_session": "Melanoma/Skin Cancers",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Skin Neoplasms | Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1154597458,'83364');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJohnson, Douglas Buckner",
"kol_full_name": "Johnson, Douglas Buckner"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Transitional Cell | Myeloid-Derived Suppressor Cells | T-Lymphocytes | Nivolumab",
"npi_num": "1154542769",
"hcp_pin_alias": "83335",
"session_name": "Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "83335",
"first_name": "Aditi",
"middle_name": "",
"last_name": "Gupta",
"org_name": "Kansas University Physicians Inc",
"Country": "United States",
"Region": "Kansas",
"City": "Kansas City",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232591",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232591",
"events_session": "Correlation of peripheral blood monocytic myeloid-derived suppressor cells (M-MDSC) and T-cell receptor (TCR) dynamics with clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with nivolumab (NIVO)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Transitional Cell | Myeloid-Derived Suppressor Cells ",
"rest_events_topic_count": 2,
"rest_events_topic": " T-Lymphocytes | Nivolumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1154542769,'83335');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGupta, Aditi",
"kol_full_name": "Gupta, Aditi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Renal Cell | Biomarkers | Axitinib | Sunitinib | Pembrolizumab",
"npi_num": "1144261231",
"hcp_pin_alias": "82787",
"session_name": "Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "82787",
"first_name": "Brian",
"middle_name": "I",
"last_name": "Rini",
"org_name": "Vanderbilt University Medical Center",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232468",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232468",
"events_session": "Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Renal Cell | Biomarkers ",
"rest_events_topic_count": 3,
"rest_events_topic": " Axitinib | Sunitinib | Pembrolizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1144261231,'82787');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERini, Brian I",
"kol_full_name": "Rini, Brian I"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Biomarkers | Neoplasms | Carcinoma, Renal Cell",
"npi_num": "1073677209",
"hcp_pin_alias": "80989",
"session_name": "Recognizing, Celebrating, and Supporting International Medical Graduates in Oncology,Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "80989",
"first_name": "Toni",
"middle_name": "K",
"last_name": "Choueiri",
"org_name": "Dana Farber Cancer Institute",
"Country": "United States",
"Region": "Massachusetts",
"City": "Milford",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232467",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232467",
"events_session": "Recognizing",
"rest_events_session_count": 3,
"rest_events_session": " Celebrating, and Supporting International Medical Graduates in Oncology,Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial",
"events_topic": "Biomarkers | Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Carcinoma, Renal Cell",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1073677209,'80989');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChoueiri, Toni K",
"kol_full_name": "Choueiri, Toni K"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genes, T-Cell Receptor | Lung Neoplasms",
"npi_num": "1396934428",
"hcp_pin_alias": "77189",
"session_name": "Characterization of T-cell receptor repertoire and correlation with tumor mutational landscape in lung cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "77189",
"first_name": "Wei",
"middle_name": "",
"last_name": "Guo",
"org_name": "Ochsner Health Center",
"Country": "United States",
"Region": "Louisiana",
"City": "Kenner",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233000",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233000",
"events_session": "Characterization of T-cell receptor repertoire and correlation with tumor mutational landscape in lung cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Genes, T-Cell Receptor | Lung Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1396934428,'77189');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGuo, Wei",
"kol_full_name": "Guo, Wei"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms | Castration",
"npi_num": "1326245275",
"hcp_pin_alias": "77151",
"session_name": "Physicians use of first-line treatment intensification in metastatic castration-sensitive prostate cancer (mCSPC): A discrete choice experiment",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "77151",
"first_name": "Stacy",
"middle_name": "",
"last_name": "Loeb",
"org_name": "New York University",
"Country": "United States",
"Region": "New York",
"City": "Rego Park",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232661",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232661",
"events_session": "Physicians use of first-line treatment intensification in metastatic castration-sensitive prostate cancer (mCSPC): A discrete choice experiment",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms | Castration",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1326245275,'77151');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELoeb, Stacy",
"kol_full_name": "Loeb, Stacy"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Recurrent Respiratory Papillomatosis | Immunotherapy",
"npi_num": "1326485228",
"hcp_pin_alias": "75399",
"session_name": "PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "75399",
"first_name": "Scott",
"middle_name": "Michael",
"last_name": "Norberg",
"org_name": "",
"Country": "United States",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232462",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232462",
"events_session": "PRGN-2012",
"rest_events_session_count": 2,
"rest_events_session": " a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients",
"events_topic": "Recurrent Respiratory Papillomatosis | Immunotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1326485228,'75399');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENorberg, Scott Michael",
"kol_full_name": "Norberg, Scott Michael"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptors, Chimeric Antigen | Ponatinib | Stem Cell Transplantation | Acute Lymphoblastic Leukemia | Obecabtagene Autoleucel | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Imatinib Mesylate",
"npi_num": "1215108303",
"hcp_pin_alias": "75248",
"session_name": "Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study,In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "75248",
"first_name": "Elias",
"middle_name": "J",
"last_name": "Jabbour",
"org_name": "Physicians Referral Service",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232337",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232337",
"events_session": "Obecabtagene autoleucel (obe-cel",
"rest_events_session_count": 4,
"rest_events_session": " AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study,In-depth analysis of responders in the phase 3 PhALLCON trial of ponatinib vs imatinib in newly diagnosed Ph+ ALL",
"events_topic": "Receptors, Chimeric Antigen | Ponatinib ",
"rest_events_topic_count": 5,
"rest_events_topic": " Stem Cell Transplantation | Acute Lymphoblastic Leukemia | Obecabtagene Autoleucel | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Imatinib Mesylate",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1215108303,'75248');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJabbour, Elias J",
"kol_full_name": "Jabbour, Elias J"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Myelodysplastic Syndromes | Hematologic Neoplasms | Leukemia | Head And Neck Neoplasms",
"npi_num": "1699881094",
"hcp_pin_alias": "65988",
"session_name": "Head and Neck Cancer: Program Commitee,Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "65988",
"first_name": "Richard",
"middle_name": "J",
"last_name": "Lin",
"org_name": "The Children's Hospital of Philadelphia",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232083",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232083",
"events_session": "Head and Neck Cancer: Program Commitee",
"rest_events_session_count": 3,
"rest_events_session": "Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant",
"events_topic": "Myelodysplastic Syndromes | Hematologic Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Leukemia | Head And Neck Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1699881094,'65988');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELin, Richard J",
"kol_full_name": "Lin, Richard J"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Olutasidenib | IDH1 Protein, Human | Leukemia, Myeloid, Acute",
"npi_num": "1578658480",
"hcp_pin_alias": "40699",
"session_name": "Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "40699",
"first_name": "Jorge",
"middle_name": "E.",
"last_name": "Cortes-Franco",
"org_name": "AU Medical Associates Inc",
"Country": "United States",
"Region": "Georgia",
"City": "Augusta",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232336",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232336",
"events_session": "Olutasidenib for mutated IDH1 acute myeloid leukemia: Final five-year results from the phase 2 pivotal cohort",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Olutasidenib | IDH1 Protein, Human ",
"rest_events_topic_count": 1,
"rest_events_topic": " Leukemia, Myeloid, Acute",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1578658480,'40699');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECortes-Franco, Jorge E.",
"kol_full_name": "Cortes-Franco, Jorge E."
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Bevacizumab",
"npi_num": "1922283431",
"hcp_pin_alias": "36313",
"session_name": "First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "36313",
"first_name": "Feng",
"middle_name": "",
"last_name": "Wang",
"org_name": "The Everett Clinic PLLC",
"Country": "United States",
"Region": "Washington",
"City": "Everett",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232878",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232878",
"events_session": "First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colorectal Neoplasms | Bevacizumab",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1922283431,'36313');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWang, Feng",
"kol_full_name": "Wang, Feng"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Pembrolizumab | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1952326654",
"hcp_pin_alias": "29462",
"session_name": "The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non–small-cell lung cancer (NSCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "29462",
"first_name": "Jay",
"middle_name": "M",
"last_name": "Lee",
"org_name": "Regents Of The University Of Ucla Thoracic Oncology Associates",
"Country": "United States",
"Region": "California",
"City": "Los Angeles",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232253",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232253",
"events_session": "The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non–small-cell lung cancer (NSCLC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pembrolizumab | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/29462/fromId'\u003ELee, Jay M\u003C/a\u003E",
"kol_full_name": "Lee, Jay M"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Early Detection Of Cancer | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1497783567",
"hcp_pin_alias": "15268",
"session_name": "Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other: Program Commitee,Milestones: Early Detection to Nodal Status and Everything in Between",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "15268",
"first_name": "Jessica",
"middle_name": "Scott",
"last_name": "Donington",
"org_name": "The University of Chicago Medical Center",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232478",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232478",
"events_session": "Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Milestones: Early Detection to Nodal Status and Everything in Between",
"events_topic": "Early Detection Of Cancer | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/15268/fromId'\u003EDonington, Jessica Scott\u003C/a\u003E",
"kol_full_name": "Donington, Jessica Scott"
},
{
"proj_kol_id": 1,
"eid": "23416",
"event_topics": "Oropharyngeal Neoplasms | Biomarkers | Human Papillomavirus Viruses",
"npi_num": "1194715649",
"hcp_pin_alias": "5945",
"session_name": "Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group,What Lies Ahead for Circulating Biomarkers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "5945",
"first_name": "Barbara",
"middle_name": "A",
"last_name": "Burtness",
"org_name": "Yale University",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232130",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232130",
"events_session": "Long-term follow up of E3311",
"rest_events_session_count": 2,
"rest_events_session": " a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group,What Lies Ahead for Circulating Biomarkers",
"events_topic": "Oropharyngeal Neoplasms | Biomarkers ",
"rest_events_topic_count": 1,
"rest_events_topic": " Human Papillomavirus Viruses",
"kol_name": "\u003Ca class='link' target='new' href='https://cardio-staging.konectar.io/kols/view/5945/fromId'\u003EBurtness, Barbara A\u003C/a\u003E",
"kol_full_name": "Burtness, Barbara A"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Squamous Cell Carcinoma Of Head And Neck | Pharmaceutical Preparations | Neoplasms | Tisotumab Vedotin | Translational Research, Biomedical | Immunotherapy | Immune Checkpoint Inhibitors",
"npi_num": "1780063610",
"hcp_pin_alias": "FU_HCP_109652",
"session_name": "Quality Care/Health Services Research: Program Commitee,Perspective on Immunotherapy Drug Holidays in Metastatic Cancers,Off-label use of checkpoint inhibitor (CPI) monotherapy in PD-L1–negative or unknown recurrent/metastatic head and neck cancer (R/M HNSCC),Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C,Quality Care/Health Services Research",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Lova Sun",
"middle_name": "",
"last_name": "",
"org_name": "University of Pennsylvania",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "5",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231986",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231986",
"events_session": "Quality Care/Health Services Research: Program Commitee",
"rest_events_session_count": 4,
"rest_events_session": "Perspective on Immunotherapy Drug Holidays in Metastatic Cancers,Off-label use of checkpoint inhibitor (CPI) monotherapy in PD-L1–negative or unknown recurrent/metastatic head and neck cancer (R/M HNSCC),Tisotumab vedotin in head and neck squamous cell carcinoma: Updated analysis from innovaTV 207 Part C,Quality Care/Health Services Research",
"events_topic": "Squamous Cell Carcinoma Of Head And Neck | Pharmaceutical Preparations ",
"rest_events_topic_count": 5,
"rest_events_topic": " Neoplasms | Tisotumab Vedotin | Translational Research, Biomedical | Immunotherapy | Immune Checkpoint Inhibitors",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1780063610,'FU_HCP_109652');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELova Sun",
"kol_full_name": "Lova Sun"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Squamous Cell Carcinoma Of Head And Neck | Artificial Intelligence | Head And Neck Neoplasms | Pembrolizumab",
"npi_num": "1134448665",
"hcp_pin_alias": "FU_HCP_5403337",
"session_name": "Head and Neck Cancer: Program Commitee,Practical Applications of Artificial Intelligence to Improve Diagnostic Accuracy and Guide Therapy,A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study,Using “Artificial” Intelligence to Achieve “Real” Improvements in Cancer Care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Alexander T. Pearson",
"middle_name": "",
"last_name": "",
"org_name": "University of Chicago",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232080",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232080",
"events_session": "Head and Neck Cancer: Program Commitee",
"rest_events_session_count": 5,
"rest_events_session": "Practical Applications of Artificial Intelligence to Improve Diagnostic Accuracy and Guide Therapy,A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study,Using “Artificial” Intelligence to Achieve “Real” Improvements in Cancer Care",
"events_topic": "Neoplasms | Squamous Cell Carcinoma Of Head And Neck ",
"rest_events_topic_count": 3,
"rest_events_topic": " Artificial Intelligence | Head And Neck Neoplasms | Pembrolizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1134448665,'FU_HCP_5403337');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAlexander T. Pearson",
"kol_full_name": "Alexander T. Pearson"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Biliary Tract Neoplasms | Hematologic Neoplasms | Drug Development | Biomarkers | Binimetinib",
"npi_num": "1992948152",
"hcp_pin_alias": "FU_HCP_225052",
"session_name": "Developmental Therapeutcs – Molecularly Targeted Agents: Program Commitee,Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial,Hematology/oncology clinical investigator training: Is current model of education adequate?,Circulating Biomarkers: Who, What, Where, When, and Why?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ardaman Shergill",
"middle_name": "",
"last_name": "",
"org_name": "University of Chicago",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231974",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231974",
"events_session": "Developmental Therapeutcs – Molecularly Targeted Agents: Program Commitee",
"rest_events_session_count": 7,
"rest_events_session": "Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial,Hematology/oncology clinical investigator training: Is current model of education adequate?,Circulating Biomarkers: Who, What, Where, When, and Why?",
"events_topic": "Biliary Tract Neoplasms | Hematologic Neoplasms ",
"rest_events_topic_count": 3,
"rest_events_topic": " Drug Development | Biomarkers | Binimetinib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1992948152,'FU_HCP_225052');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EArdaman Shergill",
"kol_full_name": "Ardaman Shergill"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Oncogenes | Pembrolizumab | Carcinoma, Non-Small-Cell Lung | Nivolumab | Ipilimumab | Mutation | Circulating Tumor DNA | Chemotherapy | Lung Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403388",
"session_name": "Metastatic Non–Small Without Oncogene Addiction/Driver Mutation,Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799,Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA,Advanced Lung Cancer: State-of-the-Art Approaches and Insights",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Martin Reck",
"middle_name": "",
"last_name": "",
"org_name": "LungenClinic",
"Country": "",
"Region": "",
"City": "",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232070",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232070",
"events_session": "Metastatic Non–Small Without Oncogene Addiction/Driver Mutation",
"rest_events_session_count": 5,
"rest_events_session": "Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799,Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA,Advanced Lung Cancer: State-of-the-Art Approaches and Insights",
"events_topic": "Oncogenes | Pembrolizumab ",
"rest_events_topic_count": 7,
"rest_events_topic": " Carcinoma, Non-Small-Cell Lung | Nivolumab | Ipilimumab | Mutation | Circulating Tumor DNA | Chemotherapy | Lung Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403388');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMartin Reck",
"kol_full_name": "Martin Reck"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Genetics | Olaparib | Endocrine Therapy | Genes, BRCA1 | Risk Reduction Behavior | Ovarian Neoplasms | Breast Neoplasms",
"npi_num": "1730323676",
"hcp_pin_alias": "FU_HCP_44633",
"session_name": "Prevention, Risk Reduction, and Hereditary Cancer: Program Commitee,Novel Approaches to Cancer Prevention in Patients With Inherited Risk for Breast and Ovarian Cancers: What Is Ready for Prime Time, What Is Not?,HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer,Prevention, Risk Reduction, and Genetics",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Payal Deepak Shah",
"middle_name": "",
"last_name": "",
"org_name": "Penn Medicine Abramson Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232062",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232062",
"events_session": "Prevention",
"rest_events_session_count": 11,
"rest_events_session": " Risk Reduction, and Hereditary Cancer: Program Commitee,Novel Approaches to Cancer Prevention in Patients With Inherited Risk for Breast and Ovarian Cancers: What Is Ready for Prime Time, What Is Not?,HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer,Prevention, Risk Reduction, and Genetics",
"events_topic": "Neoplasms | Genetics ",
"rest_events_topic_count": 6,
"rest_events_topic": " Olaparib | Endocrine Therapy | Genes, BRCA1 | Risk Reduction Behavior | Ovarian Neoplasms | Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1730323676,'FU_HCP_44633');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPayal Deepak Shah",
"kol_full_name": "Payal Deepak Shah"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Mass Screening | Neoplasms | Deep Learning | Biomarkers | Immune Checkpoint Inhibitors | Clinical Trials As Topic | Data Science | Artificial Intelligence | Palliative Care",
"npi_num": "1871906230",
"hcp_pin_alias": "FU_HCP_100167",
"session_name": "New Frontiers in Data Science: Promises and Problems,Real-world and clinical trial validation of a deep learning radiomic biomarker for PD-(L)1 immune checkpoint inhibitor response in stage IV NSCLC,BE-a-PAL: A cluster-randomized trial of algorithm-based default palliative care referral among patients with advanced cancer,Human-AI teams to improve accuracy and timeliness of oncology trial prescreening: Preplanned interim analysis of a randomized trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ravi Bharat Parikh",
"middle_name": "",
"last_name": "",
"org_name": "Perelman School of Medicine, University of Pennsylvania",
"Country": "",
"Region": "",
"City": "",
"num_sess": "4",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232481",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232481",
"events_session": "New Frontiers in Data Science: Promises and Problems",
"rest_events_session_count": 3,
"rest_events_session": "Real-world and clinical trial validation of a deep learning radiomic biomarker for PD-(L)1 immune checkpoint inhibitor response in stage IV NSCLC,BE-a-PAL: A cluster-randomized trial of algorithm-based default palliative care referral among patients with advanced cancer,Human-AI teams to improve accuracy and timeliness of oncology trial prescreening: Preplanned interim analysis of a randomized trial",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Mass Screening ",
"rest_events_topic_count": 8,
"rest_events_topic": " Neoplasms | Deep Learning | Biomarkers | Immune Checkpoint Inhibitors | Clinical Trials As Topic | Data Science | Artificial Intelligence | Palliative Care",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1871906230,'FU_HCP_100167');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERavi Bharat Parikh",
"kol_full_name": "Ravi Bharat Parikh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Myositis | Myasthenia Gravis, Neonatal | Immune Checkpoint Inhibitors | Myocarditis | Admin. & Management | Immunotherapy",
"npi_num": "1528499712",
"hcp_pin_alias": "FU_HCP_42846",
"session_name": "Melina Marmarelis: Program Commitee,Triple M overlap syndrome (TMOS): Evaluating immune checkpoint inhibitor-related overlap syndrome of myocarditis, myositis and myasthenia gravis using an international pharmacovigilance database,Developmental Therapeutics—Immunotherapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Abdul Rafeh Naqash",
"middle_name": "",
"last_name": "",
"org_name": "University of Oklahoma Health Sciences Center, Stephenson Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231998",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231998",
"events_session": "Melina Marmarelis: Program Commitee",
"rest_events_session_count": 3,
"rest_events_session": "Triple M overlap syndrome (TMOS): Evaluating immune checkpoint inhibitor-related overlap syndrome of myocarditis, myositis and myasthenia gravis using an international pharmacovigilance database,Developmental Therapeutics—Immunotherapy",
"events_topic": "Myositis | Myasthenia Gravis, Neonatal ",
"rest_events_topic_count": 4,
"rest_events_topic": " Immune Checkpoint Inhibitors | Myocarditis | Admin. & Management | Immunotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1528499712,'FU_HCP_42846');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAbdul Rafeh Naqash",
"kol_full_name": "Abdul Rafeh Naqash"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Durvalumab | Tremelimumab | Ovarian Neoplasms | Chemotherapy | Poly(ADP-ribose) Polymerase Inhibitors",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403418",
"session_name": "Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates,Targeting the CD47/TSP-1 axis: A promising strategy for patients with ovarian cancer (OC) that relapses on PARP inhibitors (PARPi),PARP Inhibitors for All or Those With the Most to Gain",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Alexandra Leary",
"middle_name": "",
"last_name": "",
"org_name": "Gustave Roussy Institute",
"Country": "France",
"Region": "Ile-De-France",
"City": "Paris",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232292",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232292",
"events_session": "Phase Ib INEOV neoadjuvant trial of durvalumab +/- tremelimumab with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): Survival outcomes and immune correlates",
"rest_events_session_count": 2,
"rest_events_session": "Targeting the CD47/TSP-1 axis: A promising strategy for patients with ovarian cancer (OC) that relapses on PARP inhibitors (PARPi),PARP Inhibitors for All or Those With the Most to Gain",
"events_topic": "Durvalumab | Tremelimumab ",
"rest_events_topic_count": 3,
"rest_events_topic": " Ovarian Neoplasms | Chemotherapy | Poly(ADP-ribose) Polymerase Inhibitors",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403418');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAlexandra Leary",
"kol_full_name": "Alexandra Leary"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Health Inequities | Clinical Trials As Topic | Leukemia, Myeloid, Acute | Neoplasms",
"npi_num": "1023457819",
"hcp_pin_alias": "FU_HCP_186959",
"session_name": "Identifying eligibility criteria that perpetuate race/ethnic disparities in acute myeloid leukemia (AML) clinical trial participation,Inequities in timely treatment (Tx) initiation for patients (pts) with acute myeloid leukemia (AML) treated in a predominantly community setting in the United States (US),Assessing the environmental and downstream human health impacts of decentralizing cancer care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Andrew Hantel",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232480",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232480",
"events_session": "Identifying eligibility criteria that perpetuate race/ethnic disparities in acute myeloid leukemia (AML) clinical trial participation",
"rest_events_session_count": 2,
"rest_events_session": "Inequities in timely treatment (Tx) initiation for patients (pts) with acute myeloid leukemia (AML) treated in a predominantly community setting in the United States (US),Assessing the environmental and downstream human health impacts of decentralizing cancer care",
"events_topic": "Health Inequities | Clinical Trials As Topic ",
"rest_events_topic_count": 2,
"rest_events_topic": " Leukemia, Myeloid, Acute | Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1023457819,'FU_HCP_186959');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAndrew Hantel",
"kol_full_name": "Andrew Hantel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Palliative Care",
"npi_num": "1285877894",
"hcp_pin_alias": "PAST_HCP_Onco_231786",
"session_name": "Symptom Science and Palliatve Care: Program Commitee,Treating Frail Populations,Symptom Science and Palliative Care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Carolyn J. Presley",
"middle_name": "",
"last_name": "",
"org_name": "The Ohio State University Wexner Medical Center",
"Country": "United States",
"Region": "Ohio",
"City": "Columbus",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232009",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232009",
"events_session": "Symptom Science and Palliatve Care: Program Commitee",
"rest_events_session_count": 2,
"rest_events_session": "Treating Frail Populations,Symptom Science and Palliative Care",
"events_topic": "Neoplasms | Palliative Care",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1285877894,'PAST_HCP_Onco_231786');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECarolyn J. Presley",
"kol_full_name": "Carolyn J. Presley"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Head And Neck Neoplasms | Sexual And Gender Minorities | Lung Neoplasms | Early Detection Of Cancer | Neoplasms",
"npi_num": "1821415084",
"hcp_pin_alias": "FU_HCP_159298",
"session_name": "GUIAR: Promoting lung cancer screening in Hispanic head and neck cancer survivors,Going back home: Understanding the challenges of international medical graduates (IMGs) in oncology,Assessing gender disparities in oncology: Less talk, more action",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Coral Olazagasti",
"middle_name": "",
"last_name": "",
"org_name": "University of Miami Sylvester Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232321",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232321",
"events_session": "GUIAR: Promoting lung cancer screening in Hispanic head and neck cancer survivors",
"rest_events_session_count": 3,
"rest_events_session": "Going back home: Understanding the challenges of international medical graduates (IMGs) in oncology,Assessing gender disparities in oncology: Less talk, more action",
"events_topic": "Head And Neck Neoplasms | Sexual And Gender Minorities ",
"rest_events_topic_count": 3,
"rest_events_topic": " Lung Neoplasms | Early Detection Of Cancer | Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1821415084,'FU_HCP_159298');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECoral Olazagasti",
"kol_full_name": "Coral Olazagasti"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Therapeutics | TACC3 Protein, Human | Glypicans | Neoplasms | Solid Tumor",
"npi_num": "1881146868",
"hcp_pin_alias": "FU_HCP_45872",
"session_name": "DUET-01: A first-in-human, phase 1/2 study of BOXR1030 in patients with advanced glypican-3-positive solid tumors,A first-in-human, phase 1 study evaluating oral TACC3 inhibitor, AO-252, in advanced solid tumors,Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ecaterina Elena Dumbrava",
"middle_name": "",
"last_name": "",
"org_name": "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232013",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232013",
"events_session": "DUET-01: A first-in-human",
"rest_events_session_count": 6,
"rest_events_session": " phase 1/2 study of BOXR1030 in patients with advanced glypican-3-positive solid tumors,A first-in-human, phase 1 study evaluating oral TACC3 inhibitor, AO-252, in advanced solid tumors,Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology",
"events_topic": "Therapeutics | TACC3 Protein, Human ",
"rest_events_topic_count": 3,
"rest_events_topic": " Glypicans | Neoplasms | Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1881146868,'FU_HCP_45872');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEcaterina Elena Dumbrava",
"kol_full_name": "Ecaterina Elena Dumbrava"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy | Chemotherapy | Colorectal Neoplasms | Atezolizumab | Biomarkers | Bevacizumab",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403383",
"session_name": "Developmental Therapeutcs – Immunotherapy: Program Commitee,A phase II open‐label study with atezolizumab (atezo) in combination with bevacizumab (bev) in patients (pts) with advanced chemotherapy-resistant colorectal cancer (CRC) and MSI‐like molecular signature: The MoTriColor Consortium CT3 study,Hitting the Mark: The Ongoing Search for Immunotherapy Biomarkers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Elena Elez",
"middle_name": "",
"last_name": "",
"org_name": "Vall d'Hebron University Hospital",
"Country": "Spain",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231969",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231969",
"events_session": "Developmental Therapeutcs – Immunotherapy: Program Commitee",
"rest_events_session_count": 2,
"rest_events_session": "A phase II open‐label study with atezolizumab (atezo) in combination with bevacizumab (bev) in patients (pts) with advanced chemotherapy-resistant colorectal cancer (CRC) and MSI‐like molecular signature: The MoTriColor Consortium CT3 study,Hitting the Mark: The Ongoing Search for Immunotherapy Biomarkers",
"events_topic": "Immunotherapy | Chemotherapy ",
"rest_events_topic_count": 4,
"rest_events_topic": " Colorectal Neoplasms | Atezolizumab | Biomarkers | Bevacizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403383');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EElena Elez",
"kol_full_name": "Elena Elez"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunoconjugates | Clinical Trials As Topic | Neoplasms | Endocrine Therapy | Biomarkers | Triple Negative Breast Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403389",
"session_name": "Biomarkers: Predicting Response and Toxicity in Patients With Cancer Treated With Antibody-Drug Conjugates,Short-term risk of recurrence in patients (pts) with HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): A meta-analysis,Unlocking the Potential: Biomarkers of Response to Antibody–Drug Conjugates",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Giuseppe Curigliano",
"middle_name": "",
"last_name": "",
"org_name": "Istituto Europeo di Oncologia, Milan, IRCCS and University of Milano",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232077",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232077",
"events_session": "Biomarkers: Predicting Response and Toxicity in Patients With Cancer Treated With Antibody-Drug Conjugates",
"rest_events_session_count": 2,
"rest_events_session": "Short-term risk of recurrence in patients (pts) with HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in randomized clinical trials (RCTs): A meta-analysis,Unlocking the Potential: Biomarkers of Response to Antibody–Drug Conjugates",
"events_topic": "Immunoconjugates | Clinical Trials As Topic ",
"rest_events_topic_count": 4,
"rest_events_topic": " Neoplasms | Endocrine Therapy | Biomarkers | Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403389');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGiuseppe Curigliano",
"kol_full_name": "Giuseppe Curigliano"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Combined Modality Therapy | Squamous Cell Carcinoma Of Head And Neck | Human Papillomavirus Viruses | Clinical Trials As Topic | Docetaxel | Circulating Tumor DNA | Solid Tumor | Duvelisib",
"npi_num": "1750602983",
"hcp_pin_alias": "FU_HCP_76246",
"session_name": "FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors,Personalized circulating tumor (ct)DNA for monitoring disease status in HPV-negative head and neck squamous cell carcinoma,Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent, or metastatic head and neck squamous cell carcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Glenn J. Hanna",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232552",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232552",
"events_session": "FIT-001: A phase 1 clinical trial of the farnesyl transferase inhibitor KO-2806 alone or as part of combination therapy for advanced solid tumors",
"rest_events_session_count": 4,
"rest_events_session": "Personalized circulating tumor (ct)DNA for monitoring disease status in HPV-negative head and neck squamous cell carcinoma,Duvelisib with docetaxel for patients with anti-PD-1 refractory, recurrent, or metastatic head and neck squamous cell carcinoma",
"events_topic": "Combined Modality Therapy | Squamous Cell Carcinoma Of Head And Neck ",
"rest_events_topic_count": 6,
"rest_events_topic": " Human Papillomavirus Viruses | Clinical Trials As Topic | Docetaxel | Circulating Tumor DNA | Solid Tumor | Duvelisib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1750602983,'FU_HCP_76246');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGlenn J. Hanna",
"kol_full_name": "Glenn J. Hanna"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Durvalumab | Neoadjuvant Therapy | Datopotamab Deruxtecan | Genital Neoplasms, Female",
"npi_num": "1831358076",
"hcp_pin_alias": "PAST_HCP_Onco_231532",
"session_name": "Gynecologic Cancer: Program Commitee,Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY22 trial,Gynecologic Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jane Lowe Meisel",
"middle_name": "",
"last_name": "",
"org_name": "Winship Canter Institute of Emory University",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232051",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232051",
"events_session": "Gynecologic Cancer: Program Commitee",
"rest_events_session_count": 2,
"rest_events_session": "Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY22 trial,Gynecologic Cancer",
"events_topic": "Durvalumab | Neoadjuvant Therapy ",
"rest_events_topic_count": 2,
"rest_events_topic": " Datopotamab Deruxtecan | Genital Neoplasms, Female",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1831358076,'PAST_HCP_Onco_231532');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJane Lowe Meisel",
"kol_full_name": "Jane Lowe Meisel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Tumor Necrosis Factor-alpha | Prostatic Neoplasms | Testicular Neoplasms | Urinary Bladder Neoplasms | Urogenital Neoplasms | Penile Neoplasms | Kidney Neoplasms",
"npi_num": "1659663979",
"hcp_pin_alias": "FU_HCP_5403330",
"session_name": "Genitourinary Cancer – Kidney and Bladder: Program Commitee,TRAMP study: A phase 2 trial of tumor necrosis factor-α blockade and AR inhibition in men with CRPC,Genitourinary Cancer—Prostate, Testicular, and Penile",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jessica E. Hawley",
"middle_name": "",
"last_name": "",
"org_name": "University of Washington & Fred Hutchinson Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231988",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231988",
"events_session": "Genitourinary Cancer – Kidney and Bladder: Program Commitee",
"rest_events_session_count": 4,
"rest_events_session": "TRAMP study: A phase 2 trial of tumor necrosis factor-α blockade and AR inhibition in men with CRPC,Genitourinary Cancer—Prostate, Testicular, and Penile",
"events_topic": "Tumor Necrosis Factor-alpha | Prostatic Neoplasms ",
"rest_events_topic_count": 5,
"rest_events_topic": " Testicular Neoplasms | Urinary Bladder Neoplasms | Urogenital Neoplasms | Penile Neoplasms | Kidney Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1659663979,'FU_HCP_5403330');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJessica E. Hawley",
"kol_full_name": "Jessica E. Hawley"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Colorectal Neoplasms | CLDN18 Protein, Human | Anus Neoplasms | Gastroesophageal Junction Adenocarcinoma | Pembrolizumab | Gastrointestinal Neoplasms | Zolbetuximab",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403459",
"session_name": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee,Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585,Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN182)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kohei Shitara",
"middle_name": "",
"last_name": "",
"org_name": "National Cancer Center Hospital East",
"Country": "Japan",
"Region": "Chiba",
"City": "Chiba",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232815",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232815",
"events_session": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"rest_events_session_count": 4,
"rest_events_session": "Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585,Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN182)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma",
"events_topic": "Chemotherapy | Colorectal Neoplasms ",
"rest_events_topic_count": 6,
"rest_events_topic": " CLDN18 Protein, Human | Anus Neoplasms | Gastroesophageal Junction Adenocarcinoma | Pembrolizumab | Gastrointestinal Neoplasms | Zolbetuximab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403459');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKohei Shitara",
"kol_full_name": "Kohei Shitara"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pancreatic Neoplasms | Immunotherapy | Gastrointestinal Neoplasms | Clinical Trials As Topic",
"npi_num": "1720400906",
"hcp_pin_alias": "FU_HCP_44576",
"session_name": "Participating in Early Phase Immunotherapy Clinical Trials: Benefits, Barriers, and Burdens,Amplifying the Patient's Voice in Early-Phase Immunotherapy Clinical Trials: Solutions to Burdens and Barriers,Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kristen Renee Spencer",
"middle_name": "",
"last_name": "",
"org_name": "Perlmutter Cancer Center, NYU Langone Health",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231965",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231965",
"events_session": "Participating in Early Phase Immunotherapy Clinical Trials: Benefits",
"rest_events_session_count": 6,
"rest_events_session": " Barriers, and Burdens,Amplifying the Patient's Voice in Early-Phase Immunotherapy Clinical Trials: Solutions to Burdens and Barriers,Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary",
"events_topic": "Pancreatic Neoplasms | Immunotherapy ",
"rest_events_topic_count": 2,
"rest_events_topic": " Gastrointestinal Neoplasms | Clinical Trials As Topic",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1720400906,'FU_HCP_44576');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKristen Renee Spencer",
"kol_full_name": "Kristen Renee Spencer"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Circulating Tumor DNA | Receptor, Epidermal Growth Factor | Abemaciclib | Breast Neoplasms | Triple Negative Breast Neoplasms",
"npi_num": "1699069880",
"hcp_pin_alias": "FU_HCP_110315",
"session_name": "Genomic alterations (GA) in ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) patients (pts) with metastatic breast cancer (MBC): Co-occurrence and prevalence along treatment course,Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study,The Dr Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: Emerging Role of ctDNA in Breast Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Manali A. Bhave",
"middle_name": "",
"last_name": "",
"org_name": "Emory University School of Medicine",
"Country": "United States",
"Region": "Georgia",
"City": "Atlanta",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232022",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232022",
"events_session": "Genomic alterations (GA) in ESR1",
"rest_events_session_count": 10,
"rest_events_session": " PIK3CA, AKT1, and PTEN in HR(+)HER2(-) patients (pts) with metastatic breast cancer (MBC): Co-occurrence and prevalence along treatment course,Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study,The Dr Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: Emerging Role of ctDNA in Breast Cancer",
"events_topic": "Circulating Tumor DNA | Receptor, Epidermal Growth Factor ",
"rest_events_topic_count": 3,
"rest_events_topic": " Abemaciclib | Breast Neoplasms | Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1699069880,'FU_HCP_110315');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EManali A. Bhave",
"kol_full_name": "Manali A. Bhave"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Dexamethasone | Multiple Myeloma | Belantamab Mafodotin | Daratumumab | Bortezomib | Admin. & Management",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403395",
"session_name": "Amandeep Godara – Track Leader: Program Commitee,Updates on Abstract 439572: Results from the Randomized Phase III DREAMM-7 Study of Belantamab Mafodotin (Belamaf) + Bortezomib, and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM),DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Maria-Victoria Mateos",
"middle_name": "",
"last_name": "",
"org_name": "Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (IBMCC-USAL, CSIC)",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232134",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232134",
"events_session": "Amandeep Godara – Track Leader: Program Commitee",
"rest_events_session_count": 7,
"rest_events_session": "Updates on Abstract 439572: Results from the Randomized Phase III DREAMM-7 Study of Belantamab Mafodotin (Belamaf) + Bortezomib, and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM),DREAMM-7 update: Subgroup analyses from a phase 3 trial of belantamab mafodotin (belamaf) + bortezomib and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM)",
"events_topic": "Dexamethasone | Multiple Myeloma ",
"rest_events_topic_count": 4,
"rest_events_topic": " Belantamab Mafodotin | Daratumumab | Bortezomib | Admin. & Management",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403395');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMaria-Victoria Mateos",
"kol_full_name": "Maria-Victoria Mateos"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lung Neoplasms | Atezolizumab | Immunotherapy | Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403385",
"session_name": "Local Treatment Options in Early-Stage Lung Cancer,Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial,Integrating Immunotherapy Into Early-Stage Lung Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Rafal Dziadziuszko",
"middle_name": "",
"last_name": "",
"org_name": "Medical University of Gdansk",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232048",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232048",
"events_session": "Local Treatment Options in Early-Stage Lung Cancer",
"rest_events_session_count": 2,
"rest_events_session": "Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial,Integrating Immunotherapy Into Early-Stage Lung Cancer",
"events_topic": "Lung Neoplasms | Atezolizumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Immunotherapy | Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403385');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERafal Dziadziuszko",
"kol_full_name": "Rafal Dziadziuszko"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Renal Cell | Multimodal Imaging | Prostatectomy | Prostatic Neoplasms | Circulating Tumor DNA | Genes, BRCA1",
"npi_num": "1306013610",
"hcp_pin_alias": "FU_HCP_0008455",
"session_name": "A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune),Molecular and clinical correlates of high PSMA/FOLH1 mRNA expression in primary and metastatic prostate cancer (PC),Matched tissue and circulating tumor DNA (ctDNA) analysis in renal cell carcinoma (RCC): Results from a multimodal real-world database",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Rana R. McKay",
"middle_name": "",
"last_name": "",
"org_name": "University of California, San Diego Health",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232582",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232582",
"events_session": "A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with BRCA1/2 gene alterations (NePtune)",
"rest_events_session_count": 2,
"rest_events_session": "Molecular and clinical correlates of high PSMA/FOLH1 mRNA expression in primary and metastatic prostate cancer (PC),Matched tissue and circulating tumor DNA (ctDNA) analysis in renal cell carcinoma (RCC): Results from a multimodal real-world database",
"events_topic": "Carcinoma, Renal Cell | Multimodal Imaging ",
"rest_events_topic_count": 4,
"rest_events_topic": " Prostatectomy | Prostatic Neoplasms | Circulating Tumor DNA | Genes, BRCA1",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1306013610,'FU_HCP_0008455');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERana R. McKay",
"kol_full_name": "Rana R. McKay"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "ESR1 Protein, Human | KIF18A Protein, Human | Fulvestrant | Ovarian Neoplasms | Alpelisib | Endometrial Neoplasms | Neoplasms",
"npi_num": "1689729212",
"hcp_pin_alias": "PAST_HCP_Onco_232576",
"session_name": "A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer,GOG3069: Phase 2 study of alpelisib and fulvestrant for PIK3CA-mutated estrogen receptor (ER)-positive endometrioid endometrial cancers,Characterization of ESR1 mutations in endometrial and ovarian cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Stephanie Gaillard",
"middle_name": "",
"last_name": "",
"org_name": "Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232436",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232436",
"events_session": "A phase I/II",
"rest_events_session_count": 5,
"rest_events_session": " first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer,GOG3069: Phase 2 study of alpelisib and fulvestrant for PIK3CA-mutated estrogen receptor (ER)-positive endometrioid endometrial cancers,Characterization of ESR1 mutations in endometrial and ovarian cancers",
"events_topic": "ESR1 Protein, Human | KIF18A Protein, Human ",
"rest_events_topic_count": 5,
"rest_events_topic": " Fulvestrant | Ovarian Neoplasms | Alpelisib | Endometrial Neoplasms | Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1689729212,'PAST_HCP_Onco_232576');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EStephanie Gaillard",
"kol_full_name": "Stephanie Gaillard"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neuroendocrine Tumors | Prostatic Neoplasms | Carcinoma, Renal Cell | Receptors, Androgen",
"npi_num": "1245694801",
"hcp_pin_alias": "FU_HCP_40312",
"session_name": "Advanced Sequencing and Targeted Therapy Strategies in Renal Cell Carcinoma: How Can We Help More Patients Not at the Expense of Toxicity?,Clinical utility of transcriptomic signatures to identify androgen receptor and neuroendocrine signaling in prostate cancer,State-of-the-Art Diagnostic and Therapeutic Strategies in Renal Cell Carcinoma: Current Advances and Future Frontiers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yu-Wei Chen",
"middle_name": "",
"last_name": "",
"org_name": "University of California, San Diego Medical Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "3",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232076",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232076",
"events_session": "Advanced Sequencing and Targeted Therapy Strategies in Renal Cell Carcinoma: How Can We Help More Patients Not at the Expense of Toxicity?",
"rest_events_session_count": 2,
"rest_events_session": "Clinical utility of transcriptomic signatures to identify androgen receptor and neuroendocrine signaling in prostate cancer,State-of-the-Art Diagnostic and Therapeutic Strategies in Renal Cell Carcinoma: Current Advances and Future Frontiers",
"events_topic": "Neuroendocrine Tumors | Prostatic Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Carcinoma, Renal Cell | Receptors, Androgen",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1245694801,'FU_HCP_40312');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYu-Wei Chen",
"kol_full_name": "Yu-Wei Chen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Pharmaceutical Preparations | Medicare Part D",
"npi_num": "1437423290",
"hcp_pin_alias": "FU_HCP_110364",
"session_name": "Trends in pharmaceutical industry payments to US cancer centers, 2014-2021,Cancer care service use intensity in Medicare Advantage versus traditional Medicare",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Aaron Philip Mitchell",
"middle_name": "",
"last_name": "",
"org_name": "Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232395",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232395",
"events_session": "Trends in pharmaceutical industry payments to US cancer centers",
"rest_events_session_count": 2,
"rest_events_session": " 2014-2021,Cancer care service use intensity in Medicare Advantage versus traditional Medicare",
"events_topic": "Neoplasms | Pharmaceutical Preparations ",
"rest_events_topic_count": 1,
"rest_events_topic": " Medicare Part D",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1437423290,'FU_HCP_110364');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAaron Philip Mitchell",
"kol_full_name": "Aaron Philip Mitchell"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptor, ErbB-3 | Solid Tumor | Head And Neck Neoplasms",
"npi_num": "1861629180",
"hcp_pin_alias": "FU_HCP_271646",
"session_name": "HERTHENA-PanTumor01: A global, multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors,Head and Neck Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Aarti K. Bhatia",
"middle_name": "",
"last_name": "",
"org_name": "Yale School of Medicine",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231960",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231960",
"events_session": "HERTHENA-PanTumor01: A global",
"rest_events_session_count": 3,
"rest_events_session": " multicohort, phase 2 trial of HER3-DXd in relapsed/refractory metastatic solid tumors,Head and Neck Cancer",
"events_topic": "Receptor, ErbB-3 | Solid Tumor ",
"rest_events_topic_count": 1,
"rest_events_topic": " Head And Neck Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1861629180,'FU_HCP_271646');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAarti K. Bhatia",
"kol_full_name": "Aarti K. Bhatia"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Translational Research, Biomedical | Health Policy",
"npi_num": "1447349477",
"hcp_pin_alias": "FU_HCP_100523",
"session_name": "Quality Care/Health Services Research: Program Commitee,Do No Harm: Impacts of Health Care Policies on Patient Outcomes",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Alexi A. Wright",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233121",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233121",
"events_session": "Quality Care/Health Services Research: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Do No Harm: Impacts of Health Care Policies on Patient Outcomes",
"events_topic": "Translational Research, Biomedical | Health Policy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1447349477,'FU_HCP_100523');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAlexi A. Wright",
"kol_full_name": "Alexi A. Wright"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Brain Neoplasms | Lifileucel | Melanoma | Lymphocytes, Tumor-Infiltrating",
"npi_num": "1174961908",
"hcp_pin_alias": "FU_HCP_39677",
"session_name": "A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases,Adopting Cutting-Edge Cell Therapies in Melanoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Allison Betof Warner",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232530",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232530",
"events_session": "A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel",
"rest_events_session_count": 2,
"rest_events_session": " LN-144) for patients with asymptomatic melanoma brain metastases,Adopting Cutting-Edge Cell Therapies in Melanoma",
"events_topic": "Brain Neoplasms | Lifileucel ",
"rest_events_topic_count": 2,
"rest_events_topic": " Melanoma | Lymphocytes, Tumor-Infiltrating",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1174961908,'FU_HCP_39677');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAllison Betof Warner",
"kol_full_name": "Allison Betof Warner"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1356518724",
"hcp_pin_alias": "FU_HCP_76036",
"session_name": "Breast Cancer – Metastatc:: Program Commitee,Breast Cancer—Metastatic",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Amy Sanders Clark",
"middle_name": "",
"last_name": "",
"org_name": "Perelman School of Medicine at the University of Pennsylvania",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231996",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231996",
"events_session": "Breast Cancer – Metastatc:: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Breast Cancer—Metastatic",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356518724,'FU_HCP_76036');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAmy Sanders Clark",
"kol_full_name": "Amy Sanders Clark"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sacituzumab Govitecan | Pembrolizumab | Disease Management | Triple Negative Breast Neoplasms",
"npi_num": "1386185874",
"hcp_pin_alias": "FU_HCP_41520",
"session_name": "SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer,Treatment Selection and Sequencing: Metastatic Disease Management in 2024 for Enhanced Survival and Quality of Life",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ana Christina Garrido-Castro",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232487",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232487",
"events_session": "SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer",
"rest_events_session_count": 1,
"rest_events_session": "Treatment Selection and Sequencing: Metastatic Disease Management in 2024 for Enhanced Survival and Quality of Life",
"events_topic": "Sacituzumab Govitecan | Pembrolizumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Disease Management | Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1386185874,'FU_HCP_41520');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAna Christina Garrido-Castro",
"kol_full_name": "Ana Christina Garrido-Castro"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Trastuzumab Deruxtecan | Brain Neoplasms | Breast Neoplasms | Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403448",
"session_name": "Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial,Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Andrea Botticelli",
"middle_name": "",
"last_name": "",
"org_name": "Department of Experimental Medicine, Sapienza University of Rome",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232679",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232679",
"events_session": "Genomics to select treatment for patients (pts) with metastatic cancer: Final analysis of Molecular Tumor Board (MTB) evaluations in the ROME trial",
"rest_events_session_count": 1,
"rest_events_session": "Trastuzumab deruxtecan in patients with breast cancer with brain metastases: The DE-REAL study",
"events_topic": "Trastuzumab Deruxtecan | Brain Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Breast Neoplasms | Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403448');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAndrea Botticelli",
"kol_full_name": "Andrea Botticelli"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Admin. & Management | Neoplasms",
"npi_num": "1528099322",
"hcp_pin_alias": "PAST_HCP_Onco_231457",
"session_name": "Scientific Program Committee,How and Where Will Public Investment Accelerate Progress in Oncology? A Discussion with the NIH and NCI Directors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Angela DeMichele",
"middle_name": "",
"last_name": "",
"org_name": "University of Pennsylvania",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232071",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232071",
"events_session": "Scientific Program Committee",
"rest_events_session_count": 1,
"rest_events_session": "How and Where Will Public Investment Accelerate Progress in Oncology? A Discussion with the NIH and NCI Directors",
"events_topic": "Admin. & Management | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1528099322,'PAST_HCP_Onco_231457');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAngela DeMichele",
"kol_full_name": "Angela DeMichele"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy | Oropharyngeal Neoplasms | Human Papillomavirus 16 | Head And Neck Neoplasms | Chemotherapy",
"npi_num": "1699017715",
"hcp_pin_alias": "FU_HCP_75860",
"session_name": "Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV,Novel Weapons: Bispecifics, Fusion Proteins, Multikinase Inhibitors, and Other Novel Weapons Against Head and Neck Cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ari Joseph Rosenberg",
"middle_name": "",
"last_name": "",
"org_name": "University of Chicago",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232122",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232122",
"events_session": "Neoadjuvant HPV16-specific arenavirus-based immunotherapy HB-200 plus chemotherapy followed by response-stratified de-intensification in HPV16+ oropharyngeal cancer: TARGET-HPV",
"rest_events_session_count": 4,
"rest_events_session": "Novel Weapons: Bispecifics, Fusion Proteins, Multikinase Inhibitors, and Other Novel Weapons Against Head and Neck Cancers",
"events_topic": "Immunotherapy | Oropharyngeal Neoplasms ",
"rest_events_topic_count": 3,
"rest_events_topic": " Human Papillomavirus 16 | Head And Neck Neoplasms | Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1699017715,'FU_HCP_75860');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAri Joseph Rosenberg",
"kol_full_name": "Ari Joseph Rosenberg"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Carcinoma, Hepatocellular | Durvalumab | Apatinib | Gemcitabine | Sorafenib | Biliary Tract Neoplasms | Camrelizumab",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403463",
"session_name": "TOURMALINE: A phase 3b study of durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer,Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Arndt Vogel",
"middle_name": "",
"last_name": "",
"org_name": "Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232829",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232829",
"events_session": "TOURMALINE: A phase 3b study of durvalumab with gemcitabine-based chemotherapy regimens in advanced biliary tract cancer",
"rest_events_session_count": 1,
"rest_events_session": "Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study",
"events_topic": "Chemotherapy | Carcinoma, Hepatocellular ",
"rest_events_topic_count": 6,
"rest_events_topic": " Durvalumab | Apatinib | Gemcitabine | Sorafenib | Biliary Tract Neoplasms | Camrelizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403463');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EArndt Vogel",
"kol_full_name": "Arndt Vogel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Breast Neoplasms",
"npi_num": "1225522816",
"hcp_pin_alias": "FU_HCP_282740",
"session_name": "International medical graduates (IMG) representation at international oncology conference meetings,Breast cancer polygenic risk score and patient survival outcomes in the Pathways study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Arya Mariam Roy",
"middle_name": "",
"last_name": "",
"org_name": "Roswell Park Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232759",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232759",
"events_session": "International medical graduates (IMG) representation at international oncology conference meetings",
"rest_events_session_count": 1,
"rest_events_session": "Breast cancer polygenic risk score and patient survival outcomes in the Pathways study",
"events_topic": "Neoplasms | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1225522816,'FU_HCP_282740');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EArya Mariam Roy",
"kol_full_name": "Arya Mariam Roy"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Amivantamab | Fianlimab | Lazertinib | Cemiplimab | ErbB Receptors | Carcinoma, Non-Small-Cell Lung | Squamous Cell Carcinoma Of Head And Neck",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403440",
"session_name": "Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2,A phase 1 study of fianlimab (anti–LAG-3) in combination with cemiplimab (anti–PD-1) in patients with advanced HNSCC",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Byoung Chul Cho",
"middle_name": "",
"last_name": "",
"org_name": "Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232556",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232556",
"events_session": "Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2",
"rest_events_session_count": 1,
"rest_events_session": "A phase 1 study of fianlimab (anti–LAG-3) in combination with cemiplimab (anti–PD-1) in patients with advanced HNSCC",
"events_topic": "Amivantamab | Fianlimab ",
"rest_events_topic_count": 5,
"rest_events_topic": " Lazertinib | Cemiplimab | ErbB Receptors | Carcinoma, Non-Small-Cell Lung | Squamous Cell Carcinoma Of Head And Neck",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403440');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EByoung Chul Cho",
"kol_full_name": "Byoung Chul Cho"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Smoking Cessation | Varenicline | Early Detection Of Cancer | Medicare Part D",
"npi_num": "1881125011",
"hcp_pin_alias": "FU_HCP_5403352",
"session_name": "Targeting Direct and Indirect Costs of Cancer: Strategies for Screening, Intervention, and Policy,Access barriers and cost of varenicline for smoking cessation: A national comparative analysis of Medicare standalone part D and Medicare Advantage plan",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Changchuan Jiang",
"middle_name": "",
"last_name": "",
"org_name": "Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232402",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232402",
"events_session": "Targeting Direct and Indirect Costs of Cancer: Strategies for Screening",
"rest_events_session_count": 3,
"rest_events_session": " Intervention, and Policy,Access barriers and cost of varenicline for smoking cessation: A national comparative analysis of Medicare standalone part D and Medicare Advantage plan",
"events_topic": "Smoking Cessation | Varenicline ",
"rest_events_topic_count": 2,
"rest_events_topic": " Early Detection Of Cancer | Medicare Part D",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1881125011,'FU_HCP_5403352');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChangchuan Jiang",
"kol_full_name": "Changchuan Jiang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Accelerometry | Solid Tumor | Neoplasms",
"npi_num": "1871853432",
"hcp_pin_alias": "FU_HCP_282228",
"session_name": "If Serious Illness Communication Is So Important, Why Is It So Difficult to Integrate in Routine Oncology Care?,Prospective and external validation of an objective performance status (OPS) in patients with metastatic solid malignancies using wearable accelerometry",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Christopher Manz",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232328",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232328",
"events_session": "If Serious Illness Communication Is So Important",
"rest_events_session_count": 2,
"rest_events_session": " Why Is It So Difficult to Integrate in Routine Oncology Care?,Prospective and external validation of an objective performance status (OPS) in patients with metastatic solid malignancies using wearable accelerometry",
"events_topic": "Accelerometry | Solid Tumor ",
"rest_events_topic_count": 1,
"rest_events_topic": " Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1871853432,'FU_HCP_282228');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChristopher Manz",
"kol_full_name": "Christopher Manz"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1356760938",
"hcp_pin_alias": "FU_HCP_41325",
"session_name": "Let's Talk About Symptoms,Bioethics of over- and undertreatment in older adults with cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Clark DuMontier",
"middle_name": "",
"last_name": "",
"org_name": "VA Boston Healthcare System and Brigham and Women's Hospital",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232268",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232268",
"events_session": "Let's Talk About Symptoms",
"rest_events_session_count": 1,
"rest_events_session": "Bioethics of over- and undertreatment in older adults with cancer",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356760938,'FU_HCP_41325');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EClark DuMontier",
"kol_full_name": "Clark DuMontier"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Smoldering Multiple Myeloma | Multiple Myeloma | Positron-Emission Tomography | Magnetic Resonance Imaging | Fluorodeoxyglucose F18",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403391",
"session_name": "Exploring the role of the combination of FDG-PET plus whole body MRI for staging patients with high-risk smoldering myeloma: A prospective trial,Exploring the role of the combination of FDG PET plus whole body MRI for staging newly diagnosed and relapsed/refractory multiple myeloma: A prospective trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Claudio Cerchione",
"middle_name": "",
"last_name": "",
"org_name": "Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232112",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232112",
"events_session": "Exploring the role of the combination of FDG-PET plus whole body MRI for staging patients with high-risk smoldering myeloma: A prospective trial",
"rest_events_session_count": 1,
"rest_events_session": "Exploring the role of the combination of FDG PET plus whole body MRI for staging newly diagnosed and relapsed/refractory multiple myeloma: A prospective trial",
"events_topic": "Smoldering Multiple Myeloma | Multiple Myeloma ",
"rest_events_topic_count": 3,
"rest_events_topic": " Positron-Emission Tomography | Magnetic Resonance Imaging | Fluorodeoxyglucose F18",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403391');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EClaudio Cerchione",
"kol_full_name": "Claudio Cerchione"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1891225033",
"hcp_pin_alias": "FU_HCP_0001329",
"session_name": "The acceptability of hospital-at-home for persons living with cancer and their caregivers,Post-acute care facility utilization and outcomes among Medicare beneficiaries undergoing inpatient cancer surgery",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Daniel E Lage",
"middle_name": "",
"last_name": "",
"org_name": "Massachusetts General Hospital",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232404",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232404",
"events_session": "The acceptability of hospital-at-home for persons living with cancer and their caregivers",
"rest_events_session_count": 1,
"rest_events_session": "Post-acute care facility utilization and outcomes among Medicare beneficiaries undergoing inpatient cancer surgery",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1891225033,'FU_HCP_0001329');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDaniel E Lage",
"kol_full_name": "Daniel E Lage"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Circulating Tumor DNA | Breast Neoplasms",
"npi_num": "1043484439",
"hcp_pin_alias": "FU_HCP_116370",
"session_name": "Breast Cancer – Metastatc:: Program Commitee,Threading the Needle in the Haystack: ctDNA Applications in Early and Advanced Breast Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Daniel G. Stover",
"middle_name": "",
"last_name": "",
"org_name": "The Ohio State University Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232491",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232491",
"events_session": "Breast Cancer – Metastatc:: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Threading the Needle in the Haystack: ctDNA Applications in Early and Advanced Breast Cancer",
"events_topic": "Circulating Tumor DNA | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1043484439,'FU_HCP_116370');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDaniel G. Stover",
"kol_full_name": "Daniel G. Stover"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "HIV Infections | Endocrine Therapy | Neoplasms | Breast Neoplasms",
"npi_num": "1962764209",
"hcp_pin_alias": "FU_HCP_5403357",
"session_name": "Associations between HIV infection status, psychosocial factors, and adjuvant endocrine therapy adherence among South African women with early-stage breast cancer,Navigating Global Cancer Care: Conflict, Access, and Delivery",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Daniel O'Neil",
"middle_name": "",
"last_name": "",
"org_name": "Yale Cancer Center, Yale",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232527",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232527",
"events_session": "Associations between HIV infection status",
"rest_events_session_count": 5,
"rest_events_session": " psychosocial factors, and adjuvant endocrine therapy adherence among South African women with early-stage breast cancer,Navigating Global Cancer Care: Conflict, Access, and Delivery",
"events_topic": "HIV Infections | Endocrine Therapy ",
"rest_events_topic_count": 2,
"rest_events_topic": " Neoplasms | Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1962764209,'FU_HCP_5403357');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDaniel O'Neil",
"kol_full_name": "Daniel O'Neil"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Immunotherapy",
"npi_num": "1003234329",
"hcp_pin_alias": "FU_HCP_396051",
"session_name": "Developmental Therapeutcs – Immunotherapy: Program Commitee,Threading the Needle Between Targets and Toxicity",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Daniel Olson",
"middle_name": "",
"last_name": "",
"org_name": "University of Chicago, Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232300",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232300",
"events_session": "Developmental Therapeutcs – Immunotherapy: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Threading the Needle Between Targets and Toxicity",
"events_topic": "Neoplasms | Immunotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1003234329,'FU_HCP_396051');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDaniel Olson",
"kol_full_name": "Daniel Olson"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Osteosarcoma | Circulating Tumor DNA | Sarcoma, Ewing | Chemotherapy",
"npi_num": "1790028140",
"hcp_pin_alias": "FU_HCP_75874",
"session_name": "Prospective evaluation of pre-treatment ctDNA burden in localized osteosarcoma to identify patients with inferior outcomes: A report from the LEOPARD study,Association of elevated ctDNA burden following one cycle of chemotherapy with inferior outcomes for patients with metastatic Ewing sarcoma: A report from the Children’s Oncology Group (COG)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "David Stephen Shulman",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber/Boston Children's Cancer and Blood Disorders Center",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232496",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232496",
"events_session": "Prospective evaluation of pre-treatment ctDNA burden in localized osteosarcoma to identify patients with inferior outcomes: A report from the LEOPARD study",
"rest_events_session_count": 1,
"rest_events_session": "Association of elevated ctDNA burden following one cycle of chemotherapy with inferior outcomes for patients with metastatic Ewing sarcoma: A report from the Children’s Oncology Group (COG)",
"events_topic": "Osteosarcoma | Circulating Tumor DNA ",
"rest_events_topic_count": 2,
"rest_events_topic": " Sarcoma, Ewing | Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790028140,'FU_HCP_75874');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDavid Stephen Shulman",
"kol_full_name": "David Stephen Shulman"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Clinical Studies As Topic | Niraparib | Pleural Effusion, Malignant | Dostarlimab | Mesothelioma | Peroxiredoxin III | Clinical Trials As Topic | Solid Tumor",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403432",
"session_name": "Niraparib and dostarlimab efficacy in patients with platinum-sensitive relapsed mesothelioma: MIST5, a phase IIa clinical trial,First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Dean Anthony Fennell",
"middle_name": "",
"last_name": "",
"org_name": "Mesothelioma Research Programme, University of Leicester and University Hospitals of Leicester NHS Trust",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232453",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232453",
"events_session": "Niraparib and dostarlimab efficacy in patients with platinum-sensitive relapsed mesothelioma: MIST5",
"rest_events_session_count": 4,
"rest_events_session": " a phase IIa clinical trial,First-in-human phase I clinical trial of RSO-021, a first-in class covalent inhibitor of mitochondrial peroxiredoxin 3 (PRX3), in patients with malignant pleural effusion due to mesothelioma and other advanced solid tumors (MITOPE)",
"events_topic": "Clinical Studies As Topic | Niraparib ",
"rest_events_topic_count": 6,
"rest_events_topic": " Pleural Effusion, Malignant | Dostarlimab | Mesothelioma | Peroxiredoxin III | Clinical Trials As Topic | Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403432');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDean Anthony Fennell",
"kol_full_name": "Dean Anthony Fennell"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Gastrointestinal Neoplasms | Substance-Related Disorders",
"npi_num": "1275734527",
"hcp_pin_alias": "FU_HCP_282178",
"session_name": "Medical Oncologist Perspective,Addressing Substance Use Disorders in the Context of Cancer: A Case-Based Discussion on Assessment and Management",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Deepa Rangachari",
"middle_name": "",
"last_name": "",
"org_name": "Beth Israel Deaconess Medical Center",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232001",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232001",
"events_session": "Medical Oncologist Perspective",
"rest_events_session_count": 1,
"rest_events_session": "Addressing Substance Use Disorders in the Context of Cancer: A Case-Based Discussion on Assessment and Management",
"events_topic": "Neoplasms | Gastrointestinal Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Substance-Related Disorders",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1275734527,'FU_HCP_282178');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDeepa Rangachari",
"kol_full_name": "Deepa Rangachari"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Human Papillomavirus Viruses | Oropharyngeal Squamous Cell Carcinoma | Oropharyngeal Neoplasms",
"npi_num": "1053348367",
"hcp_pin_alias": "FU_HCP_38551",
"session_name": "Features of HPV+ OPSCC predictive of recurrence identified by transcriptional profiling of a case-control cohort,The Risk Landscape in HPV-Positive Oropharyngeal Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Devraj Basu",
"middle_name": "",
"last_name": "",
"org_name": "University of Pennsylvania",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232140",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232140",
"events_session": "Features of HPV+ OPSCC predictive of recurrence identified by transcriptional profiling of a case-control cohort",
"rest_events_session_count": 1,
"rest_events_session": "The Risk Landscape in HPV-Positive Oropharyngeal Cancer",
"events_topic": "Human Papillomavirus Viruses | Oropharyngeal Squamous Cell Carcinoma ",
"rest_events_topic_count": 1,
"rest_events_topic": " Oropharyngeal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1053348367,'FU_HCP_38551');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDevraj Basu",
"kol_full_name": "Devraj Basu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Biliary Tract Neoplasms | Vascular Endothelial Growth Factor A | Pancreatic Neoplasms | Solid Tumor | Trastuzumab Deruxtecan | Triple Negative Breast Neoplasms | Pembrolizumab",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403462",
"session_name": "Phase 1 trial of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in monotherapy and combination with pembrolizumab in patients with advanced solid tumors,Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Do-Youn Oh",
"middle_name": "",
"last_name": "",
"org_name": "Department of Internal Medicine, Seoul National University Hospital",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232823",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232823",
"events_session": "Phase 1 trial of TU2218",
"rest_events_session_count": 2,
"rest_events_session": " TGFβ-RI and VEGF-R2 dual inhibitor in monotherapy and combination with pembrolizumab in patients with advanced solid tumors,Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02)",
"events_topic": "Biliary Tract Neoplasms | Vascular Endothelial Growth Factor A ",
"rest_events_topic_count": 5,
"rest_events_topic": " Pancreatic Neoplasms | Solid Tumor | Trastuzumab Deruxtecan | Triple Negative Breast Neoplasms | Pembrolizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403462');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDo-Youn Oh",
"kol_full_name": "Do-Youn Oh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Microsatellite Instability | Ovarian Neoplasms | Relatlimab | Immune Checkpoint Inhibitors | Nivolumab | Pembrolizumab | Biomarkers",
"npi_num": "1043553456",
"hcp_pin_alias": "FU_HCP_394615",
"session_name": "A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer,A phase 2 study evaluating response and biomarkers in patients with microsatellite stable (MSS) advanced colorectal cancer (CRC) treated with nivolumab/relatlimab",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Eric Christenson",
"middle_name": "",
"last_name": "",
"org_name": "The Sidney Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232874",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232874",
"events_session": "A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve",
"rest_events_session_count": 2,
"rest_events_session": " and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer,A phase 2 study evaluating response and biomarkers in patients with microsatellite stable (MSS) advanced colorectal cancer (CRC) treated with nivolumab/relatlimab",
"events_topic": "Colorectal Neoplasms | Microsatellite Instability ",
"rest_events_topic_count": 6,
"rest_events_topic": " Ovarian Neoplasms | Relatlimab | Immune Checkpoint Inhibitors | Nivolumab | Pembrolizumab | Biomarkers",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1043553456,'FU_HCP_394615');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEric Christenson",
"kol_full_name": "Eric Christenson"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1336121789",
"hcp_pin_alias": "PAST_HCP_Onco_231619",
"session_name": "Comparison of expert treatment recommendations versus community healthcare providers: Analysis from an online decision support tool for metastatic breast cancer,Breast Cancer—Local/Regional/Adjuvant",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Erica L. Mayer",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232117",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232117",
"events_session": "Comparison of expert treatment recommendations versus community healthcare providers: Analysis from an online decision support tool for metastatic breast cancer",
"rest_events_session_count": 1,
"rest_events_session": "Breast Cancer—Local/Regional/Adjuvant",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1336121789,'PAST_HCP_Onco_231619');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EErica L. Mayer",
"kol_full_name": "Erica L. Mayer"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1467629006",
"hcp_pin_alias": "FU_HCP_110286",
"session_name": "Breast Cancer – Local/Regional/Adjuvant: Program Commitee,Breast Cancer—Metastatic",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Erica Michelle Stringer-Reasor",
"middle_name": "",
"last_name": "",
"org_name": "O'Neal Comprehensive Cancer Center at UAB",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231995",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231995",
"events_session": "Breast Cancer – Local/Regional/Adjuvant: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Breast Cancer—Metastatic",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1467629006,'FU_HCP_110286');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EErica Michelle Stringer-Reasor",
"kol_full_name": "Erica Michelle Stringer-Reasor"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Radiotherapy | Rectal Neoplasms | Neoplasms | Organ Preservation",
"npi_num": "1932475902",
"hcp_pin_alias": "FU_HCP_225049",
"session_name": "Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX),Radiation Oncologist Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Erqi L. Pollom",
"middle_name": "",
"last_name": "",
"org_name": "Stanford Hospital and Clinics",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232309",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232309",
"events_session": "Phase II trial of organ preservation program using short-course radiation and FOLFOXIRI for rectal cancer (SHORT-FOX)",
"rest_events_session_count": 1,
"rest_events_session": "Radiation Oncologist Perspective",
"events_topic": "Radiotherapy | Rectal Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Neoplasms | Organ Preservation",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1932475902,'FU_HCP_225049');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EErqi L. Pollom",
"kol_full_name": "Erqi L. Pollom"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Tremelimumab | Pembrolizumab | Carcinoma, Non-Small-Cell Lung | Pemetrexed | Durvalumab | Chemotherapy",
"npi_num": "1679957187",
"hcp_pin_alias": "FU_HCP_44144",
"session_name": "TRITON: Phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 and/or KEAP1 and/or KRAS mutations,Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ferdinandos Skoulidis",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232190",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232190",
"events_session": "TRITON: Phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P)",
"rest_events_session_count": 3,
"rest_events_session": " in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 and/or KEAP1 and/or KRAS mutations,Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)",
"events_topic": "Tremelimumab | Pembrolizumab ",
"rest_events_topic_count": 4,
"rest_events_topic": " Carcinoma, Non-Small-Cell Lung | Pemetrexed | Durvalumab | Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1679957187,'FU_HCP_44144');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFerdinandos Skoulidis",
"kol_full_name": "Ferdinandos Skoulidis"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Multiple Myeloma",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403386",
"session_name": "Induction Strategies for Newly Diagnosed High-Risk Multiple Myeloma,Navigating High-Risk and Ultra-High-Risk Multiple Myeloma: Challenges and Emerging Strategies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Francesca Gay",
"middle_name": "",
"last_name": "",
"org_name": "University of Torino, AOU S. Giovanni Batt",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232054",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232054",
"events_session": "Induction Strategies for Newly Diagnosed High-Risk Multiple Myeloma",
"rest_events_session_count": 1,
"rest_events_session": "Navigating High-Risk and Ultra-High-Risk Multiple Myeloma: Challenges and Emerging Strategies",
"events_topic": "Multiple Myeloma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403386');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFrancesca Gay",
"kol_full_name": "Francesca Gay"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Precision Medicine | Breast Neoplasms",
"npi_num": "1811315443",
"hcp_pin_alias": "PAST_HCP_Future Events_313782",
"session_name": "Payor denial after prior authorization request for long-acting pain medication: Provider and patient perspectives,Patient-reported provider communication skills and adherence to recommended treatment in breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Fumiko Chino",
"middle_name": "",
"last_name": "",
"org_name": "Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232619",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232619",
"events_session": "Payor denial after prior authorization request for long-acting pain medication: Provider and patient perspectives",
"rest_events_session_count": 1,
"rest_events_session": "Patient-reported provider communication skills and adherence to recommended treatment in breast cancer",
"events_topic": "Precision Medicine | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1811315443,'PAST_HCP_Future Events_313782');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFumiko Chino",
"kol_full_name": "Fumiko Chino"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Leiomyosarcoma | Lurbinectedin | Irinotecan | Doxorubicin | Sarcoma, Synovial",
"npi_num": "1215064654",
"hcp_pin_alias": "FU_HCP_39974",
"session_name": "Randomized controlled, open-label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma,Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in a phase 2 expansion cohort of patients (Pts) with synovial sarcoma (SS)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Gregory Michael Cote",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232908",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232908",
"events_session": "Randomized controlled",
"rest_events_session_count": 3,
"rest_events_session": " open-label, phase IIb/III study of lurbinectedin in combination with doxorubicin versus doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma,Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in a phase 2 expansion cohort of patients (Pts) with synovial sarcoma (SS)",
"events_topic": "Leiomyosarcoma | Lurbinectedin ",
"rest_events_topic_count": 3,
"rest_events_topic": " Irinotecan | Doxorubicin | Sarcoma, Synovial",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1215064654,'FU_HCP_39974');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGregory Michael Cote",
"kol_full_name": "Gregory Michael Cote"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Immunoconjugates | Anus Neoplasms | Gastrointestinal Neoplasms | Solid Tumor",
"npi_num": "1376834325",
"hcp_pin_alias": "FU_HCP_5403356",
"session_name": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee,Antibodies Plus: Bispecifics, Antibody Drug–Conjugates, and Engagers in Solid Tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Harshabad Singh",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232504",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232504",
"events_session": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"rest_events_session_count": 3,
"rest_events_session": "Antibodies Plus: Bispecifics, Antibody Drug–Conjugates, and Engagers in Solid Tumors",
"events_topic": "Colorectal Neoplasms | Immunoconjugates ",
"rest_events_topic_count": 3,
"rest_events_topic": " Anus Neoplasms | Gastrointestinal Neoplasms | Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1376834325,'FU_HCP_5403356');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHarshabad Singh",
"kol_full_name": "Harshabad Singh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Central Nervous System Neoplasms",
"npi_num": "1083873442",
"hcp_pin_alias": "PAST_HCP_CNS_190250",
"session_name": "Central Nervous System Tumors: Program Commitee,Advancing Trial Design: Illuminating Tumor Evolution in Central Nervous System Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ian F. Parney",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232060",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232060",
"events_session": "Central Nervous System Tumors: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Advancing Trial Design: Illuminating Tumor Evolution in Central Nervous System Cancer",
"events_topic": "Central Nervous System Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1083873442,'PAST_HCP_CNS_190250');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EIan F. Parney",
"kol_full_name": "Ian F. Parney"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Clinical Trials As Topic | Clinical Trial",
"npi_num": "1124283213",
"hcp_pin_alias": "FU_HCP_39202",
"session_name": "Clinical trial participation and end-of-life care among older adults: A multi-center longitudinal observational cohort analysis of 121,717 patients with cancer,5-year multicenter analysis of clinical trial participation and total cost of care for older adults with cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ishwaria M. Subbiah",
"middle_name": "",
"last_name": "",
"org_name": "Sarah Cannon Research Institute (SCRI), SCRI Oncology Partners, The US Oncology Network",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232279",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232279",
"events_session": "Clinical trial participation and end-of-life care among older adults: A multi-center longitudinal observational cohort analysis of 121",
"rest_events_session_count": 2,
"rest_events_session": "717 patients with cancer,5-year multicenter analysis of clinical trial participation and total cost of care for older adults with cancer",
"events_topic": "Neoplasms | Clinical Trials As Topic ",
"rest_events_topic_count": 1,
"rest_events_topic": " Clinical Trial",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1124283213,'FU_HCP_39202');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EIshwaria M. Subbiah",
"kol_full_name": "Ishwaria M. Subbiah"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Solid Tumor | Squamous Cell Carcinoma Of Head And Neck | Pembrolizumab | Nivolumab | Ipatasertib",
"npi_num": "1811262967",
"hcp_pin_alias": "FU_HCP_100400",
"session_name": "Phase 1 study of BA3071, an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors,A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jacob Stephen Thomas",
"middle_name": "",
"last_name": "",
"org_name": "Norris Comprehensive Cancer Center, University of Southern California",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232576",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232576",
"events_session": "Phase 1 study of BA3071",
"rest_events_session_count": 3,
"rest_events_session": " an anti–CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors,A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck",
"events_topic": "Solid Tumor | Squamous Cell Carcinoma Of Head And Neck ",
"rest_events_topic_count": 3,
"rest_events_topic": " Pembrolizumab | Nivolumab | Ipatasertib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1811262967,'FU_HCP_100400');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJacob Stephen Thomas",
"kol_full_name": "Jacob Stephen Thomas"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Myelodysplastic Syndromes | Leukemia, Myeloid, Acute",
"npi_num": "1922260934",
"hcp_pin_alias": "FU_HCP_99740",
"session_name": "When Myelodysplastic Syndrome Evolves to Acute Myeloid Leukemia: How to Manage Progression of Disease,Advancements and Challenges in the Treatment of Acute Myeloid Leukemia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jacqueline Suen Garcia",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232047",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232047",
"events_session": "When Myelodysplastic Syndrome Evolves to Acute Myeloid Leukemia: How to Manage Progression of Disease",
"rest_events_session_count": 1,
"rest_events_session": "Advancements and Challenges in the Treatment of Acute Myeloid Leukemia",
"events_topic": "Myelodysplastic Syndromes | Leukemia, Myeloid, Acute",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1922260934,'FU_HCP_99740');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJacqueline Suen Garcia",
"kol_full_name": "Jacqueline Suen Garcia"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lymphoma | Tamoxifen | Breast Neoplasms | Leukemia",
"npi_num": "1356870612",
"hcp_pin_alias": "FU_HCP_41334",
"session_name": "Accelerated aging among survivors of childhood leukemia and lymphoma: Estimates of early onset and excess morbidity from the COMPASS model,Tamoxifen for breast cancer prevention among survivors of pediatric lymphoma previously treated with chest radiation: Clinical benefits, harms and tradeoffs",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jennifer M Yeh",
"middle_name": "",
"last_name": "",
"org_name": "Boston Children's Hospital",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232497",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232497",
"events_session": "Accelerated aging among survivors of childhood leukemia and lymphoma: Estimates of early onset and excess morbidity from the COMPASS model",
"rest_events_session_count": 2,
"rest_events_session": "Tamoxifen for breast cancer prevention among survivors of pediatric lymphoma previously treated with chest radiation: Clinical benefits, harms and tradeoffs",
"events_topic": "Lymphoma | Tamoxifen ",
"rest_events_topic_count": 2,
"rest_events_topic": " Breast Neoplasms | Leukemia",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356870612,'FU_HCP_41334');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJennifer M Yeh",
"kol_full_name": "Jennifer M Yeh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Breast Neoplasms",
"npi_num": "1619905056",
"hcp_pin_alias": "PAST_HCP_Future Events_316836",
"session_name": "Breast Cancer – Local/Regional/Adjuvant: Program Commitee,Navigating Complex Patient Scenarios: The Seasoned Clinician's Toolbox",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jennifer Ruth Bellon",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231990",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231990",
"events_session": "Breast Cancer – Local/Regional/Adjuvant: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Navigating Complex Patient Scenarios: The Seasoned Clinician's Toolbox",
"events_topic": "Neoplasms | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1619905056,'PAST_HCP_Future Events_316836');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJennifer Ruth Bellon",
"kol_full_name": "Jennifer Ruth Bellon"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptor, Platelet-Derived Growth Factor Alpha | Homologous Recombination Repair | Gastrointestinal Stromal Tumors | Esophageal Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403412",
"session_name": "Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST),Impact of pathogenic germline variants in HRR genes on gastroesophageal cancer in a large real-world Chinese population: A comprehensive study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jian Li",
"middle_name": "",
"last_name": "",
"org_name": "Department of Gastrointestinal Oncology, Beijing Cancer Hospital",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232230",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232230",
"events_session": "Phase 1 study of NB003",
"rest_events_session_count": 3,
"rest_events_session": " a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST),Impact of pathogenic germline variants in HRR genes on gastroesophageal cancer in a large real-world Chinese population: A comprehensive study",
"events_topic": "Receptor, Platelet-Derived Growth Factor Alpha | Homologous Recombination Repair ",
"rest_events_topic_count": 2,
"rest_events_topic": " Gastrointestinal Stromal Tumors | Esophageal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403412');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJian Li",
"kol_full_name": "Jian Li"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Antibodies, Bispecific | ErbB Receptors | Carcinoma, Non-Small-Cell Lung | Small Cell Lung Carcinoma",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403402",
"session_name": "ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC),Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jie Wang",
"middle_name": "",
"last_name": "",
"org_name": "National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232178",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232178",
"events_session": "ARTEMIS-001: Data from a phase 1a/b study of HS-20093 in patients with relapsed small cell lung cancer (SCLC)",
"rest_events_session_count": 3,
"rest_events_session": "Efficacy and safety of MCLA-129, an EGFR/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)",
"events_topic": "Antibodies, Bispecific | ErbB Receptors ",
"rest_events_topic_count": 2,
"rest_events_topic": " Carcinoma, Non-Small-Cell Lung | Small Cell Lung Carcinoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403402');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJie Wang",
"kol_full_name": "Jie Wang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Pancreatic Neoplasms | Anus Neoplasms | Gastrointestinal Neoplasms",
"npi_num": "1851739239",
"hcp_pin_alias": "FU_HCP_209337",
"session_name": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee,Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jingquan Jia",
"middle_name": "",
"last_name": "",
"org_name": "The University of North Carolina at Chapel Hill",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232007",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232007",
"events_session": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"rest_events_session_count": 3,
"rest_events_session": "Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary",
"events_topic": "Colorectal Neoplasms | Pancreatic Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Anus Neoplasms | Gastrointestinal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1851739239,'FU_HCP_209337');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJingquan Jia",
"kol_full_name": "Jingquan Jia"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Epigenomics | Fisetin | Chemotherapy | Breast Neoplasms",
"npi_num": "1114319423",
"hcp_pin_alias": "FU_HCP_284269",
"session_name": "A phase II randomized double-blind placebo-controlled study of fisetin to improve physical function in frail older breast cancer survivors (TROFFi),Accelerated epigenetic aging and risk of chemotoxicity in older adults with early breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jingran Ji",
"middle_name": "",
"last_name": "",
"org_name": "City of Hope Comprehensive Cancer Center",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233058",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233058",
"events_session": "A phase II randomized double-blind placebo-controlled study of fisetin to improve physical function in frail older breast cancer survivors (TROFFi)",
"rest_events_session_count": 1,
"rest_events_session": "Accelerated epigenetic aging and risk of chemotoxicity in older adults with early breast cancer",
"events_topic": "Epigenomics | Fisetin ",
"rest_events_topic_count": 2,
"rest_events_topic": " Chemotherapy | Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1114319423,'FU_HCP_284269');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJingran Ji",
"kol_full_name": "Jingran Ji"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Favezelimab | Programmed Cell Death 1 Receptor | Hodgkin Disease",
"npi_num": "1891715090",
"hcp_pin_alias": "PAST_HCP_Onco_233551",
"session_name": "A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis,A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "John Timmerman",
"middle_name": "",
"last_name": "",
"org_name": "University of California, Los Angeles Medical Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232380",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232380",
"events_session": "A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis",
"rest_events_session_count": 1,
"rest_events_session": "A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis",
"events_topic": "Favezelimab | Programmed Cell Death 1 Receptor ",
"rest_events_topic_count": 1,
"rest_events_topic": " Hodgkin Disease",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1891715090,'PAST_HCP_Onco_233551');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJohn Timmerman",
"kol_full_name": "John Timmerman"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Surgical Procedures, Operative | Carcinoma, Non-Small-Cell Lung | Nivolumab | Neoplasms | Chemotherapy",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403435",
"session_name": "Surgical Oncologist Perspective,Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jonathan Spicer",
"middle_name": "",
"last_name": "",
"org_name": "McGill University",
"Country": "Canada",
"Region": "Quebec",
"City": "Montreal",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232492",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232492",
"events_session": "Surgical Oncologist Perspective",
"rest_events_session_count": 1,
"rest_events_session": "Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816",
"events_topic": "Surgical Procedures, Operative | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 3,
"rest_events_topic": " Nivolumab | Neoplasms | Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403435');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJonathan Spicer",
"kol_full_name": "Jonathan Spicer"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms, Male | Inflammatory Breast Neoplasms | Endocrine Therapy",
"npi_num": "1659532703",
"hcp_pin_alias": "FU_HCP_43926",
"session_name": "ETHAN: A phase II study comparing different endocrine therapies for male breast cancer,Survival outcomes and treatment patterns by tumor subtype (TS) in stage III inflammatory and non-inflammatory breast cancer (BC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jose Pablo Leone",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute/Harvard Medical School",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232636",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232636",
"events_session": "ETHAN: A phase II study comparing different endocrine therapies for male breast cancer",
"rest_events_session_count": 1,
"rest_events_session": "Survival outcomes and treatment patterns by tumor subtype (TS) in stage III inflammatory and non-inflammatory breast cancer (BC)",
"events_topic": "Breast Neoplasms, Male | Inflammatory Breast Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Endocrine Therapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1659532703,'FU_HCP_43926');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJose Pablo Leone",
"kol_full_name": "Jose Pablo Leone"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Education, Medical",
"npi_num": "1538244249",
"hcp_pin_alias": "FU_HCP_5403331",
"session_name": "Medical Educaton and Professional Development: Program Commitee,Medical Education and Professional Development",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Julia Lee Close",
"middle_name": "",
"last_name": "",
"org_name": "UF Health Cancer Center, University of Florida",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232006",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232006",
"events_session": "Medical Educaton and Professional Development: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Medical Education and Professional Development",
"events_topic": "Education, Medical",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1538244249,'FU_HCP_5403331');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJulia Lee Close",
"kol_full_name": "Julia Lee Close"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "METTL3 Inhibitor | Immune Checkpoint Inhibitors | Neoplasms | Solid Tumor",
"npi_num": "1891133989",
"hcp_pin_alias": "FU_HCP_45959",
"session_name": "A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab,Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL-3 inhibitor, in patients with advanced malignancies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Justin C Moser",
"middle_name": "",
"last_name": "",
"org_name": "HonorHealth Research Institute",
"Country": "United States",
"Region": "Arizona",
"City": "Scottsdale",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233004",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233004",
"events_session": "A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab",
"rest_events_session_count": 5,
"rest_events_session": "Phase 1 dose escalation and cohort expansion study evaluating safety, PK, PD and clinical activity of STC-15, a METTL-3 inhibitor, in patients with advanced malignancies",
"events_topic": "METTL3 Inhibitor | Immune Checkpoint Inhibitors ",
"rest_events_topic_count": 2,
"rest_events_topic": " Neoplasms | Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1891133989,'FU_HCP_45959');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJustin C Moser",
"kol_full_name": "Justin C Moser"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Vaccines | Squamous Cell Carcinoma Of Head And Neck | Immunotherapy | Head And Neck Neoplasms | Immune Checkpoint Inhibitors",
"npi_num": "1093794075",
"hcp_pin_alias": "FU_HCP_38948",
"session_name": "Therapeutic Vaccines for Head and Neck Cancers,Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Katharine Andress Rowe Price",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231970",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231970",
"events_session": "Therapeutic Vaccines for Head and Neck Cancers",
"rest_events_session_count": 1,
"rest_events_session": "Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy",
"events_topic": "Vaccines | Squamous Cell Carcinoma Of Head And Neck ",
"rest_events_topic_count": 3,
"rest_events_topic": " Immunotherapy | Head And Neck Neoplasms | Immune Checkpoint Inhibitors",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1093794075,'FU_HCP_38948');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKatharine Andress Rowe Price",
"kol_full_name": "Katharine Andress Rowe Price"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Esophageal Neoplasms | Carcinoma, Non-Small-Cell Lung | Stomach Neoplasms | Enfortumab Vedotin",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403400",
"session_name": "Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202,Enfortumab vedotin (EV) in non-squamous and squamous non–small cell lung cancer (NSCLC) cohorts of EV-202",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kei Muro",
"middle_name": "",
"last_name": "",
"org_name": "Aichi Cancer Center Hospital",
"Country": "Japan",
"Region": "Aichi",
"City": "Nagoya",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232173",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232173",
"events_session": "Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202",
"rest_events_session_count": 1,
"rest_events_session": "Enfortumab vedotin (EV) in non-squamous and squamous non–small cell lung cancer (NSCLC) cohorts of EV-202",
"events_topic": "Esophageal Neoplasms | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 2,
"rest_events_topic": " Stomach Neoplasms | Enfortumab Vedotin",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403400');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKei Muro",
"kol_full_name": "Kei Muro"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hormone Therapy | Radiosurgery | Health Status Disparities | Breast Neoplasms | Brain Neoplasms",
"npi_num": "1790304509",
"hcp_pin_alias": "FU_HCP_328947",
"session_name": "Evaluating disparities in receptor status, overall survival, and time to hormone therapy among women with breast cancer,Disparities in stereotactic radiosurgery practice patterns for treatment of brain metastases: A large national cancer database study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kekoa A. Taparra",
"middle_name": "",
"last_name": "",
"org_name": "Stanford Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232406",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232406",
"events_session": "Evaluating disparities in receptor status",
"rest_events_session_count": 3,
"rest_events_session": " overall survival, and time to hormone therapy among women with breast cancer,Disparities in stereotactic radiosurgery practice patterns for treatment of brain metastases: A large national cancer database study",
"events_topic": "Hormone Therapy | Radiosurgery ",
"rest_events_topic_count": 3,
"rest_events_topic": " Health Status Disparities | Breast Neoplasms | Brain Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790304509,'FU_HCP_328947');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKekoa A. Taparra",
"kol_full_name": "Kekoa A. Taparra"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Rintatolimod | Folfirinox | Pancreatic Neoplasms | Esophageal Neoplasms",
"npi_num": "1396056149",
"hcp_pin_alias": "FU_HCP_99940",
"session_name": "Phase 2 randomized study of rintatolimod following FOLFIRINOX in patients with locally advanced pancreatic adenocarcinoma,Current Management of Nonmetastatic Gastroesophageal Cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kelsey Klute",
"middle_name": "",
"last_name": "",
"org_name": "University of Nebraska Medical Center",
"Country": "United States",
"Region": "Nebraska",
"City": "Omaha",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232124",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232124",
"events_session": "Phase 2 randomized study of rintatolimod following FOLFIRINOX in patients with locally advanced pancreatic adenocarcinoma",
"rest_events_session_count": 1,
"rest_events_session": "Current Management of Nonmetastatic Gastroesophageal Cancers",
"events_topic": "Rintatolimod | Folfirinox ",
"rest_events_topic_count": 2,
"rest_events_topic": " Pancreatic Neoplasms | Esophageal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1396056149,'FU_HCP_99940');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKelsey Klute",
"kol_full_name": "Kelsey Klute"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Human Papillomavirus Viruses | Chemoradiotherapy | Squamous Cell Carcinoma Of Head And Neck",
"npi_num": "1427102490",
"hcp_pin_alias": "FU_HCP_100094",
"session_name": "TTMV and association with relapse in patients with HPV related SCCHN undergoing CRT,Can TTMV clearance predict recurrence in HPV HNSCC?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Krzysztof Misiukiewicz",
"middle_name": "",
"last_name": "",
"org_name": "Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232561",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232561",
"events_session": "TTMV and association with relapse in patients with HPV related SCCHN undergoing CRT",
"rest_events_session_count": 1,
"rest_events_session": "Can TTMV clearance predict recurrence in HPV HNSCC?",
"events_topic": "Human Papillomavirus Viruses | Chemoradiotherapy ",
"rest_events_topic_count": 1,
"rest_events_topic": " Squamous Cell Carcinoma Of Head And Neck",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1427102490,'FU_HCP_100094');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKrzysztof Misiukiewicz",
"kol_full_name": "Krzysztof Misiukiewicz"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Germline Genetic Testing | Lung Neoplasms | Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403384",
"session_name": "Risk Factors and Germline Testing,Treating Lung Cancer in Young Adults: Considerations and Outcomes",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Laura Mezquita",
"middle_name": "",
"last_name": "",
"org_name": "Hospital Clinic Barcelona, IDIBAPS",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232000",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232000",
"events_session": "Risk Factors and Germline Testing",
"rest_events_session_count": 1,
"rest_events_session": "Treating Lung Cancer in Young Adults: Considerations and Outcomes",
"events_topic": "Germline Genetic Testing | Lung Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403384');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELaura Mezquita",
"kol_full_name": "Laura Mezquita"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunoconjugates | Solid Tumor",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403431",
"session_name": "A phase I open-label study of a novel IL-2Rβ/γ cytokine agonist, LTC004, in patients with advanced or metastatic solid tumors,Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Lin Shen",
"middle_name": "",
"last_name": "",
"org_name": "Beijing Cancer Hospital",
"Country": "China",
"Region": "Beijing",
"City": "Beijing",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232451",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232451",
"events_session": "A phase I open-label study of a novel IL-2Rβ/γ cytokine agonist",
"rest_events_session_count": 3,
"rest_events_session": " LTC004, in patients with advanced or metastatic solid tumors,Results of a phase 1/2 study of MHB088C: A novel B7H3 antibody-drug conjugate (ADC) incorporating a potent DNA topoisomerase I inhibitor in recurrent or metastatic solid tumors",
"events_topic": "Immunoconjugates | Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403431');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELin Shen",
"kol_full_name": "Lin Shen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Randomized Controlled Trials As Topic | Radiotherapy | Stomatitis | Nasopharyngeal Carcinoma | Leukemia, Lymphocytic, Chronic, B-Cell",
"npi_num": "1710412085",
"hcp_pin_alias": "FU_HCP_5403351",
"session_name": "The efficacy and safety of ulinastatin in the prevention and treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A multicenter, open-label, randomized controlled clinical trial,Evaluating CR as a surrogate endpoint for PFS in R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A meta-analysis of randomized controlled trials (RCT)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Lin Wang",
"middle_name": "",
"last_name": "",
"org_name": "Bristol Myers Squibb",
"Country": "United States",
"Region": "New Jersey",
"City": "Lawrenceville",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232376",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232376",
"events_session": "The efficacy and safety of ulinastatin in the prevention and treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A multicenter",
"rest_events_session_count": 3,
"rest_events_session": " open-label, randomized controlled clinical trial,Evaluating CR as a surrogate endpoint for PFS in R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A meta-analysis of randomized controlled trials (RCT)",
"events_topic": "Randomized Controlled Trials As Topic | Radiotherapy ",
"rest_events_topic_count": 3,
"rest_events_topic": " Stomatitis | Nasopharyngeal Carcinoma | Leukemia, Lymphocytic, Chronic, B-Cell",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1710412085,'FU_HCP_5403351');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELin Wang",
"kol_full_name": "Lin Wang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sacituzumab Govitecan | Small Cell Lung Carcinoma | Carcinoma, Non-Small-Cell Lung | Irinotecan | Chemotherapy | Lurbinectedin",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403414",
"session_name": "Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study,Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in patients (Pts) with relapsed small cell lung cancer (SCLC): Results from a phase 2 expansion cohort",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Luis G. Paz-Ares",
"middle_name": "",
"last_name": "",
"org_name": "Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232248",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232248",
"events_session": "Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study",
"rest_events_session_count": 1,
"rest_events_session": "Efficacy and safety of lurbinectedin (LUR) with irinotecan (IRI) in patients (Pts) with relapsed small cell lung cancer (SCLC): Results from a phase 2 expansion cohort",
"events_topic": "Sacituzumab Govitecan | Small Cell Lung Carcinoma ",
"rest_events_topic_count": 4,
"rest_events_topic": " Carcinoma, Non-Small-Cell Lung | Irinotecan | Chemotherapy | Lurbinectedin",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403414');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELuis G. Paz-Ares",
"kol_full_name": "Luis G. Paz-Ares"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Myeloid Malignancy | Antibody Therapy | Biomarkers | Triple Negative Breast Neoplasms",
"npi_num": "1063593473",
"hcp_pin_alias": "FU_HCP_283043",
"session_name": "Using cell-free RNA in monitoring immune system and the demonstration of significant systemic deficiency in lymphoid and myeloid biomarkers in patients with cancer,Multiple alternative splicing of HER2 transcripts and exon skipping with potential consequences on function and antibody-based therapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Maher Albitar",
"middle_name": "",
"last_name": "",
"org_name": "Genomic Testing Cooperative",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232680",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232680",
"events_session": "Using cell-free RNA in monitoring immune system and the demonstration of significant systemic deficiency in lymphoid and myeloid biomarkers in patients with cancer",
"rest_events_session_count": 1,
"rest_events_session": "Multiple alternative splicing of HER2 transcripts and exon skipping with potential consequences on function and antibody-based therapy",
"events_topic": "Myeloid Malignancy | Antibody Therapy ",
"rest_events_topic_count": 2,
"rest_events_topic": " Biomarkers | Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1063593473,'FU_HCP_283043');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMaher Albitar",
"kol_full_name": "Maher Albitar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Diversity, Equity, Inclusion | Neoplasms",
"npi_num": "1801076138",
"hcp_pin_alias": "FU_HCP_187459",
"session_name": "Utilizing Lay Health Workers and Patient Caregivers to Improve Equitable Communication of Goals of Care,Let’s Have the Conversation: Scaling Serious Illness Communication in Routine Oncology Care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Manali I. Patel",
"middle_name": "",
"last_name": "",
"org_name": "Stanford University",
"Country": "United States",
"Region": "California",
"City": "Palo Alto",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232049",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232049",
"events_session": "Utilizing Lay Health Workers and Patient Caregivers to Improve Equitable Communication of Goals of Care",
"rest_events_session_count": 1,
"rest_events_session": "Let’s Have the Conversation: Scaling Serious Illness Communication in Routine Oncology Care",
"events_topic": "Diversity, Equity, Inclusion | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1801076138,'FU_HCP_187459');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EManali I. Patel",
"kol_full_name": "Manali I. Patel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Admin. & Management | Neoplasms",
"npi_num": "1033448147",
"hcp_pin_alias": "FU_HCP_38409",
"session_name": "Pediatric Oncology: Program Commitee,Pediatric Oncology I",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Mark A. Applebaum",
"middle_name": "",
"last_name": "",
"org_name": "University of Chicago",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232050",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232050",
"events_session": "Pediatric Oncology: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Pediatric Oncology I",
"events_topic": "Admin. & Management | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1033448147,'FU_HCP_38409');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMark A. Applebaum",
"kol_full_name": "Mark A. Applebaum"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Oropharyngeal Neoplasms | Squamous Cell Carcinoma Of Head And Neck | Human Papillomavirus Viruses | Pembrolizumab | Neoadjuvant Therapy | Danvatirsen",
"npi_num": "1700847753",
"hcp_pin_alias": "FU_HCP_94343",
"session_name": "PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC),Rekindling the Old Flame of Neoadjuvant Therapy: Defining Its Role in HPV-Positive Oropharyngeal Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Marshall R. Posner",
"middle_name": "",
"last_name": "",
"org_name": "Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232143",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232143",
"events_session": "PEMDA-HN",
"rest_events_session_count": 4,
"rest_events_session": " an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC),Rekindling the Old Flame of Neoadjuvant Therapy: Defining Its Role in HPV-Positive Oropharyngeal Cancer",
"events_topic": "Oropharyngeal Neoplasms | Squamous Cell Carcinoma Of Head And Neck ",
"rest_events_topic_count": 4,
"rest_events_topic": " Human Papillomavirus Viruses | Pembrolizumab | Neoadjuvant Therapy | Danvatirsen",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700847753,'FU_HCP_94343');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMarshall R. Posner",
"kol_full_name": "Marshall R. Posner"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Clinical Trials As Topic | Artificial Intelligence | Hematologic Neoplasms",
"npi_num": "1609001361",
"hcp_pin_alias": "FU_HCP_202479",
"session_name": "Educating hematology-oncology fellows about how to communicate with patients about cancer clinical trials: A needs assessment,Harness Artificial Intelligence to Enhance Patient–Physician Relationships",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Martina Cathryn Murphy",
"middle_name": "",
"last_name": "",
"org_name": "University of Florida",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232031",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232031",
"events_session": "Educating hematology-oncology fellows about how to communicate with patients about cancer clinical trials: A needs assessment",
"rest_events_session_count": 1,
"rest_events_session": "Harness Artificial Intelligence to Enhance Patient–Physician Relationships",
"events_topic": "Clinical Trials As Topic | Artificial Intelligence ",
"rest_events_topic_count": 1,
"rest_events_topic": " Hematologic Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1609001361,'FU_HCP_202479');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMartina Cathryn Murphy",
"kol_full_name": "Martina Cathryn Murphy"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Melanoma | Solid Tumor",
"npi_num": "1437425659",
"hcp_pin_alias": "FU_HCP_110462",
"session_name": "PD-1–Refractory Advanced Melanoma: How Do We Get to the Finish Line?,A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Meredith McKean",
"middle_name": "",
"last_name": "",
"org_name": "Sarah Cannon Research Institute",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232988",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232988",
"events_session": "PD-1–Refractory Advanced Melanoma: How Do We Get to the Finish Line?",
"rest_events_session_count": 1,
"rest_events_session": "A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors",
"events_topic": "Pembrolizumab | Melanoma ",
"rest_events_topic_count": 1,
"rest_events_topic": " Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1437425659,'FU_HCP_110462');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMeredith McKean",
"kol_full_name": "Meredith McKean"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Melanoma | Immunotherapy | Biomarkers | Circulating Tumor DNA",
"npi_num": "1831728401",
"hcp_pin_alias": "FU_HCP_225402",
"session_name": "Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer,Association between circulating tumor DNA (ctDNA) and recurrence-free survival (RFS) in patients (pts) with resected stage III melanoma: An exploratory analysis of SWOG S1404",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michael Brian LaPelusa",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232795",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232795",
"events_session": "Circulating tumor DNA as a predictive biomarker for pathologic response after treatment with neoadjuvant immunotherapy for localized dMMR/MSI-H colorectal cancer",
"rest_events_session_count": 1,
"rest_events_session": "Association between circulating tumor DNA (ctDNA) and recurrence-free survival (RFS) in patients (pts) with resected stage III melanoma: An exploratory analysis of SWOG S1404",
"events_topic": "Colorectal Neoplasms | Melanoma ",
"rest_events_topic_count": 3,
"rest_events_topic": " Immunotherapy | Biomarkers | Circulating Tumor DNA",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1831728401,'FU_HCP_225402');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichael Brian LaPelusa",
"kol_full_name": "Michael Brian LaPelusa"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Electronic Health Records | Atezolizumab | Carcinoma, Hepatocellular | Neoadjuvant Therapy | Liver Function Tests | Neoplasms | Bevacizumab",
"npi_num": "1518545086",
"hcp_pin_alias": "FU_HCP_394782",
"session_name": "Atezolizumab plus bevacizumab (A+B) as first-line systemic therapy for advanced hepatocellular carcinoma (HCC): A multi-institution analysis of patient outcomes based on Child Pugh (CP) and ALBI liver function,Symptom burden in adolescents and young adults with cancer: A subgroup analysis of the enhanced, EHR-facilitated cancer symptom control (E2C2) trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michael H. Storandt",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232209",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232209",
"events_session": "Atezolizumab plus bevacizumab (A+B) as first-line systemic therapy for advanced hepatocellular carcinoma (HCC): A multi-institution analysis of patient outcomes based on Child Pugh (CP) and ALBI liver function",
"rest_events_session_count": 2,
"rest_events_session": "Symptom burden in adolescents and young adults with cancer: A subgroup analysis of the enhanced, EHR-facilitated cancer symptom control (E2C2) trial",
"events_topic": "Electronic Health Records | Atezolizumab ",
"rest_events_topic_count": 5,
"rest_events_topic": " Carcinoma, Hepatocellular | Neoadjuvant Therapy | Liver Function Tests | Neoplasms | Bevacizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1518545086,'FU_HCP_394782');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichael H. Storandt",
"kol_full_name": "Michael H. Storandt"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Myelodysplastic Syndromes | Hematologic Neoplasms | Leukemia | Head And Neck Neoplasms",
"npi_num": "1942564117",
"hcp_pin_alias": "FU_HCP_99669",
"session_name": "Head and Neck Cancer: Program Commitee,Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michael William Drazer",
"middle_name": "",
"last_name": "",
"org_name": "University of Chicago Medical Center",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232082",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232082",
"events_session": "Head and Neck Cancer: Program Commitee",
"rest_events_session_count": 3,
"rest_events_session": "Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant",
"events_topic": "Myelodysplastic Syndromes | Hematologic Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Leukemia | Head And Neck Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1942564117,'FU_HCP_99669');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichael William Drazer",
"kol_full_name": "Michael William Drazer"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nasopharyngeal Carcinoma | Induction Chemotherapy | Toripalimab | Chemoradiotherapy",
"npi_num": "1457358749",
"hcp_pin_alias": "FU_HCP_68167",
"session_name": "Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter, randomized, phase 2 trial,Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Min Kang",
"middle_name": "",
"last_name": "",
"org_name": "Department of Radiation Oncology, the First Affiliated Hospital of Guangxi Medical University",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232098",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232098",
"events_session": "Induction chemotherapy followed by concurrent chemoradiotherapy combined with toripalimab and Endostar in high-risk locally advanced nasopharyngeal carcinoma: A multicenter",
"rest_events_session_count": 6,
"rest_events_session": " randomized, phase 2 trial,Endostar combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A phase III, prospective, randomised-controlled, multicenter clinical trial",
"events_topic": "Nasopharyngeal Carcinoma | Induction Chemotherapy ",
"rest_events_topic_count": 2,
"rest_events_topic": " Toripalimab | Chemoradiotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1457358749,'FU_HCP_68167');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMin Kang",
"kol_full_name": "Min Kang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Graft Vs Host Disease | Histocompatibility Antigens | Stem Cell Transplantation | Cyclophosphamide | Hematopoietic Stem Cell Transplantation",
"npi_num": "1043489362",
"hcp_pin_alias": "FU_HCP_229365",
"session_name": "Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation,A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Monzr M. Al Malki",
"middle_name": "",
"last_name": "",
"org_name": "City of Hope Comprehensive Cancer Center",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233033",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233033",
"events_session": "Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation",
"rest_events_session_count": 2,
"rest_events_session": "A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation",
"events_topic": "Graft Vs Host Disease | Histocompatibility Antigens ",
"rest_events_topic_count": 3,
"rest_events_topic": " Stem Cell Transplantation | Cyclophosphamide | Hematopoietic Stem Cell Transplantation",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1043489362,'FU_HCP_229365');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMonzr M. Al Malki",
"kol_full_name": "Monzr M. Al Malki"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Olaparib | Triple Negative Breast Neoplasms | Chemotherapy | Biopsy, Needle | Breast Neoplasms | Chemotherapy, Adjuvant",
"npi_num": "1609800366",
"hcp_pin_alias": "PAST_HCP_Future Events_318545",
"session_name": "Automated prediction of response to neoadjuvant chemotherapy from digitized H&E slides of pre-treatment core needle biopsies in germline BRCA carriers with HER2-negative breast cancer (TBCRC 031),TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Nadine M. Tung",
"middle_name": "",
"last_name": "",
"org_name": "Beth Israel Deaconess Medical Center",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232298",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232298",
"events_session": "Automated prediction of response to neoadjuvant chemotherapy from digitized H&E slides of pre-treatment core needle biopsies in germline BRCA carriers with HER2-negative breast cancer (TBCRC 031)",
"rest_events_session_count": 1,
"rest_events_session": "TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2",
"events_topic": "Olaparib | Triple Negative Breast Neoplasms ",
"rest_events_topic_count": 4,
"rest_events_topic": " Chemotherapy | Biopsy, Needle | Breast Neoplasms | Chemotherapy, Adjuvant",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1609800366,'PAST_HCP_Future Events_318545');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENadine M. Tung",
"kol_full_name": "Nadine M. Tung"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sarcoma | Doxorubicin | Immunotherapy | Soft Tissue Sarcoma",
"npi_num": "1982994802",
"hcp_pin_alias": "FU_HCP_155371",
"session_name": "Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy,Phase 2a results of SQ3370, a doxorubicin-based click chemistry therapeutic in patients with advanced STS: Planned interim analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Nam Bui",
"middle_name": "",
"last_name": "",
"org_name": "Stanford University",
"Country": "United States",
"Region": "California",
"City": "Palo Alto",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232907",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232907",
"events_session": "Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy",
"rest_events_session_count": 2,
"rest_events_session": "Phase 2a results of SQ3370, a doxorubicin-based click chemistry therapeutic in patients with advanced STS: Planned interim analysis",
"events_topic": "Sarcoma | Doxorubicin ",
"rest_events_topic_count": 2,
"rest_events_topic": " Immunotherapy | Soft Tissue Sarcoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1982994802,'FU_HCP_155371');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENam Bui",
"kol_full_name": "Nam Bui"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Health Policy | Neoplasms",
"npi_num": "1700839263",
"hcp_pin_alias": "FU_HCP_110298",
"session_name": "Impact of Emerging Legislation on Cancer Care—A Community Oncologist's Perspective,Shaping the Future of Cancer Care: Diverse Perspectives on Emerging Health Policies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Natalie R. Dickson",
"middle_name": "",
"last_name": "",
"org_name": "Tennessee Oncology",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231983",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231983",
"events_session": "Impact of Emerging Legislation on Cancer Care—A Community Oncologist's Perspective",
"rest_events_session_count": 1,
"rest_events_session": "Shaping the Future of Cancer Care: Diverse Perspectives on Emerging Health Policies",
"events_topic": "Health Policy | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700839263,'FU_HCP_110298');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENatalie R. Dickson",
"kol_full_name": "Natalie R. Dickson"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Gastrointestinal Microbiome | Sitravatinib | Nivolumab | Dysbiosis | Immune Checkpoint Inhibitors | Carcinoma, Renal Cell",
"npi_num": "1952920019",
"hcp_pin_alias": "FU_HCP_281822",
"session_name": "Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC),A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Nazli Dizman",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232585",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232585",
"events_session": "Impact of CBM588 on gut microbiome composition and dysbiosis in patients receiving frontline immune checkpoint inhibitor (ICI) combinations for metastatic renal cell carcinoma (mRCC)",
"rest_events_session_count": 1,
"rest_events_session": "A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC)",
"events_topic": "Gastrointestinal Microbiome | Sitravatinib ",
"rest_events_topic_count": 4,
"rest_events_topic": " Nivolumab | Dysbiosis | Immune Checkpoint Inhibitors | Carcinoma, Renal Cell",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1952920019,'FU_HCP_281822');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENazli Dizman",
"kol_full_name": "Nazli Dizman"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Poly(ADP-ribose) Polymerase Inhibitors | Breast Neoplasms | Immunotherapy | Triple Negative Breast Neoplasms | Autoimmune Diseases",
"npi_num": "1669793014",
"hcp_pin_alias": "PAST_HCP_Onco_232453",
"session_name": "Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2 mutation identified in a cell-free DNA or tumor tissue genotyping assay,Immune related adverse events in patients with breast cancer and autoimmune disease treated with immunotherapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Neelima Vidula",
"middle_name": "",
"last_name": "",
"org_name": "Massachusetts General Hospital Cancer Center, Harvard Medical School",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232702",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232702",
"events_session": "Phase II study of a PARP inhibitor",
"rest_events_session_count": 3,
"rest_events_session": " talazoparib, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2 mutation identified in a cell-free DNA or tumor tissue genotyping assay,Immune related adverse events in patients with breast cancer and autoimmune disease treated with immunotherapy",
"events_topic": "Poly(ADP-ribose) Polymerase Inhibitors | Breast Neoplasms ",
"rest_events_topic_count": 3,
"rest_events_topic": " Immunotherapy | Triple Negative Breast Neoplasms | Autoimmune Diseases",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1669793014,'PAST_HCP_Onco_232453');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENeelima Vidula",
"kol_full_name": "Neelima Vidula"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms | Exercise Therapy | Alcohol Drinking | Diet, Plant-Based",
"npi_num": "1194987230",
"hcp_pin_alias": "PAST_HCP_Onco_231499",
"session_name": "Weight, Exercise, and Alcohol Consumption: Mitigating Risk of Recurrence Through Lifestyle Modification,Effects of plant-based diet (PBD) and exercise therapy (Ex) on weight and body composition in patients with primary hormone receptor (HR) positive breast cancer: A phase 2 randomized controlled trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Neil M. Iyengar",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232622",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232622",
"events_session": "Weight",
"rest_events_session_count": 3,
"rest_events_session": " Exercise, and Alcohol Consumption: Mitigating Risk of Recurrence Through Lifestyle Modification,Effects of plant-based diet (PBD) and exercise therapy (Ex) on weight and body composition in patients with primary hormone receptor (HR) positive breast cancer: A phase 2 randomized controlled trial",
"events_topic": "Breast Neoplasms | Exercise Therapy ",
"rest_events_topic_count": 2,
"rest_events_topic": " Alcohol Drinking | Diet, Plant-Based",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1194987230,'PAST_HCP_Onco_231499');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENeil M. Iyengar",
"kol_full_name": "Neil M. Iyengar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1609998707",
"hcp_pin_alias": "PAST_HCP_Onco_231592",
"session_name": "Breast Cancer – Local/Regional/Adjuvant: Program Commitee,Breast Cancer—Local/Regional/Adjuvant",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Norah Lynn Henry",
"middle_name": "",
"last_name": "",
"org_name": "University of Michigan Rogel Cancer Center",
"Country": "United States",
"Region": "Michigan",
"City": "Ann Arbor",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232090",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232090",
"events_session": "Breast Cancer – Local/Regional/Adjuvant: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Breast Cancer—Local/Regional/Adjuvant",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1609998707,'PAST_HCP_Onco_231592');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENorah Lynn Henry",
"kol_full_name": "Norah Lynn Henry"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Squamous Cell Carcinoma Of Head And Neck | Head And Neck Neoplasms | Enfortumab Vedotin",
"npi_num": "1245556851",
"hcp_pin_alias": "FU_HCP_100379",
"session_name": "Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial,Head and Neck Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Paul Swiecicki",
"middle_name": "",
"last_name": "",
"org_name": "Department of Internal Medicine, Division of Hematology/Oncology,University of Michigan Rogel Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232017",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232017",
"events_session": "Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial",
"rest_events_session_count": 1,
"rest_events_session": "Head and Neck Cancer",
"events_topic": "Pembrolizumab | Squamous Cell Carcinoma Of Head And Neck ",
"rest_events_topic_count": 2,
"rest_events_topic": " Head And Neck Neoplasms | Enfortumab Vedotin",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1245556851,'FU_HCP_100379');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPaul Swiecicki",
"kol_full_name": "Paul Swiecicki"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sorafenib | Fibromatosis, Aggressive | Oncolytic Virotherapy",
"npi_num": "1447816202",
"hcp_pin_alias": "FU_HCP_284964",
"session_name": "SH2B3 mutation as a potential resistance mechanism to oncolytic virus therapy,Sorafenib treatment duration in desmoid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Philippos Apolinario Costa",
"middle_name": "",
"last_name": "",
"org_name": "Yale New Haven Hospital",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232914",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232914",
"events_session": "SH2B3 mutation as a potential resistance mechanism to oncolytic virus therapy",
"rest_events_session_count": 1,
"rest_events_session": "Sorafenib treatment duration in desmoid tumors",
"events_topic": "Sorafenib | Fibromatosis, Aggressive ",
"rest_events_topic_count": 1,
"rest_events_topic": " Oncolytic Virotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1447816202,'FU_HCP_284964');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPhilippos Apolinario Costa",
"kol_full_name": "Philippos Apolinario Costa"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sarcoma",
"npi_num": "1407072838",
"hcp_pin_alias": "FU_HCP_186817",
"session_name": "Sarcoma: Program Commitee,Sarcoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Priscilla Merriam",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute, Harvard Medical School",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231980",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231980",
"events_session": "Sarcoma: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Sarcoma",
"events_topic": "Sarcoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1407072838,'FU_HCP_186817');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPriscilla Merriam",
"kol_full_name": "Priscilla Merriam"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Patient Selection | Durvalumab | Neoadjuvant Therapy | Datopotamab Deruxtecan",
"npi_num": "1760778526",
"hcp_pin_alias": "FU_HCP_100315",
"session_name": "Who and What?: Neoadjuvant Strategies and Patient Selection in 2024,Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY22 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Rebecca Arielle Shatsky",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232144",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232144",
"events_session": "Who and What?: Neoadjuvant Strategies and Patient Selection in 2024",
"rest_events_session_count": 1,
"rest_events_session": "Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY22 trial",
"events_topic": "Patient Selection | Durvalumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Neoadjuvant Therapy | Datopotamab Deruxtecan",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1760778526,'FU_HCP_100315');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERebecca Arielle Shatsky",
"kol_full_name": "Rebecca Arielle Shatsky"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pertuzumab | Trastuzumab | Inavolisib | Triple Negative Breast Neoplasms",
"npi_num": "1508146721",
"hcp_pin_alias": "FU_HCP_116359",
"session_name": "INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC),Real-world treatment patterns, healthcare resource utilization and costs of care among newly-diagnosed patients with HR+/HER2- metastatic breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Reva K Basho",
"middle_name": "",
"last_name": "",
"org_name": "Ellison Institute of Technology",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232692",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232692",
"events_session": "INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated",
"rest_events_session_count": 3,
"rest_events_session": " HER2-positive advanced breast cancer (HER2+ aBC),Real-world treatment patterns, healthcare resource utilization and costs of care among newly-diagnosed patients with HR+/HER2- metastatic breast cancer",
"events_topic": "Pertuzumab | Trastuzumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Inavolisib | Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1508146721,'FU_HCP_116359');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EReva K Basho",
"kol_full_name": "Reva K Basho"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy | Randomized Controlled Trials As Topic | Telemedicine | Neoplasms",
"npi_num": "1770800732",
"hcp_pin_alias": "FU_HCP_0002765",
"session_name": "Patient-reported experience with an immunotherapy telehealth platform,Acute care and overall survival results of a randomized trial of a virtual health intervention during routine cancer treatment",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Robert Michael Daly",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232103",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232103",
"events_session": "Patient-reported experience with an immunotherapy telehealth platform",
"rest_events_session_count": 1,
"rest_events_session": "Acute care and overall survival results of a randomized trial of a virtual health intervention during routine cancer treatment",
"events_topic": "Immunotherapy | Randomized Controlled Trials As Topic ",
"rest_events_topic_count": 2,
"rest_events_topic": " Telemedicine | Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1770800732,'FU_HCP_0002765');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERobert Michael Daly",
"kol_full_name": "Robert Michael Daly"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Cretostimogene Grenadenorepvec | Urinary Bladder Neoplasms",
"npi_num": "1841515525",
"hcp_pin_alias": "FU_HCP_45588",
"session_name": "Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ,Outcomes of patients with bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer who demonstrated nonresponse to pembrolizumab in KEYNOTE-057: A post hoc analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Roger Li",
"middle_name": "",
"last_name": "",
"org_name": "H. Lee Moffitt Cancer Center and Research Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232602",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232602",
"events_session": "Final results of CORE-001: A phase-2",
"rest_events_session_count": 3,
"rest_events_session": " single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ,Outcomes of patients with bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer who demonstrated nonresponse to pembrolizumab in KEYNOTE-057: A post hoc analysis",
"events_topic": "Pembrolizumab | Cretostimogene Grenadenorepvec ",
"rest_events_topic_count": 1,
"rest_events_topic": " Urinary Bladder Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1841515525,'FU_HCP_45588');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERoger Li",
"kol_full_name": "Roger Li"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hematologic Neoplasms",
"npi_num": "1518499334",
"hcp_pin_alias": "FU_HCP_5403347",
"session_name": "A multicenter analysis evaluating educational resources utilized by hematology/oncology fellows (HOF),A multicenter analysis of didactic curricula in a hematology oncology fellowship program",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ronak Mistry",
"middle_name": "",
"last_name": "",
"org_name": "Vanderbilt University Medical Center",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232263",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232263",
"events_session": "A multicenter analysis evaluating educational resources utilized by hematology/oncology fellows (HOF)",
"rest_events_session_count": 1,
"rest_events_session": "A multicenter analysis of didactic curricula in a hematology oncology fellowship program",
"events_topic": "Hematologic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1518499334,'FU_HCP_5403347');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERonak Mistry",
"kol_full_name": "Ronak Mistry"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy, Adoptive | Pembrolizumab | Clinical Trials As Topic | Melanoma | Lymphocytes, Tumor-Infiltrating | Lifileucel | Solid Tumor | Immune Checkpoint Inhibitors",
"npi_num": "1760677108",
"hcp_pin_alias": "FU_HCP_153994",
"session_name": "Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A,Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sajeve Samuel Thomas",
"middle_name": "",
"last_name": "",
"org_name": "Orlando Health Cancer Institute",
"Country": "United States",
"Region": "Florida",
"City": "Orlando",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232996",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232996",
"events_session": "Efficacy and safety of lifileucel",
"rest_events_session_count": 6,
"rest_events_session": " an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A,Initial data from a phase 1, first-in-human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors",
"events_topic": "Immunotherapy, Adoptive | Pembrolizumab ",
"rest_events_topic_count": 6,
"rest_events_topic": " Clinical Trials As Topic | Melanoma | Lymphocytes, Tumor-Infiltrating | Lifileucel | Solid Tumor | Immune Checkpoint Inhibitors",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1760677108,'FU_HCP_153994');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESajeve Samuel Thomas",
"kol_full_name": "Sajeve Samuel Thomas"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy, Adoptive | Solid Tumor | KRASG12D Inhibitor MRTX1133 | Loss Of Heterozygosity | Mesothelin | Leukocytes",
"npi_num": "1730454034",
"hcp_pin_alias": "FU_HCP_5403374",
"session_name": "EVEREST-2: A seamless phase 1/2 study of A2B694, a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH),An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT‑112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Salman Rafi Punekar",
"middle_name": "",
"last_name": "",
"org_name": "Perlmutter Cancer Center, NYU Langone Health",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233032",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233032",
"events_session": "EVEREST-2: A seamless phase 1/2 study of A2B694",
"rest_events_session_count": 7,
"rest_events_session": " a mesothelin (MSLN) logic-gated Tmod CAR T-cell therapy, in patients with solid tumors that show MSLN expression and human leukocyte antigen (HLA)-A*02 loss of heterozygosity (LOH),An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT‑112 in human leukocyte antigen-C*08:02–positive adult patients with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation",
"events_topic": "Immunotherapy, Adoptive | Solid Tumor ",
"rest_events_topic_count": 4,
"rest_events_topic": " KRASG12D Inhibitor MRTX1133 | Loss Of Heterozygosity | Mesothelin | Leukocytes",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1730454034,'FU_HCP_5403374');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESalman Rafi Punekar",
"kol_full_name": "Salman Rafi Punekar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hematologic Neoplasms | Neoplasms",
"npi_num": "1063754448",
"hcp_pin_alias": "FU_HCP_110405",
"session_name": "Formation and evaluation of the ASCO medical education community of practice (Med Ed CoP),Observing attending physician teaching behaviors during inpatient hematology/oncology consultation",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sam Brondfield",
"middle_name": "",
"last_name": "",
"org_name": "The Regents of the University of California, San Francisco",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232260",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232260",
"events_session": "Formation and evaluation of the ASCO medical education community of practice (Med Ed CoP)",
"rest_events_session_count": 1,
"rest_events_session": "Observing attending physician teaching behaviors during inpatient hematology/oncology consultation",
"events_topic": "Hematologic Neoplasms | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1063754448,'FU_HCP_110405');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESam Brondfield",
"kol_full_name": "Sam Brondfield"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Gastrointestinal Microbiome | Endocrine Therapy | Carcinoma, Intraductal, Noninfiltrating | Breast Neoplasms | Triple Negative Breast Neoplasms",
"npi_num": "1215203013",
"hcp_pin_alias": "FU_HCP_39991",
"session_name": "The immunomodulatory impacts of endocrine therapy on host immunity in early-stage hormone receptor positive, HER2 negative breast cancer,The landscape of the intestinal microbiome amongst patients with newly diagnosed invasive breast cancer (BC) and ductal carcinoma in situ (DCIS)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sarah L Sammons",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232626",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232626",
"events_session": "The immunomodulatory impacts of endocrine therapy on host immunity in early-stage hormone receptor positive",
"rest_events_session_count": 2,
"rest_events_session": " HER2 negative breast cancer,The landscape of the intestinal microbiome amongst patients with newly diagnosed invasive breast cancer (BC) and ductal carcinoma in situ (DCIS)",
"events_topic": "Gastrointestinal Microbiome | Endocrine Therapy ",
"rest_events_topic_count": 3,
"rest_events_topic": " Carcinoma, Intraductal, Noninfiltrating | Breast Neoplasms | Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1215203013,'FU_HCP_39991');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESarah L Sammons",
"kol_full_name": "Sarah L Sammons"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Programmed Cell Death 1 Receptor | Gemcitabine | Carcinoma, Transitional Cell | Eribulin",
"npi_num": "1316104797",
"hcp_pin_alias": "FU_HCP_100268",
"session_name": "A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design,Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sarmad Sadeghi",
"middle_name": "",
"last_name": "",
"org_name": "Norris Comprehensive Cancer Center, University of Southern California",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232596",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232596",
"events_session": "A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design",
"rest_events_session_count": 1,
"rest_events_session": "Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC)",
"events_topic": "Programmed Cell Death 1 Receptor | Gemcitabine ",
"rest_events_topic_count": 2,
"rest_events_topic": " Carcinoma, Transitional Cell | Eribulin",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1316104797,'FU_HCP_100268');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESarmad Sadeghi",
"kol_full_name": "Sarmad Sadeghi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sexual And Gender Minorities | Neoplasms",
"npi_num": "1114183795",
"hcp_pin_alias": "FU_HCP_100049",
"session_name": "Disparities uncovered: LGBTQ+ patients report on their cancer care journey,Beyond the binary: A transformative implementation science initiative to improve LGBTQ+ cancer care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Shail Maingi",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232277",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232277",
"events_session": "Disparities uncovered: LGBTQ+ patients report on their cancer care journey",
"rest_events_session_count": 1,
"rest_events_session": "Beyond the binary: A transformative implementation science initiative to improve LGBTQ+ cancer care",
"events_topic": "Sexual And Gender Minorities | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1114183795,'FU_HCP_100049');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShail Maingi",
"kol_full_name": "Shail Maingi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Irinotecan | Solid Tumor | Topotecan",
"npi_num": "1316444169",
"hcp_pin_alias": "FU_HCP_5403369",
"session_name": "A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation,A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Shannon Stockton",
"middle_name": "",
"last_name": "",
"org_name": "Vanderbilt-Ingram Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232951",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232951",
"events_session": "A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation",
"rest_events_session_count": 1,
"rest_events_session": "A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation",
"events_topic": "Irinotecan | Solid Tumor ",
"rest_events_topic_count": 1,
"rest_events_topic": " Topotecan",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1316444169,'FU_HCP_5403369');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShannon Stockton",
"kol_full_name": "Shannon Stockton"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hodgkin Disease",
"npi_num": "1063496792",
"hcp_pin_alias": "FU_HCP_187230",
"session_name": "Overview of Advances in Treatment of Hodgkin Lymphoma for Children, Adolescents, and Young Adults,Pediatric Hodgkin Lymphoma Treatment: Paving the Way for a Standard of Care and Shared Decision-Making",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sharon M. Castellino",
"middle_name": "",
"last_name": "",
"org_name": "Emory School of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232010",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232010",
"events_session": "Overview of Advances in Treatment of Hodgkin Lymphoma for Children",
"rest_events_session_count": 3,
"rest_events_session": " Adolescents, and Young Adults,Pediatric Hodgkin Lymphoma Treatment: Paving the Way for a Standard of Care and Shared Decision-Making",
"events_topic": "Hodgkin Disease",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1063496792,'FU_HCP_187230');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESharon M. Castellino",
"kol_full_name": "Sharon M. Castellino"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Translational Research, Biomedical",
"npi_num": "1215184577",
"hcp_pin_alias": "FU_HCP_109354",
"session_name": "Quality Care/Health Services Research: Program Commitee,Quality Care/Health Services Research",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sheetal Mehta Kircher",
"middle_name": "",
"last_name": "",
"org_name": "Robert H. Lurie Comprehensive Cancer Center, Northwestern University",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231987",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231987",
"events_session": "Quality Care/Health Services Research: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Quality Care/Health Services Research",
"events_topic": "Translational Research, Biomedical",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1215184577,'FU_HCP_109354');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESheetal Mehta Kircher",
"kol_full_name": "Sheetal Mehta Kircher"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Everolimus | Glucagon-Like Peptide 1 | Alpelisib | Breast Neoplasms",
"npi_num": "1942662127",
"hcp_pin_alias": "FU_HCP_5403344",
"session_name": "Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer,Glucagon-like peptide-1 (GLP-1) agonist use and weight change among patients with breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sherry Shen",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232234",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232234",
"events_session": "Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer",
"rest_events_session_count": 1,
"rest_events_session": "Glucagon-like peptide-1 (GLP-1) agonist use and weight change among patients with breast cancer",
"events_topic": "Everolimus | Glucagon-Like Peptide 1 ",
"rest_events_topic_count": 2,
"rest_events_topic": " Alpelisib | Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1942662127,'FU_HCP_5403344');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESherry Shen",
"kol_full_name": "Sherry Shen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Clinical Trials As Topic | Telisotuzumab Vedotin | Small Cell Lung Carcinoma | Docetaxel | ErbB Receptors | Chemotherapy | Carcinoma, Non-Small-Cell Lung",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403405",
"session_name": "Results of a phase III clinical trial with anti-PDL1 treatment in combination with chemotherapy for extensive stage small cell lung cancer,A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Shun Lu",
"middle_name": "",
"last_name": "",
"org_name": "Department of Shanghai Lung Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232195",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232195",
"events_session": "Results of a phase III clinical trial with anti-PDL1 treatment in combination with chemotherapy for extensive stage small cell lung cancer",
"rest_events_session_count": 3,
"rest_events_session": "A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01)",
"events_topic": "Clinical Trials As Topic | Telisotuzumab Vedotin ",
"rest_events_topic_count": 5,
"rest_events_topic": " Small Cell Lung Carcinoma | Docetaxel | ErbB Receptors | Chemotherapy | Carcinoma, Non-Small-Cell Lung",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403405');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShun Lu",
"kol_full_name": "Shun Lu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sigvotatug Vedotin | Small Cell Lung Carcinoma | Immunoconjugates | Carcinoma, Non-Small-Cell Lung | DLL3 Protein, Human",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403416",
"session_name": "Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001),DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Solange Peters",
"middle_name": "",
"last_name": "",
"org_name": "Centre Hospitalier Universitaire Vaudois",
"Country": "Switzerland",
"Region": "Vaud",
"City": "Lausanne",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232257",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232257",
"events_session": "Efficacy and safety of sigvotatug vedotin",
"rest_events_session_count": 9,
"rest_events_session": " an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001),DAREON-8: A phase I, open-label, dose escalation/expansion trial of the DLL3-targeting T-cell engager, BI 764532, combined with first-line (1L) standard of care (platinum, etoposide, and anti-PD-L1 antibody) in patients (pts) with extensive-stage small cell lung carcinoma (ES-SCLC)",
"events_topic": "Sigvotatug Vedotin | Small Cell Lung Carcinoma ",
"rest_events_topic_count": 3,
"rest_events_topic": " Immunoconjugates | Carcinoma, Non-Small-Cell Lung | DLL3 Protein, Human",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403416');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESolange Peters",
"kol_full_name": "Solange Peters"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Delivery Of Health Care | Neoplasms | Admin. & Management",
"npi_num": "1184736225",
"hcp_pin_alias": "PAST_HCP_Onco_231654",
"session_name": "Care Delivery/Models of Care: Program Commitee,Universal germline testing for cancer susceptibility and actionable noncancer disorders among 19,842 patients: Initial findings from the City of Hope INSPIRE study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Stacy W. Gray",
"middle_name": "",
"last_name": "",
"org_name": "City of Hope Comprehensive Cancer Center",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232233",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232233",
"events_session": "Care Delivery/Models of Care: Program Commitee",
"rest_events_session_count": 2,
"rest_events_session": "Universal germline testing for cancer susceptibility and actionable noncancer disorders among 19,842 patients: Initial findings from the City of Hope INSPIRE study",
"events_topic": "Delivery Of Health Care | Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Admin. & Management",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1184736225,'PAST_HCP_Onco_231654');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EStacy W. Gray",
"kol_full_name": "Stacy W. Gray"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Patient Reported Outcome Measures | Sexual Behavior | Neoplasms",
"npi_num": "1760572937",
"hcp_pin_alias": "FU_HCP_44893",
"session_name": "EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL),EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Stephen J. Freedland",
"middle_name": "",
"last_name": "",
"org_name": "Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Durham VA Medical Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232660",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232660",
"events_session": "EMBARK post hoc analysis of impact of treatment suspension (TxS) on health-related quality of life (HRQoL)",
"rest_events_session_count": 1,
"rest_events_session": "EMBARK post hoc analysis of sexual activity (SA) patient-reported outcomes (PROs) in patients (pts) who were sexually active or interested in sex at baseline (BL)",
"events_topic": "Patient Reported Outcome Measures | Sexual Behavior ",
"rest_events_topic_count": 1,
"rest_events_topic": " Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1760572937,'FU_HCP_44893');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EStephen J. Freedland",
"kol_full_name": "Stephen J. Freedland"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Mental Health | Immunoglobulins | Neoplasm, Residual | B-Cell Acute Lymphoblastic Leukemia | Neoplasms | Bone Marrow Diseases",
"npi_num": "1548644883",
"hcp_pin_alias": "FU_HCP_232004",
"session_name": "Patient reported symptoms after cancer diagnosis and the risk of short- and long-term severe mental health events among adolescents and young adults (AYA): A population-based study,Comparison of immunoglobulin high-throughput sequencing MRD in bone marrow and peripheral blood in pediatric B-ALL: A report from the Children's Oncology Group AALL1731",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sumit Gupta",
"middle_name": "",
"last_name": "",
"org_name": "Division of Haematology/Oncology, The Hospital for Sick Children",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232296",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232296",
"events_session": "Patient reported symptoms after cancer diagnosis and the risk of short- and long-term severe mental health events among adolescents and young adults (AYA): A population-based study",
"rest_events_session_count": 1,
"rest_events_session": "Comparison of immunoglobulin high-throughput sequencing MRD in bone marrow and peripheral blood in pediatric B-ALL: A report from the Children's Oncology Group AALL1731",
"events_topic": "Mental Health | Immunoglobulins ",
"rest_events_topic_count": 4,
"rest_events_topic": " Neoplasm, Residual | B-Cell Acute Lymphoblastic Leukemia | Neoplasms | Bone Marrow Diseases",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1548644883,'FU_HCP_232004');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESumit Gupta",
"kol_full_name": "Sumit Gupta"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Momelotinib | Hemoglobins | Primary Myelofibrosis | Anemia | Neoplasms",
"npi_num": "1790997989",
"hcp_pin_alias": "PAST_HCP_Onco_231652",
"session_name": "Association between hemoglobin (Hb) improvement and patient-reported outcomes (PROs) in patients (pts) with myelofibrosis (MF) and anemia: Post hoc pooled analysis of momelotinib (MMB) phase 3 trials,ASCO Voices",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Thomas William LeBlanc",
"middle_name": "",
"last_name": "",
"org_name": "Duke University School of Medicine",
"Country": "United States",
"Region": "North Carolina",
"City": "Durham",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232097",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232097",
"events_session": "Association between hemoglobin (Hb) improvement and patient-reported outcomes (PROs) in patients (pts) with myelofibrosis (MF) and anemia: Post hoc pooled analysis of momelotinib (MMB) phase 3 trials",
"rest_events_session_count": 1,
"rest_events_session": "ASCO Voices",
"events_topic": "Momelotinib | Hemoglobins ",
"rest_events_topic_count": 3,
"rest_events_topic": " Primary Myelofibrosis | Anemia | Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790997989,'PAST_HCP_Onco_231652');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EThomas William LeBlanc",
"kol_full_name": "Thomas William LeBlanc"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Biomarkers | Palliative Care | Precursor Cell Lymphoblastic Leukemia-Lymphoma",
"npi_num": "1952861155",
"hcp_pin_alias": "FU_HCP_284239",
"session_name": "Discovery of long non-coding RNA biomarkers for prognosis in pediatric acute lymphoblastic leukemia,Impact of palliative care on hospital length of stay and charges in hospitalized patients with cancer at end of life",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Tien-Chan Hsieh",
"middle_name": "",
"last_name": "",
"org_name": "Division of Hematology-Oncology, UMass Chan Medical School",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232210",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232210",
"events_session": "Discovery of long non-coding RNA biomarkers for prognosis in pediatric acute lymphoblastic leukemia",
"rest_events_session_count": 1,
"rest_events_session": "Impact of palliative care on hospital length of stay and charges in hospitalized patients with cancer at end of life",
"events_topic": "Neoplasms | Biomarkers ",
"rest_events_topic_count": 2,
"rest_events_topic": " Palliative Care | Precursor Cell Lymphoblastic Leukemia-Lymphoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1952861155,'FU_HCP_284239');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETien-Chan Hsieh",
"kol_full_name": "Tien-Chan Hsieh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab | Olomorasib | KRASG12D Inhibitor MRTX1133 | Fecal Microbiota Transplantation",
"npi_num": "1639225519",
"hcp_pin_alias": "FU_HCP_155035",
"session_name": "Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC,Phase I/II trial of healthy donor fecal microbiota transplant (hdFMT) in PD-1 relapsed/refractory (R/R) non-small cell lung cancer (NSCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Timothy F. Burns",
"middle_name": "",
"last_name": "",
"org_name": "Division of Hematology/Oncology, University of Pittsburgh",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232188",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232188",
"events_session": "Efficacy and safety of olomorasib (LY3537982)",
"rest_events_session_count": 3,
"rest_events_session": " a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC,Phase I/II trial of healthy donor fecal microbiota transplant (hdFMT) in PD-1 relapsed/refractory (R/R) non-small cell lung cancer (NSCLC)",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab ",
"rest_events_topic_count": 3,
"rest_events_topic": " Olomorasib | KRASG12D Inhibitor MRTX1133 | Fecal Microbiota Transplantation",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1639225519,'FU_HCP_155035');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETimothy F. Burns",
"kol_full_name": "Timothy F. Burns"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Financial Stress | Early Detection Of Cancer | Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403426",
"session_name": "Inpatient healthcare utilization in the first year following a childhood cancer diagnosis: A population-based analysis,Financial toxicity during pediatric cancer therapy: A qualitative analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Timothy James Daeeun Ohlsen",
"middle_name": "",
"last_name": "",
"org_name": "University of Washington",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232396",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232396",
"events_session": "Inpatient healthcare utilization in the first year following a childhood cancer diagnosis: A population-based analysis",
"rest_events_session_count": 1,
"rest_events_session": "Financial toxicity during pediatric cancer therapy: A qualitative analysis",
"events_topic": "Financial Stress | Early Detection Of Cancer ",
"rest_events_topic_count": 1,
"rest_events_topic": " Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403426');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETimothy James Daeeun Ohlsen",
"kol_full_name": "Timothy James Daeeun Ohlsen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Clinical Trials As Topic | Leukemia, Myeloid, Acute",
"npi_num": "1205943701",
"hcp_pin_alias": "FU_HCP_39956",
"session_name": "Options in Relapsed Pediatric Acute Myeloid Leukemia: Conventional Chemotherapy, Commercially Available Targeted Agents, or Novel Clinical Trials,Navigating Treatment Options and Communication in Relapsed Pediatric Acute Myeloid Leukemia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Todd Michael Cooper",
"middle_name": "",
"last_name": "",
"org_name": "Seattle Children's Hospital",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232042",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232042",
"events_session": "Options in Relapsed Pediatric Acute Myeloid Leukemia: Conventional Chemotherapy",
"rest_events_session_count": 3,
"rest_events_session": " Commercially Available Targeted Agents, or Novel Clinical Trials,Navigating Treatment Options and Communication in Relapsed Pediatric Acute Myeloid Leukemia",
"events_topic": "Chemotherapy | Clinical Trials As Topic ",
"rest_events_topic_count": 1,
"rest_events_topic": " Leukemia, Myeloid, Acute",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1205943701,'FU_HCP_39956');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETodd Michael Cooper",
"kol_full_name": "Todd Michael Cooper"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Translational Research, Biomedical",
"npi_num": "1982879797",
"hcp_pin_alias": "FU_HCP_46811",
"session_name": "Quality Care/Health Services Research: Program Commitee,Quality Care/Health Services Research",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Victoria Susana Blinder",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232087",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232087",
"events_session": "Quality Care/Health Services Research: Program Commitee",
"rest_events_session_count": 1,
"rest_events_session": "Quality Care/Health Services Research",
"events_topic": "Translational Research, Biomedical",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1982879797,'FU_HCP_46811');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVictoria Susana Blinder",
"kol_full_name": "Victoria Susana Blinder"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Head And Neck Neoplasms | Cisplatin | Nivolumab | Radiotherapy | Squamous Cell Carcinoma Of Head And Neck | Chemotherapy | Nimotuzumab",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403441",
"session_name": "Long term results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck,Long term results of phase 3 randomized study evaluating the addition of low dose nivolumab to palliative chemotherapy in head and neck cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Vijay Maruti Patil",
"middle_name": "",
"last_name": "",
"org_name": "P.D. Hinduja Hospital",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232558",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232558",
"events_session": "Long term results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone",
"rest_events_session_count": 2,
"rest_events_session": " in locally advanced squamous cell carcinoma of the head and neck,Long term results of phase 3 randomized study evaluating the addition of low dose nivolumab to palliative chemotherapy in head and neck cancer",
"events_topic": "Head And Neck Neoplasms | Cisplatin ",
"rest_events_topic_count": 5,
"rest_events_topic": " Nivolumab | Radiotherapy | Squamous Cell Carcinoma Of Head And Neck | Chemotherapy | Nimotuzumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403441');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVijay Maruti Patil",
"kol_full_name": "Vijay Maruti Patil"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Taletrectinib | Chidamide | Small Cell Lung Carcinoma | Colorectal Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403453",
"session_name": "Efficacy and safety of chidamide in combination with serplulimab and standard third-line treatments in advanced colorectal cancer: A single arm, exploratory phase 2 trial,Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Wei Li",
"middle_name": "",
"last_name": "",
"org_name": "Tongji University School of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232755",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232755",
"events_session": "Efficacy and safety of chidamide in combination with serplulimab and standard third-line treatments in advanced colorectal cancer: A single arm",
"rest_events_session_count": 2,
"rest_events_session": " exploratory phase 2 trial,Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study",
"events_topic": "Taletrectinib | Chidamide ",
"rest_events_topic_count": 2,
"rest_events_topic": " Small Cell Lung Carcinoma | Colorectal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403453');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWei Li",
"kol_full_name": "Wei Li"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoadjuvant Therapy | Rectal Neoplasms | Chemoradiotherapy | Leukemia, Lymphocytic, Chronic, B-Cell",
"npi_num": "1275627820",
"hcp_pin_alias": "FU_HCP_100451",
"session_name": "Association between treatment (tx) response and PFS and OS in R/R chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A 12-month landmark (LM) meta-analysis,Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Xin Wang",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232272",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232272",
"events_session": "Association between treatment (tx) response and PFS and OS in R/R chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL): A 12-month landmark (LM) meta-analysis",
"rest_events_session_count": 4,
"rest_events_session": "Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial",
"events_topic": "Neoadjuvant Therapy | Rectal Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Chemoradiotherapy | Leukemia, Lymphocytic, Chronic, B-Cell",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1275627820,'FU_HCP_100451');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EXin Wang",
"kol_full_name": "Xin Wang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lung Neoplasms | Carcinoma, Non-Small-Cell Lung | ErbB Receptors | Tyrosine Kinase Inhibitors | Furmonertinib",
"npi_num": "1720399074",
"hcp_pin_alias": "FU_HCP_44575",
"session_name": "Incorporating Tyrosine Kinase Inhibitors Into Early-Stage Lung Cancer,FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Xiuning Le",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232200",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232200",
"events_session": "Incorporating Tyrosine Kinase Inhibitors Into Early-Stage Lung Cancer",
"rest_events_session_count": 1,
"rest_events_session": "FURTHER: A global study to evaluate furmonertinib in patients with EGFR mutant NSCLC including uncommon EGFR mutations (FURMO-002)",
"events_topic": "Lung Neoplasms | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 3,
"rest_events_topic": " ErbB Receptors | Tyrosine Kinase Inhibitors | Furmonertinib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1720399074,'FU_HCP_44575');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EXiuning Le",
"kol_full_name": "Xiuning Le"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptors, Chimeric Antigen | Race Factors | Triple Negative Breast Neoplasms",
"npi_num": "1578981114",
"hcp_pin_alias": "FU_HCP_43286",
"session_name": "Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial,A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yara Abdou",
"middle_name": "",
"last_name": "",
"org_name": "The University of North Carolina at Chapel Hill",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233035",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233035",
"events_session": "Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial",
"rest_events_session_count": 2,
"rest_events_session": "A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors",
"events_topic": "Receptors, Chimeric Antigen | Race Factors ",
"rest_events_topic_count": 1,
"rest_events_topic": " Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1578981114,'FU_HCP_43286');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYara Abdou",
"kol_full_name": "Yara Abdou"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Epcoritamab | Lymphoma, Large B-Cell, Diffuse",
"npi_num": "1043659857",
"hcp_pin_alias": "FU_HCP_99892",
"session_name": "Extended follow-up results beyond 25 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL),Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yasmin Karimi",
"middle_name": "",
"last_name": "",
"org_name": "University of Michigan Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232373",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232373",
"events_session": "Extended follow-up results beyond 25 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)",
"rest_events_session_count": 1,
"rest_events_session": "Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)",
"events_topic": "Epcoritamab | Lymphoma, Large B-Cell, Diffuse",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1043659857,'FU_HCP_99892');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYasmin Karimi",
"kol_full_name": "Yasmin Karimi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Precursor Cell Lymphoblastic Leukemia-Lymphoma",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403428",
"session_name": "Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia,Reasons for unmet care needs in older adults with cancer: Analyses from the 2015–2019 National Health and Aging Trends Study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ying Wang",
"middle_name": "",
"last_name": "",
"org_name": "University of Rocheser Medical Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232410",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232410",
"events_session": "Phase I study of CN201",
"rest_events_session_count": 3,
"rest_events_session": " a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia,Reasons for unmet care needs in older adults with cancer: Analyses from the 2015–2019 National Health and Aging Trends Study",
"events_topic": "Neoplasms | Precursor Cell Lymphoblastic Leukemia-Lymphoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403428');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYing Wang",
"kol_full_name": "Ying Wang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Circulating Tumor DNA | Neoplasm, Residual | Biomarkers",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403469",
"session_name": "Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in patients with resected stage II and III colorectal cancer: A subset analysis from the GALAXY study in CIRCULATE-Japan,Prognostic and predictive value of ctDNA-based MRD and actionable biomarkers in patients with resectable colorectal cancer: CIRCULATE-Japan GALAXY",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yoshiaki Nakamura",
"middle_name": "",
"last_name": "",
"org_name": "Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232889",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232889",
"events_session": "Longitudinal clinical performance of a novel tumor-naive minimal residual disease assay in patients with resected stage II and III colorectal cancer: A subset analysis from the GALAXY study in CIRCULATE-Japan",
"rest_events_session_count": 1,
"rest_events_session": "Prognostic and predictive value of ctDNA-based MRD and actionable biomarkers in patients with resectable colorectal cancer: CIRCULATE-Japan GALAXY",
"events_topic": "Colorectal Neoplasms | Circulating Tumor DNA ",
"rest_events_topic_count": 2,
"rest_events_topic": " Neoplasm, Residual | Biomarkers",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403469');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYoshiaki Nakamura",
"kol_full_name": "Yoshiaki Nakamura"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Neoplasms | Osimertinib | Programmed Cell Death 1 Receptor | Carboplatin | Chemotherapy",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403406",
"session_name": "Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study,TOP: A phase III, multicentre, randomized controlled study comparing osimertinib in combination with carboplatin and pemetrexed to osimertinib monotherapy for untreated patients with advanced non-squamous (Non-sq) non-small cell lung cancer (NSCLC) with concurrent EGFR and TP53 mutations",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yunpeng Yang",
"middle_name": "",
"last_name": "",
"org_name": "State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "2",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232198",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232198",
"events_session": "Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study",
"rest_events_session_count": 3,
"rest_events_session": "TOP: A phase III, multicentre, randomized controlled study comparing osimertinib in combination with carboplatin and pemetrexed to osimertinib monotherapy for untreated patients with advanced non-squamous (Non-sq) non-small cell lung cancer (NSCLC) with concurrent EGFR and TP53 mutations",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Neoplasms ",
"rest_events_topic_count": 4,
"rest_events_topic": " Osimertinib | Programmed Cell Death 1 Receptor | Carboplatin | Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403406');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYunpeng Yang",
"kol_full_name": "Yunpeng Yang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Immunotherapy",
"npi_num": "1699020560",
"hcp_pin_alias": "FU_HCP_57149",
"session_name": "Enhancing inpatient chemo/immunotherapy stewardship: A novel scoring rubric approach to optimize utilization and reduce costs",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Aarti Sonia Bhardwaj",
"middle_name": "",
"last_name": "",
"org_name": "Icahn School of Medicine at Mount Sinai",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232415",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232415",
"events_session": "Enhancing inpatient chemo/immunotherapy stewardship: A novel scoring rubric approach to optimize utilization and reduce costs",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Chemotherapy | Immunotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1699020560,'FU_HCP_57149');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAarti Sonia Bhardwaj",
"kol_full_name": "Aarti Sonia Bhardwaj"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Urinary Bladder Neoplasms | Health Status Disparities",
"npi_num": "1851951511",
"hcp_pin_alias": "FU_HCP_283179",
"session_name": "Disparities in trends in bladder cancer mortality between urban and rural patients: A 2000-2020 analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Abdul Rahman Al Armashi",
"middle_name": "",
"last_name": "",
"org_name": "Case Western Reserve University",
"Country": "United States",
"Region": "Ohio",
"City": "Cleveland",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232598",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232598",
"events_session": "Disparities in trends in bladder cancer mortality between urban and rural patients: A 2000-2020 analysis",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Urinary Bladder Neoplasms | Health Status Disparities",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1851951511,'FU_HCP_283179');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAbdul Rahman Al Armashi",
"kol_full_name": "Abdul Rahman Al Armashi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Myeloid Malignancy",
"npi_num": "1659789634",
"hcp_pin_alias": "FU_HCP_232183",
"session_name": "Therapy-related myeloid neoplasm risk score (TMNRS): A convenient clinical score for TMN risk assessment at presentation in adult patients (pts) with cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Abhay Singh",
"middle_name": "",
"last_name": "",
"org_name": "Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232421",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232421",
"events_session": "Therapy-related myeloid neoplasm risk score (TMNRS): A convenient clinical score for TMN risk assessment at presentation in adult patients (pts) with cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Myeloid Malignancy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1659789634,'FU_HCP_232183');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAbhay Singh",
"kol_full_name": "Abhay Singh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Positron-Emission Tomography | Prostatic Neoplasms",
"npi_num": "1760612808",
"hcp_pin_alias": "PAST_HCP_Future Events_316451",
"session_name": "Veterans Affairs seamless phase II/III randomized trial of standard systemic therapy with or without PET-directed local therapy for oligometastatic prostate cancer (VA STARPORT)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Abhishek A Solanki",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232671",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232671",
"events_session": "Veterans Affairs seamless phase II/III randomized trial of standard systemic therapy with or without PET-directed local therapy for oligometastatic prostate cancer (VA STARPORT)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Positron-Emission Tomography | Prostatic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1760612808,'PAST_HCP_Future Events_316451');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAbhishek A Solanki",
"kol_full_name": "Abhishek A Solanki"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Central Nervous System Neoplasms",
"npi_num": "1740416973",
"hcp_pin_alias": "PAST_HCP_CNS_215476",
"session_name": "Advancing Trial Design: Illuminating Tumor Evolution in Central Nervous System Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Adrienne Ann Boire",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232061",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232061",
"events_session": "Advancing Trial Design: Illuminating Tumor Evolution in Central Nervous System Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Central Nervous System Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1740416973,'PAST_HCP_CNS_215476');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAdrienne Ann Boire",
"kol_full_name": "Adrienne Ann Boire"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms | Paclitaxel | Trastuzumab | Pertuzumab",
"npi_num": "1922392042",
"hcp_pin_alias": "FU_HCP_232416",
"session_name": "Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Adrienne Gropper Waks",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute, Harvard Medical School",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232631",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232631",
"events_session": "Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Triple Negative Breast Neoplasms | Paclitaxel ",
"rest_events_topic_count": 2,
"rest_events_topic": " Trastuzumab | Pertuzumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1922392042,'FU_HCP_232416');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAdrienne Gropper Waks",
"kol_full_name": "Adrienne Gropper Waks"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Retroperitoneal Neoplasms",
"npi_num": "1649234121",
"hcp_pin_alias": "FU_HCP_283615",
"session_name": "Management of relapsed stage I nonseminomatous germ-cell tumor with retroperitoneal only relapse",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ahmed Bilal Khalid",
"middle_name": "",
"last_name": "",
"org_name": "Indiana University School of Medicine",
"Country": "United States",
"Region": "Indiana",
"City": "Indianapolis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232645",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232645",
"events_session": "Management of relapsed stage I nonseminomatous germ-cell tumor with retroperitoneal only relapse",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Retroperitoneal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1649234121,'FU_HCP_283615');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAhmed Bilal Khalid",
"kol_full_name": "Ahmed Bilal Khalid"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Palliative Care",
"npi_num": "1124361712",
"hcp_pin_alias": "FU_HCP_232162",
"session_name": "Palliative Care Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Akanksha Sharma",
"middle_name": "",
"last_name": "",
"org_name": "Pacific Neuroscience Institute",
"Country": "United States",
"Region": "California",
"City": "Santa Monica",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232508",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232508",
"events_session": "Palliative Care Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Palliative Care",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1124361712,'FU_HCP_232162');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAkanksha Sharma",
"kol_full_name": "Akanksha Sharma"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Palliative Care | Healthcare Disparities | Breast Neoplasms",
"npi_num": "1386211191",
"hcp_pin_alias": "FU_HCP_394714",
"session_name": "Palliative care utilization and disparities in deceased patients with breast cancer in US hospitals: A retrospective study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Akshit Chitkara",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233053",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233053",
"events_session": "Palliative care utilization and disparities in deceased patients with breast cancer in US hospitals: A retrospective study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Palliative Care | Healthcare Disparities ",
"rest_events_topic_count": 1,
"rest_events_topic": " Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1386211191,'FU_HCP_394714');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAkshit Chitkara",
"kol_full_name": "Akshit Chitkara"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1417945049",
"hcp_pin_alias": "FU_HCP_41834",
"session_name": "Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Alexandra Thomas",
"middle_name": "",
"last_name": "",
"org_name": "Duke Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232629",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232629",
"events_session": "Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1417945049,'FU_HCP_41834');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAlexandra Thomas",
"kol_full_name": "Alexandra Thomas"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hypomethylating Agents | Venetoclax | Leukemia, Myeloid, Acute",
"npi_num": "1669045514",
"hcp_pin_alias": "FU_HCP_232261",
"session_name": "A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Alexandre Bazinet",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233112",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233112",
"events_session": "A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Hypomethylating Agents | Venetoclax ",
"rest_events_topic_count": 1,
"rest_events_topic": " Leukemia, Myeloid, Acute",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1669045514,'FU_HCP_232261');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAlexandre Bazinet",
"kol_full_name": "Alexandre Bazinet"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Palbociclib | Endocrine Therapy | Triple Negative Breast Neoplasms",
"npi_num": "1275192932",
"hcp_pin_alias": "FU_HCP_5403362",
"session_name": "A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Alexis Ann LeVee",
"middle_name": "",
"last_name": "",
"org_name": "City of Hope Comprehensive Cancer Center",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232682",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232682",
"events_session": "A phase I/II trial of palbociclib",
"rest_events_session_count": 2,
"rest_events_session": " pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling",
"events_topic": "Pembrolizumab | Palbociclib ",
"rest_events_topic_count": 2,
"rest_events_topic": " Endocrine Therapy | Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1275192932,'FU_HCP_5403362');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAlexis Ann LeVee",
"kol_full_name": "Alexis Ann LeVee"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ovarian Neoplasms",
"npi_num": "1407299530",
"hcp_pin_alias": "FU_HCP_99909",
"session_name": "Safety, efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic ovarian cancer: Results from a multi-center multi-country phase 1/2a expansion cohort",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ali Raza Khaki",
"middle_name": "",
"last_name": "",
"org_name": "Stanford University",
"Country": "United States",
"Region": "California",
"City": "Palo Alto",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232431",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232431",
"events_session": "Safety",
"rest_events_session_count": 4,
"rest_events_session": " efficacy, and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced or metastatic ovarian cancer: Results from a multi-center multi-country phase 1/2a expansion cohort",
"events_topic": "Ovarian Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1407299530,'FU_HCP_99909');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAli Raza Khaki",
"kol_full_name": "Ali Raza Khaki"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy, Adjuvant | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1609305614",
"hcp_pin_alias": "FU_HCP_284783",
"session_name": "Multi-institution real world analysis of patients with non-small cell lung cancer (NSCLC) treated with standard of care (SOC) neoadjuvant chemo-immunotherapy (chemoIO)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Alissa Jamie Cooper",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232240",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232240",
"events_session": "Multi-institution real world analysis of patients with non-small cell lung cancer (NSCLC) treated with standard of care (SOC) neoadjuvant chemo-immunotherapy (chemoIO)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Chemotherapy, Adjuvant | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1609305614,'FU_HCP_284783');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAlissa Jamie Cooper",
"kol_full_name": "Alissa Jamie Cooper"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lymphoma, Large B-Cell, Diffuse | Immunotherapy, Adoptive | Epcoritamab",
"npi_num": "1003347097",
"hcp_pin_alias": "FU_HCP_386560",
"session_name": "Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Allison Marie Bock",
"middle_name": "",
"last_name": "",
"org_name": "Huntsman Cancer Institute/University of Utah",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232391",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232391",
"events_session": "Multicenter",
"rest_events_session_count": 1,
"rest_events_session": " randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T)",
"events_topic": "Lymphoma, Large B-Cell, Diffuse | Immunotherapy, Adoptive ",
"rest_events_topic_count": 1,
"rest_events_topic": " Epcoritamab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1003347097,'FU_HCP_386560');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAllison Marie Bock",
"kol_full_name": "Allison Marie Bock"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colonoscopy | Artificial Intelligence",
"npi_num": "1922250281",
"hcp_pin_alias": "FU_HCP_284122",
"session_name": "AI virtual patient navigation to promote re-engagement of US inner city patients nonadherent with colonoscopy appointments: A quality improvement initiative",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Alyson B. Moadel",
"middle_name": "",
"last_name": "",
"org_name": "Montefiore Einstein Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233088",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233088",
"events_session": "AI virtual patient navigation to promote re-engagement of US inner city patients nonadherent with colonoscopy appointments: A quality improvement initiative",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colonoscopy | Artificial Intelligence",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1922250281,'FU_HCP_284122');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAlyson B. Moadel",
"kol_full_name": "Alyson B. Moadel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptors, Somatostatin | Neuroendocrine Tumors",
"npi_num": "1902193147",
"hcp_pin_alias": "FU_HCP_46052",
"session_name": "A phase II randomized control trial of triapine plus lutetium 177 DOTATATE versus lutetium 177 DOTATATE alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Aman Chauhan",
"middle_name": "",
"last_name": "",
"org_name": "Sylvester Comprehensive Cancer Center, University of Miami",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232860",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232860",
"events_session": "A phase II randomized control trial of triapine plus lutetium 177 DOTATATE versus lutetium 177 DOTATATE alone for well-differentiated somatostatin receptor-positive neuroendocrine tumors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Receptors, Somatostatin | Neuroendocrine Tumors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1902193147,'FU_HCP_46052');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAman Chauhan",
"kol_full_name": "Aman Chauhan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Paraproteinemias | Hematologic Neoplasms",
"npi_num": "1487094066",
"hcp_pin_alias": "FU_HCP_185933",
"session_name": "Hematologic Malignancies—Plasma Cell Dyscrasia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Amandeep Godara",
"middle_name": "",
"last_name": "",
"org_name": "Huntsman Cancer Institute",
"Country": "United States",
"Region": "Utah",
"City": "Salt Lake City",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232118",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232118",
"events_session": "Hematologic Malignancies—Plasma Cell Dyscrasia",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Paraproteinemias | Hematologic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1487094066,'FU_HCP_185933');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAmandeep Godara",
"kol_full_name": "Amandeep Godara"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Neuroendocrine",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403415",
"session_name": "Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Amin Nassar",
"middle_name": "",
"last_name": "",
"org_name": "Yale Cancer Center",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232250",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232250",
"events_session": "Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Neuroendocrine",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403415');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAmin Nassar",
"kol_full_name": "Amin Nassar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1487917951",
"hcp_pin_alias": "FU_HCP_5403333",
"session_name": "Pediatric Oncology",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Amy E. Armstrong",
"middle_name": "",
"last_name": "",
"org_name": "Washington University in St Louis",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232027",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232027",
"events_session": "Pediatric Oncology",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1487917951,'FU_HCP_5403333');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAmy E. Armstrong",
"kol_full_name": "Amy E. Armstrong"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Abemaciclib | Letrozole | Triple Negative Breast Neoplasms",
"npi_num": "1922242932",
"hcp_pin_alias": "FU_HCP_159518",
"session_name": "I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Amy Jo Chien",
"middle_name": "",
"last_name": "",
"org_name": "University of California, San Francisco",
"Country": "United States",
"Region": "California",
"City": "San Francisco",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232633",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232633",
"events_session": "I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Abemaciclib | Letrozole ",
"rest_events_topic_count": 1,
"rest_events_topic": " Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1922242932,'FU_HCP_159518');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAmy Jo Chien",
"kol_full_name": "Amy Jo Chien"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Thoracic Neoplasms | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1043552243",
"hcp_pin_alias": "FU_HCP_109646",
"session_name": "Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Amy Lauren Cummings",
"middle_name": "",
"last_name": "",
"org_name": "University of California Los Angeles Translational Oncology Research",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232025",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232025",
"events_session": "Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Thoracic Neoplasms | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1043552243,'FU_HCP_109646');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAmy Lauren Cummings",
"kol_full_name": "Amy Lauren Cummings"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Clinical Trials As Topic",
"npi_num": "1144647421",
"hcp_pin_alias": "FU_HCP_39401",
"session_name": "Challenges and solutions to recruiting diverse populations to oncology clinical trials: A mixed-methods study of clinical research coordinators",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ana I. Velazquez Manana",
"middle_name": "",
"last_name": "",
"org_name": "University of California, San Francisco",
"Country": "United States",
"Region": "California",
"City": "San Francisco",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233057",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233057",
"events_session": "Challenges and solutions to recruiting diverse populations to oncology clinical trials: A mixed-methods study of clinical research coordinators",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms | Clinical Trials As Topic",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1144647421,'FU_HCP_39401');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAna I. Velazquez Manana",
"kol_full_name": "Ana I. Velazquez Manana"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neuroendocrine Tumors",
"npi_num": "1336110378",
"hcp_pin_alias": "PAST_HCP_CNS_195377",
"session_name": "Solid Foundation or House of Cards: Molecular Targets in Neuro-Oncology",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Andrew B. Lassman",
"middle_name": "",
"last_name": "",
"org_name": "Neuro-Oncology, Columbia University",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232457",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232457",
"events_session": "Solid Foundation or House of Cards: Molecular Targets in Neuro-Oncology",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neuroendocrine Tumors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1336110378,'PAST_HCP_CNS_195377');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAndrew B. Lassman",
"kol_full_name": "Andrew B. Lassman"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy, Adjuvant | Melanoma",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403456",
"session_name": "Serum multiplex analysis of checkpoint proteins in association with immune-related adverse events in patients with melanoma receiving adjuvant anti-PD-1 therapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Andrew David Knight",
"middle_name": "",
"last_name": "",
"org_name": "University of Pittsburgh Medical Center (UPMC)",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232799",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232799",
"events_session": "Serum multiplex analysis of checkpoint proteins in association with immune-related adverse events in patients with melanoma receiving adjuvant anti-PD-1 therapy",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Chemotherapy, Adjuvant | Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403456');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAndrew David Knight",
"kol_full_name": "Andrew David Knight"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Multiple Myeloma | B-Cell Maturation Antigen",
"npi_num": "1306102934",
"hcp_pin_alias": "FU_HCP_167022",
"session_name": "Expression of alternatively spliced BCMA RNA with skipping of transmembrane domain",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Andrew Ip",
"middle_name": "",
"last_name": "",
"org_name": "John Theurer Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232113",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232113",
"events_session": "Expression of alternatively spliced BCMA RNA with skipping of transmembrane domain",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Multiple Myeloma | B-Cell Maturation Antigen",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1306102934,'FU_HCP_167022');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAndrew Ip",
"kol_full_name": "Andrew Ip"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Clinical Research",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403398",
"session_name": "Clinical Research Investigator Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Andrew Jacob McKenzie",
"middle_name": "",
"last_name": "",
"org_name": "Sarah Cannon Research Institute",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232156",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232156",
"events_session": "Clinical Research Investigator Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Clinical Research",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403398');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAndrew Jacob McKenzie",
"kol_full_name": "Andrew Jacob McKenzie"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Merkel Cell | Carcinoma, Squamous Cell | Immune Checkpoint Inhibitors",
"npi_num": "1609022870",
"hcp_pin_alias": "FU_HCP_5403363",
"session_name": "Phase 1b trial of IFx-Hu20, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Andrew Scott Brohl",
"middle_name": "",
"last_name": "",
"org_name": "H. Lee Moffitt Cancer Center and Research Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232800",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232800",
"events_session": "Phase 1b trial of IFx-Hu20",
"rest_events_session_count": 2,
"rest_events_session": " a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC)",
"events_topic": "Carcinoma, Merkel Cell | Carcinoma, Squamous Cell ",
"rest_events_topic_count": 1,
"rest_events_topic": " Immune Checkpoint Inhibitors",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1609022870,'FU_HCP_5403363');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAndrew Scott Brohl",
"kol_full_name": "Andrew Scott Brohl"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nerve Sheath Neoplasms",
"npi_num": "1710115951",
"hcp_pin_alias": "FU_HCP_44423",
"session_name": "Current and Emerging Therapies for Metastatic Malignant Peripheral Nerve Sheath Tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Angela C. Hirbe",
"middle_name": "",
"last_name": "",
"org_name": "Washington University in St. Louis",
"Country": "United States",
"Region": "Missouri",
"City": "St. Louis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233104",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233104",
"events_session": "Current and Emerging Therapies for Metastatic Malignant Peripheral Nerve Sheath Tumors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Nerve Sheath Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1710115951,'FU_HCP_44423');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAngela C. Hirbe",
"kol_full_name": "Angela C. Hirbe"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1720164692",
"hcp_pin_alias": "FU_HCP_5403336",
"session_name": "Breast Cancer—Metastatic",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Anne F. Schott",
"middle_name": "",
"last_name": "",
"org_name": "University of Michigan Rogel Cancer Center",
"Country": "United States",
"Region": "Michigan",
"City": "Ann Arbor",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232066",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232066",
"events_session": "Breast Cancer—Metastatic",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1720164692,'FU_HCP_5403336');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAnne F. Schott",
"kol_full_name": "Anne F. Schott"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Atezolizumab | Zanzalintinib | Regorafenib | Colorectal Neoplasms",
"npi_num": "1447490974",
"hcp_pin_alias": "FU_HCP_166687",
"session_name": "STELLAR-303: A randomized phase 3 study of zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Anwaar Saeed",
"middle_name": "",
"last_name": "",
"org_name": "University of Pittsburgh",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Pittsburgh",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232896",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232896",
"events_session": "STELLAR-303: A randomized phase 3 study of zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Atezolizumab | Zanzalintinib ",
"rest_events_topic_count": 2,
"rest_events_topic": " Regorafenib | Colorectal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1447490974,'FU_HCP_166687');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAnwaar Saeed",
"kol_full_name": "Anwaar Saeed"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Chemoradiotherapy | Combined Modality Therapy",
"npi_num": "1528591047",
"hcp_pin_alias": "FU_HCP_284267",
"session_name": "Feasibility of induction chemoimmunotherapy (ID chemo-IO) followed by chemoradiation for locally advanced unresectable non-small cell lung cancer (NSCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Arthi Sridhar",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232243",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232243",
"events_session": "Feasibility of induction chemoimmunotherapy (ID chemo-IO) followed by chemoradiation for locally advanced unresectable non-small cell lung cancer (NSCLC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Chemoradiotherapy ",
"rest_events_topic_count": 1,
"rest_events_topic": " Combined Modality Therapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1528591047,'FU_HCP_284267');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EArthi Sridhar",
"kol_full_name": "Arthi Sridhar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colonic Neoplasms | Neoplasm, Residual | Chemotherapy, Adjuvant",
"npi_num": "1497927123",
"hcp_pin_alias": "FU_HCP_57958",
"session_name": "Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Arvind Dasari",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232900",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232900",
"events_session": "Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA): NRG-GI008",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colonic Neoplasms | Neoplasm, Residual ",
"rest_events_topic_count": 1,
"rest_events_topic": " Chemotherapy, Adjuvant",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1497927123,'FU_HCP_57958');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EArvind Dasari",
"kol_full_name": "Arvind Dasari"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Triple Negative Breast Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403450",
"session_name": "Real-world immune-related adverse events in patients with early triple negative breast cancer who received pembrolizumab",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Athira Jayan",
"middle_name": "",
"last_name": "",
"org_name": "Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232701",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232701",
"events_session": "Real-world immune-related adverse events in patients with early triple negative breast cancer who received pembrolizumab",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pembrolizumab | Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403450');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAthira Jayan",
"kol_full_name": "Athira Jayan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1669806857",
"hcp_pin_alias": "FU_HCP_284979",
"session_name": "Medical students' views on oncology specialty: A cross-sectional study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Aydah Al-Awadhi",
"middle_name": "",
"last_name": "",
"org_name": "Tawam Hospital, Abu Dhabi Health Services Co.",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232264",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232264",
"events_session": "Medical students' views on oncology specialty: A cross-sectional study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1669806857,'FU_HCP_284979');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EAydah Al-Awadhi",
"kol_full_name": "Aydah Al-Awadhi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Urinary Bladder Neoplasms | Enfortumab Vedotin",
"npi_num": "1215349964",
"hcp_pin_alias": "FU_HCP_159266",
"session_name": "Enfortumab vedotin plus pembrolizumab in the treatment of locally advanced or metastatic bladder cancer of variant histology: A phase II study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Bassel Nazha",
"middle_name": "",
"last_name": "",
"org_name": "Department of Hematology and Medical Oncology, Emory University School of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232611",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232611",
"events_session": "Enfortumab vedotin plus pembrolizumab in the treatment of locally advanced or metastatic bladder cancer of variant histology: A phase II study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pembrolizumab | Urinary Bladder Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Enfortumab Vedotin",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1215349964,'FU_HCP_159266');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBassel Nazha",
"kol_full_name": "Bassel Nazha"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pharmacokinetics | Solid Tumor",
"npi_num": "1265489371",
"hcp_pin_alias": "FU_HCP_110453",
"session_name": "A phase 1/1b, first-in-human, multi-part study of DF6215, an engineered IL-2Rα-active agonist, to investigate the safety, tolerability, pharmacokinetics, and biological and clinical activity in patients with advanced solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Benedito A. Carneiro",
"middle_name": "",
"last_name": "",
"org_name": "Legorreta Cancer Center at Brown University",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233045",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233045",
"events_session": "A phase 1/1b",
"rest_events_session_count": 7,
"rest_events_session": " first-in-human, multi-part study of DF6215, an engineered IL-2Rα-active agonist, to investigate the safety, tolerability, pharmacokinetics, and biological and clinical activity in patients with advanced solid tumors",
"events_topic": "Pharmacokinetics | Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1265489371,'FU_HCP_110453');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBenedito A. Carneiro",
"kol_full_name": "Benedito A. Carneiro"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403387",
"session_name": "Lung Cancer—Non-Small Cell Metastatic",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Benjamin Besse",
"middle_name": "",
"last_name": "",
"org_name": "Gustave Roussy Institute",
"Country": "France",
"Region": "Ile-De-France",
"City": "Paris",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232059",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232059",
"events_session": "Lung Cancer—Non-Small Cell Metastatic",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403387');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBenjamin Besse",
"kol_full_name": "Benjamin Besse"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Gastrointestinal Neoplasms",
"npi_num": "1427410331",
"hcp_pin_alias": "FU_HCP_283160",
"session_name": "RNA-based fusion testing in gastrointestinal (GI) carcinomas: A single-institution experience",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Bennett Adam Caughey",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232948",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232948",
"events_session": "RNA-based fusion testing in gastrointestinal (GI) carcinomas: A single-institution experience",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Gastrointestinal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1427410331,'FU_HCP_283160');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBennett Adam Caughey",
"kol_full_name": "Bennett Adam Caughey"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nanoparticles | Antibody Therapy | Melanoma",
"npi_num": "1992182604",
"hcp_pin_alias": "FU_HCP_281744",
"session_name": "Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Bently Patrick Doonan",
"middle_name": "",
"last_name": "",
"org_name": "University of Florida College of Medicine",
"Country": "United States",
"Region": "Florida",
"City": "Gainesville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232806",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232806",
"events_session": "Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Nanoparticles | Antibody Therapy ",
"rest_events_topic_count": 1,
"rest_events_topic": " Melanoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1992182604,'FU_HCP_281744');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBently Patrick Doonan",
"kol_full_name": "Bently Patrick Doonan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Clinical Trials As Topic",
"npi_num": "1184734501",
"hcp_pin_alias": "PAST_HCP_Onco_233778",
"session_name": "Too Many Options: Assessing the Best Trial Designs",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Bernardo Haddock Lobo Goulart",
"middle_name": "",
"last_name": "",
"org_name": "U.S. Food and Drug Administration",
"Country": "United States",
"Region": "Maryland",
"City": "Silver Spring",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232549",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232549",
"events_session": "Too Many Options: Assessing the Best Trial Designs",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Clinical Trials As Topic",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1184734501,'PAST_HCP_Onco_233778');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBernardo Haddock Lobo Goulart",
"kol_full_name": "Bernardo Haddock Lobo Goulart"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immune Checkpoint Inhibitors | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1902515448",
"hcp_pin_alias": "FU_HCP_408514",
"session_name": "Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Biagio Ricciuti",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232184",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232184",
"events_session": "Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immune Checkpoint Inhibitors | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1902515448,'FU_HCP_408514');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBiagio Ricciuti",
"kol_full_name": "Biagio Ricciuti"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Penpulimab | Anlotinib | Non-Muscle Invasive Bladder Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403443",
"session_name": "Updated results from a phase II study of penpulimab plus anlotinib as first-line therapy in metastatic urothelial cancer (mUC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Bo Yang",
"middle_name": "",
"last_name": "",
"org_name": "Chinese PLA General Hospital",
"Country": "China",
"Region": "Beijing",
"City": "Beijing",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232593",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232593",
"events_session": "Updated results from a phase II study of penpulimab plus anlotinib as first-line therapy in metastatic urothelial cancer (mUC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Penpulimab | Anlotinib ",
"rest_events_topic_count": 1,
"rest_events_topic": " Non-Muscle Invasive Bladder Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403443');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBo Yang",
"kol_full_name": "Bo Yang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Clustered Regularly Interspaced Short Palindromic Repeats | Lymphoma, Non-Hodgkin | Immunotherapy, Adoptive | Antigens, CD19",
"npi_num": "1033478144",
"hcp_pin_alias": "FU_HCP_38418",
"session_name": "A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Boyu Hu",
"middle_name": "",
"last_name": "",
"org_name": "Huntsman Cancer Institute",
"Country": "United States",
"Region": "Utah",
"City": "Salt Lake City",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232370",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232370",
"events_session": "A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Clustered Regularly Interspaced Short Palindromic Repeats | Lymphoma, Non-Hodgkin ",
"rest_events_topic_count": 2,
"rest_events_topic": " Immunotherapy, Adoptive | Antigens, CD19",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1033478144,'FU_HCP_38418');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBoyu Hu",
"kol_full_name": "Boyu Hu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Sacituzumab Govitecan | Enfortumab Vedotin | Carcinoma, Transitional Cell",
"npi_num": "1902018559",
"hcp_pin_alias": "FU_HCP_46026",
"session_name": "Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Bradley Alexander McGregor",
"middle_name": "",
"last_name": "",
"org_name": "Lank Center for Genitourinary Oncology",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232614",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232614",
"events_session": "Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pembrolizumab | Sacituzumab Govitecan ",
"rest_events_topic_count": 2,
"rest_events_topic": " Enfortumab Vedotin | Carcinoma, Transitional Cell",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1902018559,'FU_HCP_46026');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBradley Alexander McGregor",
"kol_full_name": "Bradley Alexander McGregor"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neuroblastoma",
"npi_num": "1710958111",
"hcp_pin_alias": "FU_HCP_99959",
"session_name": "N9: Pilot study of novel shortened induction for high-risk neuroblastoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Brian H. Kushner",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232902",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232902",
"events_session": "N9: Pilot study of novel shortened induction for high-risk neuroblastoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neuroblastoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1710958111,'FU_HCP_99959');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBrian H. Kushner",
"kol_full_name": "Brian H. Kushner"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immune Checkpoint Inhibitors | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1316212533",
"hcp_pin_alias": "FU_HCP_109639",
"session_name": "A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Brian S. Henick",
"middle_name": "",
"last_name": "",
"org_name": "Columbia University Irving Medical Center",
"Country": "United States",
"Region": "New York",
"City": "Yonkers",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233062",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233062",
"events_session": "A phase IV study of ApricityCARE program for cancer adverse events rapid evaluation to improve treatment outcomes of ethnic/racial minority patients with non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors (ICI)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immune Checkpoint Inhibitors | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1316212533,'FU_HCP_109639');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBrian S. Henick",
"kol_full_name": "Brian S. Henick"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Anemia, Sickle Cell | Solid Tumor",
"npi_num": "1982133658",
"hcp_pin_alias": "FU_HCP_284512",
"session_name": "The prevalence of sickle cell phenotype and its association with clinical outcomes in patients with solid malignancies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Brianna R. Bakow",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232227",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232227",
"events_session": "The prevalence of sickle cell phenotype and its association with clinical outcomes in patients with solid malignancies",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Anemia, Sickle Cell | Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1982133658,'FU_HCP_284512');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBrianna R. Bakow",
"kol_full_name": "Brianna R. Bakow"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Clinical Trials As Topic | Brain Neoplasms",
"npi_num": "1093210775",
"hcp_pin_alias": "FU_HCP_322231",
"session_name": "Neuro-oncology anywhere: A decentralized approach to clinical trials in brain tumors and beyond",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Bryan Neth",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233066",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233066",
"events_session": "Neuro-oncology anywhere: A decentralized approach to clinical trials in brain tumors and beyond",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Clinical Trials As Topic | Brain Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1093210775,'FU_HCP_322231');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EBryan Neth",
"kol_full_name": "Bryan Neth"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403427",
"session_name": "Health-related quality of life (HRQoL) and symptoms in LIBRETTO-431 patients with RET fusion-positive advanced non-small-cell lung cancer (NSCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Caicun Zhou",
"middle_name": "",
"last_name": "",
"org_name": "Shanghai Pulmonary Hospital",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232399",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232399",
"events_session": "Health-related quality of life (HRQoL) and symptoms in LIBRETTO-431 patients with RET fusion-positive advanced non-small-cell lung cancer (NSCLC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403427');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECaicun Zhou",
"kol_full_name": "Caicun Zhou"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1932307600",
"hcp_pin_alias": "PAST_HCP_Onco_232748",
"session_name": "Discussion on Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Cardinale B. Smith",
"middle_name": "",
"last_name": "",
"org_name": "Icahn School of Medicine at Mount Sinai",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232489",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232489",
"events_session": "Discussion on Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1932307600,'PAST_HCP_Onco_232748');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECardinale B. Smith",
"kol_full_name": "Cardinale B. Smith"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy | Breast Neoplasms",
"npi_num": "1114138534",
"hcp_pin_alias": "FU_HCP_39068",
"session_name": "Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Carmen Julia Calfa",
"middle_name": "",
"last_name": "",
"org_name": "Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232299",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232299",
"events_session": "Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT",
"rest_events_session_count": 1,
"rest_events_session": " an allogeneic whole cell immunotherapy",
"events_topic": "Immunotherapy | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1114138534,'FU_HCP_39068');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECarmen Julia Calfa",
"kol_full_name": "Carmen Julia Calfa"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "B-Cell Maturation Antigen | Multiple Myeloma",
"npi_num": "1942516182",
"hcp_pin_alias": "FU_HCP_100284",
"session_name": "Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Carolina D. Schinke",
"middle_name": "",
"last_name": "",
"org_name": "Myeloma Center, University of Arkansas for Medical Sciences",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232364",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232364",
"events_session": "Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "B-Cell Maturation Antigen | Multiple Myeloma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1942516182,'FU_HCP_100284');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECarolina D. Schinke",
"kol_full_name": "Carolina D. Schinke"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Molecular Targeted Therapy | Colorectal Neoplasms",
"npi_num": "1356804173",
"hcp_pin_alias": "FU_HCP_282718",
"session_name": "Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Celine Yeh",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232870",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232870",
"events_session": "Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Molecular Targeted Therapy | Colorectal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356804173,'FU_HCP_282718');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECeline Yeh",
"kol_full_name": "Celine Yeh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Squamous Cell Carcinoma Of Head And Neck | Immunoconjugates",
"npi_num": "1538322003",
"hcp_pin_alias": "FU_HCP_282659",
"session_name": "Emerging Data for Antibody Drug Conjugates in Head and Neck Squamous Cell Carcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Cesar Augusto Perez",
"middle_name": "",
"last_name": "",
"org_name": "Sarah Cannon Research Institute at Florida Cancer Specialists",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232123",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232123",
"events_session": "Emerging Data for Antibody Drug Conjugates in Head and Neck Squamous Cell Carcinoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Squamous Cell Carcinoma Of Head And Neck | Immunoconjugates",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1538322003,'FU_HCP_282659');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECesar Augusto Perez",
"kol_full_name": "Cesar Augusto Perez"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nivolumab | Cabozantinib | Sunitinib | Carcinoma, Renal Cell",
"npi_num": "1831503218",
"hcp_pin_alias": "FU_HCP_283312",
"session_name": "Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Charlene Mantia",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232470",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232470",
"events_session": "Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Nivolumab | Cabozantinib ",
"rest_events_topic_count": 2,
"rest_events_topic": " Sunitinib | Carcinoma, Renal Cell",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1831503218,'FU_HCP_283312');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECharlene Mantia",
"kol_full_name": "Charlene Mantia"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Circulating Tumor DNA | Prostatic Neoplasms | Receptors, Androgen",
"npi_num": "1720645393",
"hcp_pin_alias": "FU_HCP_284755",
"session_name": "Dynamic androgen receptor alterations (ARa) ctDNA profiles and clinical outcomes in metastatic prostate cancer (mPC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Chinmay Jani",
"middle_name": "",
"last_name": "",
"org_name": "University of Miami Sylvester Comprehensive Cancer Center/Jackson Health System",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232654",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232654",
"events_session": "Dynamic androgen receptor alterations (ARa) ctDNA profiles and clinical outcomes in metastatic prostate cancer (mPC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Circulating Tumor DNA | Prostatic Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Receptors, Androgen",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1720645393,'FU_HCP_284755');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChinmay Jani",
"kol_full_name": "Chinmay Jani"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pancreatic Neoplasms | Folfirinox | Granulocyte Colony-Stimulating Factor",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403464",
"session_name": "Primary prophylaxis with pegylated-granulocyte colony-stimulating factor for patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: A randomized phase II trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Choong-kun Lee",
"middle_name": "",
"last_name": "",
"org_name": "Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research,Yonsei University College of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232840",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232840",
"events_session": "Primary prophylaxis with pegylated-granulocyte colony-stimulating factor for patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: A randomized phase II trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pancreatic Neoplasms | Folfirinox ",
"rest_events_topic_count": 1,
"rest_events_topic": " Granulocyte Colony-Stimulating Factor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403464');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChoong-kun Lee",
"kol_full_name": "Choong-kun Lee"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Programmed Cell Death 1 Receptor | Solid Tumor | Pembrolizumab",
"npi_num": "1043509912",
"hcp_pin_alias": "FU_HCP_283441",
"session_name": "Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Chrisann Kyi",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232525",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232525",
"events_session": "Phase I study of MCLA-145",
"rest_events_session_count": 3,
"rest_events_session": " a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab",
"events_topic": "Programmed Cell Death 1 Receptor | Solid Tumor ",
"rest_events_topic_count": 1,
"rest_events_topic": " Pembrolizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1043509912,'FU_HCP_283441');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChrisann Kyi",
"kol_full_name": "Chrisann Kyi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sarcoma | Immunotherapy",
"npi_num": "1104972835",
"hcp_pin_alias": "FU_HCP_373585",
"session_name": "Managing the Facts and Hopes Surrounding Immunotherapy in Patients With Sarcoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Christian Frederick Meyer",
"middle_name": "",
"last_name": "",
"org_name": "Johns Hopkins Hospital",
"Country": "United States",
"Region": "Maryland",
"City": "Baltimore",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233149",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233149",
"events_session": "Managing the Facts and Hopes Surrounding Immunotherapy in Patients With Sarcoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Sarcoma | Immunotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1104972835,'FU_HCP_373585');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChristian Frederick Meyer",
"kol_full_name": "Christian Frederick Meyer"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lymphoma | Ibrutinib | Emavusertib | Central Nervous System Neoplasms",
"npi_num": "1720291727",
"hcp_pin_alias": "FU_HCP_44561",
"session_name": "Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Christian Grommes",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233080",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233080",
"events_session": "Emavusertib (CA-4948) in combination with ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (R/R PCNSL)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Lymphoma | Ibrutinib ",
"rest_events_topic_count": 2,
"rest_events_topic": " Emavusertib | Central Nervous System Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1720291727,'FU_HCP_44561');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChristian Grommes",
"kol_full_name": "Christian Grommes"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Gemcitabine | Protein-Arginine Deiminase Type 6",
"npi_num": "1952896888",
"hcp_pin_alias": "FU_HCP_5403370",
"session_name": "Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in combination with gemcitabine and docetaxel in non-small cell and small cell lung cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Christine Auberle",
"middle_name": "",
"last_name": "",
"org_name": "Washington University in St. Louis",
"Country": "United States",
"Region": "Missouri",
"City": "St. Louis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232987",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232987",
"events_session": "Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in combination with gemcitabine and docetaxel in non-small cell and small cell lung cancers",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Gemcitabine ",
"rest_events_topic_count": 1,
"rest_events_topic": " Protein-Arginine Deiminase Type 6",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1952896888,'FU_HCP_5403370');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChristine Auberle",
"kol_full_name": "Christine Auberle"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cryotherapy | Peripheral Nervous System Diseases | Chemotherapy",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403449",
"session_name": "Prospective, randomized trial on efficacy and safety of cryotherapy and cryocompression therapy as prevention of chemotherapy-induced peripheral neuropathy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Christine Brunner",
"middle_name": "",
"last_name": "",
"org_name": "Department of Obstetrics and Gynecology, Medical University of Innsbruck",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232694",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232694",
"events_session": "Prospective",
"rest_events_session_count": 1,
"rest_events_session": " randomized trial on efficacy and safety of cryotherapy and cryocompression therapy as prevention of chemotherapy-induced peripheral neuropathy",
"events_topic": "Cryotherapy | Peripheral Nervous System Diseases ",
"rest_events_topic_count": 1,
"rest_events_topic": " Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403449');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChristine Brunner",
"kol_full_name": "Christine Brunner"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "KRAS Protein, Human | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1720354137",
"hcp_pin_alias": "FU_HCP_44568",
"session_name": "Targeting KRAS in Non–Small Cell Lung Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Christine M. Bestvina",
"middle_name": "",
"last_name": "",
"org_name": "University of Chicago",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232073",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232073",
"events_session": "Targeting KRAS in Non–Small Cell Lung Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "KRAS Protein, Human | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1720354137,'FU_HCP_44568');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChristine M. Bestvina",
"kol_full_name": "Christine M. Bestvina"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Early Goal-Directed Therapy | Leukemia, Myeloid, Acute",
"npi_num": "1356600464",
"hcp_pin_alias": "FU_HCP_154782",
"session_name": "Intensive Therapy or Not? What to Offer Younger Patients With Acute Myeloid Leukemia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Christine McMahon",
"middle_name": "",
"last_name": "",
"org_name": "University of Colorado",
"Country": "United States",
"Region": "Colorado",
"City": "Aurora",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232545",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232545",
"events_session": "Intensive Therapy or Not? What to Offer Younger Patients With Acute Myeloid Leukemia",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Early Goal-Directed Therapy | Leukemia, Myeloid, Acute",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356600464,'FU_HCP_154782');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EChristine McMahon",
"kol_full_name": "Christine McMahon"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms",
"npi_num": "1427495357",
"hcp_pin_alias": "FU_HCP_41931",
"session_name": "Exploring New Partnerships in HER2-Positive Breast Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ciara Catherine O'Sullivan",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232777",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232777",
"events_session": "Exploring New Partnerships in HER2-Positive Breast Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1427495357,'FU_HCP_41931');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECiara Catherine O'Sullivan",
"kol_full_name": "Ciara Catherine O'Sullivan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Human-specific STING Agonist G10 | Solid Tumor",
"npi_num": "1144696485",
"hcp_pin_alias": "FU_HCP_5403375",
"session_name": "Phase I trial of CRD3874-SI, a systemically administered STING agonist, in patients with advanced solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ciara Marie Kelly",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233038",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233038",
"events_session": "Phase I trial of CRD3874-SI",
"rest_events_session_count": 2,
"rest_events_session": " a systemically administered STING agonist, in patients with advanced solid tumors",
"events_topic": "Human-specific STING Agonist G10 | Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1144696485,'FU_HCP_5403375');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECiara Marie Kelly",
"kol_full_name": "Ciara Marie Kelly"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1811090715",
"hcp_pin_alias": "PAST_HCP_Onco_231500",
"session_name": "Discussion on Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Clifford A. Hudis",
"middle_name": "",
"last_name": "",
"org_name": "ASCO",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232938",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232938",
"events_session": "Discussion on Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1811090715,'PAST_HCP_Onco_231500');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EClifford A. Hudis",
"kol_full_name": "Clifford A. Hudis"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Nivolumab | Squamous Cell Carcinoma Of Head And Neck",
"npi_num": "1679830699",
"hcp_pin_alias": "FU_HCP_44119",
"session_name": "Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Colette Shen",
"middle_name": "",
"last_name": "",
"org_name": "Department of Radiation Oncology, The University of North Carolina School of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232554",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232554",
"events_session": "Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pembrolizumab | Nivolumab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Squamous Cell Carcinoma Of Head And Neck",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1679830699,'FU_HCP_44119');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EColette Shen",
"kol_full_name": "Colette Shen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ixazomib | Multiple Myeloma | Iberdomide | Dexamethasone",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403396",
"session_name": "All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Cyrille Touzeau",
"middle_name": "",
"last_name": "",
"org_name": "Centre Hospitalier Universitaire de Nantes",
"Country": "France",
"Region": "Pays de la Loire",
"City": "Nantes",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232137",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232137",
"events_session": "All-oral triplet iberdomide",
"rest_events_session_count": 2,
"rest_events_session": " ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D",
"events_topic": "Ixazomib | Multiple Myeloma ",
"rest_events_topic_count": 2,
"rest_events_topic": " Iberdomide | Dexamethasone",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403396');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ECyrille Touzeau",
"kol_full_name": "Cyrille Touzeau"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Patient Care",
"npi_num": "1598911547",
"hcp_pin_alias": "FU_HCP_43435",
"session_name": "Facing Patients' Fears and Rebuilding Trust When Worrisome News Comes Electronically",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Daniel Curtis McFarland",
"middle_name": "",
"last_name": "",
"org_name": "University of Rochester Medical Center",
"Country": "United States",
"Region": "New York",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232534",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232534",
"events_session": "Facing Patients' Fears and Rebuilding Trust When Worrisome News Comes Electronically",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Patient Care",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1598911547,'FU_HCP_43435');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDaniel Curtis McFarland",
"kol_full_name": "Daniel Curtis McFarland"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Artificial Intelligence | Radiotherapy | Pancreatic Neoplasms",
"npi_num": "1801281894",
"hcp_pin_alias": "FU_HCP_350600",
"session_name": "An AI-assisted navigation approach for patients with radiographic suspicion of new pancreas cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Daniel King",
"middle_name": "",
"last_name": "",
"org_name": "Northwell Health Cancer Institute",
"Country": "United States",
"Region": "New York",
"City": "New Hyde Park",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233117",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233117",
"events_session": "An AI-assisted navigation approach for patients with radiographic suspicion of new pancreas cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Artificial Intelligence | Radiotherapy ",
"rest_events_topic_count": 1,
"rest_events_topic": " Pancreatic Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1801281894,'FU_HCP_350600');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDaniel King",
"kol_full_name": "Daniel King"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Solid Tumor",
"npi_num": "1356679831",
"hcp_pin_alias": "FU_HCP_41307",
"session_name": "Polyploid circulating stromal cells in blood to identify invasive solid tumors and to prognosticate for highly aggressive cancer subtypes",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Daniel L Adams",
"middle_name": "",
"last_name": "",
"org_name": "Creatv MicroTech, Inc.",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232946",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232946",
"events_session": "Polyploid circulating stromal cells in blood to identify invasive solid tumors and to prognosticate for highly aggressive cancer subtypes",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356679831,'FU_HCP_41307');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDaniel L Adams",
"kol_full_name": "Daniel L Adams"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lung Neoplasms",
"npi_num": "1912022716",
"hcp_pin_alias": "FU_HCP_282262",
"session_name": "Multi-stakeholder, intentional outreach for improving representative recruitment in Pragmatica–Lung (SWOG S2302)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Daniel R. Carrizosa",
"middle_name": "",
"last_name": "",
"org_name": "Atrium Health Wake Forest Baptist Medical Center",
"Country": "United States",
"Region": "North Carolina",
"City": "Winston Salem",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232392",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232392",
"events_session": "Multi-stakeholder",
"rest_events_session_count": 1,
"rest_events_session": " intentional outreach for improving representative recruitment in Pragmatica–Lung (SWOG S2302)",
"events_topic": "Lung Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1912022716,'FU_HCP_282262');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDaniel R. Carrizosa",
"kol_full_name": "Daniel R. Carrizosa"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403484",
"session_name": "Gilead and Kite Oncology's Commitment to Transformative Sciences",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Darren Tayama",
"middle_name": "",
"last_name": "",
"org_name": "Gilead",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233155",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233155",
"events_session": "Gilead and Kite Oncology's Commitment to Transformative Sciences",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403484');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDarren Tayama",
"kol_full_name": "Darren Tayama"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Early Detection Of Cancer | Breast Neoplasms",
"npi_num": "1902176811",
"hcp_pin_alias": "FU_HCP_283606",
"session_name": "Outcomes of a program to improve breast cancer early detection in Cote d’Ivoire",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Darya Aleksandrovna Kizub",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232225",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232225",
"events_session": "Outcomes of a program to improve breast cancer early detection in Cote d’Ivoire",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Early Detection Of Cancer | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1902176811,'FU_HCP_283606');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDarya Aleksandrovna Kizub",
"kol_full_name": "Darya Aleksandrovna Kizub"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms | Chemotherapy | Alopecia",
"npi_num": "1922241140",
"hcp_pin_alias": "FU_HCP_46232",
"session_name": "Pilot evaluation of portable scalp cooling for chemotherapy-associated alopecia in early-stage breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "David B. Page",
"middle_name": "",
"last_name": "",
"org_name": "Providence Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232219",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232219",
"events_session": "Pilot evaluation of portable scalp cooling for chemotherapy-associated alopecia in early-stage breast cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms | Chemotherapy ",
"rest_events_topic_count": 1,
"rest_events_topic": " Alopecia",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1922241140,'FU_HCP_46232');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDavid B. Page",
"kol_full_name": "David B. Page"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nivolumab | Programmed Cell Death 1 Receptor | Carcinoma, Transitional Cell",
"npi_num": "1194168955",
"hcp_pin_alias": "FU_HCP_75752",
"session_name": "IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "David H Aggen",
"middle_name": "",
"last_name": "",
"org_name": "Genitourinary Oncology, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233008",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233008",
"events_session": "IK-175",
"rest_events_session_count": 2,
"rest_events_session": " an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors",
"events_topic": "Nivolumab | Programmed Cell Death 1 Receptor ",
"rest_events_topic_count": 1,
"rest_events_topic": " Carcinoma, Transitional Cell",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1194168955,'FU_HCP_75752');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDavid H Aggen",
"kol_full_name": "David H Aggen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms | Genetic Testing",
"npi_num": "1689846834",
"hcp_pin_alias": "FU_HCP_228377",
"session_name": "Practical Approach to Genetic Testing and Treatment Selection in Prostate Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "David James VanderWeele",
"middle_name": "",
"last_name": "",
"org_name": "Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233102",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233102",
"events_session": "Practical Approach to Genetic Testing and Treatment Selection in Prostate Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms | Genetic Testing",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1689846834,'FU_HCP_228377');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDavid James VanderWeele",
"kol_full_name": "David James VanderWeele"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptors, Thyroid Hormone | Methimazole | Glioma",
"npi_num": "1548262512",
"hcp_pin_alias": "FU_HCP_42959",
"session_name": "Targeting glioma stem cells with thyroid hormone suppression: Phase 1/2 trial of methimazole in patients with progressive grade 4 gliomas",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "David M. Peereboom",
"middle_name": "",
"last_name": "",
"org_name": "Cleveland Clinic",
"Country": "United States",
"Region": "Ohio",
"City": "Cleveland",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233070",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233070",
"events_session": "Targeting glioma stem cells with thyroid hormone suppression: Phase 1/2 trial of methimazole in patients with progressive grade 4 gliomas",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Receptors, Thyroid Hormone | Methimazole ",
"rest_events_topic_count": 1,
"rest_events_topic": " Glioma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1548262512,'FU_HCP_42959');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDavid M. Peereboom",
"kol_full_name": "David M. Peereboom"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Squamous Cell Carcinoma Of Head And Neck",
"npi_num": "1558436337",
"hcp_pin_alias": "PAST_HCP_Onco_231583",
"session_name": "Clinical validation of a mesenchymal gene expression signature for prognosis and treatment decision making in early-stage oral cavity squamous cell carcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "David N. Hayes",
"middle_name": "",
"last_name": "",
"org_name": "The University of Tennessee Health Science Center",
"Country": "United States",
"Region": "Tennessee",
"City": "Memphis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232566",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232566",
"events_session": "Clinical validation of a mesenchymal gene expression signature for prognosis and treatment decision making in early-stage oral cavity squamous cell carcinoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Squamous Cell Carcinoma Of Head And Neck",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1558436337,'PAST_HCP_Onco_231583');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDavid N. Hayes",
"kol_full_name": "David N. Hayes"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Datopotamab Deruxtecan | Carcinoma, Non-Small-Cell Lung | Biomarkers",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403481",
"session_name": "ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "David Planchard",
"middle_name": "",
"last_name": "",
"org_name": "Gustave Roussy Institute",
"Country": "France",
"Region": "Ile-De-France",
"City": "Paris",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233135",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233135",
"events_session": "ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC)",
"rest_events_session_count": 1,
"rest_events_session": " with sequential tissue biopsies and biomarkers analysis to predict treatment outcome",
"events_topic": "Datopotamab Deruxtecan | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 1,
"rest_events_topic": " Biomarkers",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403481');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDavid Planchard",
"kol_full_name": "David Planchard"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Receptor, ErbB-2 | Solid Tumor",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403474",
"session_name": "Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Dazhi Liu",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232964",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232964",
"events_session": "Characterization of diverse targetable ERBB2 alterations in 512",
"rest_events_session_count": 1,
"rest_events_session": "993 patients with solid tumors",
"events_topic": "Receptor, ErbB-2 | Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403474');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDazhi Liu",
"kol_full_name": "Dazhi Liu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Brain Neoplasms | Randomized Controlled Trials As Topic",
"npi_num": "1770800146",
"hcp_pin_alias": "PAST_HCP_CNS_204732",
"session_name": "Coping in caregivers of patients with primary malignant brain tumors: A mediation analysis of a randomized controlled trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Deborah Anne Forst",
"middle_name": "",
"last_name": "",
"org_name": "Massachusetts General Hospital",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232214",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232214",
"events_session": "Coping in caregivers of patients with primary malignant brain tumors: A mediation analysis of a randomized controlled trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Brain Neoplasms | Randomized Controlled Trials As Topic",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1770800146,'PAST_HCP_CNS_204732');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDeborah Anne Forst",
"kol_full_name": "Deborah Anne Forst"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Enzalutamide | Prostatic Neoplasms | Hormone Therapy | Castration",
"npi_num": "1164652947",
"hcp_pin_alias": "FU_HCP_159124",
"session_name": "A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Deepak Kilari",
"middle_name": "",
"last_name": "",
"org_name": "Division of Hematology and Oncology, The Medical College of Wisconsin",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232662",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232662",
"events_session": "A phase II trial of enzalutamide (Enz) with 5-alpha reductase inhibitors (5-ARI) as an androgen deprivation therapy (ADT)–sparing approach for older men with castration-sensitive prostate cancer (CSPC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Enzalutamide | Prostatic Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Hormone Therapy | Castration",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1164652947,'FU_HCP_159124');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDeepak Kilari",
"kol_full_name": "Deepak Kilari"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Gastrointestinal Neoplasms",
"npi_num": "1255727392",
"hcp_pin_alias": "FU_HCP_5403365",
"session_name": "Non-colorectal GI malignancies in the young: Incidence trends, demographic disparities, and survival analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Deepak Vadehra",
"middle_name": "",
"last_name": "",
"org_name": "Roswell Park Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232812",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232812",
"events_session": "Non-colorectal GI malignancies in the young: Incidence trends",
"rest_events_session_count": 2,
"rest_events_session": " demographic disparities, and survival analysis",
"events_topic": "Gastrointestinal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1255727392,'FU_HCP_5403365');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDeepak Vadehra",
"kol_full_name": "Deepak Vadehra"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Folfirinox | Carcinoma, Pancreatic Ductal | Atezolizumab",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403465",
"session_name": "Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Dirk Arnold",
"middle_name": "",
"last_name": "",
"org_name": "AK Altona, Asklepios Tumourzentrum Hamburg",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232861",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232861",
"events_session": "Phase 1/2 randomized",
"rest_events_session_count": 3,
"rest_events_session": " open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma",
"events_topic": "Folfirinox | Carcinoma, Pancreatic Ductal ",
"rest_events_topic_count": 1,
"rest_events_topic": " Atezolizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403465');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDirk Arnold",
"kol_full_name": "Dirk Arnold"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hematopoietic Stem Cell Transplantation | Biomarkers",
"npi_num": "1114192242",
"hcp_pin_alias": "FU_HCP_187182",
"session_name": "Biomarkers in a phase 1b study of investigational microbiome therapeutic SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Doris M. Ponce",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232342",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232342",
"events_session": "Biomarkers in a phase 1b study of investigational microbiome therapeutic SER-155 in adults undergoing allogeneic hematopoietic cell transplantation (allo-HCT)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Hematopoietic Stem Cell Transplantation | Biomarkers",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1114192242,'FU_HCP_187182');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EDoris M. Ponce",
"kol_full_name": "Doris M. Ponce"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Stomach Neoplasms | Gastroesophageal Junction Adenocarcinoma | Nivolumab",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403460",
"session_name": "Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Elena Elimova",
"middle_name": "",
"last_name": "",
"org_name": "Princess Margaret Cancer Centre",
"Country": "Canada",
"Region": "Ontario",
"City": "Toronto",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232816",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232816",
"events_session": "Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Chemotherapy | Stomach Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Gastroesophageal Junction Adenocarcinoma | Nivolumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403460');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EElena Elimova",
"kol_full_name": "Elena Elimova"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Enfortumab Vedotin | Genitourinary Tumors",
"npi_num": "1972279818",
"hcp_pin_alias": "FU_HCP_5403359",
"session_name": "A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Elias Chandran",
"middle_name": "",
"last_name": "",
"org_name": "Genitourinary Malignancies Branch, CCR, NCI, NIH",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232615",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232615",
"events_session": "A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pembrolizumab | Enfortumab Vedotin ",
"rest_events_topic_count": 1,
"rest_events_topic": " Genitourinary Tumors",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1972279818,'FU_HCP_5403359');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EElias Chandran",
"kol_full_name": "Elias Chandran"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Bruton's Tyrosine Kinase | Leukemia, Lymphocytic, Chronic, B-Cell",
"npi_num": "1255776092",
"hcp_pin_alias": "FU_HCP_99608",
"session_name": "A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed/refractory B-cell malignancies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Elise A. Chong",
"middle_name": "",
"last_name": "",
"org_name": "Lymphoma Program, Division of Hematology-Oncology, Hospital of the University of Pennsylvania",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232388",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232388",
"events_session": "A first-in-human study of the potent and highly selective BTK degrader ABBV-101 in patients with relapsed/refractory B-cell malignancies",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Bruton's Tyrosine Kinase | Leukemia, Lymphocytic, Chronic, B-Cell",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1255776092,'FU_HCP_99608');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EElise A. Chong",
"kol_full_name": "Elise A. Chong"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Gastrointestinal Neoplasms | Pancreatic Neoplasms | Biomarkers",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403434",
"session_name": "Clinical Application of New Biomarkers in Upper Gastrointestinal and Hepatopancreaticobiliary Cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Elizabeth Catherine Smyth",
"middle_name": "",
"last_name": "",
"org_name": "Oxford University Hospitals NHS Foundation Trust",
"Country": "United Kingdom",
"Region": "England",
"City": "Oxford",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232484",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232484",
"events_session": "Clinical Application of New Biomarkers in Upper Gastrointestinal and Hepatopancreaticobiliary Cancers",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Gastrointestinal Neoplasms | Pancreatic Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Biomarkers",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403434');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EElizabeth Catherine Smyth",
"kol_full_name": "Elizabeth Catherine Smyth"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Skin Neoplasms | Melanoma",
"npi_num": "1437292828",
"hcp_pin_alias": "FU_HCP_41982",
"session_name": "Melanoma/Skin Cancers: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Elizabeth Iannot Buchbinder",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233241",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233241",
"events_session": "Melanoma/Skin Cancers: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Skin Neoplasms | Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1437292828,'FU_HCP_41982');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EElizabeth Iannot Buchbinder",
"kol_full_name": "Elizabeth Iannot Buchbinder"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1275876989",
"hcp_pin_alias": "FU_HCP_0008700",
"session_name": "Care Delivery/Models of Care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Elizabeth Jane Cathcart-Rake",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232019",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232019",
"events_session": "Care Delivery/Models of Care",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1275876989,'FU_HCP_0008700');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EElizabeth Jane Cathcart-Rake",
"kol_full_name": "Elizabeth Jane Cathcart-Rake"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1689969206",
"hcp_pin_alias": "FU_HCP_283997",
"session_name": "Pediatric Oncology",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Elizabeth Sokol",
"middle_name": "",
"last_name": "",
"org_name": "Lurie Children's Hospital",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232026",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232026",
"events_session": "Pediatric Oncology",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1689969206,'FU_HCP_283997');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EElizabeth Sokol",
"kol_full_name": "Elizabeth Sokol"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carboplatin | Cisplatin | Solid Tumor",
"npi_num": "1528202579",
"hcp_pin_alias": "FU_HCP_42793",
"session_name": "Impact of carboplatin and cisplatin shortages on treatment patterns in patients with metastatic solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Emily Castellanos",
"middle_name": "",
"last_name": "",
"org_name": "Flatiron Health",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232420",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232420",
"events_session": "Impact of carboplatin and cisplatin shortages on treatment patterns in patients with metastatic solid tumors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carboplatin | Cisplatin ",
"rest_events_topic_count": 1,
"rest_events_topic": " Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1528202579,'FU_HCP_42793');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEmily Castellanos",
"kol_full_name": "Emily Castellanos"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Trastuzumab Deruxtecan | Desmoplastic Small Round Cell Tumor",
"npi_num": "1841599636",
"hcp_pin_alias": "FU_HCP_45600",
"session_name": "Off-label use of fam-trastuzumab deruxtecan-nxki with early activity in a cohort of patients with desmoplastic small round cell tumor",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Emily K Slotkin",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232913",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232913",
"events_session": "Off-label use of fam-trastuzumab deruxtecan-nxki with early activity in a cohort of patients with desmoplastic small round cell tumor",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Trastuzumab Deruxtecan | Desmoplastic Small Round Cell Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1841599636,'FU_HCP_45600');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEmily K Slotkin",
"kol_full_name": "Emily K Slotkin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cardiovascular Diseases | Cancer Survivors",
"npi_num": "1881700235",
"hcp_pin_alias": "FU_HCP_186825",
"session_name": "Communicating cardiovascular health information and improving coordination with primary care: A Childhood Cancer Survivor Study randomized trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Eric Jessen Chow",
"middle_name": "",
"last_name": "",
"org_name": "Fred Hutchinson Cancer Center",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232294",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232294",
"events_session": "Communicating cardiovascular health information and improving coordination with primary care: A Childhood Cancer Survivor Study randomized trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Cardiovascular Diseases | Cancer Survivors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1881700235,'FU_HCP_186825');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEric Jessen Chow",
"kol_full_name": "Eric Jessen Chow"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Early Detection Of Cancer",
"npi_num": "1083612568",
"hcp_pin_alias": "FU_HCP_250258",
"session_name": "Changing the Paradigm: Use of a Multi-Cancer Early Detection Test to Screen for Many Aggressive Cancers That Lack Recommended Screenings",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Eric Klein",
"middle_name": "",
"last_name": "",
"org_name": "GRAIL, LLC",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233153",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233153",
"events_session": "Changing the Paradigm: Use of a Multi-Cancer Early Detection Test to Screen for Many Aggressive Cancers That Lack Recommended Screenings",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Early Detection Of Cancer",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1083612568,'FU_HCP_250258');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEric Klein",
"kol_full_name": "Eric Klein"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms",
"npi_num": "1790282499",
"hcp_pin_alias": "FU_HCP_394408",
"session_name": "Genomic alterations in early-onset versus average-onset stage IV colorectal cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Eric Michael Lander",
"middle_name": "",
"last_name": "",
"org_name": "Division of Hematology/Oncology, Vanderbilt University Medical Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232882",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232882",
"events_session": "Genomic alterations in early-onset versus average-onset stage IV colorectal cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colorectal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790282499,'FU_HCP_394408');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEric Michael Lander",
"kol_full_name": "Eric Michael Lander"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immune Checkpoint Inhibitors | Colorectal Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403468",
"session_name": "Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO26 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Eric Xueyu Chen",
"middle_name": "",
"last_name": "",
"org_name": "University Health Network",
"Country": "Canada",
"Region": "Ontario",
"City": "Toronto",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232883",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232883",
"events_session": "Artemin and immune checkpoint inhibitor (ICI) efficacy in metastatic colorectal cancer (mCRC): A correlative analysis of the Canadian Cancer Trials Group (CCTG) CO26 trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immune Checkpoint Inhibitors | Colorectal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403468');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEric Xueyu Chen",
"kol_full_name": "Eric Xueyu Chen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Delivery Of Health Care | Admin. & Management",
"npi_num": "1699031740",
"hcp_pin_alias": "PAST_HCP_Future Events_316858",
"session_name": "Care Delivery/Models of Care: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Erin F. Gillespie",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233175",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233175",
"events_session": "Care Delivery/Models of Care: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Delivery Of Health Care | Admin. & Management",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1699031740,'PAST_HCP_Future Events_316858');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EErin F. Gillespie",
"kol_full_name": "Erin F. Gillespie"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms",
"npi_num": "1093949745",
"hcp_pin_alias": "FU_HCP_110396",
"session_name": "Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Erin Frances Cobain",
"middle_name": "",
"last_name": "",
"org_name": "University of Michigan",
"Country": "United States",
"Region": "Michigan",
"City": "Ann Arbor",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232149",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232149",
"events_session": "Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1093949745,'FU_HCP_110396');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EErin Frances Cobain",
"kol_full_name": "Erin Frances Cobain"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nivolumab | Ipilimumab | Trabectedin | Soft Tissue Sarcoma",
"npi_num": "1922191717",
"hcp_pin_alias": "FU_HCP_0000931",
"session_name": "Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I), nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Erlinda Maria Gordon",
"middle_name": "",
"last_name": "",
"org_name": "Sarcoma Oncology Research Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232912",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232912",
"events_session": "Seven year update on SOC-1702: A phase 2 study using trabectedin (T) in combination with ipilimumab (I)",
"rest_events_session_count": 1,
"rest_events_session": " nivolumab (N) and trabectedin (T) in previously untreated patients with advanced soft tissue sarcoma",
"events_topic": "Nivolumab | Ipilimumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Trabectedin | Soft Tissue Sarcoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1922191717,'FU_HCP_0000931');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EErlinda Maria Gordon",
"kol_full_name": "Erlinda Maria Gordon"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms | Enoblituzumab | Neoadjuvant Therapy",
"npi_num": "1720358633",
"hcp_pin_alias": "FU_HCP_44569",
"session_name": "A phase 2 randomized trial of neoadjuvant enoblituzumab versus standard of care in men with high-risk localized prostate cancer: The help elucidate and attack longitudinally (HEAT) prostate cancer randomized study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Eugene Shenderov",
"middle_name": "",
"last_name": "",
"org_name": "Johns Hopkins University School of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232672",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232672",
"events_session": "A phase 2 randomized trial of neoadjuvant enoblituzumab versus standard of care in men with high-risk localized prostate cancer: The help elucidate and attack longitudinally (HEAT) prostate cancer randomized study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms | Enoblituzumab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Neoadjuvant Therapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1720358633,'FU_HCP_44569');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEugene Shenderov",
"kol_full_name": "Eugene Shenderov"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immune Checkpoint Inhibitors | Sarcoma | Myxofibrosarcoma",
"npi_num": "1104246032",
"hcp_pin_alias": "FU_HCP_282024",
"session_name": "Do patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma have different clinical outcomes to immune checkpoint blockade-based therapy?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Evan Rosenbaum",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232910",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232910",
"events_session": "Do patients with myxofibrosarcoma and undifferentiated pleomorphic sarcoma have different clinical outcomes to immune checkpoint blockade-based therapy?",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immune Checkpoint Inhibitors | Sarcoma ",
"rest_events_topic_count": 1,
"rest_events_topic": " Myxofibrosarcoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1104246032,'FU_HCP_282024');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EEvan Rosenbaum",
"kol_full_name": "Evan Rosenbaum"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Transcription Factors | Glioblastoma",
"npi_num": "1053623934",
"hcp_pin_alias": "PAST_HCP_CNS_220333",
"session_name": "Efficacy and biomarker analysis of phase 2 (P2) and window-of-opportunity (WoO) cohorts of patients with recurrent glioblastoma (rGBM) treated with ST101, an inhibitor of the transcription factor C/EBPβ",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Fabio Massaiti Iwamoto",
"middle_name": "",
"last_name": "",
"org_name": "Columbia University Irving Medical Center",
"Country": "United States",
"Region": "New York",
"City": "Yonkers",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232757",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232757",
"events_session": "Efficacy and biomarker analysis of phase 2 (P2) and window-of-opportunity (WoO) cohorts of patients with recurrent glioblastoma (rGBM) treated with ST101",
"rest_events_session_count": 1,
"rest_events_session": " an inhibitor of the transcription factor C/EBPβ",
"events_topic": "Transcription Factors | Glioblastoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1053623934,'PAST_HCP_CNS_220333');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFabio Massaiti Iwamoto",
"kol_full_name": "Fabio Massaiti Iwamoto"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab | Sotorasib | Chemotherapy",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403404",
"session_name": "Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Fabrice Barlesi",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232192",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232192",
"events_session": "Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced",
"rest_events_session_count": 2,
"rest_events_session": " PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Sotorasib | Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403404');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFabrice Barlesi",
"kol_full_name": "Fabrice Barlesi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Psychological Distress | Small Cell Lung Cancer",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403409",
"session_name": "Association between psychological distress and treatment efficacy in patients with newly diagnosed SCLC",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Fang Wu",
"middle_name": "",
"last_name": "",
"org_name": "The Second Xiangya Hospital, Central South University",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232212",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232212",
"events_session": "Association between psychological distress and treatment efficacy in patients with newly diagnosed SCLC",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Psychological Distress | Small Cell Lung Cancer",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403409');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFang Wu",
"kol_full_name": "Fang Wu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Fruquintinib | Paclitaxel | Gastroesophageal Junction Adenocarcinoma",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403472",
"session_name": "Updates on Abstract 438730: Fruquintinib Plus Paclitaxel Versus Paclitaxel as Second-Line Therapy for Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (FRUTIGA): A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Feng Wang",
"middle_name": "",
"last_name": "",
"org_name": "Sun Yat-sen University Cancer Center",
"Country": "China",
"Region": "Guangdong",
"City": "Guangzhou",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232937",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232937",
"events_session": "Updates on Abstract 438730: Fruquintinib Plus Paclitaxel Versus Paclitaxel as Second-Line Therapy for Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (FRUTIGA): A Randomized",
"rest_events_session_count": 4,
"rest_events_session": " Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study",
"events_topic": "Fruquintinib | Paclitaxel ",
"rest_events_topic_count": 1,
"rest_events_topic": " Gastroesophageal Junction Adenocarcinoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403472');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFeng Wang",
"kol_full_name": "Feng Wang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Radiotherapy | Durvalumab | Carcinoma, Pancreatic Ductal",
"npi_num": "1275290165",
"hcp_pin_alias": "FU_HCP_394590",
"session_name": "Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and correlative insights",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Fergus Keane",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232845",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232845",
"events_session": "Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and correlative insights",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Radiotherapy | Durvalumab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Carcinoma, Pancreatic Ductal",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1275290165,'FU_HCP_394590');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFergus Keane",
"kol_full_name": "Fergus Keane"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1902333545",
"hcp_pin_alias": "FU_HCP_5403339",
"session_name": "Navigating ASCO 2024: Tips to Optimize Your Meeting Experience",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Fernando Cristobal Diaz",
"middle_name": "",
"last_name": "",
"org_name": "The University of North Carolina at Chapel Hill",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232096",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232096",
"events_session": "Navigating ASCO 2024: Tips to Optimize Your Meeting Experience",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1902333545,'FU_HCP_5403339');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFernando Cristobal Diaz",
"kol_full_name": "Fernando Cristobal Diaz"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Clinical Trials As Topic | Artificial Intelligence",
"npi_num": "1518191071",
"hcp_pin_alias": "FU_HCP_5403377",
"session_name": "Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Frank Po-Yen Lin",
"middle_name": "",
"last_name": "",
"org_name": "NHMRC Clinical Trials Centre, The University of Sydney",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233050",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233050",
"events_session": "Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Clinical Trials As Topic | Artificial Intelligence",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1518191071,'FU_HCP_5403377');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EFrank Po-Yen Lin",
"kol_full_name": "Frank Po-Yen Lin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1902420268",
"hcp_pin_alias": "FU_HCP_232409",
"session_name": "Start low, go slow: A systematic review and meta-analysis of upfront tailored treatment dosing in older adults with advanced cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Gabriel Aleixo",
"middle_name": "",
"last_name": "",
"org_name": "University of Pennsylvania",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233059",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233059",
"events_session": "Start low",
"rest_events_session_count": 1,
"rest_events_session": " go slow: A systematic review and meta-analysis of upfront tailored treatment dosing in older adults with advanced cancer",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1902420268,'FU_HCP_232409');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGabriel Aleixo",
"kol_full_name": "Gabriel Aleixo"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Temozolomide | Ibudilast | Glioblastoma",
"npi_num": "1891250981",
"hcp_pin_alias": "FU_HCP_249518",
"session_name": "Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Gilbert Youssef",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232521",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232521",
"events_session": "Phase 1b/2a study evaluating the combination of MN-166 (ibudilast) and temozolomide in patients with newly diagnosed and recurrent glioblastoma (GBM)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Temozolomide | Ibudilast ",
"rest_events_topic_count": 1,
"rest_events_topic": " Glioblastoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1891250981,'FU_HCP_249518');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGilbert Youssef",
"kol_full_name": "Gilbert Youssef"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Digital Health | Neoplasms",
"npi_num": "1326207507",
"hcp_pin_alias": "FU_HCP_186965",
"session_name": "Integrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Gita Thanarajasingam",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233051",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233051",
"events_session": "Integrating 4 Methods (In4M) to evaluate physical function in patients with cancer: Results of a comprehensive digital health study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Digital Health | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1326207507,'FU_HCP_186965');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EGita Thanarajasingam",
"kol_full_name": "Gita Thanarajasingam"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Palliative Care",
"npi_num": "1700840683",
"hcp_pin_alias": "FU_HCP_154787",
"session_name": "Symptom Science and Palliatve Care: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Halle C. F. Moore",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233257",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233257",
"events_session": "Symptom Science and Palliatve Care: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Palliative Care",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700840683,'FU_HCP_154787');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHalle C. F. Moore",
"kol_full_name": "Halle C. F. Moore"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "CDK7 Protein, Human | Solid Tumor",
"npi_num": "1417368085",
"hcp_pin_alias": "FU_HCP_75888",
"session_name": "A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Hao Xie",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232953",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232953",
"events_session": "A first-in-human trial of selective CDK7 inhibitor Q901",
"rest_events_session_count": 1,
"rest_events_session": " in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009)",
"events_topic": "CDK7 Protein, Human | Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1417368085,'FU_HCP_75888');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHao Xie",
"kol_full_name": "Hao Xie"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Circulating Tumor DNA",
"npi_num": "1063655710",
"hcp_pin_alias": "FU_HCP_100171",
"session_name": "Are We There Yet? Moving ctDNA Into Clinical Practice",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Heather Anne Parsons",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute, Harvard Medical School",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232490",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232490",
"events_session": "Are We There Yet? Moving ctDNA Into Clinical Practice",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Circulating Tumor DNA",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1063655710,'FU_HCP_100171');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHeather Anne Parsons",
"kol_full_name": "Heather Anne Parsons"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Monoclonal Gammopathy Of Undetermined Significance",
"npi_num": "1841600186",
"hcp_pin_alias": "FU_HCP_230131",
"session_name": "Long term follow up of monoclonal gammopathy of undetermined significance (MGUS) in US Veterans: Racial differences and associations with other malignancies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Helen Ma",
"middle_name": "",
"last_name": "",
"org_name": "VA Long Beach Healthcare System",
"Country": "United States",
"Region": "California",
"City": "Long Beach",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232366",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232366",
"events_session": "Long term follow up of monoclonal gammopathy of undetermined significance (MGUS) in US Veterans: Racial differences and associations with other malignancies",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms | Monoclonal Gammopathy Of Undetermined Significance",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1841600186,'FU_HCP_230131');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHelen Ma",
"kol_full_name": "Helen Ma"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Radiotherapy | Neoplasms",
"npi_num": "1730441544",
"hcp_pin_alias": "FU_HCP_44659",
"session_name": "Radiation Oncologist Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Henry Soo-Min Park",
"middle_name": "",
"last_name": "",
"org_name": "Yale School of Medicine",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232532",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232532",
"events_session": "Radiation Oncologist Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Radiotherapy | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1730441544,'FU_HCP_44659');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHenry Soo-Min Park",
"kol_full_name": "Henry Soo-Min Park"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cdh1 Proteins",
"npi_num": "1619549177",
"hcp_pin_alias": "FU_HCP_5403345",
"session_name": "Large cohort analysis of incidental CDH1 PVs among patients undergoing MGPT",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Hiam Abdel-Salam",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232236",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232236",
"events_session": "Large cohort analysis of incidental CDH1 PVs among patients undergoing MGPT",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Cdh1 Proteins",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1619549177,'FU_HCP_5403345');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHiam Abdel-Salam",
"kol_full_name": "Hiam Abdel-Salam"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403445",
"session_name": "Germline gene-specific associations in a large prostate cancer cohort",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Hiba M Khan",
"middle_name": "",
"last_name": "",
"org_name": "University of Washington/Fred Hutch Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232665",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232665",
"events_session": "Germline gene-specific associations in a large prostate cancer cohort",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403445');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHiba M Khan",
"kol_full_name": "Hiba M Khan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Small Cell Lung Carcinoma | Monalizumab | Durvalumab | Chemotherapy",
"npi_num": "1437446820",
"hcp_pin_alias": "FU_HCP_42008",
"session_name": "A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Hirva Mamdani",
"middle_name": "",
"last_name": "",
"org_name": "Wayne State University",
"Country": "United States",
"Region": "Michigan",
"City": "Detroit",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232259",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232259",
"events_session": "A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART): Hoosier Cancer Research Network LUN21-530 study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Small Cell Lung Carcinoma | Monalizumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Durvalumab | Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1437446820,'FU_HCP_42008');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHirva Mamdani",
"kol_full_name": "Hirva Mamdani"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immune Checkpoint Inhibitors",
"npi_num": "1902254188",
"hcp_pin_alias": "FU_HCP_284773",
"session_name": "The toxicity swimmer plot: A novel approach for evaluating patient-level toxicity following immune checkpoint inhibitor (ICI) therapy on the Checkmate 214 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Hollis Viray",
"middle_name": "",
"last_name": "",
"org_name": "Beth Israel Deaconess Medical Center",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232280",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232280",
"events_session": "The toxicity swimmer plot: A novel approach for evaluating patient-level toxicity following immune checkpoint inhibitor (ICI) therapy on the Checkmate 214 trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immune Checkpoint Inhibitors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1902254188,'FU_HCP_284773');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHollis Viray",
"kol_full_name": "Hollis Viray"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms | Neoplasm, Residual | Circulating Tumor DNA | Chemotherapy, Adjuvant",
"npi_num": "1356541957",
"hcp_pin_alias": "FU_HCP_41287",
"session_name": "Personalized circulating tumor DNA for minimal residual disease and dynamic assessment in patients undergoing neoadjuvant chemotherapy for breast cancer: Preliminary analysis from MSK-LINC",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Hong-Kyu Kim",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232945",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232945",
"events_session": "Personalized circulating tumor DNA for minimal residual disease and dynamic assessment in patients undergoing neoadjuvant chemotherapy for breast cancer: Preliminary analysis from MSK-LINC",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms | Neoplasm, Residual ",
"rest_events_topic_count": 2,
"rest_events_topic": " Circulating Tumor DNA | Chemotherapy, Adjuvant",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356541957,'FU_HCP_41287');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EHong-Kyu Kim",
"kol_full_name": "Hong-Kyu Kim"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Esophageal Squamous Cell Carcinoma | Nivolumab",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403458",
"session_name": "Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ian Chau",
"middle_name": "",
"last_name": "",
"org_name": "Royal Marsden Hospital",
"Country": "United Kingdom",
"Region": "England",
"City": "London",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232814",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232814",
"events_session": "Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 45-month (mo) follow-up from CheckMate 648",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Chemotherapy | Esophageal Squamous Cell Carcinoma ",
"rest_events_topic_count": 1,
"rest_events_topic": " Nivolumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403458');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EIan Chau",
"kol_full_name": "Ian Chau"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms | Chemotherapy, Adjuvant",
"npi_num": "1598380297",
"hcp_pin_alias": "FU_HCP_284059",
"session_name": "Trends, patterns, and outcomes of neoadjuvant chemotherapy (NACT) use among patients with early invasive triple negative breast cancer (TNBC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Inimfon Jackson",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232634",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232634",
"events_session": "Trends",
"rest_events_session_count": 2,
"rest_events_session": " patterns, and outcomes of neoadjuvant chemotherapy (NACT) use among patients with early invasive triple negative breast cancer (TNBC)",
"events_topic": "Triple Negative Breast Neoplasms | Chemotherapy, Adjuvant",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1598380297,'FU_HCP_284059');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EInimfon Jackson",
"kol_full_name": "Inimfon Jackson"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms | Artificial Intelligence",
"npi_num": "1033460316",
"hcp_pin_alias": "FU_HCP_100243",
"session_name": "Using Artificial Intelligence to Optimize Systemic Therapy for Prostate Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Irbaz Bin Riaz",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232307",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232307",
"events_session": "Using Artificial Intelligence to Optimize Systemic Therapy for Prostate Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms | Artificial Intelligence",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1033460316,'FU_HCP_100243');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EIrbaz Bin Riaz",
"kol_full_name": "Irbaz Bin Riaz"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1942852876",
"hcp_pin_alias": "FU_HCP_229525",
"session_name": "Linking in with advice and supports for men impacted by metastatic cancer: The LIAM Mc trial (NCT05946993)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jack Gleeson",
"middle_name": "",
"last_name": "",
"org_name": "University College Cork",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233065",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233065",
"events_session": "Linking in with advice and supports for men impacted by metastatic cancer: The LIAM Mc trial (NCT05946993)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1942852876,'FU_HCP_229525');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJack Gleeson",
"kol_full_name": "Jack Gleeson"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Pancreatic Ductal | Genetic Profile",
"npi_num": "1033565163",
"hcp_pin_alias": "FU_HCP_38434",
"session_name": "Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jacquelyne Janean Gaddy",
"middle_name": "",
"last_name": "",
"org_name": "Yale Cancer Center",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232838",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232838",
"events_session": "Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Pancreatic Ductal | Genetic Profile",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1033565163,'FU_HCP_38434');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJacquelyne Janean Gaddy",
"kol_full_name": "Jacquelyne Janean Gaddy"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hematologic Neoplasms",
"npi_num": "1528446242",
"hcp_pin_alias": "FU_HCP_5403349",
"session_name": "Artful oncology: A comprehensive psychosocial oncology curriculum for hematology/oncology fellows",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jafar Al-Mondhiry",
"middle_name": "",
"last_name": "",
"org_name": "Inova Schar Cancer Institute",
"Country": "United States",
"Region": "Virginia",
"City": "Falls Church",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232319",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232319",
"events_session": "Artful oncology: A comprehensive psychosocial oncology curriculum for hematology/oncology fellows",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Hematologic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1528446242,'FU_HCP_5403349');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJafar Al-Mondhiry",
"kol_full_name": "Jafar Al-Mondhiry"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Surgical Procedures, Operative | Breast Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403479",
"session_name": "Use of surgery for de novo metastatic breast cancer (mBC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "James Dickerson",
"middle_name": "",
"last_name": "",
"org_name": "Stanford Hospital and Clinics",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233055",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233055",
"events_session": "Use of surgery for de novo metastatic breast cancer (mBC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Surgical Procedures, Operative | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403479');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJames Dickerson",
"kol_full_name": "James Dickerson"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Relatlimab | Nivolumab | Melanoma",
"npi_num": "1215467097",
"hcp_pin_alias": "FU_HCP_5403364",
"session_name": "A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "James William Smithy",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232803",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232803",
"events_session": "A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated",
"rest_events_session_count": 1,
"rest_events_session": " unresectable melanoma",
"events_topic": "Relatlimab | Nivolumab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Melanoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1215467097,'FU_HCP_5403364');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJames William Smithy",
"kol_full_name": "James William Smithy"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Tumor Microenvironment | Breast Neoplasms | Carcinoma, Lobular",
"npi_num": "1750793204",
"hcp_pin_alias": "FU_HCP_282702",
"session_name": "The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jason A Mouabbi",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232683",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232683",
"events_session": "The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Tumor Microenvironment | Breast Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Carcinoma, Lobular",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1750793204,'FU_HCP_282702');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJason A Mouabbi",
"kol_full_name": "Jason A Mouabbi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1619142023",
"hcp_pin_alias": "FU_HCP_229848",
"session_name": "How to Communicate About Prognosis When Faced With the Extremes of Prognostic Uncertainty",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jason Webb",
"middle_name": "",
"last_name": "",
"org_name": "Oregon Health & Science University",
"Country": "United States",
"Region": "Oregon",
"City": "Portland",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232305",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232305",
"events_session": "How to Communicate About Prognosis When Faced With the Extremes of Prognostic Uncertainty",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1619142023,'FU_HCP_229848');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJason Webb",
"kol_full_name": "Jason Webb"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colonic Neoplasms | Chemotherapy, Adjuvant | Circulating Tumor DNA",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403420",
"session_name": "Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jeanne Tie",
"middle_name": "",
"last_name": "",
"org_name": "Peter MacCallum Cancer Centre and Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232313",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232313",
"events_session": "Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colonic Neoplasms | Chemotherapy, Adjuvant ",
"rest_events_topic_count": 1,
"rest_events_topic": " Circulating Tumor DNA",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403420');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJeanne Tie",
"kol_full_name": "Jeanne Tie"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Squamous Cell Carcinoma Of Head And Neck",
"npi_num": "1881650356",
"hcp_pin_alias": "FU_HCP_5403332",
"session_name": "Cutaneous Squamous Cell Carcinoma in the Head and Neck: A Multidisciplinary Case-Based Approach to Treatment",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jennifer E. Schwartz",
"middle_name": "",
"last_name": "",
"org_name": "Indiana University School of Medicine",
"Country": "United States",
"Region": "Indiana",
"City": "Indianapolis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232011",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232011",
"events_session": "Cutaneous Squamous Cell Carcinoma in the Head and Neck: A Multidisciplinary Case-Based Approach to Treatment",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Squamous Cell Carcinoma Of Head And Neck",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1881650356,'FU_HCP_5403332');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJennifer E. Schwartz",
"kol_full_name": "Jennifer E. Schwartz"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1700949609",
"hcp_pin_alias": "FU_HCP_44393",
"session_name": "Discussion on Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jennifer J. Griggs",
"middle_name": "",
"last_name": "",
"org_name": "Rogel Cancer Center, University of Michigan",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232745",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232745",
"events_session": "Discussion on Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700949609,'FU_HCP_44393');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJennifer J. Griggs",
"kol_full_name": "Jennifer J. Griggs"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Brain Neoplasms",
"npi_num": "1184193013",
"hcp_pin_alias": "FU_HCP_283393",
"session_name": "Management of progressive brain metastases in patients (pts) with relapsed germ-cell tumor (GCT) treated with salvage high-dose chemotherapy (HDCT)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jennifer King",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232646",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232646",
"events_session": "Management of progressive brain metastases in patients (pts) with relapsed germ-cell tumor (GCT) treated with salvage high-dose chemotherapy (HDCT)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Chemotherapy | Brain Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1184193013,'FU_HCP_283393');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJennifer King",
"kol_full_name": "Jennifer King"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Surgical Procedures, Operative | Neoplasms",
"npi_num": "1609850395",
"hcp_pin_alias": "PAST_HCP_Onco_232853",
"session_name": "Surgical Oncologist Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jennifer Tseng",
"middle_name": "",
"last_name": "",
"org_name": "City of Hope Comprehensive Cancer Center",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232289",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232289",
"events_session": "Surgical Oncologist Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Surgical Procedures, Operative | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1609850395,'PAST_HCP_Onco_232853');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJennifer Tseng",
"kol_full_name": "Jennifer Tseng"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Renal Cell | Carcinoma",
"npi_num": "1104804970",
"hcp_pin_alias": "FU_HCP_110406",
"session_name": "A Multidisciplinary Approach to Managing the Toxicities Associated With Renal Cell Carcinoma Therapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jeremy Paul Cetnar",
"middle_name": "",
"last_name": "",
"org_name": "Oregon Health & Science University",
"Country": "United States",
"Region": "Oregon",
"City": "Portland",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231973",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231973",
"events_session": "A Multidisciplinary Approach to Managing the Toxicities Associated With Renal Cell Carcinoma Therapy",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Renal Cell | Carcinoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1104804970,'FU_HCP_110406');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJeremy Paul Cetnar",
"kol_full_name": "Jeremy Paul Cetnar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Melphalan | Multiple Myeloma | Stem Cell Transplantation | Neoplasm, Residual",
"npi_num": "1104479880",
"hcp_pin_alias": "FU_HCP_5403350",
"session_name": "Effect of dose-adjusted melphalan on MRD-negativity to full dose melphalan in patients with multiple myeloma post-autologous stem cell transplant",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jeries Kort",
"middle_name": "",
"last_name": "",
"org_name": "University Hospitals Cleveland Medical Center/ Case Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232362",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232362",
"events_session": "Effect of dose-adjusted melphalan on MRD-negativity to full dose melphalan in patients with multiple myeloma post-autologous stem cell transplant",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Melphalan | Multiple Myeloma ",
"rest_events_topic_count": 2,
"rest_events_topic": " Stem Cell Transplantation | Neoplasm, Residual",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1104479880,'FU_HCP_5403350');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJeries Kort",
"kol_full_name": "Jeries Kort"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Anaplastic Lymphoma Kinase | ErbB Receptors",
"npi_num": "1528320975",
"hcp_pin_alias": "FU_HCP_42815",
"session_name": "Striking the Balance With Next-Generation Targeted Therapies for ALK and EGFR",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jessica Jiyeong Lin",
"middle_name": "",
"last_name": "",
"org_name": "Massachusetts General Hospital, Harvard Medical School",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233138",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233138",
"events_session": "Striking the Balance With Next-Generation Targeted Therapies for ALK and EGFR",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Anaplastic Lymphoma Kinase | ErbB Receptors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1528320975,'FU_HCP_42815');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJessica Jiyeong Lin",
"kol_full_name": "Jessica Jiyeong Lin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Adebrelimab | Fuzuloparib | Homologous Recombination Deficiency | Ovarian Neoplasms",
"npi_num": "1801956099",
"hcp_pin_alias": "FU_HCP_99600",
"session_name": "Open-label, phase 2 study of adebrelimab combined with fuzuloparib in the treatment of patients with HRD-positive, recurrent platinum-resistant ovarian cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jian Chen",
"middle_name": "",
"last_name": "",
"org_name": "Department of Gynecology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232443",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232443",
"events_session": "Open-label",
"rest_events_session_count": 2,
"rest_events_session": " phase 2 study of adebrelimab combined with fuzuloparib in the treatment of patients with HRD-positive, recurrent platinum-resistant ovarian cancer",
"events_topic": "Adebrelimab | Fuzuloparib ",
"rest_events_topic_count": 2,
"rest_events_topic": " Homologous Recombination Deficiency | Ovarian Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1801956099,'FU_HCP_99600');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJian Chen",
"kol_full_name": "Jian Chen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Avelumab | Proton Therapy | Radiotherapy | Meningioma",
"npi_num": "1922205004",
"hcp_pin_alias": "FU_HCP_229390",
"session_name": "A phase Ib, window-of-opportunity study of neoadjuvant avelumab and hypofractionated proton beam therapy for recurrent radiation-relapsed meningioma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jiayi Huang",
"middle_name": "",
"last_name": "",
"org_name": "Washington University School of Medicine in St. Louis",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232520",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232520",
"events_session": "A phase Ib",
"rest_events_session_count": 1,
"rest_events_session": " window-of-opportunity study of neoadjuvant avelumab and hypofractionated proton beam therapy for recurrent radiation-relapsed meningioma",
"events_topic": "Avelumab | Proton Therapy ",
"rest_events_topic_count": 2,
"rest_events_topic": " Radiotherapy | Meningioma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1922205004,'FU_HCP_229390');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJiayi Huang",
"kol_full_name": "Jiayi Huang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy, Adoptive | Leukemia, Myeloid, Acute",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403423",
"session_name": "Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jing Pan",
"middle_name": "",
"last_name": "",
"org_name": "State Key Laboratory of Experimental Hematology, Department of Hematology, Beijing Boren Hospital",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232335",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232335",
"events_session": "Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunotherapy, Adoptive | Leukemia, Myeloid, Acute",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403423');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJing Pan",
"kol_full_name": "Jing Pan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genitourinary Tumors | Radiosurgery",
"npi_num": "1295723294",
"hcp_pin_alias": "PAST_HCP_Future Events_313749",
"session_name": "PROSTOX, a signature of late GU toxicity after SBRT radiotherapy in MIRAGE, a prospective trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Joanne B. Weidhaas",
"middle_name": "",
"last_name": "",
"org_name": "Department of Radiation Oncology, University of California, Los Angeles",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232205",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232205",
"events_session": "PROSTOX",
"rest_events_session_count": 2,
"rest_events_session": " a signature of late GU toxicity after SBRT radiotherapy in MIRAGE, a prospective trial",
"events_topic": "Genitourinary Tumors | Radiosurgery",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1295723294,'PAST_HCP_Future Events_313749');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJoanne B. Weidhaas",
"kol_full_name": "Joanne B. Weidhaas"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms | Castration | Circulating Tumor DNA",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403455",
"session_name": "Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Johann S. De Bono",
"middle_name": "",
"last_name": "",
"org_name": "The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232765",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232765",
"events_session": "Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms | Castration ",
"rest_events_topic_count": 1,
"rest_events_topic": " Circulating Tumor DNA",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403455');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJohann S. De Bono",
"kol_full_name": "Johann S. De Bono"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "KRAS Protein, Human | Tumor Suppressor Protein P53 | Pancreatic Neoplasms | Magnetic Resonance Imaging",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403473",
"session_name": "A novel MRI-based tumor-targeting theragnostic agent: Magnetoelectric nanoparticles in an in vivo murine KRAS/P53 pancreatic flank tumor model",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "John Michael Bryant",
"middle_name": "",
"last_name": "",
"org_name": "Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232950",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232950",
"events_session": "A novel MRI-based tumor-targeting theragnostic agent: Magnetoelectric nanoparticles in an in vivo murine KRAS/P53 pancreatic flank tumor model",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "KRAS Protein, Human | Tumor Suppressor Protein P53 ",
"rest_events_topic_count": 2,
"rest_events_topic": " Pancreatic Neoplasms | Magnetic Resonance Imaging",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403473');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJohn Michael Bryant",
"kol_full_name": "John Michael Bryant"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Paclitaxel | Appendiceal Neoplasms",
"npi_num": "1386806131",
"hcp_pin_alias": "FU_HCP_394743",
"session_name": "A phase I/II study of intraperitoneal (IP) paclitaxel (PTX) in patients with metastatic appendiceal adenocarcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "John Paul Y.C. Shen",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232867",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232867",
"events_session": "A phase I/II study of intraperitoneal (IP) paclitaxel (PTX) in patients with metastatic appendiceal adenocarcinoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Paclitaxel | Appendiceal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1386806131,'FU_HCP_394743');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJohn Paul Y.C. Shen",
"kol_full_name": "John Paul Y.C. Shen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Early Detection Of Cancer",
"npi_num": "1427216753",
"hcp_pin_alias": "FU_HCP_282446",
"session_name": "Multicancer Detection: Is It Ready for Prime Time?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jonathan M. Marron",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber/Boston Children's Cancer and Blood Disorders Center",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232094",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232094",
"events_session": "Multicancer Detection: Is It Ready for Prime Time?",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Early Detection Of Cancer",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1427216753,'FU_HCP_282446');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJonathan M. Marron",
"kol_full_name": "Jonathan M. Marron"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms | Anthracyclines | Chemotherapy, Adjuvant | Carboplatin",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403397",
"session_name": "A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Joohyuk Sohn",
"middle_name": "",
"last_name": "",
"org_name": "Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232145",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232145",
"events_session": "A randomized",
"rest_events_session_count": 3,
"rest_events_session": " multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial",
"events_topic": "Triple Negative Breast Neoplasms | Anthracyclines ",
"rest_events_topic_count": 2,
"rest_events_topic": " Chemotherapy, Adjuvant | Carboplatin",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403397');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJoohyuk Sohn",
"kol_full_name": "Joohyuk Sohn"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Afatinib | Solid Tumor | Neuregulin-1",
"npi_num": "1841733102",
"hcp_pin_alias": "PAST_HCP_Onco_231629",
"session_name": "Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jordi Rodon Ahnert",
"middle_name": "",
"last_name": "",
"org_name": "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232966",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232966",
"events_session": "Afatinib in patients (pts) with solid tumors with neuregulin 1 (NRG1) fusions: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Afatinib | Solid Tumor ",
"rest_events_topic_count": 1,
"rest_events_topic": " Neuregulin-1",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1841733102,'PAST_HCP_Onco_231629');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJordi Rodon Ahnert",
"kol_full_name": "Jordi Rodon Ahnert"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Tipiracil | Liver Neoplasms | Trifluridine | Bevacizumab",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403467",
"session_name": "Impact of colorectal liver metastases (CRLM) in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Josep Tabernero",
"middle_name": "",
"last_name": "",
"org_name": "Vall d’Hebron Barcelona Hospital Campus and Institute of Oncology (VHIO)",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232881",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232881",
"events_session": "Impact of colorectal liver metastases (CRLM) in patients with metastatic colorectal cancer (mCRC) receiving trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in the phase 3 SUNLIGHT trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colorectal Neoplasms | Tipiracil ",
"rest_events_topic_count": 3,
"rest_events_topic": " Liver Neoplasms | Trifluridine | Bevacizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403467');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJosep Tabernero",
"kol_full_name": "Josep Tabernero"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cemiplimab | Lymphoma",
"npi_num": "1710333455",
"hcp_pin_alias": "FU_HCP_232408",
"session_name": "A phase 1 dose-escalation and expansion study of an intratumorally administered dual STING agonist (ONM-501) alone and in combination with cemiplimab in patients with advanced solid tumors and lymphomas",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Julia Foldi",
"middle_name": "",
"last_name": "",
"org_name": "University of Pittsburgh Medical Center (UPMC)",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233040",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233040",
"events_session": "A phase 1 dose-escalation and expansion study of an intratumorally administered dual STING agonist (ONM-501) alone and in combination with cemiplimab in patients with advanced solid tumors and lymphomas",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Cemiplimab | Lymphoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1710333455,'FU_HCP_232408');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJulia Foldi",
"kol_full_name": "Julia Foldi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Gastrointestinal Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403419",
"session_name": "Medical Oncologist Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Julien Edeline",
"middle_name": "",
"last_name": "",
"org_name": "Centre Eugène Marquis",
"Country": "France",
"Region": "Bretagne",
"City": "Rennes",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232308",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232308",
"events_session": "Medical Oncologist Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Gastrointestinal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403419');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJulien Edeline",
"kol_full_name": "Julien Edeline"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemoradiotherapy | Cervical Squamous Cell Carcinoma | Nimotuzumab",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403480",
"session_name": "Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jun jie Wang",
"middle_name": "",
"last_name": "",
"org_name": "Peking University Third Hospital",
"Country": "China",
"Region": "Beijing",
"City": "Beijing",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233091",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233091",
"events_session": "Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized",
"rest_events_session_count": 1,
"rest_events_session": " phase 3 CC3 study",
"events_topic": "Chemoradiotherapy | Cervical Squamous Cell Carcinoma ",
"rest_events_topic_count": 1,
"rest_events_topic": " Nimotuzumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403480');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJun jie Wang",
"kol_full_name": "Jun jie Wang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immune Checkpoint Inhibitors | Organ-specific Neoantigen | Neoplasms",
"npi_num": "1578586301",
"hcp_pin_alias": "FU_HCP_100456",
"session_name": "Organ-specific immune-related adverse events and survival in patients with cancer with immune checkpoint inhibitors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Jun Wang",
"middle_name": "",
"last_name": "",
"org_name": "The First Affiliated Hospital with Shandong First Medical University",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232216",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232216",
"events_session": "Organ-specific immune-related adverse events and survival in patients with cancer with immune checkpoint inhibitors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immune Checkpoint Inhibitors | Organ-specific Neoantigen ",
"rest_events_topic_count": 1,
"rest_events_topic": " Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1578586301,'FU_HCP_100456');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJun Wang",
"kol_full_name": "Jun Wang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Palliative Care",
"npi_num": "1164589917",
"hcp_pin_alias": "FU_HCP_5403382",
"session_name": "Symptom Science and Palliatve Care: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "June M. McKoy",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233256",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233256",
"events_session": "Symptom Science and Palliatve Care: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Palliative Care",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1164589917,'FU_HCP_5403382');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJune M. McKoy",
"kol_full_name": "June M. McKoy"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cancer Survivors",
"npi_num": "1356968069",
"hcp_pin_alias": "FU_HCP_281875",
"session_name": "High deductible health plans and survival among cancer survivors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Justin Michael Barnes",
"middle_name": "",
"last_name": "",
"org_name": "Department of Radiation Oncology, Washington University School of Medicine in St. Louis",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233120",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233120",
"events_session": "High deductible health plans and survival among cancer survivors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Cancer Survivors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356968069,'FU_HCP_281875');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EJustin Michael Barnes",
"kol_full_name": "Justin Michael Barnes"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Myeloid Malignancy",
"npi_num": "1700133360",
"hcp_pin_alias": "FU_HCP_0003705",
"session_name": "The Art and Science of Caring for Older Adults With Myeloid Malignancies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kah Poh Loh",
"middle_name": "",
"last_name": "",
"org_name": "James P. Wilmot Cancer Center, University of Rochester Medical Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233114",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233114",
"events_session": "The Art and Science of Caring for Older Adults With Myeloid Malignancies",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Myeloid Malignancy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700133360,'FU_HCP_0003705');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKah Poh Loh",
"kol_full_name": "Kah Poh Loh"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Solid Tumor | Ovarian Neoplasms",
"npi_num": "1346488525",
"hcp_pin_alias": "FU_HCP_282908",
"session_name": "A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kaiwen Li",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232650",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232650",
"events_session": "A phase 1",
"rest_events_session_count": 5,
"rest_events_session": " multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors",
"events_topic": "Solid Tumor | Ovarian Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1346488525,'FU_HCP_282908');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKaiwen Li",
"kol_full_name": "Kaiwen Li"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms | Alisertib | Liquid Biopsy",
"npi_num": "1962778183",
"hcp_pin_alias": "FU_HCP_46625",
"session_name": "Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Karthik Giridhar",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232681",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232681",
"events_session": "Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms | Alisertib ",
"rest_events_topic_count": 1,
"rest_events_topic": " Liquid Biopsy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1962778183,'FU_HCP_46625');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKarthik Giridhar",
"kol_full_name": "Karthik Giridhar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Thyroid Neoplasms | Regorafenib",
"npi_num": "1699188573",
"hcp_pin_alias": "FU_HCP_232181",
"session_name": "Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kartik Sehgal",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232571",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232571",
"events_session": "Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Thyroid Neoplasms | Regorafenib",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1699188573,'FU_HCP_232181');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKartik Sehgal",
"kol_full_name": "Kartik Sehgal"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Antibody Therapy | Mesothelin",
"npi_num": "1316440126",
"hcp_pin_alias": "FU_HCP_5403371",
"session_name": "Soluble mesothelin neutralizes mesothelin antibody-based therapies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Katherine Emilie Rhoades Smith",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232998",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232998",
"events_session": "Soluble mesothelin neutralizes mesothelin antibody-based therapies",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Antibody Therapy | Mesothelin",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1316440126,'FU_HCP_5403371');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKatherine Emilie Rhoades Smith",
"kol_full_name": "Katherine Emilie Rhoades Smith"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "KRAS Protein, Human",
"npi_num": "1366741191",
"hcp_pin_alias": "FU_HCP_109769",
"session_name": "Setting the Stage: The Science of Targeting KRAS",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kathryn C. Arbour",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232922",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232922",
"events_session": "Setting the Stage: The Science of Targeting KRAS",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "KRAS Protein, Human",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1366741191,'FU_HCP_109769');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKathryn C. Arbour",
"kol_full_name": "Kathryn C. Arbour"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Palliative Care",
"npi_num": "1336596774",
"hcp_pin_alias": "FU_HCP_284796",
"session_name": "Symptom Science and Palliative Care",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kathryn DeCarli",
"middle_name": "",
"last_name": "",
"org_name": "Brown University",
"Country": "United States",
"Region": "Rhode Island",
"City": "Providence",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232053",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232053",
"events_session": "Symptom Science and Palliative Care",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Palliative Care",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1336596774,'FU_HCP_284796');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKathryn DeCarli",
"kol_full_name": "Kathryn DeCarli"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Multiple Myeloma",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403452",
"session_name": "Novel Treatment Approaches and Caring for Older Adults With Multiple Myeloma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Katja C Weisel",
"middle_name": "",
"last_name": "",
"org_name": "University Medical Center Hamburg-Eppendorf",
"Country": "Germany",
"Region": "Hamburg",
"City": "Hamburg",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232742",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232742",
"events_session": "Novel Treatment Approaches and Caring for Older Adults With Multiple Myeloma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Multiple Myeloma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403452');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKatja C Weisel",
"kol_full_name": "Katja C Weisel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy, Adjuvant | Melanoma",
"npi_num": "1417275827",
"hcp_pin_alias": "FU_HCP_159025",
"session_name": "Navigating Melanoma Management From Early Stages to Post-Adjuvant Therapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Katy K. Tsai",
"middle_name": "",
"last_name": "",
"org_name": "UCSF Helen Diller Family Comprehensive Cancer Center",
"Country": "United States",
"Region": "California",
"City": "San Francisco",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232085",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232085",
"events_session": "Navigating Melanoma Management From Early Stages to Post-Adjuvant Therapy",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Chemotherapy, Adjuvant | Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1417275827,'FU_HCP_159025');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKaty K. Tsai",
"kol_full_name": "Katy K. Tsai"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Precision Medicine | Lung Neoplasms",
"npi_num": "1326101718",
"hcp_pin_alias": "FU_HCP_110445",
"session_name": "Precision medicine preceptorship in breast and lung cancer for Latin American oncologists",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Keerthi Gogineni",
"middle_name": "",
"last_name": "",
"org_name": "Emory University Winship Cancer Institute",
"Country": "United States",
"Region": "Georgia",
"City": "Atlanta",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232265",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232265",
"events_session": "Precision medicine preceptorship in breast and lung cancer for Latin American oncologists",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Precision Medicine | Lung Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1326101718,'FU_HCP_110445');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKeerthi Gogineni",
"kol_full_name": "Keerthi Gogineni"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Myelodysplastic Syndromes | Myeloid Cell Leukemia Sequence 1 Protein | Tapotoclax",
"npi_num": "1710322359",
"hcp_pin_alias": "FU_HCP_229380",
"session_name": "A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kelly Sharon Chien",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232345",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232345",
"events_session": "A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Myelodysplastic Syndromes | Myeloid Cell Leukemia Sequence 1 Protein ",
"rest_events_topic_count": 1,
"rest_events_topic": " Tapotoclax",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1710322359,'FU_HCP_229380');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKelly Sharon Chien",
"kol_full_name": "Kelly Sharon Chien"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Esophageal Neoplasms | Neoadjuvant Therapy | Radiotherapy | Docetaxel | Cisplatin",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403461",
"session_name": "A phase III trial comparing 5-FU plus cisplatin (CF) versus CF plus docetaxel or radiotherapy as neoadjuvant treatment for locally advanced esophageal cancer: 5-year follow-up from JCOG1109",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ken Kato",
"middle_name": "",
"last_name": "",
"org_name": "Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232822",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232822",
"events_session": "A phase III trial comparing 5-FU plus cisplatin (CF) versus CF plus docetaxel or radiotherapy as neoadjuvant treatment for locally advanced esophageal cancer: 5-year follow-up from JCOG1109",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Esophageal Neoplasms | Neoadjuvant Therapy ",
"rest_events_topic_count": 3,
"rest_events_topic": " Radiotherapy | Docetaxel | Cisplatin",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403461');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKen Kato",
"kol_full_name": "Ken Kato"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Electronic Health Records | Artificial Intelligence",
"npi_num": "1649439076",
"hcp_pin_alias": "FU_HCP_282539",
"session_name": "Shareable artificial intelligence to extract cancer outcomes from electronic health records",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kenneth L. Kehl",
"middle_name": "",
"last_name": "",
"org_name": "Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233115",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233115",
"events_session": "Shareable artificial intelligence to extract cancer outcomes from electronic health records",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms | Electronic Health Records ",
"rest_events_topic_count": 1,
"rest_events_topic": " Artificial Intelligence",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1649439076,'FU_HCP_282539');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKenneth L. Kehl",
"kol_full_name": "Kenneth L. Kehl"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms, Second Primary",
"npi_num": "1285846790",
"hcp_pin_alias": "PAST_HCP_Onco_232352",
"session_name": "Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kerin B. Adelson",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232405",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232405",
"events_session": "Systemic anti-cancer therapy and cost at end of life: A SEER Medicare analysis",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms, Second Primary",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1285846790,'PAST_HCP_Onco_232352');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKerin B. Adelson",
"kol_full_name": "Kerin B. Adelson"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Palliative Care",
"npi_num": "1972573814",
"hcp_pin_alias": "FU_HCP_155223",
"session_name": "Palliative Care Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kimberly A. Curseen",
"middle_name": "",
"last_name": "",
"org_name": "Emory School of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232744",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232744",
"events_session": "Palliative Care Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Palliative Care",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1972573814,'FU_HCP_155223');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKimberly A. Curseen",
"kol_full_name": "Kimberly A. Curseen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Education, Medical",
"npi_num": "1780973271",
"hcp_pin_alias": "FU_HCP_109685",
"session_name": "Medical Education and Professional Development",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kristen A. Marrone",
"middle_name": "",
"last_name": "",
"org_name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232005",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232005",
"events_session": "Medical Education and Professional Development",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Education, Medical",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1780973271,'FU_HCP_109685');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKristen A. Marrone",
"kol_full_name": "Kristen A. Marrone"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Belinostat | Guadecitabine | Decitabine | Chondrosarcoma",
"npi_num": "1114424967",
"hcp_pin_alias": "FU_HCP_5403368",
"session_name": "Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kristine Peregrino Lacuna",
"middle_name": "",
"last_name": "",
"org_name": "Columbia University Irving Medical Center",
"Country": "United States",
"Region": "New York",
"City": "Yonkers",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232905",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232905",
"events_session": "Correlative results from NCI CTEP/ETCTN 10330: A phase 2 study of belinostat with SGI-110 (guadecitabine) or ASTX727 (decitabine/cedazuridine) for advanced conventional chondrosarcoma (cCS)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Belinostat | Guadecitabine ",
"rest_events_topic_count": 2,
"rest_events_topic": " Decitabine | Chondrosarcoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1114424967,'FU_HCP_5403368');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKristine Peregrino Lacuna",
"kol_full_name": "Kristine Peregrino Lacuna"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Machine Learning | Microsatellite Instability | Biomarkers",
"npi_num": "1861816308",
"hcp_pin_alias": "FU_HCP_45765",
"session_name": "A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Kyle C Strickland",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233049",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233049",
"events_session": "A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Machine Learning | Microsatellite Instability ",
"rest_events_topic_count": 1,
"rest_events_topic": " Biomarkers",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1861816308,'FU_HCP_45765');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EKyle C Strickland",
"kol_full_name": "Kyle C Strickland"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Biomarkers | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1003268954",
"hcp_pin_alias": "PAST_HCP_Future Events_316288",
"session_name": "Impact of lung biomarker testing on out-of-pocket costs for metastatic non-small cell lung cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Laila A Gharzai",
"middle_name": "",
"last_name": "",
"org_name": "Northwestern University",
"Country": "United States",
"Region": "Illinois",
"City": "Evanston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232403",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232403",
"events_session": "Impact of lung biomarker testing on out-of-pocket costs for metastatic non-small cell lung cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Biomarkers | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1003268954,'PAST_HCP_Future Events_316288');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELaila A Gharzai",
"kol_full_name": "Laila A Gharzai"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sexual Health | Breast Neoplasms",
"npi_num": "1366670234",
"hcp_pin_alias": "FU_HCP_5403343",
"session_name": "Women’s insights on sexual health after breast cancer (WISH-BREAST)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Laila Agrawal",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232218",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232218",
"events_session": "Women’s insights on sexual health after breast cancer (WISH-BREAST)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Sexual Health | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1366670234,'FU_HCP_5403343');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELaila Agrawal",
"kol_full_name": "Laila Agrawal"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sacituzumab Govitecan | Trastuzumab Deruxtecan | Breast Neoplasms",
"npi_num": "1568857456",
"hcp_pin_alias": "FU_HCP_282212",
"session_name": "Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age, sites of disease, and use of intervening therapies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Laura Ann Huppert",
"middle_name": "",
"last_name": "",
"org_name": "University of California, San Francisco",
"Country": "United States",
"Region": "California",
"City": "San Francisco",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232696",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232696",
"events_session": "Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC): Updated data and subgroup analyses by age",
"rest_events_session_count": 2,
"rest_events_session": " sites of disease, and use of intervening therapies",
"events_topic": "Sacituzumab Govitecan | Trastuzumab Deruxtecan ",
"rest_events_topic_count": 1,
"rest_events_topic": " Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1568857456,'FU_HCP_282212');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELaura Ann Huppert",
"kol_full_name": "Laura Ann Huppert"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Monoclonal Gammopathy Of Undetermined Significance | Multiple Myeloma | Diabetes Mellitus",
"npi_num": "1255890380",
"hcp_pin_alias": "FU_HCP_386893",
"session_name": "Uncontrolled diabetes mellitus and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Lawrence Liu",
"middle_name": "",
"last_name": "",
"org_name": "City of Hope Comprehensive Cancer Center",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232360",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232360",
"events_session": "Uncontrolled diabetes mellitus and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Monoclonal Gammopathy Of Undetermined Significance | Multiple Myeloma ",
"rest_events_topic_count": 1,
"rest_events_topic": " Diabetes Mellitus",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1255890380,'FU_HCP_386893');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELawrence Liu",
"kol_full_name": "Lawrence Liu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ivonescimab | Carcinoma, Non-Small-Cell Lung | ErbB Receptors | Chemotherapy",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403483",
"session_name": "Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized, double-blind, multi-center, phase 3 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Li Zhang",
"middle_name": "",
"last_name": "",
"org_name": "Sun Yat-sen University Cancer Center",
"Country": "China",
"Region": "Guangdong",
"City": "Guangzhou",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233140",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233140",
"events_session": "Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): A randomized",
"rest_events_session_count": 3,
"rest_events_session": " double-blind, multi-center, phase 3 trial",
"events_topic": "Ivonescimab | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 2,
"rest_events_topic": " ErbB Receptors | Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403483');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELi Zhang",
"kol_full_name": "Li Zhang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Gastroesophageal Junction Adenocarcinoma | Disitamab Vedotin",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403436",
"session_name": "Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter, single-arm, phase II trial (RCTS)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Lian Liu",
"middle_name": "",
"last_name": "",
"org_name": "Qilu Hospital of Shandong University",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232505",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232505",
"events_session": "Efficacy of disitamab vedotin (RC48) plus tislelizumab and S-1 as first-line therapy for HER2-overexpressing advanced stomach or gastroesophageal junction adenocarcinoma: A multicenter",
"rest_events_session_count": 2,
"rest_events_session": " single-arm, phase II trial (RCTS)",
"events_topic": "Gastroesophageal Junction Adenocarcinoma | Disitamab Vedotin",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403436');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELian Liu",
"kol_full_name": "Lian Liu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nivolumab | Relatlimab | Melanoma",
"npi_num": "1174973135",
"hcp_pin_alias": "FU_HCP_39683",
"session_name": "Randomized phase II evaluation of nivolumab (nivo), or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Lilit Karapetyan",
"middle_name": "",
"last_name": "",
"org_name": "H. Lee Moffitt Cancer Center and Research Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232788",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232788",
"events_session": "Randomized phase II evaluation of nivolumab (nivo)",
"rest_events_session_count": 2,
"rest_events_session": " or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel)",
"events_topic": "Nivolumab | Relatlimab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Melanoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1174973135,'FU_HCP_39683');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELilit Karapetyan",
"kol_full_name": "Lilit Karapetyan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Sonodynamic Therapy | Ultrasonography | Magnetic Resonance Imaging | Diffuse Intrinsic Pontine Glioma",
"npi_num": "1023215944",
"hcp_pin_alias": "FU_HCP_99915",
"session_name": "Interim report of a phase 2 study of sonodynamic therapy (SDT) using SONALA-001 together with MR-guided low-intensity focused ultrasound (MRgFUS) in children with diffuse intrinsic pontine glioma (DIPG)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Lindsay Baker Kilburn",
"middle_name": "",
"last_name": "",
"org_name": "Children's National Hospital",
"Country": "United States",
"Region": "District of Columbia",
"City": "Washington",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233073",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233073",
"events_session": "Interim report of a phase 2 study of sonodynamic therapy (SDT) using SONALA-001 together with MR-guided low-intensity focused ultrasound (MRgFUS) in children with diffuse intrinsic pontine glioma (DIPG)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Sonodynamic Therapy | Ultrasonography ",
"rest_events_topic_count": 2,
"rest_events_topic": " Magnetic Resonance Imaging | Diffuse Intrinsic Pontine Glioma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1023215944,'FU_HCP_99915');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELindsay Baker Kilburn",
"kol_full_name": "Lindsay Baker Kilburn"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Radiotherapy | Triple Negative Breast Neoplasms",
"npi_num": "1548554769",
"hcp_pin_alias": "FU_HCP_43008",
"session_name": "A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Lior Zvi Braunstein",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232638",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232638",
"events_session": "A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Radiotherapy | Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1548554769,'FU_HCP_43008');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELior Zvi Braunstein",
"kol_full_name": "Lior Zvi Braunstein"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Head And Neck Neoplasms | Immunotherapy",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403437",
"session_name": "Updates in Anti-PD1/PD-L1 Immunotherapy for Locoregionally Advanced and Metastatic Head and Neck Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Lisa F. Licitra",
"middle_name": "",
"last_name": "",
"org_name": "Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232509",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232509",
"events_session": "Updates in Anti-PD1/PD-L1 Immunotherapy for Locoregionally Advanced and Metastatic Head and Neck Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Head And Neck Neoplasms | Immunotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403437');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELisa F. Licitra",
"kol_full_name": "Lisa F. Licitra"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Killer Cells, Natural | Lymphoma, Non-Hodgkin | Antigens, CD20",
"npi_num": "1417392937",
"hcp_pin_alias": "FU_HCP_41807",
"session_name": "A phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Lorenzo Falchi",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232389",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232389",
"events_session": "A phase 1/2",
"rest_events_session_count": 6,
"rest_events_session": " open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma",
"events_topic": "Killer Cells, Natural | Lymphoma, Non-Hodgkin ",
"rest_events_topic_count": 1,
"rest_events_topic": " Antigens, CD20",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1417392937,'FU_HCP_41807');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELorenzo Falchi",
"kol_full_name": "Lorenzo Falchi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Liquid Biopsy | Bone Marrow Diseases",
"npi_num": "1760568794",
"hcp_pin_alias": "FU_HCP_282170",
"session_name": "Practice makes perfect: Using simulation to build and assess competency in bone marrow biopsy for heme/onc fellows",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Lori J Rosenstein",
"middle_name": "",
"last_name": "",
"org_name": "Gundersen Health System",
"Country": "United States",
"Region": "Wisconsin",
"City": "La Crosse",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232267",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232267",
"events_session": "Practice makes perfect: Using simulation to build and assess competency in bone marrow biopsy for heme/onc fellows",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Liquid Biopsy | Bone Marrow Diseases",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1760568794,'FU_HCP_282170');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELori J Rosenstein",
"kol_full_name": "Lori J Rosenstein"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1699975052",
"hcp_pin_alias": "FU_HCP_155340",
"session_name": "Treatment modifications and mortality among female patients with subsequent breast cancer: A report from the Childhood Cancer Survivor Study (CCSS)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Lucie Marie Turcotte",
"middle_name": "",
"last_name": "",
"org_name": "University of Minnesota Medical School",
"Country": "United States",
"Region": "Minnesota",
"City": "Minneapolis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232498",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232498",
"events_session": "Treatment modifications and mortality among female patients with subsequent breast cancer: A report from the Childhood Cancer Survivor Study (CCSS)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1699975052,'FU_HCP_155340');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELucie Marie Turcotte",
"kol_full_name": "Lucie Marie Turcotte"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1285675918",
"hcp_pin_alias": "FU_HCP_100292",
"session_name": "Drugging the “Undruggable” Target: Successes, Challenges, and the Road Ahead",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Lynn M. Schuchter",
"middle_name": "",
"last_name": "",
"org_name": "University of Pennsylvania",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232044",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232044",
"events_session": "Drugging the “Undruggable” Target: Successes",
"rest_events_session_count": 2,
"rest_events_session": " Challenges, and the Road Ahead",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1285675918,'FU_HCP_100292');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ELynn M. Schuchter",
"kol_full_name": "Lynn M. Schuchter"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "ErbB Receptors | Colorectal Neoplasms",
"npi_num": "1932631892",
"hcp_pin_alias": "FU_HCP_225169",
"session_name": "Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Madhulika Eluri",
"middle_name": "",
"last_name": "",
"org_name": "Department of Gastrointestinal Oncology, The University of Texas MD Anderson Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232871",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232871",
"events_session": "Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "ErbB Receptors | Colorectal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1932631892,'FU_HCP_225169');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMadhulika Eluri",
"kol_full_name": "Madhulika Eluri"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Decitabine | Myelodysplastic Syndromes | Venetoclax | Leukemia, Myeloid, Acute",
"npi_num": "1851798284",
"hcp_pin_alias": "FU_HCP_186692",
"session_name": "A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Mahesh Swaminathan",
"middle_name": "",
"last_name": "",
"org_name": "Department of Leukemia, The University of Texas MD Anderson Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232341",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232341",
"events_session": "A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML)",
"rest_events_session_count": 1,
"rest_events_session": " or high-risk myelodysplastic syndrome (HR-MDS)",
"events_topic": "Decitabine | Myelodysplastic Syndromes ",
"rest_events_topic_count": 2,
"rest_events_topic": " Venetoclax | Leukemia, Myeloid, Acute",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1851798284,'FU_HCP_186692');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMahesh Swaminathan",
"kol_full_name": "Mahesh Swaminathan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genes, ErbB-2 | Breast Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5397573",
"session_name": "Evaluation of recurrence rate in Canadian patients with stage II/III HR+/HER2- early breast cancer in the real-world setting",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Mahmoud Abdelsalam",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233260",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233260",
"events_session": "Evaluation of recurrence rate in Canadian patients with stage II/III HR+/HER2- early breast cancer in the real-world setting",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Genes, ErbB-2 | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5397573');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMahmoud Abdelsalam",
"kol_full_name": "Mahmoud Abdelsalam"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Biomarkers | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1578724126",
"hcp_pin_alias": "FU_HCP_230154",
"session_name": "Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Makenzi Colleen Evangelist",
"middle_name": "",
"last_name": "",
"org_name": "New York Oncology Hematology",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232239",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232239",
"events_session": "Biomarker testing in early-stage NSCLC: Results from the MYLUNG Consortium",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Biomarkers | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1578724126,'FU_HCP_230154');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMakenzi Colleen Evangelist",
"kol_full_name": "Makenzi Colleen Evangelist"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Squamous Cell Carcinoma Of Head And Neck | Chemoradiotherapy | Ipatasertib | Oncogene Protein V-akt",
"npi_num": "1770889511",
"hcp_pin_alias": "FU_HCP_229922",
"session_name": "CTEP 10492, a phase 1/1b study of the AKT inhibitor ipatasertib with chemoradiation for locally advanced head and neck squamous cell carcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Malcolm David Mattes",
"middle_name": "",
"last_name": "",
"org_name": "Rutgers Cancer Institue of New Jersey",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232578",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232578",
"events_session": "CTEP 10492",
"rest_events_session_count": 1,
"rest_events_session": " a phase 1/1b study of the AKT inhibitor ipatasertib with chemoradiation for locally advanced head and neck squamous cell carcinoma",
"events_topic": "Squamous Cell Carcinoma Of Head And Neck | Chemoradiotherapy ",
"rest_events_topic_count": 2,
"rest_events_topic": " Ipatasertib | Oncogene Protein V-akt",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1770889511,'FU_HCP_229922');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMalcolm David Mattes",
"kol_full_name": "Malcolm David Mattes"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1720549561",
"hcp_pin_alias": "FU_HCP_282797",
"session_name": "Goals of care discordance in advanced cancer compared to other advanced conditions",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Manan P Shah",
"middle_name": "",
"last_name": "",
"org_name": "Division of Hematology/Oncology, University of California, Los Angeles",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232204",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232204",
"events_session": "Goals of care discordance in advanced cancer compared to other advanced conditions",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1720549561,'FU_HCP_282797');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EManan P Shah",
"kol_full_name": "Manan P Shah"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab | Olomorasib | Chemotherapy",
"npi_num": "1376070300",
"hcp_pin_alias": "FU_HCP_110979",
"session_name": "SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Marcelo Vailati Negrao",
"middle_name": "",
"last_name": "",
"org_name": "Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232189",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232189",
"events_session": "SUNRAY-01",
"rest_events_session_count": 2,
"rest_events_session": " a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Olomorasib | Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1376070300,'FU_HCP_110979');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMarcelo Vailati Negrao",
"kol_full_name": "Marcelo Vailati Negrao"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nivolumab | Relatlimab | Carcinoma, Merkel Cell",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403457",
"session_name": "A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Maria Gonzalez",
"middle_name": "",
"last_name": "",
"org_name": "Melanoma Institute Australia",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232809",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232809",
"events_session": "A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Nivolumab | Relatlimab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Carcinoma, Merkel Cell",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403457');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMaria Gonzalez",
"kol_full_name": "Maria Gonzalez"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab",
"npi_num": "1053999599",
"hcp_pin_alias": "FU_HCP_159091",
"session_name": "Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Marina Chiara Garassino",
"middle_name": "",
"last_name": "",
"org_name": "Fondazione IRCCS Istituto Nazionale dei Tumori (currently at Knapp Center for Biomedical Discovery, University of Chicago Medicine & Biological Sciences, Chicago, IL, USA)",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232494",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232494",
"events_session": "Health-related quality of life (HRQoL) outcomes from the randomized",
"rest_events_session_count": 1,
"rest_events_session": " double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Pembrolizumab",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1053999599,'FU_HCP_159091');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMarina Chiara Garassino",
"kol_full_name": "Marina Chiara Garassino"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung",
"npi_num": "1144404161",
"hcp_pin_alias": "PAST_HCP_Onco_232397",
"session_name": "Lung Cancer – Non-Small Cell Metastatc: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Marjorie Glass Zauderer",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233236",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233236",
"events_session": "Lung Cancer – Non-Small Cell Metastatc: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1144404161,'PAST_HCP_Onco_232397');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMarjorie Glass Zauderer",
"kol_full_name": "Marjorie Glass Zauderer"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1134186729",
"hcp_pin_alias": "FU_HCP_0005068",
"session_name": "Patient Advocate and Medical Oncologist Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Mark Andrew Lewis",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232290",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232290",
"events_session": "Patient Advocate and Medical Oncologist Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1134186729,'FU_HCP_0005068');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMark Andrew Lewis",
"kol_full_name": "Mark Andrew Lewis"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms | Artificial Intelligence",
"npi_num": "1689809188",
"hcp_pin_alias": "FU_HCP_159270",
"session_name": "Prognostic validation of a digital pathology-based multi-modal artificial intelligence (MMAI) biomarker in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the CHAARTED trial (ECOG-ACRIN EA3805)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Mark Christopher Markowski",
"middle_name": "",
"last_name": "",
"org_name": "Johns Hopkins University",
"Country": "United States",
"Region": "Maryland",
"City": "Baltimore",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232657",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232657",
"events_session": "Prognostic validation of a digital pathology-based multi-modal artificial intelligence (MMAI) biomarker in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the CHAARTED trial (ECOG-ACRIN EA3805)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms | Artificial Intelligence",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1689809188,'FU_HCP_159270');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMark Christopher Markowski",
"kol_full_name": "Mark Christopher Markowski"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Circulating Tumor DNA | Breast Neoplasms",
"npi_num": "1689105124",
"hcp_pin_alias": "FU_HCP_282559",
"session_name": "Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-institutional study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Marla Lipsyc-Sharf",
"middle_name": "",
"last_name": "",
"org_name": "UCLA Health Jonsson Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232623",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232623",
"events_session": "Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-institutional study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Circulating Tumor DNA | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1689105124,'FU_HCP_282559');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMarla Lipsyc-Sharf",
"kol_full_name": "Marla Lipsyc-Sharf"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Squamous Cell Carcinoma Of Head And Neck | Early Detection Of Cancer",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403442",
"session_name": "HERD: A multi-centre prospective cohort study to facilitate early detection of relapse in radically treated, high risk head and neck squamous cell carcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Martin Forster",
"middle_name": "",
"last_name": "",
"org_name": "University College London Cancer Institute, University College London Hospital NHS Trust",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232579",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232579",
"events_session": "HERD: A multi-centre prospective cohort study to facilitate early detection of relapse in radically treated",
"rest_events_session_count": 1,
"rest_events_session": " high risk head and neck squamous cell carcinoma",
"events_topic": "Squamous Cell Carcinoma Of Head And Neck | Early Detection Of Cancer",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403442');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMartin Forster",
"kol_full_name": "Martin Forster"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung",
"npi_num": "1275037848",
"hcp_pin_alias": "FU_HCP_5403346",
"session_name": "Treatment outcomes in locally advanced, unresectable NSCLC treated with concurrent chemoradiation and PD-L1 consolidation: Real-world data from a NCI comprehensive cancer center with a racially diverse, high poverty catchment area",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Matthew M. Mirsky",
"middle_name": "",
"last_name": "",
"org_name": "Case Western Reserve University",
"Country": "United States",
"Region": "Ohio",
"City": "Cleveland",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232242",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232242",
"events_session": "Treatment outcomes in locally advanced",
"rest_events_session_count": 2,
"rest_events_session": " unresectable NSCLC treated with concurrent chemoradiation and PD-L1 consolidation: Real-world data from a NCI comprehensive cancer center with a racially diverse, high poverty catchment area",
"events_topic": "Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1275037848,'FU_HCP_5403346');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMatthew M. Mirsky",
"kol_full_name": "Matthew M. Mirsky"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Abemaciclib | Prostatic Neoplasms | Abiraterone Acetate | Castration",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403454",
"session_name": "CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Matthew Raymond Smith",
"middle_name": "",
"last_name": "",
"org_name": "Massachusetts General Hospital Cancer Center and Harvard Medical School",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232762",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232762",
"events_session": "CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Abemaciclib | Prostatic Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Abiraterone Acetate | Castration",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403454');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMatthew Raymond Smith",
"kol_full_name": "Matthew Raymond Smith"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Brain Neoplasms",
"npi_num": "1952796385",
"hcp_pin_alias": "FU_HCP_5403334",
"session_name": "Striving for Comfort and Cure: Comprehensive Treatment of Patients With Brain Tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Megan Dupuis",
"middle_name": "",
"last_name": "",
"org_name": "Vanderbilt-Ingram Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232030",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232030",
"events_session": "Striving for Comfort and Cure: Comprehensive Treatment of Patients With Brain Tumors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Brain Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1952796385,'FU_HCP_5403334');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMegan Dupuis",
"kol_full_name": "Megan Dupuis"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Peripheral Nervous System Diseases",
"npi_num": "1689993537",
"hcp_pin_alias": "FU_HCP_44229",
"session_name": "Risk prediction model for taxane-induced peripheral neuropathy (TIPN) in patients with early-stage cancer receiving taxane therapy: SWOG S1714",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Meghna S. Trivedi",
"middle_name": "",
"last_name": "",
"org_name": "Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232738",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232738",
"events_session": "Risk prediction model for taxane-induced peripheral neuropathy (TIPN) in patients with early-stage cancer receiving taxane therapy: SWOG S1714",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms | Peripheral Nervous System Diseases",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1689993537,'FU_HCP_44229');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMeghna S. Trivedi",
"kol_full_name": "Meghna S. Trivedi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1346688793",
"hcp_pin_alias": "FU_HCP_41223",
"session_name": "Discussion on Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Melina Elpi Marmarelis",
"middle_name": "",
"last_name": "",
"org_name": "University of Pennsylvania",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232475",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232475",
"events_session": "Discussion on Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1346688793,'FU_HCP_41223');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMelina Elpi Marmarelis",
"kol_full_name": "Melina Elpi Marmarelis"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Vaccines | Neoplasms | Immune Checkpoint Inhibitors | COVID-19",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403477",
"session_name": "The impact of COVID-19 mRNA vaccines on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Mengni Guo",
"middle_name": "",
"last_name": "",
"org_name": "Department of Oncology/Hematology, Loma Linda University Medical Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233023",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233023",
"events_session": "The impact of COVID-19 mRNA vaccines on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Vaccines | Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Immune Checkpoint Inhibitors | COVID-19",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403477');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMengni Guo",
"kol_full_name": "Mengni Guo"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "CLDN4 Protein, Human | Solid Tumor | Antibodies, Bispecific",
"npi_num": "1881936334",
"hcp_pin_alias": "FU_HCP_283070",
"session_name": "Phase 1 study of ASP1002, a bispecific antibody targeting claudin 4 (CLDN4) and CD137, in patients with locally advanced (LA) or metastatic solid tumors that express CLDN4",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Meredith Pelster",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233030",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233030",
"events_session": "Phase 1 study of ASP1002",
"rest_events_session_count": 2,
"rest_events_session": " a bispecific antibody targeting claudin 4 (CLDN4) and CD137, in patients with locally advanced (LA) or metastatic solid tumors that express CLDN4",
"events_topic": "CLDN4 Protein, Human | Solid Tumor ",
"rest_events_topic_count": 1,
"rest_events_topic": " Antibodies, Bispecific",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1881936334,'FU_HCP_283070');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMeredith Pelster",
"kol_full_name": "Meredith Pelster"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1548345994",
"hcp_pin_alias": "PAST_HCP_Onco_232426",
"session_name": "Presenter Share: Maintaining Personal Wellness and Resiliency As a Leader",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Merry Jennifer Markham",
"middle_name": "",
"last_name": "",
"org_name": "University of Florida",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233100",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233100",
"events_session": "Presenter Share: Maintaining Personal Wellness and Resiliency As a Leader",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1548345994,'PAST_HCP_Onco_232426');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMerry Jennifer Markham",
"kol_full_name": "Merry Jennifer Markham"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Patient Reported Outcome Measures",
"npi_num": "1952397655",
"hcp_pin_alias": "FU_HCP_99946",
"session_name": "Symptoms reported by patients using an ePRO compared with those reported to nurses via telephone triage",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michael A. Kolodziej",
"middle_name": "",
"last_name": "",
"org_name": "ADVI",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233047",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233047",
"events_session": "Symptoms reported by patients using an ePRO compared with those reported to nurses via telephone triage",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Patient Reported Outcome Measures",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1952397655,'FU_HCP_99946');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichael A. Kolodziej",
"kol_full_name": "Michael A. Kolodziej"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Transitional Cell",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403444",
"session_name": "FGFR3-mutated urothelial carcinoma of bladder and upper tract including ureter and renal pelvis: A comparative genomic profiling study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michael Basin",
"middle_name": "",
"last_name": "",
"org_name": "SUNY Upstate Medical University",
"Country": "United States",
"Region": "New York",
"City": "Syracuse",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232600",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232600",
"events_session": "FGFR3-mutated urothelial carcinoma of bladder and upper tract including ureter and renal pelvis: A comparative genomic profiling study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Transitional Cell",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403444');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichael Basin",
"kol_full_name": "Michael Basin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Computer Simulation | Carcinoma, Non-Small-Cell Lung | ErbB Receptors | Clinical Trials As Topic",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403403",
"session_name": "Prospective validation of in silico clinical trials prediction using an EGFR-mutated NSCLC mechanistic computational disease model",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michaël Duruisseaux",
"middle_name": "",
"last_name": "",
"org_name": "Respiratory Department and Early Phase, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232179",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232179",
"events_session": "Prospective validation of in silico clinical trials prediction using an EGFR-mutated NSCLC mechanistic computational disease model",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Computer Simulation | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 2,
"rest_events_topic": " ErbB Receptors | Clinical Trials As Topic",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403403');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichaël Duruisseaux",
"kol_full_name": "Michaël Duruisseaux"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Gastrointestinal Neoplasms",
"npi_num": "1396726113",
"hcp_pin_alias": "FU_HCP_99844",
"session_name": "Medical Oncologist Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michael E. Hurwitz",
"middle_name": "",
"last_name": "",
"org_name": "Yale School of Medicine",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233145",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233145",
"events_session": "Medical Oncologist Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Gastrointestinal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1396726113,'FU_HCP_99844');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichael E. Hurwitz",
"kol_full_name": "Michael E. Hurwitz"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1699886358",
"hcp_pin_alias": "PAST_HCP_Onco_231538",
"session_name": "Efficacy of eSyM: Acute care utilization among patients with cancer who do versus do not report ePROs",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michael J. Hassett",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233116",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233116",
"events_session": "Efficacy of eSyM: Acute care utilization among patients with cancer who do versus do not report ePROs",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1699886358,'PAST_HCP_Onco_231538');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichael J. Hassett",
"kol_full_name": "Michael J. Hassett"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Telemedicine",
"npi_num": "1316048408",
"hcp_pin_alias": "FU_HCP_396053",
"session_name": "Quality of telehealth-provided cancer care in VA",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michael J. Kelley",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233060",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233060",
"events_session": "Quality of telehealth-provided cancer care in VA",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Telemedicine",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1316048408,'FU_HCP_396053');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichael J. Kelley",
"kol_full_name": "Michael J. Kelley"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Mesothelioma | Nivolumab | Chemotherapy, Adjuvant",
"npi_num": "1134564701",
"hcp_pin_alias": "FU_HCP_39307",
"session_name": "Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: Results of a prospective pilot study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michael Offin",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232474",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232474",
"events_session": "Feasibility and safety of neoadjuvant nivolumab and chemotherapy for resectable diffuse pleural mesotheliomas: Results of a prospective pilot study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Mesothelioma | Nivolumab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Chemotherapy, Adjuvant",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1134564701,'FU_HCP_39307');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichael Offin",
"kol_full_name": "Michael Offin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "KRASG12D Inhibitor MRTX1133 | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1356345979",
"hcp_pin_alias": "PAST_HCP_Future Events_316453",
"session_name": "Impact of trial eligibility criteria on enrollment to KRASG12C inhibitor trials in patients with non-small cell lung cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michael S. May",
"middle_name": "",
"last_name": "",
"org_name": "Columbia University Medical Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232278",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232278",
"events_session": "Impact of trial eligibility criteria on enrollment to KRASG12C inhibitor trials in patients with non-small cell lung cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "KRASG12D Inhibitor MRTX1133 | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356345979,'PAST_HCP_Future Events_316453');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichael S. May",
"kol_full_name": "Michael S. May"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Multiple Myeloma | Kidney Diseases | CD38 Protein, Human",
"npi_num": "1194788331",
"hcp_pin_alias": "FU_HCP_284583",
"session_name": "Outcomes of myeloma cast nephropathy in the era of anti-CD38 monoclonal antibody-based frontline therapy: A retrospective cohort study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michael Sang Hughes",
"middle_name": "",
"last_name": "",
"org_name": "Columbia University Medical Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232361",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232361",
"events_session": "Outcomes of myeloma cast nephropathy in the era of anti-CD38 monoclonal antibody-based frontline therapy: A retrospective cohort study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Multiple Myeloma | Kidney Diseases ",
"rest_events_topic_count": 1,
"rest_events_topic": " CD38 Protein, Human",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1194788331,'FU_HCP_284583');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichael Sang Hughes",
"kol_full_name": "Michael Sang Hughes"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lymphoma, Mantle-Cell | Venetoclax | Tumor Suppressor Protein P53 | Ibrutinib",
"npi_num": "1437189768",
"hcp_pin_alias": "PAST_HCP_Onco_232442",
"session_name": "Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michael Wang",
"middle_name": "",
"last_name": "",
"org_name": "Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232779",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232779",
"events_session": "Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Lymphoma, Mantle-Cell | Venetoclax ",
"rest_events_topic_count": 2,
"rest_events_topic": " Tumor Suppressor Protein P53 | Ibrutinib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1437189768,'PAST_HCP_Onco_232442');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichael Wang",
"kol_full_name": "Michael Wang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Zotiraciclib | Biomarkers | Glioblastoma",
"npi_num": "1154616183",
"hcp_pin_alias": "PAST_HCP_Onco_231685",
"session_name": "Zotiraciclib for newly diagnosed or recurrent glioblastoma: Updated outcome and biomarker analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Michael Weller",
"middle_name": "",
"last_name": "",
"org_name": "Department of Neurology, University Hospital Zurich, and Brain Tumor Centre, University Hospital and University of Zurich, University Hospital Zurich",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233071",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233071",
"events_session": "Zotiraciclib for newly diagnosed or recurrent glioblastoma: Updated outcome and biomarker analysis",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Zotiraciclib | Biomarkers ",
"rest_events_topic_count": 1,
"rest_events_topic": " Glioblastoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1154616183,'PAST_HCP_Onco_231685');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMichael Weller",
"kol_full_name": "Michael Weller"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Fadraciclib | Cyclin-Dependent Kinase 2 | Lymphoma",
"npi_num": "1780692939",
"hcp_pin_alias": "PAST_HCP_Onco_233469",
"session_name": "A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Miguel Angel Villalona-Calero",
"middle_name": "",
"last_name": "",
"org_name": "City of Hope Comprehensive Cancer Center",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232962",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232962",
"events_session": "A phase 1 study evaluating the safety",
"rest_events_session_count": 4,
"rest_events_session": " pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma",
"events_topic": "Fadraciclib | Cyclin-Dependent Kinase 2 ",
"rest_events_topic_count": 1,
"rest_events_topic": " Lymphoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1780692939,'PAST_HCP_Onco_233469');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMiguel Angel Villalona-Calero",
"kol_full_name": "Miguel Angel Villalona-Calero"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Brain Neoplasms | Triple Negative Breast Neoplasms | Bevacizumab",
"npi_num": "1447499710",
"hcp_pin_alias": "FU_HCP_229376",
"session_name": "Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter, single-arm phase II study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Min Yan",
"middle_name": "",
"last_name": "",
"org_name": "Department of Breast, Henan Cancer Hospital",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232695",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232695",
"events_session": "Utidelone plus bevacizumab for the treatment of HER2-negative breast cancer brain metastases (U-BOMB): A multicenter",
"rest_events_session_count": 1,
"rest_events_session": " single-arm phase II study",
"events_topic": "Brain Neoplasms | Triple Negative Breast Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Bevacizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1447499710,'FU_HCP_229376');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMin Yan",
"kol_full_name": "Min Yan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Temozolomide | Glioblastoma",
"npi_num": "1063832046",
"hcp_pin_alias": "FU_HCP_361492",
"session_name": "INB-200: Fully enrolled phase 1 study of gene-modified autologous gamma-delta (γδ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Mina Lobbous",
"middle_name": "",
"last_name": "",
"org_name": "University of Alabama at Birmingham",
"Country": "United States",
"Region": "Alabama",
"City": "Birmingham",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233069",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233069",
"events_session": "INB-200: Fully enrolled phase 1 study of gene-modified autologous gamma-delta (γδ) T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Temozolomide | Glioblastoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1063832046,'FU_HCP_361492');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMina Lobbous",
"kol_full_name": "Mina Lobbous"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Translational Research, Biomedical",
"npi_num": "1770801862",
"hcp_pin_alias": "FU_HCP_45001",
"session_name": "Quality Care/Health Services Research: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Mina S. Sedrak",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233252",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233252",
"events_session": "Quality Care/Health Services Research: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Translational Research, Biomedical",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1770801862,'FU_HCP_45001');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMina S. Sedrak",
"kol_full_name": "Mina S. Sedrak"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1265635924",
"hcp_pin_alias": "FU_HCP_284159",
"session_name": "A phase 1/2 study of BDC-3042, a novel dectin-2 agonistic antibody, in patients with advanced cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Mohamad Adham Salkeni",
"middle_name": "",
"last_name": "",
"org_name": "NEXT Oncology",
"Country": "United States",
"Region": "Texas",
"City": "San Antonio",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233041",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233041",
"events_session": "A phase 1/2 study of BDC-3042",
"rest_events_session_count": 2,
"rest_events_session": " a novel dectin-2 agonistic antibody, in patients with advanced cancers",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1265635924,'FU_HCP_284159');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMohamad Adham Salkeni",
"kol_full_name": "Mohamad Adham Salkeni"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lung Neoplasms | Osimertinib | ErbB Receptors | Etoposide",
"npi_num": "1003313800",
"hcp_pin_alias": "FU_HCP_82913",
"session_name": "Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Monica F Chen",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232169",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232169",
"events_session": "Osimertinib",
"rest_events_session_count": 2,
"rest_events_session": " platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations",
"events_topic": "Lung Neoplasms | Osimertinib ",
"rest_events_topic_count": 2,
"rest_events_topic": " ErbB Receptors | Etoposide",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1003313800,'FU_HCP_82913');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMonica F Chen",
"kol_full_name": "Monica F Chen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Urinary Bladder Neoplasms | Artificial Intelligence",
"npi_num": "1265626303",
"hcp_pin_alias": "FU_HCP_99879",
"session_name": "A multi-institutional observer study of AI-aided oncologists' performance on treatment response assessment of bladder cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Monika Joshi",
"middle_name": "",
"last_name": "",
"org_name": "Penn State Cancer Institute",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Hershey",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232603",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232603",
"events_session": "A multi-institutional observer study of AI-aided oncologists' performance on treatment response assessment of bladder cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Urinary Bladder Neoplasms | Artificial Intelligence",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1265626303,'FU_HCP_99879');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMonika Joshi",
"kol_full_name": "Monika Joshi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cardiovascular Diseases | Hematologic Neoplasms | Bruton's Tyrosine Kinase",
"npi_num": "1295258911",
"hcp_pin_alias": "FU_HCP_284133",
"session_name": "Risk assessment of cardiovascular adverse events with BTK inhibitors in hematological malignancies: Insights from FAERS",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Muhammad Salman Faisal",
"middle_name": "",
"last_name": "",
"org_name": "Roswell Park Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232221",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232221",
"events_session": "Risk assessment of cardiovascular adverse events with BTK inhibitors in hematological malignancies: Insights from FAERS",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Cardiovascular Diseases | Hematologic Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Bruton's Tyrosine Kinase",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1295258911,'FU_HCP_284133');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMuhammad Salman Faisal",
"kol_full_name": "Muhammad Salman Faisal"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lymphocytes, Tumor-Infiltrating | Melanoma | Fludarabine | Cyclophosphamide",
"npi_num": "1245646397",
"hcp_pin_alias": "FU_HCP_362182",
"session_name": "Reduced dose fludarabine/cyclophosphamide lymphodepletion for tumor-infiltrating lymphocytes therapy (LN-144, lifileucel) in metastatic melanoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Muhammad Umair Mushtaq",
"middle_name": "",
"last_name": "",
"org_name": "University of Kansas Cancer Center",
"Country": "United States",
"Region": "Kansas",
"City": "Kansas City",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232805",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232805",
"events_session": "Reduced dose fludarabine/cyclophosphamide lymphodepletion for tumor-infiltrating lymphocytes therapy (LN-144",
"rest_events_session_count": 1,
"rest_events_session": " lifileucel) in metastatic melanoma",
"events_topic": "Lymphocytes, Tumor-Infiltrating | Melanoma ",
"rest_events_topic_count": 2,
"rest_events_topic": " Fludarabine | Cyclophosphamide",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1245646397,'FU_HCP_362182');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EMuhammad Umair Mushtaq",
"kol_full_name": "Muhammad Umair Mushtaq"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Niraparib | Glioblastoma",
"npi_num": "1699899047",
"hcp_pin_alias": "PAST_HCP_CNS_203124",
"session_name": "Niraparib efficacy in patients with newly-diagnosed glioblastoma: Clinical readout of a phase 0/2 \"trigger\" trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Nader Sanai",
"middle_name": "",
"last_name": "",
"org_name": "Ivy Brain Tumor Center at Barrow Neurological Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232456",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232456",
"events_session": "Niraparib efficacy in patients with newly-diagnosed glioblastoma: Clinical readout of a phase 0/2 \"trigger\" trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Niraparib | Glioblastoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1699899047,'PAST_HCP_CNS_203124');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENader Sanai",
"kol_full_name": "Nader Sanai"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Patient Reported Outcome Measures | Clinical Research",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403422",
"session_name": "The Role of Patient Reported Outcomes in Early Phase Clinical Research",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Natalie Cook",
"middle_name": "",
"last_name": "",
"org_name": "The Christie NHS Foundation Trust and University of Manchester",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232333",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232333",
"events_session": "The Role of Patient Reported Outcomes in Early Phase Clinical Research",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Patient Reported Outcome Measures | Clinical Research",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403422');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENatalie Cook",
"kol_full_name": "Natalie Cook"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Amivantamab | Lazertinib | ErbB Receptors | Carcinoma, Non-Small-Cell Lung",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403482",
"session_name": "Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Natasha B. Leighl",
"middle_name": "",
"last_name": "",
"org_name": "Princess Margaret Cancer Centre",
"Country": "Canada",
"Region": "Ontario",
"City": "Toronto",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233137",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233137",
"events_session": "Subcutaneous amivantamab vs intravenous amivantamab",
"rest_events_session_count": 7,
"rest_events_session": " both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial",
"events_topic": "Amivantamab | Lazertinib ",
"rest_events_topic_count": 2,
"rest_events_topic": " ErbB Receptors | Carcinoma, Non-Small-Cell Lung",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403482');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENatasha B. Leighl",
"kol_full_name": "Natasha B. Leighl"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1538326632",
"hcp_pin_alias": "FU_HCP_100204",
"session_name": "Pediatric Oncologist Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Navin Pinto",
"middle_name": "",
"last_name": "",
"org_name": "Seattle Children's Hospital",
"Country": "United States",
"Region": "Washington",
"City": "Seattle",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232153",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232153",
"events_session": "Pediatric Oncologist Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1538326632,'FU_HCP_100204');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENavin Pinto",
"kol_full_name": "Navin Pinto"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Glioblastoma | Peposertib | Clinical Trials As Topic",
"npi_num": "1164721882",
"hcp_pin_alias": "FU_HCP_75825",
"session_name": "Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Nazanin Majd",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233076",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233076",
"events_session": "Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Glioblastoma | Peposertib ",
"rest_events_topic_count": 1,
"rest_events_topic": " Clinical Trials As Topic",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1164721882,'FU_HCP_75825');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENazanin Majd",
"kol_full_name": "Nazanin Majd"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms | Carcinoma, Non-Small-Cell Lung",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403401",
"session_name": "Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Nicolas Girard",
"middle_name": "",
"last_name": "",
"org_name": "Institut Curie",
"Country": "France",
"Region": "Ile-De-France",
"City": "Paris",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232176",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232176",
"events_session": "Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Triple Negative Breast Neoplasms | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403401');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENicolas Girard",
"kol_full_name": "Nicolas Girard"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Tocilizumab | Cytokine Release Syndrome | Teclistamab | Multiple Myeloma",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403392",
"session_name": "Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Niels W.C.J. van de Donk",
"middle_name": "",
"last_name": "",
"org_name": "Amsterdam UMC",
"Country": "Netherlands",
"Region": "Noord-Holland",
"City": "Amsterdam",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232114",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232114",
"events_session": "Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Tocilizumab | Cytokine Release Syndrome ",
"rest_events_topic_count": 2,
"rest_events_topic": " Teclistamab | Multiple Myeloma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403392');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENiels W.C.J. van de Donk",
"kol_full_name": "Niels W.C.J. van de Donk"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Education, Medical",
"npi_num": "1629308515",
"hcp_pin_alias": "FU_HCP_5403381",
"session_name": "Medical Educaton and Professional Development: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Niki Tank Patel",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233239",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233239",
"events_session": "Medical Educaton and Professional Development: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Education, Medical",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1629308515,'FU_HCP_5403381');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENiki Tank Patel",
"kol_full_name": "Niki Tank Patel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Transplant Recipients",
"npi_num": "1003475195",
"hcp_pin_alias": "FU_HCP_284323",
"session_name": "Outcomes of liver transplant recipients with pretransplant malignancies: Insights from a single institution’s experience",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Nikitha Vobugari",
"middle_name": "",
"last_name": "",
"org_name": "University of Minnesota",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232424",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232424",
"events_session": "Outcomes of liver transplant recipients with pretransplant malignancies: Insights from a single institution’s experience",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms | Transplant Recipients",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1003475195,'FU_HCP_284323');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENikitha Vobugari",
"kol_full_name": "Nikitha Vobugari"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cancer Survivors",
"npi_num": "1285618793",
"hcp_pin_alias": "FU_HCP_187367",
"session_name": "All Too Well: Improving Communication and Care in Childhood Cancer Survivors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Nina S. Kadan-Lottick",
"middle_name": "",
"last_name": "",
"org_name": "Georgetown University Lombardi Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232295",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232295",
"events_session": "All Too Well: Improving Communication and Care in Childhood Cancer Survivors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Cancer Survivors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1285618793,'FU_HCP_187367');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENina S. Kadan-Lottick",
"kol_full_name": "Nina S. Kadan-Lottick"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms, Male",
"npi_num": "1962998559",
"hcp_pin_alias": "FU_HCP_387368",
"session_name": "Demographics and survival outcomes of stage IV male breast cancer: A retrospective analysis of SEER database",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Nishanth Thalambedu",
"middle_name": "",
"last_name": "",
"org_name": "University of Arkansas for Medical Sciences",
"Country": "United States",
"Region": "Arkansas",
"City": "Little Rock",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232419",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232419",
"events_session": "Demographics and survival outcomes of stage IV male breast cancer: A retrospective analysis of SEER database",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms, Male",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1962998559,'FU_HCP_387368');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENishanth Thalambedu",
"kol_full_name": "Nishanth Thalambedu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Education, Medical",
"npi_num": "1598941908",
"hcp_pin_alias": "FU_HCP_5403380",
"session_name": "Medical Educaton and Professional Development: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Nishin Bhadkamkar",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233238",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233238",
"events_session": "Medical Educaton and Professional Development: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Education, Medical",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1598941908,'FU_HCP_5403380');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENishin Bhadkamkar",
"kol_full_name": "Nishin Bhadkamkar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Multiple Myeloma | Venetoclax | Pomalidomide | Biomarkers | Dexamethasone",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403390",
"session_name": "Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Nizar J. Bahlis",
"middle_name": "",
"last_name": "",
"org_name": "University of Calgary",
"Country": "Canada",
"Region": "Alberta",
"City": "Calgary",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232111",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232111",
"events_session": "Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Multiple Myeloma | Venetoclax ",
"rest_events_topic_count": 3,
"rest_events_topic": " Pomalidomide | Biomarkers | Dexamethasone",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403390');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENizar J. Bahlis",
"kol_full_name": "Nizar J. Bahlis"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Sotevtamab | Combined Modality Therapy",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403399",
"session_name": "A phase II trial to evaluate the epithelial-to-mesenchymal (EMT) inhibitor sotevtamab combined with docetaxel in patients with metastatic non-small cell lung cancer following failure of primary chemoimmunotherapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Normand Blais",
"middle_name": "",
"last_name": "",
"org_name": "Hematology-Oncology Division, University of Montreal Health Centre (CHUM)",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232171",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232171",
"events_session": "A phase II trial to evaluate the epithelial-to-mesenchymal (EMT) inhibitor sotevtamab combined with docetaxel in patients with metastatic non-small cell lung cancer following failure of primary chemoimmunotherapy",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Sotevtamab ",
"rest_events_topic_count": 1,
"rest_events_topic": " Combined Modality Therapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403399');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENormand Blais",
"kol_full_name": "Normand Blais"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Elacestrant | Abemaciclib | Triple Negative Breast Neoplasms",
"npi_num": "1528153715",
"hcp_pin_alias": "FU_HCP_116343",
"session_name": "Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Nuhad K. Ibrahim",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232690",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232690",
"events_session": "Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+)",
"rest_events_session_count": 4,
"rest_events_session": " HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study",
"events_topic": "Elacestrant | Abemaciclib ",
"rest_events_topic_count": 1,
"rest_events_topic": " Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1528153715,'FU_HCP_116343');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ENuhad K. Ibrahim",
"kol_full_name": "Nuhad K. Ibrahim"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1790980613",
"hcp_pin_alias": "FU_HCP_99701",
"session_name": "Breast Cancer – Local/Regional/Adjuvant: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Oluwadamilola Motunrayo Fayanju",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233170",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233170",
"events_session": "Breast Cancer – Local/Regional/Adjuvant: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790980613,'FU_HCP_99701');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EOluwadamilola Motunrayo Fayanju",
"kol_full_name": "Oluwadamilola Motunrayo Fayanju"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1912445255",
"hcp_pin_alias": "PAST_HCP_Onco_231477",
"session_name": "Women, Power, and Cancer: Global and North American Findings and Recommendations",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ophira Ginsburg",
"middle_name": "",
"last_name": "",
"org_name": "National Cancer Institute",
"Country": "United States",
"Region": "Maryland",
"City": "Bethesda",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232746",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232746",
"events_session": "Women",
"rest_events_session_count": 2,
"rest_events_session": " Power, and Cancer: Global and North American Findings and Recommendations",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1912445255,'PAST_HCP_Onco_231477');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EOphira Ginsburg",
"kol_full_name": "Ophira Ginsburg"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hematologic Neoplasms | Hypertension, Pulmonary | Myeloproliferative Disorders",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403424",
"session_name": "Association of elevated pulmonary artery systolic pressure with hematologic progression in myeloproliferative neoplasms",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Orly Leiva",
"middle_name": "",
"last_name": "",
"org_name": "New York University Grossman School of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232349",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232349",
"events_session": "Association of elevated pulmonary artery systolic pressure with hematologic progression in myeloproliferative neoplasms",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Hematologic Neoplasms | Hypertension, Pulmonary ",
"rest_events_topic_count": 1,
"rest_events_topic": " Myeloproliferative Disorders",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403424');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EOrly Leiva",
"kol_full_name": "Orly Leiva"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Endocrine Therapy | Palbociclib | Triple Negative Breast Neoplasms",
"npi_num": "1275875155",
"hcp_pin_alias": "FU_HCP_40590",
"session_name": "Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Otto Metzger",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232620",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232620",
"events_session": "Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Endocrine Therapy | Palbociclib ",
"rest_events_topic_count": 1,
"rest_events_topic": " Triple Negative Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1275875155,'FU_HCP_40590');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EOtto Metzger",
"kol_full_name": "Otto Metzger"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Myeloproliferative Disorders",
"npi_num": "1982968764",
"hcp_pin_alias": "FU_HCP_187374",
"session_name": "BETter Therapies for Myeloproliferative Neoplasms",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Pankit Vachhani",
"middle_name": "",
"last_name": "",
"org_name": "O'Neal Comprehensive Cancer Center at UAB",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233107",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233107",
"events_session": "BETter Therapies for Myeloproliferative Neoplasms",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Myeloproliferative Disorders",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1982968764,'FU_HCP_187374');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPankit Vachhani",
"kol_full_name": "Pankit Vachhani"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1851360515",
"hcp_pin_alias": "FU_HCP_155355",
"session_name": "Discussion on Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Patricia Spears",
"middle_name": "",
"last_name": "",
"org_name": "UNC Patient Advocates for Research Council",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232311",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232311",
"events_session": "Discussion on Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1851360515,'FU_HCP_155355');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPatricia Spears",
"kol_full_name": "Patricia Spears"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Irinotecan | Sarcoma, Ewing",
"npi_num": "1225175201",
"hcp_pin_alias": "FU_HCP_5403340",
"session_name": "SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Patrick Joseph Grohar",
"middle_name": "",
"last_name": "",
"org_name": "Children's Hospital of Philadelphia",
"Country": "United States",
"Region": "Pennsylvania",
"City": "Philadelphia",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232152",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232152",
"events_session": "SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Irinotecan | Sarcoma, Ewing",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1225175201,'FU_HCP_5403340');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPatrick Joseph Grohar",
"kol_full_name": "Patrick Joseph Grohar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Dendritic Cells | Triple Negative Breast Neoplasms",
"npi_num": "1841582285",
"hcp_pin_alias": "FU_HCP_45595",
"session_name": "A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Peter A. J. Forsyth",
"middle_name": "",
"last_name": "",
"org_name": "H. Lee Moffitt Cancer Center and Research Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233082",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233082",
"events_session": "A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Dendritic Cells | Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1841582285,'FU_HCP_45595');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPeter A. J. Forsyth",
"kol_full_name": "Peter A. J. Forsyth"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy, Adoptive | Prostatic Neoplasms | Radiotherapy | Castration",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403446",
"session_name": "A phase 1b study of PSCA CAR T cells plus or minus radiation for the treatment of patients with PSCA+ metastatic castration-resistant prostate cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Peter D. Zang",
"middle_name": "",
"last_name": "",
"org_name": "City of Hope Comprehensive Cancer Center",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232668",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232668",
"events_session": "A phase 1b study of PSCA CAR T cells plus or minus radiation for the treatment of patients with PSCA+ metastatic castration-resistant prostate cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunotherapy, Adoptive | Prostatic Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Radiotherapy | Castration",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403446');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPeter D. Zang",
"kol_full_name": "Peter D. Zang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cisplatin | Enfortumab Vedotin | Urinary Bladder Neoplasms",
"npi_num": "1861695819",
"hcp_pin_alias": "FU_HCP_250346",
"session_name": "Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)—2-year event-free survival and safety data for Cohort H",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Peter H. O'Donnell",
"middle_name": "",
"last_name": "",
"org_name": "University of Chicago",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232589",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232589",
"events_session": "Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)—2-year event-free survival and safety data for Cohort H",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Cisplatin | Enfortumab Vedotin ",
"rest_events_topic_count": 1,
"rest_events_topic": " Urinary Bladder Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1861695819,'FU_HCP_250346');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPeter H. O'Donnell",
"kol_full_name": "Peter H. O'Donnell"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Castration | Clinical Trials As Topic | Prostatic Neoplasms | Artificial Intelligence",
"npi_num": "1376100255",
"hcp_pin_alias": "FU_HCP_281832",
"session_name": "Validation of a digital pathology-based multimodal artificial intelligence model in oliogmetastatic castration-sensitive prostate cancer, including in patients from the STOMP and ORIOLE phase II randomized clinical trials",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Philip Anthony Sutera",
"middle_name": "",
"last_name": "",
"org_name": "Johns Hopkins University",
"Country": "United States",
"Region": "Maryland",
"City": "Baltimore",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232658",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232658",
"events_session": "Validation of a digital pathology-based multimodal artificial intelligence model in oliogmetastatic castration-sensitive prostate cancer",
"rest_events_session_count": 1,
"rest_events_session": " including in patients from the STOMP and ORIOLE phase II randomized clinical trials",
"events_topic": "Castration | Clinical Trials As Topic ",
"rest_events_topic_count": 2,
"rest_events_topic": " Prostatic Neoplasms | Artificial Intelligence",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1376100255,'FU_HCP_281832');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPhilip Anthony Sutera",
"kol_full_name": "Philip Anthony Sutera"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Multiple Endocrine Neoplasia Type 1 | Familial Medullary Thyroid Carcinoma | Selpercatinib",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403475",
"session_name": "Selpercatinib in non-MTC, RET-mutated tumors: Efficacy in MEN-associated and other tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Philippe Alexandre Cassier",
"middle_name": "",
"last_name": "",
"org_name": "Centre Léon Bérard",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232969",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232969",
"events_session": "Selpercatinib in non-MTC",
"rest_events_session_count": 1,
"rest_events_session": " RET-mutated tumors: Efficacy in MEN-associated and other tumors",
"events_topic": "Multiple Endocrine Neoplasia Type 1 | Familial Medullary Thyroid Carcinoma ",
"rest_events_topic_count": 1,
"rest_events_topic": " Selpercatinib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403475');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPhilippe Alexandre Cassier",
"kol_full_name": "Philippe Alexandre Cassier"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1841558723",
"hcp_pin_alias": "FU_HCP_5403378",
"session_name": "Molecular Pathologist Perspective",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Phillip Michaels",
"middle_name": "",
"last_name": "",
"org_name": "Brigham and Women's Hospital",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233146",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233146",
"events_session": "Molecular Pathologist Perspective",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1841558723,'FU_HCP_5403378');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPhillip Michaels",
"kol_full_name": "Phillip Michaels"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms | Prostatectomy | Neoplasm, Residual | Receptors, Androgen",
"npi_num": "1528447703",
"hcp_pin_alias": "FU_HCP_5403361",
"session_name": "Prognostic impact of residual cancer burden (RCB) on long-term outcomes after neoadjuvant (neo) androgen receptor pathway inhibitor (ARPI) and radical prostatectomy (RP) for high-risk localized prostate cancer (HRLPC): A pooled analysis of phase 2 trials",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Praful Ravi",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232663",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232663",
"events_session": "Prognostic impact of residual cancer burden (RCB) on long-term outcomes after neoadjuvant (neo) androgen receptor pathway inhibitor (ARPI) and radical prostatectomy (RP) for high-risk localized prostate cancer (HRLPC): A pooled analysis of phase 2 trials",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms | Prostatectomy ",
"rest_events_topic_count": 2,
"rest_events_topic": " Neoplasm, Residual | Receptors, Androgen",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1528447703,'FU_HCP_5403361');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPraful Ravi",
"kol_full_name": "Praful Ravi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Leukemia, Myeloid, Acute",
"npi_num": "1578946406",
"hcp_pin_alias": "FU_HCP_232099",
"session_name": "Improved overall survival in acute myeloid leukemia over the last 15 years",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Prajwal Dhakal",
"middle_name": "",
"last_name": "",
"org_name": "University of Iowa",
"Country": "United States",
"Region": "Iowa",
"City": "Iowa City",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232340",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232340",
"events_session": "Improved overall survival in acute myeloid leukemia over the last 15 years",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Leukemia, Myeloid, Acute",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1578946406,'FU_HCP_232099');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPrajwal Dhakal",
"kol_full_name": "Prajwal Dhakal"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Premenopause | Breast Neoplasms",
"npi_num": "1245726371",
"hcp_pin_alias": "FU_HCP_284353",
"session_name": "Prognostic value of Oncotype recurrence score (RS) and Mammaprint (MP) in premenopausal patients with hormone positive (HR+) breast cancer (BC) with low genomic risk, stratified by race: A study of the National Cancer Database (NCDB)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Prashanth Ashok Kumar",
"middle_name": "",
"last_name": "",
"org_name": "SUNY Upstate University Hospital",
"Country": "United States",
"Region": "New York",
"City": "Syracuse",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232625",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232625",
"events_session": "Prognostic value of Oncotype recurrence score (RS) and Mammaprint (MP) in premenopausal patients with hormone positive (HR+) breast cancer (BC) with low genomic risk",
"rest_events_session_count": 1,
"rest_events_session": " stratified by race: A study of the National Cancer Database (NCDB)",
"events_topic": "Premenopause | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1245726371,'FU_HCP_284353');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPrashanth Ashok Kumar",
"kol_full_name": "Prashanth Ashok Kumar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms | Receptors, Androgen",
"npi_num": "1962768671",
"hcp_pin_alias": "FU_HCP_225391",
"session_name": "Molecular and immunological characterization of androgen receptor expression in different breast cancer subtypes",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Priya Jayachandran",
"middle_name": "",
"last_name": "",
"org_name": "Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232707",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232707",
"events_session": "Molecular and immunological characterization of androgen receptor expression in different breast cancer subtypes",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms | Receptors, Androgen",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1962768671,'FU_HCP_225391');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EPriya Jayachandran",
"kol_full_name": "Priya Jayachandran"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Immunotherapy",
"npi_num": "1619112034",
"hcp_pin_alias": "FU_HCP_0004789",
"session_name": "Optimizing Treatment of Locally Advanced Non–Small Cell Lung Cancer: A Multimodal Approach in the Immunotherapy Era",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Rami Manochakian",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic Florida",
"Country": "United States",
"Region": "Florida",
"City": "Jacksonville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232040",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232040",
"events_session": "Optimizing Treatment of Locally Advanced Non–Small Cell Lung Cancer: A Multimodal Approach in the Immunotherapy Era",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Immunotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1619112034,'FU_HCP_0004789');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERami Manochakian",
"kol_full_name": "Rami Manochakian"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Surgical Procedures, Operative | Head And Neck Neoplasms",
"npi_num": "1245256551",
"hcp_pin_alias": "FU_HCP_40245",
"session_name": "Novel Treatment Approaches in Head and Neck Cancer Surgery: Improving Quality of Life",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ravindra Uppaluri",
"middle_name": "",
"last_name": "",
"org_name": "Brigham and Women's Hospital",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232510",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232510",
"events_session": "Novel Treatment Approaches in Head and Neck Cancer Surgery: Improving Quality of Life",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Surgical Procedures, Operative | Head And Neck Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1245256551,'FU_HCP_40245');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERavindra Uppaluri",
"kol_full_name": "Ravindra Uppaluri"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms, Second Primary",
"npi_num": "1619107596",
"hcp_pin_alias": "FU_HCP_43545",
"session_name": "Improving Global Access to Cancer Therapies Through Regulatory Authority Collaboration",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Richard Pazdur",
"middle_name": "",
"last_name": "",
"org_name": "U.S. Food and Drug Administration",
"Country": "United States",
"Region": "Maryland",
"City": "Silver Spring",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "231993",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "231993",
"events_session": "Improving Global Access to Cancer Therapies Through Regulatory Authority Collaboration",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms, Second Primary",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1619107596,'FU_HCP_43545');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERichard Pazdur",
"kol_full_name": "Richard Pazdur"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Cannabis",
"npi_num": "1316947385",
"hcp_pin_alias": "FU_HCP_110446",
"session_name": "Evidence Evaluating Cannabis’ Efficacy Across the Cancer Care Continuum",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Richard T. Lee",
"middle_name": "",
"last_name": "",
"org_name": "City of Hope Comprehensive Cancer Center",
"Country": "United States",
"Region": "California",
"City": "Duarte",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232488",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232488",
"events_session": "Evidence Evaluating Cannabis’ Efficacy Across the Cancer Care Continuum",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms | Cannabis",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1316947385,'FU_HCP_110446');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERichard T. Lee",
"kol_full_name": "Richard T. Lee"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1124556659",
"hcp_pin_alias": "FU_HCP_377718",
"session_name": "Impact of race/ethnicity on the MammaPrint genomic assay risk and prognosis in early breast cancer (EBC): A National Cancer Database (NCDB) analysis",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Rima Patel",
"middle_name": "",
"last_name": "",
"org_name": "Icahn School of Medicine at Mount Sinai",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232627",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232627",
"events_session": "Impact of race/ethnicity on the MammaPrint genomic assay risk and prognosis in early breast cancer (EBC): A National Cancer Database (NCDB) analysis",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1124556659,'FU_HCP_377718');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERima Patel",
"kol_full_name": "Rima Patel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cholangiocarcinoma",
"npi_num": "1053963140",
"hcp_pin_alias": "FU_HCP_394643",
"session_name": "Genomic signature analysis and survival outcomes in cholangiocarcinoma (CCA) using oncology research information exchange network (ORIEN) database",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Riya Jayesh Patel",
"middle_name": "",
"last_name": "",
"org_name": "Roswell Park Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232828",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232828",
"events_session": "Genomic signature analysis and survival outcomes in cholangiocarcinoma (CCA) using oncology research information exchange network (ORIEN) database",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Cholangiocarcinoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1053963140,'FU_HCP_394643');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERiya Jayesh Patel",
"kol_full_name": "Riya Jayesh Patel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1356322812",
"hcp_pin_alias": "FU_HCP_229979",
"session_name": "The Epidemiologist’s Perspective: Pros of Early Adoption",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Robert A. Smith",
"middle_name": "",
"last_name": "",
"org_name": "American Cancer Society",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233142",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233142",
"events_session": "The Epidemiologist’s Perspective: Pros of Early Adoption",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1356322812,'FU_HCP_229979');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERobert A. Smith",
"kol_full_name": "Robert A. Smith"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "ESR2 Protein, Human | Carcinoma, Non-Small-Cell Lung | ESR1 Protein, Human",
"npi_num": "1669835740",
"hcp_pin_alias": "FU_HCP_5403341",
"session_name": "Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Robert Hsu",
"middle_name": "",
"last_name": "",
"org_name": "Norris Comprehensive Cancer Center, University of Southern California",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232161",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232161",
"events_session": "Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "ESR2 Protein, Human | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 1,
"rest_events_topic": " ESR1 Protein, Human",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1669835740,'FU_HCP_5403341');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERobert Hsu",
"kol_full_name": "Robert Hsu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cognitive Dysfunction | Telemedicine | Clinical Trials As Topic",
"npi_num": "1811930456",
"hcp_pin_alias": "FU_HCP_45364",
"session_name": "Telehealth cognitive-behavioral therapy for cancer-related cognitive impairment: 2024 update of a model for remote clinical trial participation",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Robert J. Ferguson",
"middle_name": "",
"last_name": "",
"org_name": "University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232222",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232222",
"events_session": "Telehealth cognitive-behavioral therapy for cancer-related cognitive impairment: 2024 update of a model for remote clinical trial participation",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Cognitive Dysfunction | Telemedicine ",
"rest_events_topic_count": 1,
"rest_events_topic": " Clinical Trials As Topic",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1811930456,'FU_HCP_45364');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERobert J. Ferguson",
"kol_full_name": "Robert J. Ferguson"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Microsatellite Repeats | Pembrolizumab | Cetuximab",
"npi_num": "1881056323",
"hcp_pin_alias": "FU_HCP_347131",
"session_name": "Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Robert William Lentz",
"middle_name": "",
"last_name": "",
"org_name": "University of Colorado Cancer Center",
"Country": "United States",
"Region": "Colorado",
"City": "Aurora",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232868",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232868",
"events_session": "Results of a phase 2 study of evorpacept (E",
"rest_events_session_count": 3,
"rest_events_session": " ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC)",
"events_topic": "Colorectal Neoplasms | Microsatellite Repeats ",
"rest_events_topic_count": 2,
"rest_events_topic": " Pembrolizumab | Cetuximab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1881056323,'FU_HCP_347131');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERobert William Lentz",
"kol_full_name": "Robert William Lentz"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Penile Neoplasms | Papillomavirus Infections",
"npi_num": "1184902884",
"hcp_pin_alias": "FU_HCP_39768",
"session_name": "Implications of HPV infection on survival outcomes in patients with penile squamous cell carcinoma: Insights from a nationwide study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Rohan Garje",
"middle_name": "",
"last_name": "",
"org_name": "Miami Cancer Institute, Baptist Health South Florida",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232648",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232648",
"events_session": "Implications of HPV infection on survival outcomes in patients with penile squamous cell carcinoma: Insights from a nationwide study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Penile Neoplasms | Papillomavirus Infections",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1184902884,'FU_HCP_39768');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERohan Garje",
"kol_full_name": "Rohan Garje"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "ErbB Receptors | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1003307513",
"hcp_pin_alias": "FU_HCP_409027",
"session_name": "Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Rohit Thummalapalli",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232177",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232177",
"events_session": "Genomic landscape of MTAP deletions and association with EGFR alterations in NSCLC",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "ErbB Receptors | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1003307513,'FU_HCP_409027');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERohit Thummalapalli",
"kol_full_name": "Rohit Thummalapalli"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Renal Cell | Brain Diseases",
"npi_num": "1720529985",
"hcp_pin_alias": "FU_HCP_75790",
"session_name": "Tumor evolution of brain-specific tropism in metastatic renal cell carcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Roy Elias",
"middle_name": "",
"last_name": "",
"org_name": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232580",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232580",
"events_session": "Tumor evolution of brain-specific tropism in metastatic renal cell carcinoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Renal Cell | Brain Diseases",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1720529985,'FU_HCP_75790');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERoy Elias",
"kol_full_name": "Roy Elias"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Social Determinants Of Health | Atherosclerosis | Neoplasms",
"npi_num": "1083794960",
"hcp_pin_alias": "FU_HCP_229494",
"session_name": "Association of social determinants of health (SDH), allostatic load (AL) and incident cancers in the multi-ethnic study of atherosclerosis (MESA)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ruth C. Carlos",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232226",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232226",
"events_session": "Association of social determinants of health (SDH)",
"rest_events_session_count": 1,
"rest_events_session": " allostatic load (AL) and incident cancers in the multi-ethnic study of atherosclerosis (MESA)",
"events_topic": "Social Determinants Of Health | Atherosclerosis ",
"rest_events_topic_count": 1,
"rest_events_topic": " Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1083794960,'FU_HCP_229494');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERuth C. Carlos",
"kol_full_name": "Ruth C. Carlos"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "1215981238",
"hcp_pin_alias": "FU_HCP_40049",
"session_name": "Balancing Efficacy and Quality of Life in Hormone Receptor-Positive Metastatic Breast Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ruth O'Regan",
"middle_name": "",
"last_name": "",
"org_name": "University of Rochester",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232774",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232774",
"events_session": "Balancing Efficacy and Quality of Life in Hormone Receptor-Positive Metastatic Breast Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1215981238,'FU_HCP_40049');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ERuth O'Regan",
"kol_full_name": "Ruth O'Regan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Rhabdomyosarcoma",
"npi_num": "1548609910",
"hcp_pin_alias": "FU_HCP_43023",
"session_name": "Local Control of Intermediate-Risk Rhabdomyosarcoma: I Knew You Were Trouble",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Safia K. Ahmed",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic Arizona",
"Country": "United States",
"Region": "Florida",
"City": "Fort Lauderdale",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232727",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232727",
"events_session": "Local Control of Intermediate-Risk Rhabdomyosarcoma: I Knew You Were Trouble",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Rhabdomyosarcoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1548609910,'FU_HCP_43023');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESafia K. Ahmed",
"kol_full_name": "Safia K. Ahmed"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ceftazidime | Carcinoma, Transitional Cell | Enfortumab Vedotin",
"npi_num": "1922324193",
"hcp_pin_alias": "FU_HCP_46244",
"session_name": "­­­­­­Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Samuel A Funt",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232595",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232595",
"events_session": "­­­­­­Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Ceftazidime | Carcinoma, Transitional Cell ",
"rest_events_topic_count": 1,
"rest_events_topic": " Enfortumab Vedotin",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1922324193,'FU_HCP_46244');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESamuel A Funt",
"kol_full_name": "Samuel A Funt"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Small Cell Lung Carcinoma",
"npi_num": "1386149516",
"hcp_pin_alias": "FU_HCP_282734",
"session_name": "The genomic, transcriptomic, and immunologic landscape of TEM8 (ANTXR1) in small-cell lung cancer (SCLC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Samuel A. Kareff",
"middle_name": "",
"last_name": "",
"org_name": "University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232963",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232963",
"events_session": "The genomic",
"rest_events_session_count": 2,
"rest_events_session": " transcriptomic, and immunologic landscape of TEM8 (ANTXR1) in small-cell lung cancer (SCLC)",
"events_topic": "Small Cell Lung Carcinoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1386149516,'FU_HCP_282734');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESamuel A. Kareff",
"kol_full_name": "Samuel A. Kareff"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Therapeutics | Neoplasms",
"npi_num": "1821436254",
"hcp_pin_alias": "FU_HCP_281878",
"session_name": "Tailoring Treatment and Navigating Patient Preferences",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Samuel U Takvorian",
"middle_name": "",
"last_name": "",
"org_name": "Perelman School of Medicine, University of Pennsylvania",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232466",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232466",
"events_session": "Tailoring Treatment and Navigating Patient Preferences",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Therapeutics | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1821436254,'FU_HCP_281878');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESamuel U Takvorian",
"kol_full_name": "Samuel U Takvorian"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Leukemia | Colorectal Neoplasms",
"npi_num": "1861886707",
"hcp_pin_alias": "FU_HCP_45772",
"session_name": "Time to target TIM-3 in colorectal cancer: TIM-3 expression to predict survival outcomes in patients in CALGB (Alliance)/SWOG 80405",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sandra Algaze",
"middle_name": "",
"last_name": "",
"org_name": "Norris Comprehensive Cancer Center, University of Southern California",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232880",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232880",
"events_session": "Time to target TIM-3 in colorectal cancer: TIM-3 expression to predict survival outcomes in patients in CALGB (Alliance)/SWOG 80405",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Leukemia | Colorectal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1861886707,'FU_HCP_45772');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESandra Algaze",
"kol_full_name": "Sandra Algaze"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Mesothelioma | Atezolizumab | Bevacizumab",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403433",
"session_name": "BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sanjay Popat",
"middle_name": "",
"last_name": "",
"org_name": "Royal Marsden Hospital NHS Foundation Trust",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232473",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232473",
"events_session": "BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A)",
"rest_events_session_count": 1,
"rest_events_session": " as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial",
"events_topic": "Chemotherapy | Mesothelioma ",
"rest_events_topic_count": 2,
"rest_events_topic": " Atezolizumab | Bevacizumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403433');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESanjay Popat",
"kol_full_name": "Sanjay Popat"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Clinical Trials As Topic | Primary Myelofibrosis | Ruxolitinib | Azacitidine",
"npi_num": "1700494200",
"hcp_pin_alias": "FU_HCP_225282",
"session_name": "Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sankalp Arora",
"middle_name": "",
"last_name": "",
"org_name": "Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232347",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232347",
"events_session": "Long term follow-up results of phase II clinical trial evaluating ruxolitinib (RUX) and azacitidine (AZA) combination therapy in patients (pts) with myelofibrosis (MF)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Clinical Trials As Topic | Primary Myelofibrosis ",
"rest_events_topic_count": 2,
"rest_events_topic": " Ruxolitinib | Azacitidine",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700494200,'FU_HCP_225282');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESankalp Arora",
"kol_full_name": "Sankalp Arora"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Skin Neoplasms | Melanoma",
"npi_num": "1629356803",
"hcp_pin_alias": "FU_HCP_230089",
"session_name": "Melanoma/Skin Cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sarah A. Weiss",
"middle_name": "",
"last_name": "",
"org_name": "Rutgers Cancer Institute of NJ",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232450",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232450",
"events_session": "Melanoma/Skin Cancers",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Skin Neoplasms | Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1629356803,'FU_HCP_230089');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESarah A. Weiss",
"kol_full_name": "Sarah A. Weiss"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ovarian Neoplasms | Atovaquone",
"npi_num": "1013413988",
"hcp_pin_alias": "FU_HCP_394499",
"session_name": "Repurposing atovaquone as a STAT3 inhibitor for the treatment of platinum resistant ovarian cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sarah Jeanne Wood",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232442",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232442",
"events_session": "Repurposing atovaquone as a STAT3 inhibitor for the treatment of platinum resistant ovarian cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Ovarian Neoplasms | Atovaquone",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1013413988,'FU_HCP_394499');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESarah Jeanne Wood",
"kol_full_name": "Sarah Jeanne Wood"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms | Admin. & Management",
"npi_num": "1013027077",
"hcp_pin_alias": "PAST_HCP_Future Events_317490",
"session_name": "Pediatric Oncology: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sarah K. Tasian",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233246",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233246",
"events_session": "Pediatric Oncology: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms | Admin. & Management",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1013027077,'PAST_HCP_Future Events_317490');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESarah K. Tasian",
"kol_full_name": "Sarah K. Tasian"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ovarian Neoplasms | Prostatic Neoplasms | Early Detection Of Cancer | Lung Neoplasms | Ultrasonography",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403411",
"session_name": "Association of a polygenic risk score with risk of abnormal ultrasound findings and ovarian cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sarah Phillips",
"middle_name": "",
"last_name": "",
"org_name": "National Cancer Institute",
"Country": "United States",
"Region": "Maryland",
"City": "Bethesda",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232224",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232224",
"events_session": "Association of a polygenic risk score with risk of abnormal ultrasound findings and ovarian cancer in the Prostate",
"rest_events_session_count": 3,
"rest_events_session": " Lung, Colorectal, and Ovarian Cancer Screening Trial",
"events_topic": "Ovarian Neoplasms | Prostatic Neoplasms ",
"rest_events_topic_count": 3,
"rest_events_topic": " Early Detection Of Cancer | Lung Neoplasms | Ultrasonography",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403411');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESarah Phillips",
"kol_full_name": "Sarah Phillips"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Solid Tumor",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403476",
"session_name": "Pilot study of CBX-12 pharmacodynamics in patients with advanced solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sarah Shin",
"middle_name": "",
"last_name": "",
"org_name": "Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232986",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232986",
"events_session": "Pilot study of CBX-12 pharmacodynamics in patients with advanced solid tumors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403476');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESarah Shin",
"kol_full_name": "Sarah Shin"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Idecabtagene Vicleucel | Multiple Myeloma",
"npi_num": "1245890003",
"hcp_pin_alias": "FU_HCP_387049",
"session_name": "Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Saurabh Zanwar",
"middle_name": "",
"last_name": "",
"org_name": "Division of Hematology, Mayo Clinic",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232138",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232138",
"events_session": "Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Idecabtagene Vicleucel | Multiple Myeloma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1245890003,'FU_HCP_387049');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESaurabh Zanwar",
"kol_full_name": "Saurabh Zanwar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Cetuximab | Colorectal Neoplasms | Encorafenib | Carcinoma",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403466",
"session_name": "Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma: First effectiveness data of the European multi-centric, multi-national, non-interventional study—BERING-CRC",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sebastian Stintzing",
"middle_name": "",
"last_name": "",
"org_name": "Medical Department, Division of Hematology, Oncology, and Cancer Immunology (CCM), Charité Universitätsmedizin Berlin",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232872",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232872",
"events_session": "Encorafenib plus cetuximab in patients with metastatic",
"rest_events_session_count": 4,
"rest_events_session": " BRAF V600E-mutated, colorectal carcinoma: First effectiveness data of the European multi-centric, multi-national, non-interventional study—BERING-CRC",
"events_topic": "Cetuximab | Colorectal Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Encorafenib | Carcinoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403466');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESebastian Stintzing",
"kol_full_name": "Sebastian Stintzing"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Giredestrant | Everolimus | Breast Neoplasms",
"npi_num": "1790123792",
"hcp_pin_alias": "FU_HCP_45145",
"session_name": "Interim analysis (IA) of the giredestrant (G) + everolimus (EVERO) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Seth Andrew Wander",
"middle_name": "",
"last_name": "",
"org_name": "Massachusetts General Hospital",
"Country": "United States",
"Region": "Massachusetts",
"City": "Boston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232688",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232688",
"events_session": "Interim analysis (IA) of the giredestrant (G) + everolimus (EVERO) arm in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive (ER+)",
"rest_events_session_count": 2,
"rest_events_session": " HER2-negative, locally advanced/metastatic BC (LA/mBC)",
"events_topic": "Giredestrant | Everolimus ",
"rest_events_topic_count": 1,
"rest_events_topic": " Breast Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790123792,'FU_HCP_45145');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESeth Andrew Wander",
"kol_full_name": "Seth Andrew Wander"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Pancreatic Ductal",
"npi_num": "1548713977",
"hcp_pin_alias": "FU_HCP_5403366",
"session_name": "Molecular landscape and site of metastasis in PDAC",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Shafia Rahman",
"middle_name": "",
"last_name": "",
"org_name": "The Ohio State University Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232841",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232841",
"events_session": "Molecular landscape and site of metastasis in PDAC",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Pancreatic Ductal",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1548713977,'FU_HCP_5403366');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShafia Rahman",
"kol_full_name": "Shafia Rahman"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lymphocytes, Tumor-Infiltrating | Triple Negative Breast Neoplasms | Combined Modality Therapy",
"npi_num": "1730506932",
"hcp_pin_alias": "FU_HCP_5403360",
"session_name": "NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Shane R Stecklein",
"middle_name": "",
"last_name": "",
"org_name": "University of Kansas Medical Center",
"Country": "United States",
"Region": "Kansas",
"City": "Wichita",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232641",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232641",
"events_session": "NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Lymphocytes, Tumor-Infiltrating | Triple Negative Breast Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Combined Modality Therapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1730506932,'FU_HCP_5403360');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShane R Stecklein",
"kol_full_name": "Shane R Stecklein"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Triple Negative Breast Neoplasms | Ovarian Neoplasms | Endocrine Therapy | Chemotherapy, Adjuvant",
"npi_num": "1326251299",
"hcp_pin_alias": "FU_HCP_118865",
"session_name": "A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Shannon L. Puhalla",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232637",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232637",
"events_session": "A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1",
"rest_events_session_count": 1,
"rest_events_session": " HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009",
"events_topic": "Triple Negative Breast Neoplasms | Ovarian Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Endocrine Therapy | Chemotherapy, Adjuvant",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1326251299,'FU_HCP_118865');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShannon L. Puhalla",
"kol_full_name": "Shannon L. Puhalla"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Anthracyclines | Alopecia",
"npi_num": "1750547105",
"hcp_pin_alias": "PAST_HCP_Onco_232567",
"session_name": "Improving chemotherapy-induced alopecia for women receiving anthracycline plus taxane chemotherapy using the Paxman scalp cooling system at lower temperatures",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Shari Beth Goldfarb",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232220",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232220",
"events_session": "Improving chemotherapy-induced alopecia for women receiving anthracycline plus taxane chemotherapy using the Paxman scalp cooling system at lower temperatures",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Chemotherapy | Anthracyclines ",
"rest_events_topic_count": 1,
"rest_events_topic": " Alopecia",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1750547105,'PAST_HCP_Onco_232567');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShari Beth Goldfarb",
"kol_full_name": "Shari Beth Goldfarb"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Renal Cell",
"npi_num": "1790277754",
"hcp_pin_alias": "FU_HCP_5403358",
"session_name": "Disparate outcomes among Latino and non-Hispanic White (NHW) patients with metastatic clear cell renal cell carcinoma (mccRCC)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sharon Choi",
"middle_name": "",
"last_name": "",
"org_name": "University of California, San Diego",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232588",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232588",
"events_session": "Disparate outcomes among Latino and non-Hispanic White (NHW) patients with metastatic clear cell renal cell carcinoma (mccRCC)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Renal Cell",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1790277754,'FU_HCP_5403358');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESharon Choi",
"kol_full_name": "Sharon Choi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Randomized Controlled Trials As Topic | Neoplasms",
"npi_num": "1750573127",
"hcp_pin_alias": "FU_HCP_44815",
"session_name": "Accuracy of medical oncology prognosis for patients with metastatic cancer evaluated for enrollment onto an ongoing randomized clinical trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Shearwood McClelland",
"middle_name": "",
"last_name": "",
"org_name": "Case Western Reserve University",
"Country": "United States",
"Region": "Ohio",
"City": "Cleveland",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232208",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232208",
"events_session": "Accuracy of medical oncology prognosis for patients with metastatic cancer evaluated for enrollment onto an ongoing randomized clinical trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Randomized Controlled Trials As Topic | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1750573127,'FU_HCP_44815');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShearwood McClelland",
"kol_full_name": "Shearwood McClelland"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Urogenital Neoplasms",
"npi_num": "1811213697",
"hcp_pin_alias": "FU_HCP_99785",
"session_name": "Association between wildfire PM25 and genitourinary cancer survival in California",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Shuchi Gulati",
"middle_name": "",
"last_name": "",
"org_name": "University of California, Davis Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232228",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232228",
"events_session": "Association between wildfire PM25 and genitourinary cancer survival in California",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Urogenital Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1811213697,'FU_HCP_99785');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EShuchi Gulati",
"kol_full_name": "Shuchi Gulati"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Genes, BRCA1 | Triple Negative Breast Neoplasms",
"npi_num": "1306134143",
"hcp_pin_alias": "FU_HCP_100528",
"session_name": "Real-world tumor BRCA testing patterns and PARP inhibitor use in HER2-negative metastatic breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Siddhartha Yadav",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic",
"Country": "United States",
"Region": "Minnesota",
"City": "Rochester",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232706",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232706",
"events_session": "Real-world tumor BRCA testing patterns and PARP inhibitor use in HER2-negative metastatic breast cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Genes, BRCA1 | Triple Negative Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1306134143,'FU_HCP_100528');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESiddhartha Yadav",
"kol_full_name": "Siddhartha Yadav"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "KRAS Protein, Human | Appendiceal Neoplasms",
"npi_num": "1912350042",
"hcp_pin_alias": "FU_HCP_100141",
"session_name": "KRAS mutations and their prognostic implications in appendiceal cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Snigdha Nutalapati",
"middle_name": "",
"last_name": "",
"org_name": "University of Kentucky HealthCare",
"Country": "United States",
"Region": "Kentucky",
"City": "Lexington",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232847",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232847",
"events_session": "KRAS mutations and their prognostic implications in appendiceal cancers",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "KRAS Protein, Human | Appendiceal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1912350042,'FU_HCP_100141');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESnigdha Nutalapati",
"kol_full_name": "Snigdha Nutalapati"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Central Nervous System Neoplasms",
"npi_num": "1821265232",
"hcp_pin_alias": "FU_HCP_229574",
"session_name": "Central Nervous System Tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Solmaz Sahebjam",
"middle_name": "",
"last_name": "",
"org_name": "Johns Hopkins Medicine",
"Country": "United States",
"Region": "Maryland",
"City": "Laurel",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232035",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232035",
"events_session": "Central Nervous System Tumors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Central Nervous System Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1821265232,'FU_HCP_229574');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESolmaz Sahebjam",
"kol_full_name": "Solmaz Sahebjam"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms | Major Histocompatibility Complex | Biomarkers",
"npi_num": "1457795239",
"hcp_pin_alias": "FU_HCP_75855",
"session_name": "Associations of predictive biomarkers, MHC-I and MHC-II, with clinical and molecular features in a diverse breast cancer cohort",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sonya A. Reid",
"middle_name": "",
"last_name": "",
"org_name": "Vanderbilt University Medical Center",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233133",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233133",
"events_session": "Associations of predictive biomarkers",
"rest_events_session_count": 2,
"rest_events_session": " MHC-I and MHC-II, with clinical and molecular features in a diverse breast cancer cohort",
"events_topic": "Breast Neoplasms | Major Histocompatibility Complex ",
"rest_events_topic_count": 1,
"rest_events_topic": " Biomarkers",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1457795239,'FU_HCP_75855');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESonya A. Reid",
"kol_full_name": "Sonya A. Reid"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colonic Neoplasms | Chemotherapy, Adjuvant",
"npi_num": "1821351198",
"hcp_pin_alias": "FU_HCP_100168",
"session_name": "Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter, randomized, open-label, phase 3 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Soo Yeun Park",
"middle_name": "",
"last_name": "",
"org_name": "Colorectal Cancer Center, Kyungpook National University Chilgok Hospital",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232869",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232869",
"events_session": "Early versus conventional adjuvant chemotherapy in stage III colon cancer: A multicenter",
"rest_events_session_count": 3,
"rest_events_session": " randomized, open-label, phase 3 trial",
"events_topic": "Colonic Neoplasms | Chemotherapy, Adjuvant",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1821351198,'FU_HCP_100168');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESoo Yeun Park",
"kol_full_name": "Soo Yeun Park"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Colorectal Neoplasms | Anus Neoplasms | Gastrointestinal Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403485",
"session_name": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sorbarikor Piawah",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233197",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233197",
"events_session": "Gastrointestnal Cancer – Colorectal and Anal: Program Commitee",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Colorectal Neoplasms | Anus Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Gastrointestinal Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403485');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESorbarikor Piawah",
"kol_full_name": "Sorbarikor Piawah"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Castration | Prostatic Neoplasms",
"npi_num": "1174085096",
"hcp_pin_alias": "FU_HCP_339675",
"session_name": "Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Secondary analysis of the SPARTAN trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Soumyajit Roy",
"middle_name": "",
"last_name": "",
"org_name": "Rush University Medical Center",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232649",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232649",
"events_session": "Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Secondary analysis of the SPARTAN trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Castration | Prostatic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1174085096,'FU_HCP_339675');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESoumyajit Roy",
"kol_full_name": "Soumyajit Roy"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Fatigue | Neoplasms | Dexamethasone",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403407",
"session_name": "Physical activity and dexamethasone for cancer related fatigue: A preliminary placebo controlled randomized control trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sriram Yennu",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232207",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232207",
"events_session": "Physical activity and dexamethasone for cancer related fatigue: A preliminary placebo controlled randomized control trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Fatigue | Neoplasms ",
"rest_events_topic_count": 1,
"rest_events_topic": " Dexamethasone",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403407');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESriram Yennu",
"kol_full_name": "Sriram Yennu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Gastrointestinal Neoplasms | Circulating Tumor DNA",
"npi_num": "1205099702",
"hcp_pin_alias": "FU_HCP_174352",
"session_name": "Clinical Utility of ctDNA in Gastrointestinal Cancers: Is It Ready for Prime Time?",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Stacey A. Cohen",
"middle_name": "",
"last_name": "",
"org_name": "University of Washington.",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232314",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232314",
"events_session": "Clinical Utility of ctDNA in Gastrointestinal Cancers: Is It Ready for Prime Time?",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Gastrointestinal Neoplasms | Circulating Tumor DNA",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1205099702,'FU_HCP_174352');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EStacey A. Cohen",
"kol_full_name": "Stacey A. Cohen"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pelvic Neoplasms | Androgen Deprivation Therapy | Prostatic Neoplasms | Radiotherapy | Darolutamide",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403447",
"session_name": "ALADDIN: Evaluation of darolutamide addition to androgen deprivation therapy and radiation therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Stephane Oudard",
"middle_name": "",
"last_name": "",
"org_name": "Georges Pompidou European Hospital, University of Paris",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232673",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232673",
"events_session": "ALADDIN: Evaluation of darolutamide addition to androgen deprivation therapy and radiation therapy in newly diagnosed prostate cancer with pelvic lymph nodes metastases",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pelvic Neoplasms | Androgen Deprivation Therapy ",
"rest_events_topic_count": 3,
"rest_events_topic": " Prostatic Neoplasms | Radiotherapy | Darolutamide",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403447');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EStephane Oudard",
"kol_full_name": "Stephane Oudard"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Head And Neck Neoplasms",
"npi_num": "1548454291",
"hcp_pin_alias": "FU_HCP_110502",
"session_name": "Evaluating perceived barriers to optimal care in head and neck cancer: A mixed-methods study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Steven Francis Powell",
"middle_name": "",
"last_name": "",
"org_name": "Sanford Cancer Center",
"Country": "United States",
"Region": "South Dakota",
"City": "Sioux Falls",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232564",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232564",
"events_session": "Evaluating perceived barriers to optimal care in head and neck cancer: A mixed-methods study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Head And Neck Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1548454291,'FU_HCP_110502');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESteven Francis Powell",
"kol_full_name": "Steven Francis Powell"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Precision Medicine | Neoplasms",
"npi_num": "1003269085",
"hcp_pin_alias": "FU_HCP_284893",
"session_name": "Comprehensive molecular pathology review service to reduce barriers to precision oncology in rural eastern North Carolina",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sunil Badami",
"middle_name": "",
"last_name": "",
"org_name": "East Carolina University Health",
"Country": "United States",
"Region": "North Carolina",
"City": "Greenville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232414",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232414",
"events_session": "Comprehensive molecular pathology review service to reduce barriers to precision oncology in rural eastern North Carolina",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Precision Medicine | Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1003269085,'FU_HCP_284893');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESunil Badami",
"kol_full_name": "Sunil Badami"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Stomach Neoplasms | Immune Checkpoint Inhibitors | Artificial Intelligence",
"npi_num": "1699732453",
"hcp_pin_alias": "FU_HCP_44279",
"session_name": "AI based PD-L1 CPS quantifier software to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sunil S Badve",
"middle_name": "",
"last_name": "",
"org_name": "Emory University School of Medicine",
"Country": "United States",
"Region": "Georgia",
"City": "Atlanta",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233021",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233021",
"events_session": "AI based PD-L1 CPS quantifier software to identify more patients for checkpoint therapy in gastric cancer at pathologist-level interobserver concordance",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Stomach Neoplasms | Immune Checkpoint Inhibitors ",
"rest_events_topic_count": 1,
"rest_events_topic": " Artificial Intelligence",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1699732453,'FU_HCP_44279');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESunil S Badve",
"kol_full_name": "Sunil S Badve"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Esophageal Neoplasms",
"npi_num": "1770726465",
"hcp_pin_alias": "FU_HCP_308351",
"session_name": "Trials and Technologies That Will Define the Next 5 Years in Gastroesophageal Cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sunnie S. Kim",
"middle_name": "",
"last_name": "",
"org_name": "University of Colorado Cancer Center",
"Country": "United States",
"Region": "Colorado",
"City": "Aurora",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232125",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232125",
"events_session": "Trials and Technologies That Will Define the Next 5 Years in Gastroesophageal Cancers",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Esophageal Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1770726465,'FU_HCP_308351');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESunnie S. Kim",
"kol_full_name": "Sunnie S. Kim"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hepatic Arterial Infusion | Cholangiocarcinoma | Carcinoma, Hepatocellular | Nelitolimod",
"npi_num": "1003159054",
"hcp_pin_alias": "FU_HCP_5403372",
"session_name": "PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Sunyoung S. Lee",
"middle_name": "",
"last_name": "",
"org_name": "Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233017",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233017",
"events_session": "PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101)",
"rest_events_session_count": 2,
"rest_events_session": " a class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma",
"events_topic": "Hepatic Arterial Infusion | Cholangiocarcinoma ",
"rest_events_topic_count": 2,
"rest_events_topic": " Carcinoma, Hepatocellular | Nelitolimod",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1003159054,'FU_HCP_5403372');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESunyoung S. Lee",
"kol_full_name": "Sunyoung S. Lee"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Breast Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403451",
"session_name": "Transcriptomic analysis of cAMP/PKA/CREB signaling in invasive lobular breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Susrutha Puthanmadhom Narayanan",
"middle_name": "",
"last_name": "",
"org_name": "Washington University School of Medicine",
"Country": "United States",
"Region": "Missouri",
"City": "St. Louis",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232704",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232704",
"events_session": "Transcriptomic analysis of cAMP/PKA/CREB signaling in invasive lobular breast cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403451');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESusrutha Puthanmadhom Narayanan",
"kol_full_name": "Susrutha Puthanmadhom Narayanan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1679197396",
"hcp_pin_alias": "FU_HCP_284543",
"session_name": "Trends in mortality from secondary malignancy in the United States, 1999-2019",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Syed Hamza Bin Waqar",
"middle_name": "",
"last_name": "",
"org_name": "H. Lee Moffitt Cancer Center and Research Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232422",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232422",
"events_session": "Trends in mortality from secondary malignancy in the United States",
"rest_events_session_count": 1,
"rest_events_session": " 1999-2019",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1679197396,'FU_HCP_284543');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ESyed Hamza Bin Waqar",
"kol_full_name": "Syed Hamza Bin Waqar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Telemedicine | Colorectal Neoplasms, Hereditary Nonpolyposis",
"npi_num": "1386794329",
"hcp_pin_alias": "FU_HCP_41554",
"session_name": "Uptake of germline cancer genetic services in a randomized trial of remote telehealth services as compared to usual care: A report from the Childhood Cancer Survivor Study (CCSS)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Tara O. Henderson",
"middle_name": "",
"last_name": "",
"org_name": "University of Chicago Pritzker School of Medicine",
"Country": "United States",
"Region": "Illinois",
"City": "Chicago",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232293",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232293",
"events_session": "Uptake of germline cancer genetic services in a randomized trial of remote telehealth services as compared to usual care: A report from the Childhood Cancer Survivor Study (CCSS)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Telemedicine | Colorectal Neoplasms, Hereditary Nonpolyposis",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1386794329,'FU_HCP_41554');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETara O. Henderson",
"kol_full_name": "Tara O. Henderson"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Peripheral Nervous System Diseases | Breast Neoplasms",
"npi_num": "1417217639",
"hcp_pin_alias": "FU_HCP_99513",
"session_name": "ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Tarah Jean Ballinger",
"middle_name": "",
"last_name": "",
"org_name": "Indiana University Simon Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232146",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232146",
"events_session": "ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Peripheral Nervous System Diseases | Breast Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1417217639,'FU_HCP_99513');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETarah Jean Ballinger",
"kol_full_name": "Tarah Jean Ballinger"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Atezolizumab | Biliary Tract Neoplasms | Cobimetinib | Varlilumab",
"npi_num": "1649626797",
"hcp_pin_alias": "FU_HCP_225210",
"session_name": "A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Thatcher Ross Heumann",
"middle_name": "",
"last_name": "",
"org_name": "Vanderbilt-Ingram Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232323",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232323",
"events_session": "A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Atezolizumab | Biliary Tract Neoplasms ",
"rest_events_topic_count": 2,
"rest_events_topic": " Cobimetinib | Varlilumab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1649626797,'FU_HCP_225210');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EThatcher Ross Heumann",
"kol_full_name": "Thatcher Ross Heumann"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Hematologic Neoplasms",
"npi_num": "1326576463",
"hcp_pin_alias": "FU_HCP_5403348",
"session_name": "Longitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Thejal Srikumar",
"middle_name": "",
"last_name": "",
"org_name": "Yale New Haven Hospital",
"Country": "United States",
"Region": "Connecticut",
"City": "New Haven",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232316",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232316",
"events_session": "Longitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Hematologic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1326576463,'FU_HCP_5403348');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EThejal Srikumar",
"kol_full_name": "Thejal Srikumar"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pancreatic Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403421",
"session_name": "Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Thejus Jayakrishnan",
"middle_name": "",
"last_name": "",
"org_name": "Taussig Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232322",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232322",
"events_session": "Tumor microbiome differences in early-onset versus average-onset pancreatic adenocarcinoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pancreatic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403421');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EThejus Jayakrishnan",
"kol_full_name": "Thejus Jayakrishnan"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Dexamethasone | Multiple Myeloma | Isatuximab | Lenalidomide | Bortezomib",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403393",
"session_name": "Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Thierry Facon",
"middle_name": "",
"last_name": "",
"org_name": "University of Lille, CHU Lille",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232132",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232132",
"events_session": "Phase 3 study results of isatuximab",
"rest_events_session_count": 3,
"rest_events_session": " bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ)",
"events_topic": "Dexamethasone | Multiple Myeloma ",
"rest_events_topic_count": 3,
"rest_events_topic": " Isatuximab | Lenalidomide | Bortezomib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403393');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EThierry Facon",
"kol_full_name": "Thierry Facon"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Solid Tumor",
"npi_num": "1821363029",
"hcp_pin_alias": "FU_HCP_0002135",
"session_name": "Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Thomas Urban Marron",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233007",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233007",
"events_session": "Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418",
"rest_events_session_count": 1,
"rest_events_session": " alone or in combination with pembrolizumab",
"events_topic": "Pembrolizumab | Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1821363029,'FU_HCP_0002135');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EThomas Urban Marron",
"kol_full_name": "Thomas Urban Marron"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Graft Vs Host Disease | Stem Cell Transplantation",
"npi_num": "1053963181",
"hcp_pin_alias": "FU_HCP_5403342",
"session_name": "“Things we deal with in exchange for cure”: How hematologists discuss graft versus host disease with patients considering allogeneic stem cell transplant",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Thorunn Halldora Thordardottir",
"middle_name": "",
"last_name": "",
"org_name": "University of Wisconsin Carbone Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232213",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232213",
"events_session": "“Things we deal with in exchange for cure”: How hematologists discuss graft versus host disease with patients considering allogeneic stem cell transplant",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Graft Vs Host Disease | Stem Cell Transplantation",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1053963181,'FU_HCP_5403342');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EThorunn Halldora Thordardottir",
"kol_full_name": "Thorunn Halldora Thordardottir"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Nivolumab | Carcinoma, Non-Small-Cell Lung",
"npi_num": "1922353135",
"hcp_pin_alias": "FU_HCP_0000898",
"session_name": "Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Tina Cascone",
"middle_name": "",
"last_name": "",
"org_name": "The University of Texas MD Anderson Cancer Center",
"Country": "United States",
"Region": "Texas",
"City": "Houston",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232477",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232477",
"events_session": "Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Nivolumab | Carcinoma, Non-Small-Cell Lung",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1922353135,'FU_HCP_0000898');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETina Cascone",
"kol_full_name": "Tina Cascone"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy",
"npi_num": "1700802220",
"hcp_pin_alias": "FU_HCP_0003679",
"session_name": "Communication on Immunotherapy Toxicity",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Toby Christopher Campbell",
"middle_name": "",
"last_name": "",
"org_name": "University of Wisconsin",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233098",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233098",
"events_session": "Communication on Immunotherapy Toxicity",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700802220,'FU_HCP_0003679');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EToby Christopher Campbell",
"kol_full_name": "Toby Christopher Campbell"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Delivery Of Health Care",
"npi_num": "1568583045",
"hcp_pin_alias": "FU_HCP_329265",
"session_name": "Examining patient preferences in the delivery of healthcare education",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Tomas Dvorak",
"middle_name": "",
"last_name": "",
"org_name": "Orlando Health Cancer Institute",
"Country": "United States",
"Region": "Florida",
"City": "Orlando",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232215",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232215",
"events_session": "Examining patient preferences in the delivery of healthcare education",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Delivery Of Health Care",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1568583045,'FU_HCP_329265');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETomas Dvorak",
"kol_full_name": "Tomas Dvorak"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Docetaxel | Carcinoma, Non-Small-Cell Lung | Adagrasib",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403470",
"session_name": "KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Tony S. K. Mok",
"middle_name": "",
"last_name": "",
"org_name": "The Chinese University of Hong Kong",
"Country": "Hong Kong (SAR)",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232923",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232923",
"events_session": "KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Docetaxel | Carcinoma, Non-Small-Cell Lung ",
"rest_events_topic_count": 1,
"rest_events_topic": " Adagrasib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403470');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETony S. K. Mok",
"kol_full_name": "Tony S. K. Mok"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Ezabenlimab | Solid Tumor",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403478",
"session_name": "A phase Ia/Ib, non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Toshihiko Doi",
"middle_name": "",
"last_name": "",
"org_name": "National Cancer Center Hospital East",
"Country": "Japan",
"Region": "Chiba",
"City": "Chiba",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233029",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233029",
"events_session": "A phase Ia/Ib",
"rest_events_session_count": 3,
"rest_events_session": " non-randomized, open-label, dose escalation and expansion trial of the B7-H6/CD3 T-cell engager BI 765049 with or without ezabenlimab in Asian patients with advanced solid tumors",
"events_topic": "Ezabenlimab | Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403478');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EToshihiko Doi",
"kol_full_name": "Toshihiko Doi"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Transitional Cell",
"npi_num": "1699110676",
"hcp_pin_alias": "FU_HCP_283346",
"session_name": "Landscape analysis and oncologic outcomes in advanced urothelial carcinoma (UC) by NECTIN4 RNA expression",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Tyler F. Stewart",
"middle_name": "",
"last_name": "",
"org_name": "University of California, San Diego, Moores Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232599",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232599",
"events_session": "Landscape analysis and oncologic outcomes in advanced urothelial carcinoma (UC) by NECTIN4 RNA expression",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Transitional Cell",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1699110676,'FU_HCP_283346');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETyler F. Stewart",
"kol_full_name": "Tyler F. Stewart"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Practice Management, Medical",
"npi_num": "1689945362",
"hcp_pin_alias": "FU_HCP_0026788",
"session_name": "How We Can Enhance Compassion in the Practice of Medicine",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Tyler Paul Johnson",
"middle_name": "",
"last_name": "",
"org_name": "Stanford University Hospital",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232546",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232546",
"events_session": "How We Can Enhance Compassion in the Practice of Medicine",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Practice Management, Medical",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1689945362,'FU_HCP_0026788');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003ETyler Paul Johnson",
"kol_full_name": "Tyler Paul Johnson"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms | Body Mass Index",
"npi_num": "1447545520",
"hcp_pin_alias": "FU_HCP_42101",
"session_name": "Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Umang Swami",
"middle_name": "",
"last_name": "",
"org_name": "Huntsman Cancer Institute at the University of Utah",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232659",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232659",
"events_session": "Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms | Body Mass Index",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1447545520,'FU_HCP_42101');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EUmang Swami",
"kol_full_name": "Umang Swami"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | Fulzerasib | Cetuximab",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403471",
"session_name": "KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Vanesa Gregorc",
"middle_name": "",
"last_name": "",
"org_name": "Candiolo Cancer Institute, FPO-IRCCS",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232925",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232925",
"events_session": "KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Carcinoma, Non-Small-Cell Lung | Fulzerasib ",
"rest_events_topic_count": 1,
"rest_events_topic": " Cetuximab",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403471');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVanesa Gregorc",
"kol_full_name": "Vanesa Gregorc"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pregabalin | Chronic Cough | Lung Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403408",
"session_name": "Randomized double-blind placebo-controlled trial evaluating pregabalin for chronic cough in patients with lung cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Vanita Noronha",
"middle_name": "",
"last_name": "",
"org_name": "Tata Memorial Centre",
"Country": "India",
"Region": "Maharashtra",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232211",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232211",
"events_session": "Randomized double-blind placebo-controlled trial evaluating pregabalin for chronic cough in patients with lung cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pregabalin | Chronic Cough ",
"rest_events_topic_count": 1,
"rest_events_topic": " Lung Neoplasms",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403408');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVanita Noronha",
"kol_full_name": "Vanita Noronha"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Prostatic Neoplasms",
"npi_num": "1760777635",
"hcp_pin_alias": "FU_HCP_5403335",
"session_name": "Advanced Prostate Cancer: A Case-Based Approach to Sequencing and Symptom Management",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Vatche Tchekmedyian",
"middle_name": "",
"last_name": "",
"org_name": "MaineHealth Cancer Care Network",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232055",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232055",
"events_session": "Advanced Prostate Cancer: A Case-Based Approach to Sequencing and Symptom Management",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Prostatic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1760777635,'FU_HCP_5403335');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVatche Tchekmedyian",
"kol_full_name": "Vatche Tchekmedyian"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Tyrosine Kinase Inhibitors",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403430",
"session_name": "Disparities in frontline treatment and overall survival in the era of targeted tyrosine kinase inhibitor therapy for chronic myeloid leukemia: 2004-2021",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Victoria Vardell",
"middle_name": "",
"last_name": "",
"org_name": "Department of Hematology and Hematologic Malignancies, University of Utah",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232426",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232426",
"events_session": "Disparities in frontline treatment and overall survival in the era of targeted tyrosine kinase inhibitor therapy for chronic myeloid leukemia: 2004-2021",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Tyrosine Kinase Inhibitors",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403430');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVictoria Vardell",
"kol_full_name": "Victoria Vardell"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Tifcemalimab | Toripalimab | Neoplasms | BTLA Protein, Human",
"npi_num": "1437530722",
"hcp_pin_alias": "FU_HCP_187578",
"session_name": "Phase I dose-escalation and cohort expansion study of the anti-BTLA antibody, tifcemalimab, in combination with toripalimab (anti-PD-1) in heavily pretreated patients (pts) with advanced malignancies",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Vincent T Ma",
"middle_name": "",
"last_name": "",
"org_name": "University of Wisconsin Carbone Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233006",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233006",
"events_session": "Phase I dose-escalation and cohort expansion study of the anti-BTLA antibody",
"rest_events_session_count": 2,
"rest_events_session": " tifcemalimab, in combination with toripalimab (anti-PD-1) in heavily pretreated patients (pts) with advanced malignancies",
"events_topic": "Tifcemalimab | Toripalimab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Neoplasms | BTLA Protein, Human",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1437530722,'FU_HCP_187578');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVincent T Ma",
"kol_full_name": "Vincent T Ma"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "WEE1 Protein, Human | Azenosertib | Gemcitabine | Osteosarcoma",
"npi_num": "1255759163",
"hcp_pin_alias": "FU_HCP_284143",
"session_name": "Phase 1 results of the WEE1 inhibitor, azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R/R) osteosarcoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Viswatej Avutu",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232904",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232904",
"events_session": "Phase 1 results of the WEE1 inhibitor",
"rest_events_session_count": 2,
"rest_events_session": " azenosertib, in combination with gemcitabine (gem) in adult and pediatric patients (pts) with relapsed or refractory (R/R) osteosarcoma",
"events_topic": "WEE1 Protein, Human | Azenosertib ",
"rest_events_topic_count": 2,
"rest_events_topic": " Gemcitabine | Osteosarcoma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1255759163,'FU_HCP_284143');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EViswatej Avutu",
"kol_full_name": "Viswatej Avutu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Randomized Controlled Trials As Topic | Hematologic Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403417",
"session_name": "Integration of a focused podcast curriculum (PC) to improve hematology oncology fellow (HOF) knowledge: A multi-center cluster randomized controlled trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Vivek Patel",
"middle_name": "",
"last_name": "",
"org_name": "Vanderbilt University Medical Center",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232266",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232266",
"events_session": "Integration of a focused podcast curriculum (PC) to improve hematology oncology fellow (HOF) knowledge: A multi-center cluster randomized controlled trial",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Randomized Controlled Trials As Topic | Hematologic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403417');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EVivek Patel",
"kol_full_name": "Vivek Patel"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immunotherapy | Solid Tumor | Diagnostic Imaging",
"npi_num": "1134485410",
"hcp_pin_alias": "FU_HCP_39300",
"session_name": "Relationship between dynamic changes in circulating tumor fraction and real-world imaging with real-world survival in patients with solid tumors treated with immunotherapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Wade Thomas Iams",
"middle_name": "",
"last_name": "",
"org_name": "Vanderbilt University Medical Center",
"Country": "United States",
"Region": "Tennessee",
"City": "Nashville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232943",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232943",
"events_session": "Relationship between dynamic changes in circulating tumor fraction and real-world imaging with real-world survival in patients with solid tumors treated with immunotherapy",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immunotherapy | Solid Tumor ",
"rest_events_topic_count": 1,
"rest_events_topic": " Diagnostic Imaging",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1134485410,'FU_HCP_39300');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWade Thomas Iams",
"kol_full_name": "Wade Thomas Iams"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Chemotherapy | Peripheral Nervous System Diseases | Acupuncture",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403410",
"session_name": "Preventing chemotherapy-induced peripheral neuropathy with acupuncture, a multinational parallel randomized controlled trials project (PACT)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Weidong Lu",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232223",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232223",
"events_session": "Preventing chemotherapy-induced peripheral neuropathy with acupuncture",
"rest_events_session_count": 1,
"rest_events_session": " a multinational parallel randomized controlled trials project (PACT)",
"events_topic": "Chemotherapy | Peripheral Nervous System Diseases ",
"rest_events_topic_count": 1,
"rest_events_topic": " Acupuncture",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403410');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWeidong Lu",
"kol_full_name": "Weidong Lu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Kidney Neoplasms | Biomarkers",
"npi_num": "1710390778",
"hcp_pin_alias": "FU_HCP_44472",
"session_name": "The Needle in the Haystack: Finding Biomarkers in Kidney Cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Wenxin Xu",
"middle_name": "",
"last_name": "",
"org_name": "Dana-Farber Cancer Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232469",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232469",
"events_session": "The Needle in the Haystack: Finding Biomarkers in Kidney Cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Kidney Neoplasms | Biomarkers",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1710390778,'FU_HCP_44472');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWenxin Xu",
"kol_full_name": "Wenxin Xu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Solid Tumor",
"npi_num": "1457617771",
"hcp_pin_alias": "FU_HCP_42190",
"session_name": "Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Wungki Park",
"middle_name": "",
"last_name": "",
"org_name": "Memorial Sloan Kettering Cancer Center",
"Country": "United States",
"Region": "New York",
"City": "New York",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232767",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232767",
"events_session": "Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Solid Tumor",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1457617771,'FU_HCP_42190');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EWungki Park",
"kol_full_name": "Wungki Park"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Dexamethasone | Multiple Myeloma | Isatuximab | Lenalidomide | Bortezomib",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403394",
"session_name": "Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Xavier P Leleu",
"middle_name": "",
"last_name": "",
"org_name": "Université de Poitiers et Centre Hospitalier Universitaire de Poitiers, INSERM U1313 and CIC 1082",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232133",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232133",
"events_session": "Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Dexamethasone | Multiple Myeloma ",
"rest_events_topic_count": 3,
"rest_events_topic": " Isatuximab | Lenalidomide | Bortezomib",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403394');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EXavier P Leleu",
"kol_full_name": "Xavier P Leleu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Lung Neoplasms | Immunotherapy",
"npi_num": "1346731957",
"hcp_pin_alias": "FU_HCP_111195",
"session_name": "Patterns and risk factors of immune-related adverse events in a real-world cohort with lung cancer receiving immunotherapy",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Xiao Hu",
"middle_name": "",
"last_name": "",
"org_name": "Tufts Medical Center (Cancer Center)",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232217",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232217",
"events_session": "Patterns and risk factors of immune-related adverse events in a real-world cohort with lung cancer receiving immunotherapy",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Lung Neoplasms | Immunotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1346731957,'FU_HCP_111195');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EXiao Hu",
"kol_full_name": "Xiao Hu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Olaparib | Durvalumab | Isocitrate Dehydrogenase | Glioma",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403438",
"session_name": "A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Xin Wang",
"middle_name": "",
"last_name": "",
"org_name": "Princess Margaret Cancer Centre",
"Country": "Canada",
"Region": "Ontario",
"City": "Toronto",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232518",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232518",
"events_session": "A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Olaparib | Durvalumab ",
"rest_events_topic_count": 2,
"rest_events_topic": " Isocitrate Dehydrogenase | Glioma",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403438');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EXin Wang",
"kol_full_name": "Xin Wang"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "DNA Damage | Lutetium Lu 177 Dotatate | Recombinational DNA Repair",
"npi_num": "1225533904",
"hcp_pin_alias": "FU_HCP_387467",
"session_name": "Enrichment of somatic mosaic states involving DNA damage response and repair genes in patients treated with 177Lutetium",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yael Kusne",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic Arizona",
"Country": "United States",
"Region": "Florida",
"City": "Fort Lauderdale",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232454",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232454",
"events_session": "Enrichment of somatic mosaic states involving DNA damage response and repair genes in patients treated with 177Lutetium",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "DNA Damage | Lutetium Lu 177 Dotatate ",
"rest_events_topic_count": 1,
"rest_events_topic": " Recombinational DNA Repair",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1225533904,'FU_HCP_387467');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYael Kusne",
"kol_full_name": "Yael Kusne"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Plasma Cell Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403425",
"session_name": "Supplement use habits and perceptions in patients with plasma cell disorders",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yan Leyfman",
"middle_name": "",
"last_name": "",
"org_name": "Icahn School of Medicine at Mount Sinai South Nassau",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232357",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232357",
"events_session": "Supplement use habits and perceptions in patients with plasma cell disorders",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Plasma Cell Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403425');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYan Leyfman",
"kol_full_name": "Yan Leyfman"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Pembrolizumab | Organ-specific Neoantigen | Solid Tumor",
"npi_num": "1659505915",
"hcp_pin_alias": "FU_HCP_0004264",
"session_name": "A phase I pilot study of personalized neoantigen peptide-based vaccine in combination with pembrolizumab in advanced solid tumors (PNeoVCA)",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yanyan Lou",
"middle_name": "",
"last_name": "",
"org_name": "Mayo Clinic Florida",
"Country": "United States",
"Region": "Florida",
"City": "Jacksonville",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233044",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233044",
"events_session": "A phase I pilot study of personalized neoantigen peptide-based vaccine in combination with pembrolizumab in advanced solid tumors (PNeoVCA)",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Pembrolizumab | Organ-specific Neoantigen ",
"rest_events_topic_count": 1,
"rest_events_topic": " Solid Tumor",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1659505915,'FU_HCP_0004264');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYanyan Lou",
"kol_full_name": "Yanyan Lou"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1326347931",
"hcp_pin_alias": "PAST_HCP_Onco_231742",
"session_name": "Challenges and Opportunities in Global Cancer Care Delivery",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yehoda M. Martei",
"middle_name": "",
"last_name": "",
"org_name": "Perelman School of Medicine, University of Pennsylvania",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232038",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232038",
"events_session": "Challenges and Opportunities in Global Cancer Care Delivery",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1326347931,'PAST_HCP_Onco_231742');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYehoda M. Martei",
"kol_full_name": "Yehoda M. Martei"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Radiation Pneumonitis | Thoracic Neoplasms",
"npi_num": "1700401254",
"hcp_pin_alias": "FU_HCP_111418",
"session_name": "In-hospital outcomes and mortality of drug-induced pneumonitis and radiation pneumonitis in patients with thoracic cancer",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yi Lee",
"middle_name": "",
"last_name": "",
"org_name": "",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232206",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232206",
"events_session": "In-hospital outcomes and mortality of drug-induced pneumonitis and radiation pneumonitis in patients with thoracic cancer",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Radiation Pneumonitis | Thoracic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1700401254,'FU_HCP_111418');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYi Lee",
"kol_full_name": "Yi Lee"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Carcinoma, Non-Small-Cell Lung | SHR-1701 | Chemotherapy",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403413",
"session_name": "Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy, safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yi-Long Wu",
"middle_name": "",
"last_name": "",
"org_name": "Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232245",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232245",
"events_session": "Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III NSCLC (TRAILBLAZER): Efficacy",
"rest_events_session_count": 2,
"rest_events_session": " safety and feasibility of surgical conversion outcomes from a proof-of-concept, phase 2 trial",
"events_topic": "Carcinoma, Non-Small-Cell Lung | SHR-1701 ",
"rest_events_topic_count": 1,
"rest_events_topic": " Chemotherapy",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403413');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYi-Long Wu",
"kol_full_name": "Yi-Long Wu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403429",
"session_name": "Effect of real-time data-driven physician engagement on appropriate precision oncology testing",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Ying Liu",
"middle_name": "",
"last_name": "",
"org_name": "Diaceutics",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232423",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232423",
"events_session": "Effect of real-time data-driven physician engagement on appropriate precision oncology testing",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403429');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYing Liu",
"kol_full_name": "Ying Liu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Neoplasms",
"npi_num": "1083009773",
"hcp_pin_alias": "FU_HCP_283379",
"session_name": "Challenges and Opportunities in Global Cancer Care Delivery",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yoanna S Pumpalova",
"middle_name": "",
"last_name": "",
"org_name": "Columbia University Medical Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232039",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232039",
"events_session": "Challenges and Opportunities in Global Cancer Care Delivery",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1083009773,'FU_HCP_283379');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYoanna S Pumpalova",
"kol_full_name": "Yoanna S Pumpalova"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Melanoma | Leptomeningeal Disease | Cerebrospinal Fluid",
"npi_num": "1639564040",
"hcp_pin_alias": "FU_HCP_232259",
"session_name": "Tumor reactive T cells from the cerebrospinal fluid of patients with leptomeningeal disease from melanoma",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yolanda Pina",
"middle_name": "",
"last_name": "",
"org_name": "H. Lee Moffitt Cancer Center and Research Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233067",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233067",
"events_session": "Tumor reactive T cells from the cerebrospinal fluid of patients with leptomeningeal disease from melanoma",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Melanoma | Leptomeningeal Disease ",
"rest_events_topic_count": 1,
"rest_events_topic": " Cerebrospinal Fluid",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1639564040,'FU_HCP_232259');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYolanda Pina",
"kol_full_name": "Yolanda Pina"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Immune Checkpoint Inhibitors | Pancreatic Neoplasms",
"npi_num": "1437764586",
"hcp_pin_alias": "FU_HCP_5403373",
"session_name": "Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Yu Fujiwara",
"middle_name": "",
"last_name": "",
"org_name": "Roswell Park Comprehensive Cancer Center",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "233020",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "233020",
"events_session": "Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Immune Checkpoint Inhibitors | Pancreatic Neoplasms",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1437764586,'FU_HCP_5403373');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EYu Fujiwara",
"kol_full_name": "Yu Fujiwara"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Skin Neoplasms | Melanoma",
"npi_num": "1760614739",
"hcp_pin_alias": "PAST_HCP_Onco_233173",
"session_name": "Melanoma/Skin Cancers",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Zeynep Eroglu",
"middle_name": "",
"last_name": "",
"org_name": "H. Lee Moffitt Cancer Center and Research Institute",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232088",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232088",
"events_session": "Melanoma/Skin Cancers",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Skin Neoplasms | Melanoma",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(1760614739,'PAST_HCP_Onco_233173');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EZeynep Eroglu",
"kol_full_name": "Zeynep Eroglu"
},
{
"proj_kol_id": 0,
"eid": "23416",
"event_topics": "Endocrine System Diseases | Immunotherapy",
"npi_num": "0",
"hcp_pin_alias": "FU_HCP_5403439",
"session_name": "HLA associations with immunotherapy related endocrine toxicity",
"name": "2024 American Society of Clinical Oncology Annual Meeting (ASCO)",
"kol_id": "0",
"first_name": "Zoe Quandt",
"middle_name": "",
"last_name": "",
"org_name": "University of California, San Francisco Department of Medicine",
"Country": "",
"Region": "",
"City": "",
"num_sess": "1",
"opt_in_out_status": "",
"url1": "https://conferences.asco.org/am/attend",
"session_note": "",
"cnt_notes": "0",
"event_attendees_id": "232523",
"medical_insight_id": "",
"cnt_medical_insight": "0",
"id": "232523",
"events_session": "HLA associations with immunotherapy related endocrine toxicity",
"rest_events_session_count": 0,
"rest_events_session": "",
"events_topic": "Endocrine System Diseases | Immunotherapy",
"rest_events_topic_count": 0,
"rest_events_topic": "",
"kol_name": "\u003Cdiv class=\"sprite_iconSet newIconSet\"\u003E\n\t\t\t\t\t\t\u003Ca class=\"requestProfileIcon \" href=\"#\" onclick=\"requestProfile(0,'FU_HCP_5403439');return false;\" rel=\"tooltip\" data-original-title=\"Request Profile\"\u003E \u003C/a\u003E\n\t\t\t\t\t\t\u003C/div\u003EZoe Quandt",
"kol_full_name": "Zoe Quandt"
}
]
}
}